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This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the toxic substances each profile describes.  Each peer-reviewed profile identifies and
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is
also presented but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with 
a public health statement that describes, in nontechnical language, a substance's relevant toxicological
properties.  Following the public health statement is information concerning levels of significant human 
exposure and, where known, significant health effects. A health effects summary describes the adequacy
of information to determine a substance's health effects. ATSDR identifies data needs that are significant
to protection of public health. 
Each profile:
(A) Examines, summarizes, and interprets available toxicologic information and
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) Determines whether adequate information on the health effects of each substance is
available or being developed to determine levels of exposure that present a significant risk to
human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of
exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are federal, state, and local health professionals;
interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed.  Staff of the Centers for Disease Control and Prevention and other federal scientists also 
have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel
and was made available for public review.  Final responsibility for the contents and views expressed in
this toxicological profile resides with ATSDR. 
Christopher J. Portier, Ph.D. 
Assistant Administrator















    






   
 
  
     
       
 
  vi URANIUM
*Legislative Background
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise











QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
 
 
Primary Chapters/Sections of Interest 
 
Chapter 1:  Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
 
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
 
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
 NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting.  Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
 
Pediatrics:  Four sections in each Toxicological Profile address child health issues: 
 Section 1.6 How Can (Chemical X) Affect Children? 
 Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 
 Section 3.7 Children’s Susceptibility 
 Section 6.6 Exposures of Children 
 
Other Sections of Interest: 
 Section 3.8  Biomarkers of Exposure and Effect 
 Section 3.11  Methods for Reducing Toxic Effects 
 
 
ATSDR Information Center 
 Phone:   1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)   Fax:   (770) 488-4178 
 E-mail:   cdcinfo@cdc.gov  Internet:   http://www.atsdr.cdc.gov 
 
The following additional material can be ordered through the ATSDR Information Center: 
 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 












Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III—
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
 
 
Other Agencies and Organizations 
 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
 
Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. 
Department of Energy, the World Health Organization, and the International Atomic Energy 
Agency in the medical management of radiation accidents.  A 24-hour emergency response 
program at the Oak Ridge Institute for Science and Education (ORISE), REAC/TS trains, 
consults, or assists in the response to all kinds of radiation accidents.  Contact: Oak Ridge 
Institute for Science and Education, REAC/TS, PO Box 117, MS 39, Oak Ridge, TN 37831-0117 
• Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour Emergency Phone 865-576-1005 (ask for 






The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:  
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 












The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
 
 
1. Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
 
2. Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
 
3. Data Needs Review.  The Environmental Toxicology Branch reviews data needs sections to 
assure consistency across profiles and adherence to instructions in the Guidance. 
 




























A peer review panel was assembled for uranium.  The panel consisted of the following members: 
 
1. Rudolfs K. Zalups, Ph.D., Mercer University School of Medicine, Macon, Georgia; 
 
2. Walter W. Piegorsch, Ph.D., University of Arizona, Tucson, Arizona; 
 
3. Fletcher F. Hahn, DVM, Ph.D., DACVP, Lovelace Respiratory Research Institute, Albuquerque, 
New Mexico. 
 
These experts collectively have knowledge of uranium and uranium compound’s physical and chemical 
properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound. 
 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
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1.  PUBLIC HEALTH STATEMENT FOR URANIUM 
Overview 
We define a public health statement and show how it can help you learn about uranium.  
 
Introduction A public health statement summarizes information about a hazardous substance.  The 
information is taken from a toxicological profile developed by ATSDR’s Division of 
Toxicology and Human Health Sciences (DTHHS).  A toxicological profile is a thorough 
review of a hazardous substance. 
 
This toxicological profile examines uranium.  This public health statement 
summarizes the DTHHS findings on uranium, describes the effects of exposure to it, 
and describes what you can do to limit that exposure. 
 
Uranium at The U.S. Environmental Protection Agency (U.S. EPA) identifies the most serious 
hazardous hazardous waste sites in the nation.  U.S. EPA then includes these sites on the 
waste sites National Priorities List (NPL) and targets them for federal clean-up activities.  U.S. 
EPA has found uranium in at least 67 of the 1,699 current or former NPL sites. 
 
The total number of NPL sites evaluated for uranium is not known.  But the 
possibility remains that as more sites are evaluated, the number of sites at which 
uranium is found may increase.  This information is important; these future sites may 
be sources of exposure, and exposure to uranium may be harmful. 
 
Why a uranium When a contaminant is released from a large area such as an industrial plant or from 
release can be a container such as a drum or bottle, it enters the environment.  But such a release 
harmful does not always lead to exposure.  You normally are exposed to a contaminant when 
you come in contact with it.  That contact—and therefore that exposure—can occur 
when you breathe, eat, or drink the contaminant, or when it touches your skin.  
However, since uranium is radioactive, you can also be exposed to its radiation if 
you are near it. 
 
Even if you are exposed to uranium, you might not be harmed.  Whether you are 
harmed will depend on such factors as the dose (how much), the duration (how 
long), and how you happen to contact it.  Harm might also depend on whether you 
have been exposed to any other chemicals or radioactive materials, as well as your 
age, sex, diet, family traits, lifestyle, and state of health. 
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A Closer Look at Uranium 
Overview 
This section describes uranium in detail and how you can be exposed to it.  
 
What is Uranium is a naturally occurring radioactive element.  Natural uranium is a mixture 
uranium? of three isotopes:  234U, 235U, and 238U.  The most common isotope is 238U; it makes 
up about 99% of natural uranium by mass. 
 
All three isotopes behave the same chemically, but they have different radioactive 
properties. 
 
The half-lives of uranium isotopes (the amount of time needed for half of the isotope 
to give off its radiation and change into a different element) are very long.  The least 
radioactive isotope is 238U with a half-life of 4.5 billion years. 
 
Depleted uranium is a mixture of the same three uranium isotopes, except that it has 
very little 234U and 235U.  It is less radioactive than natural uranium.   
 
Enriched uranium is another mixture of isotopes that has more 234U and 235U than 
natural uranium.  Enriched uranium is more radioactive than natural uranium. 
 
How is Uranium is almost as hard as steel and much denser than lead.  Natural uranium is 
uranium used? used to make enriched uranium; depleted uranium is the leftover product.   
 
Enriched uranium is used to make fuel for nuclear power plants. 
 
Depleted uranium is used as a counterbalance on helicopter rotors and airplane 
control surfaces, as a shield to protect against ionizing radiation, as a component of 
munitions to help them penetrate enemy armored vehicles, and as armor in some 
parts of military vehicles. 
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Where is Uranium can be released into the environment through wind and water erosion and 
uranium volcanic eruptions.   
found?  
Industries involved in mining, milling, and processing of uranium can also release it 
into the environment.  Inactive uranium industries may continue to release uranium 




Possible Sources Outcome 
Air:  In the air, uranium exists as dust. The very small particles of uranium 
found in dust can fall onto water, 
plants, and land.  Rain increases the 
amount of uranium in air that can settle 
to the ground.  
Water:  Uranium can be found in 
drinking water; higher levels tend to be 
from wells drilled in uranium-rich rock 
formations. 
Uranium in surface water can be 
transported large distances.  Some of 
the uranium in water will stick to 
sediment and other particles in the 
water. 
Soil:  Uranium is naturally present 
nearly all rocks and soils.   
in Uranium deposited on land can mix 
into soil, wash into surface water, or 
stick to plant roots. 
Food:  Human daily intake has been 
estimated to range from 0.9 to 
1.5 micrograms of uranium per day 
(µg/day). 
Uranium can stick to plant roots.  
Unwashed potatoes, radishes, and other 
root vegetables are a primary source of 
uranium in the diet. 
How Can You Be Exposed to Uranium 
 
Primary For most people, food and drinking water are the main sources of uranium exposure. 
uranium  
exposure Root crops such as potatoes, parsnips, turnips, and sweet potatoes contribute the 
sources highest amounts of uranium to the diet.  The amount of uranium in these foods is 
directly related to the amount of uranium in the soil in which they are grown. 
 
Other uranium People who work with materials and products that contain uranium may be exposed 
exposure at work.  This includes workers who mine, mill, or process uranium or make items 
sources that contain uranium.  People who work with phosphate fertilizers may also be 
exposed to higher levels of uranium.   
 
People who live near uranium mining, processing, and manufacturing facilities could 
be exposed to more uranium than the general population.  
 
People may also be exposed if they live near areas where depleted uranium weapons 
are used.   
URANIUM  4 
 








Secondary In most areas of the United States, low levels of uranium are found in the drinking 
uranium water.  Higher levels may be found in areas with elevated levels of naturally 
exposure occurring uranium in rocks and soil. 
sources 
 
How Uranium Can Affect Your Health 
Overview 
This section looks at how uranium enters your body and potential uranium health effects found in human 





Uranium can enter your body from the air, water, food, or from dermal contact. 
 
Possible Sources Possible Exposure Pathway 
Air  Only about 0.76–5% of the uranium a 
person breathes will get into the 
bloodstream through the respiratory 
tract (nose, mouth, throat, lungs).  
Some uranium compounds are slowly 
cleared from the lungs. 
Food and water  Only about 0.1–6% of the uranium a 
person ingests will get into the 
bloodstream through the 
gastrointestinal tract (mouth, stomach, 
intestines).  Uranium compounds that 
dissolve in water enter the bloodstream 
more easily than uranium compounds 
poorly soluble in water.   
Dermal contact  
 
A very small amount of uranium can be 
absorbed through the skin; water-
soluble uranium compounds are the 





Most of the inhaled and ingested uranium is not absorbed and leaves the body in the 
feces.  Absorbed uranium leaves your body in the urine.  Some inhaled uranium can 
stay in the lungs for a long time. 
 
Uranium that is absorbed is deposited throughout the body; the highest levels are 
found in the bones, liver, and kidneys.  Sixty-six percent of the uranium in the body 
is found in your bones.  It can remain in the bones for a long time; the half-life of 
uranium in bones is 70–200 days (this is the amount of time that it takes for half of 
the uranium to leave the bones).  Most of the uranium that is not in bones leaves the 
body in 1–2 weeks.  
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Natural and depleted uranium have the identical chemical effect on your body. 
 
The health effects of natural and depleted uranium are due to chemical effects and 






Uranium’s main target is the kidneys.  Kidney damage has been seen in humans and 
animals after inhaling or ingesting uranium compounds.  However, kidney damage 
has not been consistently found in soldiers who have had uranium metal fragments in 
their bodies for several years.  Ingesting water-soluble uranium compounds will 
result in kidney effects at lower doses than following exposure to insoluble uranium 
compounds. 
 
Workers who inhaled uranium hexafluoride have experienced respiratory irritation 
and accumulation of fluid in the lungs.  However, these effects were attributed to the 
irritant hydrofluoric acid rather than the uranium. 
 




No health effects, other than kidney damage, have been consistently found in 
humans after inhaling or ingesting uranium compounds or in soldiers with uranium 
metal fragments in their bodies. 
 
Rats ingesting uranium over a long time had neurobehavioral changes and changes in 
the levels of certain chemicals in the brain. 
 
Uranium has been shown to decrease fertility in some studies of rats and mice; other 
studies have not found this effect. 
 
Very soluble uranium compounds on the skin caused skin irritation and mild skin 




Neither the National Toxicology Program (NTP), International Agency for Research 
on Cancer (IARC), nor the EPA have classified natural uranium or depleted uranium 
with respect to carcinogenicity.   
Children and Uranium 
Overview 
This section discusses potential health effects of uranium exposure in humans from when they are first 
conceived to 18 years of age, and how you might protect against such effects. 
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Exposure No data describe the effects of exposure to uranium on children or young animals.  
effects for Although we think that children would likely show the same health effects as adults, 





We do not know whether uranium can harm an unborn child.  No scientifically 
strong human study that has shown birth defects due to uranium exposure has been 
identified. 
 
Some studies in animals exposed to high levels of uranium during pregnancy, which 
caused toxicity in the mothers, have resulted in early deaths and birth defects in the 
young.  It is not clear if this can happen in the absence of effects on the mother.  
Other studies have not found birth defects. 
 
In some rat studies, enriched uranium exposure during pregnancy caused changes in 
brain function in the offspring.  Similar studies found changes in the ovaries of the 
female offspring. 
 
One study reported that giving a high amount of uranium to newborn rats altered the 
tooth formation. 
 
How Can You Lower Your Exposure to Uranium 
 
Food Avoid eating root vegetables grown in soils with high levels of uranium.  Consider 
washing fruits and vegetables grown in that soil and discard the outside portion of 
root vegetables. 
 
Drinking water Consider having your water tested if you suspect that your drinking water might have 
elevated levels of uranium.  If elevated levels are found, consider using bottled 
water. 
 
If you live near 
a hazardous 
waste site 
If you live near a hazardous waste site with high amounts of uranium that are not 
controlled, do not let your children play outside in the dirt.  Children put dirt in their 
mouths, and uranium is in this dirt.  Also, make sure your children wash their hands 
often, especially before eating. 
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Medical Tests to Determine Uranium Exposure 
Overview 
Natural uranium is in your normal diet, so there will always be some level of uranium in all parts of your 
body.  If in addition you are exposed to depleted uranium, it adds to the total uranium level in your body.  
We identify medical tests that can detect whether uranium is in your body, and we recommend safe toxic-
substance practices.  
 
Uranium can 
be measured in 
blood and urine 
Uranium can be measured in blood, urine, hair, and body tissues.  Normally, urinary 
sampling is the preferred method for assessing uranium exposure.  The amount of 
radiation from uranium in your body can also be measured. 
 
Most tests are for total uranium; however, expensive tests are available to estimate 






Most uranium leaves the body within a few days.  High amounts in your urine might 
show that you have been exposed to high amounts of uranium within the last week or 
so. 
 
Federal Government Recommendations to Protect Human 
Health  
Overview 
One way the federal government promotes public health is by regulating toxic substances or 






Regulations are enforceable by law.  The U.S. EPA, the Occupational Safety and 
Health Administration (OSHA), the Nuclear Regulatory Commission (USNRC), and 
the Food and Drug Administration (FDA) are some federal agencies that develop 








The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) have made recommendations 
about toxic substances.  Unlike enforceable regulations, these recommendations are 
advisory only.  
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Regulations and recommendations can be expressed as “not-to-exceed” levels, that 
is, levels of a toxic substance in air, water, soil, or food that do not exceed a critical 
value usually based on levels that affect animals; levels are then adjusted to help 
protect humans.  Sometimes, these not-to-exceed levels differ among federal 
organizations.  Different organizations use different exposure times (an 8-hour 
workday or a 24-hour day), different animal studies, or emphasize some factors over 






Recommendations and regulations are also updated periodically as more information 
becomes available.  For the most current information, check with the federal agency 
or organization that issued the regulation or recommendation.  
 
Some regulations and recommendations for uranium include:  
 
Federal Organization Regulation or Recommendation 
U.S. Environmental Protection Agency 
(EPA) 
The U.S. EPA has established a 
maximum contaminant level of 
0.03 mg/L and set a maximum 
contaminant level goal of no uranium in 
drinking water. 
Occupational Safety and Health 
Administration (OSHA) 
OSHA set a legal limit for worker 
exposure to uranium in workplace air of 
0.05 mg uranium/m3 for soluble uranium 
and 0.25 mg uranium/m3 for insoluble 
uranium averaged over an 8-hour work 
day. 
National Institute of Occupational 
and Health (NIOSH) 
Safety NIOSH recommends that worker 
exposure to uranium in workplace air not 
exceed an exposure limit of 0.05 mg 
uranium/m3 for soluble uranium and 
0.2 mg uranium/m3 for insoluble uranium 
averaged for up to a 10-hour work day.  
NIOSH also recommends that exposure to 
3soluble uranium not exceed 0.6 mg U/m  




Regulatory Commission The USNRC has established derived air 
concentrations of 0.0005, 0.0003, and 
30.00002 microcuries/m , averaged for a 
working year of 2,000 hours for workers 
exposed to a form of uranium that is 
excreted at fast, medium, and slow rates, 
respectively. 
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If you have questions or concerns, please contact your community or state health or 





ATSDR can also tell you the location of occupational and environmental health 
clinics.  These clinics specialize in recognizing, evaluating, and treating illnesses that 





Toxicological profiles are also available online at www.atsdr.cdc.gov and on 
CD-ROM.  Request a copy of the ATSDR ToxProfiles CD-ROM by 
• Calling the toll-free information and technical assistance number at  
1-800-CDCINFO (1-800-232-4636),  
• E-mailing cdcinfo@cdc.gov, or  
• Writing to 
 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Human Health Sciences 
1600 Clifton Road NE 
Mailstop F-57 




For-profit organizations should request final toxicological profile copies from  
 
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
 
Web site:  http://www.ntis.gov/ 
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2.  RELEVANCE TO PUBLIC HEALTH 
 
2.1   BACKGROUND AND ENVIRONMENTAL EXPOSURES TO URANIUM IN THE UNITED 
STATES 
 
Uranium is an alpha-emitting, radioactive, heavy metal that occurs naturally in nearly all rocks and soils.  
Twenty-two isotopic forms of uranium have been identified, mainly associated with nuclear reactor 
operations or high-energy physics experiments; the most prevalent isotopes found in the environment are 
the three naturally-occurring isotopes: 234U, 235U, and 238U.  Most uranium isotopes undergo decay by 
alpha emission, a few undergo beta emission, and several isotopes, including 238U, can also undergo 
spontaneous fission.  238U decays through 16 radioactive progeny, including 234U, to reach stable lead-206 
(206Pb), while 235U decays through 13 radioactive progeny to reach stable 207Pb.  The rate of decay (or 
half-life) for most uranium isotopes is long; the half-lives of 238U, 235U and 234U are 4.5x109, 7.0x108 and 
2.5x105 years, respectively.  Since the activity of a given mass of uranium depends on the mass and half-
life of each isotope present, the greater the relative abundance of the more rapidly decaying 234U and 235U, 
the higher the specific activity.  Naturally occurring uranium is an isotopic mixture containing 99.284% 
238U, 0.711% 235U, and 0.005% 234U by mass (49% 238U, 2% 235U, and 49% 234U by radioactivity) and has 
a specific activity of 0.68 μCi/g.  The industrial process of enrichment separates natural uranium into 
enriched uranium (increased percentage of 235U) and depleted uranium (decreased percentage of 235U).  
The process of enrichment also increases the percentage of 234U (thus, enriched uranium is more reactive); 
depleted uranium has a decreased percentage of 234U and is less radioactive.  Uranium enrichment for 
commercial nuclear energy produces uranium that contains about 3% 235U by activity.  Uranium 
enrichment for other purposes, including nuclear weapons production, can produce uranium containing as 
much as 97.3% 235U and having a higher specific activity (~50 μCi/g).  Depleted uranium is the byproduct 
of the enrichment process.  Depleted uranium has even less specific activity (0.33 μCi/g) than natural 
uranium. 
 
The average concentration of uranium in U.S. soils is about 3 ppm (2 pCi/g).  Some parts of the United 
States, particularly the western portion, exhibit higher-than-average uranium levels due to natural 
geological formations.  Most uranium ores contain between 0.2 and 5% uranium by weight; however, 
levels as high as 22% have been reported in the Athabasca Basin region of Canada.  Anthropogenic 
sources of uranium include uranium mining and milling, uranium conversion and enrichment, uranium 
fuel fabrication, nuclear weapons production, production of phosphate fertilizers from phosphate rocks 
containing uranium, and the improper disposal of uranium mine tailings.  Essentially no uranium is 
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released from nuclear power plants because of the fuel assembly design and the chemical and physical 
nature of the uranium oxide fuel. 
 
The general population is exposed to uranium via ingestion of food and drinking water and inhalation of 
air, with food being the primary contributor to body burden.  The daily intake of uranium from food 
sources ranges from 0.6 to 1.0 pCi/day (0.9–1.5 µg/day).  Uranium from soil is not taken up by plants, but 
rather is adsorbed onto the roots.  Thus, the highest levels of uranium are found in root vegetables, 
primarily unwashed potatoes.  Populations living near uranium mills or mines or other areas with elevated 
uranium in soil may be exposed to higher levels of uranium from locally grown vegetables.  Uranium 
levels in drinking water vary widely, with a mean population-weighted average of 0.8 pCi/L.  Compared 
to the ingestion route, the intake of uranium via inhalation is small; intakes range from 0.0007 to 
0.007 pCi/day (0.001–0.01 µg/day). 
 
Uranium is poorly absorbed following inhalation, oral, or dermal exposure and the amount absorbed is 
heavily dependent on the solubility of the compound.  The site of deposition of inhaled particles in the 
respiratory tract also influences absorption.  The more soluble compounds are more likely to be absorbed 
into the blood at the alveolar level within days.  The less soluble compounds are more likely to remain in 
the lung tissue and associated lymph nodes either for weeks (uranium trioxide, uranium tetrafluoride) or 
years (uranium dioxide, triuranium octaoxide), resulting in significant pulmonary retention in inhalation-
exposure toxicity and a greater dose of alpha radiation.  Absorption efficiencies of 18–40 and 23% have 
been reported in animals exposed to uranium hexafluoride or uranium trioxide aerosols, respectively.  
Following oral exposure, <0.1–6% of the uranium is absorbed, depending on the solubility of the uranium 
compound.  Following dermal application of uranyl nitrate, 0.4% of the dose was absorbed through the 
skin of hairless rats.  Damage to the skin resulted in substantially higher absorption efficiencies.  
Transdermally absorbed uranium and uranium released from embedded fragments is expected to behave 
identically to uranium compounds absorbed through the lungs and the gastrointestinal tract.  Regardless 
of solubility, a portion of uranium quickly reaches the systemic circulation.  Uranium is usually found in 
compounds that can break down and recomplex to form other compounds.  In body fluids, tetravalent 
uranium is likely to oxidize to the hexavalent form, followed by formation of the uranyl ion.  Uranium 
generally complexes with citrate, bicarbonates, or protein in plasma.  Approximately 67% of uranium in 
the blood is filtered in the kidneys and leaves the body in urine within 24 hours; the remainder distributes 
to tissues, primarily the bone, liver, and kidney.  The retention half-time for uranium in bone following 
inhalation exposure to soluble uranium compounds is 70–200 days.  The main sites of long-term retention 
for inhaled insoluble compounds that are deposited in the deep respiratory tract are the lungs and 
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pulmonary lymph nodes.  The normal adult body burden is approximately 90 μg of which 66% is found in 
bone, 16% is in the liver, 8% is in the kidneys, and 10% is in other tissues.   
 
2.2   SUMMARY OF HEALTH EFFECTS  
 
The following discussion of the chemical and radiological health effects of uranium is divided into the 
three groupings of uranium isotope mixtures (natural uranium, enriched uranium, and depleted uranium) 
and the various compounds in which uranium is usually found.  The health effects of daughter radioactive 
elements (radium and radon) are addressed in other toxicological profiles (consult the ATSDR 
toxicological profiles for radium and radon for more information regarding these radioactive elements).  
The preponderance of the available toxicity data comes from animal studies of natural uranium; studies 
over the last 20 years have also evaluated the toxicity of enriched uranium in animals and depleted 
uranium in military personnel with embedded depleted uranium fragments and in animals.  Comparisons 
across studies provide evidence that the chemical action of all isotopes and isotopic mixtures of uranium 
is identical, regardless of the specific activity, because chemical action depends only on chemical 
properties.  Thus, the chemical toxicities of natural, depleted, and enriched uranium are identical.  Some 
recent studies also suggest that exposure to enriched uranium can also result in radiotoxic effects. 
 
Natural Uranium.  Current evidence from animal studies suggests that the toxicity of uranium is mainly 
due to its chemical damage to kidney tubular cells following exposure to soluble uranium compounds and 
the respiratory tract following chronic inhalation exposure to insoluble uranium compounds.  Other 
potential targets of toxicity include the reproductive system and the developing organism.  There are 
limited data on the renal toxicity of uranium following inhalation exposure in humans.  A number of 
studies found no alterations in mortality due to renal disease in uranium workers.  An autopsy study of 
long-time workers exposed to low levels of uranium did not find evidence of renal injury years after 
exposure termination.  However, a study of uranium mill workers exposed to uranium found evidence of 
renal dysfunction (β-2-microglobinuria, aminoaciduria); the severity and incidence of the effects appeared 
to be related to exposure duration.  Several epidemiology studies have found associations between 
nonspecific parameters of renal dysfunction (e.g., urine levels of albumin, β2-microglobulin, glucose, and 
protein HC) and elevated uranium levels in drinking water.  These studies did not find overt signs of 
toxicity and in many cases, the biomarkers of renal dysfunction were within the normal range.  Although 
most of the epidemiology studies provided information on uranium levels in the drinking water, there was 
often a large range of exposure levels; thus, the human oral exposure studies do not provide reliable dose-
response data.   
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Renal effects have been observed in a number of animal species exposed to various uranium compounds.  
The observed effects have primarily involved damage to the proximal tubules and have been observed 
following inhalation, oral, or dermal exposures.  The majority of the data on the renal toxicity of uranium 
come from a collection of experiments conducted in late 1940s and early 1950s.  The results of these 
studies demonstrate compound- and species-related differences in toxicity.  Soluble uranium compounds 
(e.g., uranyl nitrate, uranyl fluoride, uranium hexafluoride, and uranium tetrachloride) are more toxic than 
insoluble uranium compounds (e.g., uranium dioxide, uranium peroxide, uranium trioxide, and triuranium 
oxtaoxide).  Renal effects have been observed in animals exposed to aerosols of soluble uranium 
compounds at concentrations of ≥0.13 mg U/m3 for intermediate durations.  However, no renal effects 
were observed in animals exposed to 1.0 mg U/m3 as insoluble compounds; the lowest-observed-adverse-
effect level (LOAEL) was 8.2 mg U/m3.  These data suggest that soluble compounds are at least 5 times 
more toxic than insoluble compounds.  The difference in toxicity is likely due to the more efficient 
absorption of soluble uranium compounds.  Of the animals tested in intermediate-duration inhalation 
studies, dogs and rabbits are the most sensitive followed by rats, mice, and guinea pigs.  The severity of 
renal lesions increases with increasing exposure concentrations; very slight renal tubular damage is 
observed at low concentrations and marked degeneration and necrosis are observed at higher 
concentrations.  The available data on the oral and dermal toxicity of uranium are more limited than by 
the inhalation route.  Acute-, intermediate-, and chronic-duration oral studies in laboratory animals (rats, 
mice, rabbits, and dogs) provide strong support for identifying the kidney as a sensitive target of uranium 
toxicity.  Acute exposure to lethal doses of uranyl nitrate or uranyl acetate resulted in renal dysfunction in 
rats and mice as evidenced by increases in urine volume, plasma urea, blood urea nitrogen (BUN), and 
urinary total protein.  Minimal histological alterations in the glomerulus, proximal tubules, and/or 
interstitium have been observed in rats and rabbits exposed to intermediate-duration doses of soluble 
uranium compounds as low as 0.05 mg U/kg/day; the severity of the renal lesions increased with dose.  
Additionally, a rabbit study demonstrated that renal lesions persisted up to 91 days following termination 
of a 91-day oral exposure.  Chronic oral exposure to soluble uranium compounds resulted in minimal 
tubular damage at 81 mg U/kg/day and tubular atrophy at ≥140 mg U/kg/day.  Due to the poor absorption 
of ingested insoluble uranium compounds, there are significant differences in the renal toxicity of various 
uranium compounds.  No renal effects were observed in rats exposed to doses as high as 11,000–
12,000 mg U/kg/day as uranium dioxide, uranium trioxide, uranyl octaoxide, or uranium tetrafluoride for 
30 days; after 2 years of exposure to 11,000 mg U/kg/day as uranium tetrafluoride, mild tubular 
degeneration was observed in rats, but no adverse effects were observed in rats exposed to 12,000 mg 
U/kg/day as uranium dioxide for 2 years.  In contrast, adverse renal effects were observed after a 30-day 
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exposure to doses of 140–270 mg U/kg/day as uranyl nitrate, uranium peroxide, or uranyl fluoride and 
doses of 440–790 mg U/kg/day as uranium tetrachloride or uranium acetate and a 2-year exposure to 81–
170 mg U/kg/day as uranyl fluoride or uranyl nitrate.  Available inhalation and oral exposure studies 
suggest that following exposure to low levels of uranium (doses or concentrations resulting in minimal 
renal effects), toxicity is not strongly influenced by the duration of exposure.  As with other routes of 
exposure, proteinuria, renal failure, and renal lesions were observed in laboratory animals following acute 
dermal exposure to uranyl nitrate.  
 
General damage to pulmonary structures, usually noncancerous alveolar epithelium damage of type II 
cells, can occur upon inhalation of insoluble reactive chemicals such as some uranium compounds 
(uranium tetrafluoride, uranium dioxide, uranium trioxide, triuranium octaoxide).  In acute exposures, 
pulmonary damage may be limited to interstitial inflammation of the alveolar epithelium leading 
eventually to emphysema or pulmonary fibrosis.  In studies of the pulmonary effects of airborne uranium 
dust in uranium miners, the respiratory diseases reported were aggravated by the insoluble aerosol 
particles (mine dust) to which these miners were exposed because most of the noncancerous respiratory 
diseases reported in these studies were consistent with toxicity of inhalable dust particles other than 
uranium, such as crystalline silica and diesel engine exhaust particles.  Respiratory effects reported in 
workers acutely exposed to uranium hexafluoride were caused by hydrogen fluoride, a potent lung irritant 
and a spontaneous byproduct of the reaction between uranium hexafluoride and water, such as in mucous 
membranes.  A follow-up study of three of the workers did not detect uranium in the lungs or evidence of 
lung damage 38 years after the initial exposure.  Similar to human studies, signs of respiratory irritation 
(rhinitis and lung edema, hemorrhage, and emphysema) have been observed in animals exposed to ≥2 mg 
U/m3 uranium hexafluoride, uranyl fluoride, and uranium tetrafluoride.  It is likely that these effects were 
due to co-exposure to hydrogen fluoride.  Inhalation exposure to insoluble uranium compounds also 
results in pulmonary damage.  Very slight pulmonary lesions were observed in rats and dogs exposed to 
16 mg U/m3 as uranium trioxide for 4 weeks; mild to severe renal tubular necrosis was also observed at 
this concentration.  In contrast, chronic exposure to 5.1 mg U/m3 as uranium dioxide for at least 3.5 years 
resulted in lung fibrosis in monkey and dogs; renal effects were not observed in either species. 
 
Limited data are available regarding reproductive effects of uranium in humans.  Studies of uranium 
miners, millers, and processors found that male uranium miners had more first-born female children than 
expected, suggesting that uranium’s alpha radiation damaged the y-chromosomes of the miners.  
However, the workers were also exposed to 222Rn, chlorine, hydrofluoric acid, lead sulfate, nickel, nitric 
acid and nitrogen oxides, silicon dioxide, sulfuric acid, tobacco smoke, and diesel exhaust.  Uranium 
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reduced fertility, likely due to reductions in spermatozoa counts, was observed in male mice exposed to 
≥5.6 mg U/kg/day in drinking water and mated with untreated females.  However, fertility was not 
significantly affected in another study in mice in which males and females were treated by gavage with up 
to 14 mg U/kg/day.  These apparently discrepant results may be due to the different mode of dosing 
between the two studies (i.e., gavage vs. drinking water), which may have resulted in different rates of 
absorption.  Uranium also reduced fertility in male rats dosed with 11.2 mg/kg/day and mated with 
untreated females; the NOAEL was 5.6 mg U/kg/day.  Effects on female reproductive health have also 
been observed in mice orally exposed to uranium.  Alterations in ovarian folliculogenesis were observed 
at ≥1.25 mg U/kg/day.   
 
Developmental effects have been observed in the offspring of mice; these effects have often been 
observed at maternally toxic doses.  Elevated uranium levels were measured in the offspring of rats 
exposed to uranyl acetate prior to mating and during gestation and lactation, suggesting transplacental 
and/or lactational transfer of uranium.  The observed effects included lethality, reductions in growth, 
increase in visceral and skeletal abnormalities, and reproductive effects.  Lethality effects consisted of 
reductions in viability on postnatal day 21 in offspring of mice dosed with 28 mg U/kg/day on gestation 
day 13 to postnatal day 21, decreases neonatal viability in the offspring of mice exposed to 5.6 mg 
U/kg/day prior to mating and throughout gestation and lactation, and increases in late resorptions and 
decreases in the number of live fetuses in the offspring of mice exposed to 14 mg U/kg/day prior to 
mating and during gestation.  Reductions in fetal body weight were observed in the offspring of mice 
dosed with ≥2.8 mg U/kg/day on gestation days 6–15.  This study also reported significant increases in 
the total number of external malformations at ≥2.8 mg U/kg/day and the total number of skeletal defects 
at ≥14 mg U/kg/day.  Maternal toxicity may have played a role in this study since maternal weight gain 
during exposure was reduced by at least 33%.  Alterations in ovarian folliculogenesis, similar to those 
described in the discussion of reproductive toxicity have been observed in the female pups of mice 
exposed to uranium prior to mating and/or during gestation; as discussed in the previous paragraph on 
reproduction toxicity, the doses tested in the study were much lower than effect levels reported in other 
studies, were below the detection limit, and are lower than normal background levels.  In rats, doses of 
22.5 or 45 mg U/kg/day administered from before mating until gestation day 14 were not fetotoxic; 
however, continued dosing during lactation resulted in a significant reduction in pup weight on postnatal 
day 21.  Uranium did not affect developmental landmarks or neuromotor maturation in the pups, but the 
high dose altered learning and memory.  Uranium was also shown to interfere with tooth eruption and 
development in young rats. 
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Since uranium is weakly radioactive, it has been assumed to be potentially carcinogenic at occupational 
levels by NIOSH.  The International Agency for Research on Cancer (IARC) has no classification for 
uranium.  Although significant increases in the occurrence of respiratory tract cancer (predominantly lung 
cancer) have been found in numerous studies of uranium miners, radon progeny in the mines, and not the 
uranium, were clearly identified as the carcinogenic agents.  Exposure to crystalline silica and diesel 
engine exhaust, known human carcinogens, may also have contributed to carcinogenicity of the mine dust 
and their potential contributions have not been evaluated.  Studies of workers at uranium milling or 
nuclear facilities and residents living near uranium mining and milling facilities have not found 
significant increases in cancer mortality associated with uranium exposure.  There are limited data on the 
carcinogenicity of uranium in laboratory animals and no cancer bioassays with adequate numbers of 
animals and multiple concentration/dose levels were identified.  Chronic-duration studies have not 
reported increases in the incidence of malignant tumors in hamsters exposed to 19 mg U/m3 as carnotite 
uranium ore dust for 16 months; monkeys exposed to 5.1 mg U/m3 as uranium dioxide for 5 years; dogs 
exposed to 8–8,815 mg U/kg/day as uranyl nitrate, uranyl fluoride, uranium tetrachloride, uranium 
tetrafluoride, or uranium dioxide for 1 year; or rats exposed to 664–12,341 mg U/kg/day as uranyl nitrate, 
uranium tetrafluoride, or uranium dioxide for 1 year.  The limited number of animals tested and the less-
than-lifetime exposure duration makes these studies less than ideal for evaluating the carcinogenicity of 
uranium.  Several studies have found significant associations between uranium exposure and an increased 
incidence of malignant tumors.  Increases in the incidence of pulmonary neoplasms were observed in 
dogs exposed to 5.1 mg U/m3 as uranium dioxide for 5 years and rats exposed to 8.4 or 22 mg U/m3 as 
uranium ore dust for 65 weeks.  As with the negative carcinogenicity studies, these studies are also 
limited by the small number of animals tested and the less-than-lifetime exposure.  The increases in the 
incidence of lung tumors may have been the result of uranium chemical toxicity, radiation exposure, or 
both.   
 
Depleted Uranium.  Like natural uranium, depleted uranium is primarily composed of 238U, but has a 
smaller amount of 235U and 234U.  Thus, depleted uranium is less radioactive than natural uranium.  
Although, the toxicity of depleted uranium has not been as well studied, the health effects associated with 
exposure to depleted uranium will be the same as natural uranium because the toxicity of natural uranium 
is primarily due to chemical toxicity to uranium rather than uranium radiotoxicity.  Information on the 
toxicity of depleted uranium in humans comes from a series of studies of Gulf War veterans with 
embedded fragments containing depleted uranium.  The studies examined a number of potential targets 
including the liver, kidney, bone, and the hematological, nervous, and reproductive systems.  No 
significant alterations in biomarkers of liver function, bone turnover and metabolism, or hematological 
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function; neuroendocrine hormone levels; or sperm parameters were observed.  Alterations in biomarkers 
of renal function (e.g., urinary retinol binding protein and β2-microglobulin levels) were observed; 
however, the alterations were not statistically significant, as compared to veterans with normal urinary 
uranium levels.  Although poorer performance on neurological tests were observed in Gulf War veterans 
exposed to depleted uranium from embedded fragments, the effects were not consistently observed, and 
were found to be strongly influenced by two subjects with extremely high uranium levels and severely 
complex co-morbid conditions. 
 
A small number of animal studies have examined the toxicity of depleted uranium; these studies focused 
on renal toxicity and neurotoxicity.  As with exposure to natural uranium, alterations in renal function and 
histopathology (swollen glomeruli, necrosis, and fibrosis) were observed in rats exposed to depleted 
uranium via fragments embedded in the gastrocnemius muscle.  Acute exposure to depleted uranyl acetate 
in drinking water resulted in increased motor activity in male rats exposed to 28 mg U/kg/day and female 
mice exposed to 6 mg U/kg/day.  No alterations were observed in tests of spontaneous motor activity in 
rats implanted with up to 20 depleted uranium pellets (approximately 760 mg depleted uranium) for 
150 days.  The difference in the exposure routes and the lack of data on blood and/or brain uranium levels 
from the drinking water studies and implantation study preclude a meaningful comparison of the three 
studies.  No effects on spatial working memory were observed in rats dosed with 2.7 mg U/kg/day as 
depleted uranyl nitrate for 9 months.  Investigators have tried to identify biochemical and morphological 
substrates that, when altered, could explain the behavioral alterations.  Increased motor activity showed a 
weak correlation with increased lipid oxidation in the brain of rats in a 2-week study.  Uranium also 
altered the levels of neurotransmitters and their metabolites in brain areas from mice and rats.  Of various 
brain areas examined, the hippocampus from rats exposed to natural uranium in the drinking water for 
90 days had the most uranium, suggesting that this area may play an important role in the neurobehavioral 
alterations caused by exposure to uranium.  However, alterations in the levels of oxidative stress 
indicators were greater in other regions of the brain with lower uranium concentrations.  Implantation of 
depleted uranium pellets in rats resulted in measurable uranium in the brain at 6–18 months after 
implantation and was accompanied by electrophysiological changes in hippocampal slices from the 
treated animals at 6 and 12 months, but not at 18 months.  The mechanism(s) by which uranium induces 
neurological alterations is not known.   
 
A decrease in the number of small primary ovarian follicles was found in mice exposed to ≥0.00039 mg 
U/kg/day in the drinking water for 30 days prior to breeding, during the mating period, and during 
gestation.  However, all other follicle populations including primordial, secondary/growing, healthy, and 
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atretic were unchanged.  It would be helpful to try to replicate these results because effects were reported 
at considerably lower doses than the adverse effect levels in other studies, effects were only observed in 
one type of follicle population, and the doses were below the detection limit and normal drinking water 
background levels.  Uranium also showed estrogenic properties in mice at very low doses.  Exposure of 
ovariectomized mice to depleted uranyl nitrate at 0.005 mg U/kg/day for 10 days or 0.009 mg U/kg/day 
for 30 days significantly increased uterine weight; an increase in the presence of cornified vaginal cells, 
indicative of an estrogenic effect, was also observed at 0.005 and 0.009 mg U/kg/day.  However, these 
effects were not observed at higher doses (0.09 or 0.9 mg U/kg/day for 30 days).  Again, it would be 
helpful to try to replicate these results observed at such low doses, particularly since the study only found 
effects at the lower doses tested, but not at the higher doses.   
 
Exposure to depleted uranium did not alter the levels of serum testosterone or 17β-estradiol or the 
expression of transcription factors involved in the regulation of steroidogenic genes in male rats in a 
9-month drinking water study.   
 
Information on the carcinogenicity of depleted uranium is limited to an animal study that found an 
increased incidence of malignant fibrous histiocytoma at the depleted uranium implantation site in rats.  
However, an increase in tumors was only observed in the group with the largest implant. 
 
Enriched Uranium.  Enriched uranium is also primarily composed of 238U, 235U, and 234U; however, the 
percentage of 235U is increased to 2–4% (low enriched uranium) and >90% (high enriched uranium).  The 
chemical toxicity of enriched uranium is the same as natural uranium; however, because enriched 
uranium is more radioactive than natural uranium, there is an increased risk of radiotoxicity.  No human 
studies have examined the toxicity of enriched uranium and a limited number of animal studies on 
enriched uranium have been conducted.  The chemical toxicity of uranium is identical to natural and/or 
depleted uranium; however, effects associated with exposure to radiation are also possible.  Two studies 
have compared the toxicity of enriched uranium with that of depleted uranium.  Enriched uranium, but not 
depleted uranium, increased serum testosterone and the expression of genes involved in steroidogenesis in 
male rats in a 9-month drinking water study.  In addition, enriched uranium significantly increased the 
expression of transcription factors involved in the regulation of steroidogenic genes.  These results 
suggested that the observed effects were mainly due to the radiation emitted by enriched uranium.  
Exposure to enriched uranium resulted in increases in the amount of paradoxical sleep and decreases in 
spatial working memory in rats dosed with 2.5–2.7 mg U/kg/day as enriched uranyl nitrate for 9 months.  
However, these effects were not observed in rats similarly exposed to depleted uranium.  An additional 
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study reported delayed hyperactivity and decreased spatial memory in 5- or 9-month-old offspring of rats 
exposed to 4.3 mg U/kg/day as enriched uranyl nitrate in drinking water during gestation.  A 9-month 
drinking water exposure to enriched uranyl nitrate resulted in increased serum testosterone levels in male 
rats.  In addition, enriched uranium significantly increased the expression of transcription factors involved 
in the regulation of steroidogenic genes.  These effects were not observed in rats similarly exposed to 
depleted uranium, suggesting that the observed effects were mainly due to the radiation emitted by 
enriched uranium. 
 
2.3   MINIMAL RISK LEVELS (MRLs) 
 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for uranium.  An 
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate 
methodology does not exist to develop MRLs for dermal exposure. 
 
Although methods have been established to derive MRLs (Barnes and Dourson 1988; EPA 1990, 2012c), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be reevaluated. 
 
Minimal Risk Levels (MRLs) have been derived for the effects from inhalation and oral exposure to 
uranium, and those values are identified in this section and their bases are detailed in Appendix A.  
Although most of the health effects associated with exposure to natural uranium appear to be solely 
chemical in nature and not radiological and the contribution of the radiation toxicity to the overall mode 
of action is not known, the result of any combined chemical and radiological toxicity is accounted for in 
the study results.  The chemical toxicity of depleted uranium is the same as natural uranium; however, the 
radiological toxicity of depleted uranium would be lower than natural uranium due to its lower specific 
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activity.  Since the toxicity of natural uranium is primarily due to chemical toxicity, the MRLs calculated 
for natural uranium are applicable to depleted uranium.  Exposure to enriched uranium is more likely to 
include a radiological component, but the data are limited.  The toxicity of a variety of uranium 
compounds has been investigated in a number of animal species; the results of these studies support the 
findings of the available human studies.  Regardless of the exposure duration or route, the animal data 
provide strong evidence that kidney damage is the principal toxic effect of uranium and that the toxicity 
varies according to solubility of the uranium compound.  Other sensitive end points include the 
respiratory tract following chronic exposure to insoluble uranium compounds and developmental toxicity 
following acute oral exposure to soluble uranium compounds.  The more soluble uranium compounds 
(uranium hexafluoride, uranium tetrachloride, uranyl fluoride, uranyl nitrate) have the highest renal 
toxicity, followed by the less soluble compounds (ammonium diuranate, sodium diuranate, uranium 
tetrafluoride) and the insoluble uranium compounds (uranium dioxide, uranium trioxide, uranium 
peroxide, triuranium octaoxide).  The difference in toxicity is due to the easier absorption of soluble 
compounds from the lung or gastrointestinal tract into the blood and distribution to other tissues 
(Tannenbaum et al. 1951).  The more insoluble uranium compounds have a greater potential for long-term 
respiratory toxicity due to long retention of the compound in the lung and may be due to chemical and/or 
radiological toxicity. 
 
ATSDR has determined that the toxicity database for uranium justifies the derivation of separate MRLs 
for soluble and insoluble forms of uranium for certain durations and routes of exposure.  This is based on 
toxicokinetic evidence that absorption of uranium (and concentration in target tissue) is significantly 
greater during exposure to the more water-soluble compounds.  Where the database is not extensive 
enough to allow separate MRLs, the MRL for the soluble form should be protective for health effects due 




Acute-Duration Inhalation MRL 
 
There are limited data on the toxicity of uranium compounds in humans and animals following acute-
duration inhalation exposure.  Several case reports of individuals briefly exposed to uranium hexafluoride 
(Kathren and Moore 1986; USNRC 1986) or uranium tetrafluoride (Lu and Zhao 1990) are available.  
The observed effects included eye irritation and respiratory irritation, chemical burns, renal toxicity, and 
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gastrointestinal irritation; however, some of these effects may have been caused by the rapid release of 
hydrogen fluoride when uranium hexafluoride reacted with water in the air and mucous membranes. 
 
Respiratory and renal effects have been observed in acutely exposed laboratory animals.  Severe alveolar 
septal fibrosis was observed in rats exposed to 5,051 mg U/m3 as enriched uranium dioxide for 
100 minutes (Morris et al. 1990) and gasping and nasal irritation were observed in mice exposed to 
637 mg U/m3 as uranium hexafluoride for 10 minutes (Spiegl 1949).  The renal effects included 
proteinuria and glucosuria in rats exposed to 426 mg U/m3 for 10 minutes or 1,430 mg U/m3 for 2 minutes 
as uranium hexafluoride (Leach et al. 1984) or in guinea pigs exposed to 23,040 mg U/m3 as uranium 
hexafluoride for 2 minutes (Leach et al. 1984). 
 
The available data were not considered adequate for derivation of an acute-duration inhalation MRL for 
uranium; the human studies did not reliably report exposure levels and the animal studies involved very 
short (<2 hours) exposure durations.  Using one of the short exposure animal studies to derive an MRL 
may not be protective for continuous exposure for 2 weeks; longer-term animal studies with serial 
sacrifices (Stokinger et al. 1953) reported renal lesions following 3 days of exposure to soluble uranium 
compounds.  These data are poorly reported and involved very small number of animals and are not 
suitable for MRL derivation. 
 
Intermediate-Duration Inhalation MRL 
 
• An MRL of 0.002 mg U/m3 has been derived for intermediate-duration inhalation exposure (15–
364 days) to insoluble compounds of uranium. 
 
Intermediate-duration inhalation studies in animals have examined the toxicity of various insoluble 
uranium compounds including uranium dioxide, uranium peroxide, uranium trioxide, and triuranium 
octaoxide in several animal species.  The results of these studies suggest that the kidney and the 
respiratory tract are sensitive targets of uranium toxicity, with the kidney being the most sensitive target.  
A summary of the adverse effect levels for renal effects identified in reliable intermediate duration studies 
is presented in Table 2-1.  Renal effects were observed at ≥8.2 mg U/m3; the severity of the lesions was 
concentration-related.  Very slight tubular lesions were observed in dogs exposed to 8.2 mg U/m3, and 
mild to severe necrosis was observed in rats, rabbits, and dogs exposed to 16 mg U/m3.  Although there 
are limited data to make species comparisons, data for uranium dioxide suggest that rabbits are more 
sensitive than rats, mice, or guinea pigs; the data do not allow for a comparison between rabbits and dogs.  
In addition to the renal effects observed in rats, rabbits, and dogs exposed to uranium trioxide, very slight  
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Table 2-1.  Renal Effects Following Intermediate-Duration Inhalation Exposure to 






(mg U/m3) Effect Reference 
Uranium dioxide 
 Rat 5 weeks 19.4   Rothstein 1949b 
 Mouse 5 weeks 19.4   Rothstein 1949b 
 Rabbit 5 weeks  19.4 Marked tubular necrosis Rothstein 1949b 
 Rabbit 7 months 10   Stokinger et al. 1953 
 Guinea pig 5 weeks 19.4   Rothstein 1949b 
 Guinea pig 7 months 10   Stokinger et al. 1953 
 Dog 5 weeks 1.1 8.2 Very slight tubular injury Rothstein 1949b 
Uranium peroxide 
 Rabbit 23 days  15.4 Moderate necrosis Dygert 1949d 
Uranium trioxide 
 Rat 4 weeks  16 Mild to severe necrosis Rothstein 1949c 
 Rabbit 4 weeks  16 Mild to severe necrosis Rothstein 1949c 
 Dog 4 weeks  16 Mild to severe necrosis Rothstein 1949c 
Triuranium octaoxide 
 Rat 26 days 14   Dygert 1949c 
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pulmonary lesions were observed in dogs and rats exposed to 16 mg U/m3 and severe effects were 
observed in rabbits dying early after exposure to 16 mg U/m3 (Rothstein 1949c). 
 
The lowest LOAEL for renal or pulmonary effects following intermediate-duration exposure to an 
insoluble uranium compound was 8.2 mg U/m3 identified in dogs exposed to uranium dioxide for 5 weeks 
(Rothstein 1949b).  In this study, groups of 6–19 dogs of unspecified strain and gender were exposed to 
1.3, 9.3, or 10.4 mg/m3 uranium dioxide (1.1, 8.2, or 9.2 mg U/m3) 6 days/week for 5 weeks, presumably 
for 6 hours/day.  The following parameters were used to assess toxicity: mortality, body weight changes, 
standard hematology, clinical chemistry, urinalysis, and histopathology.  No dogs died from exposure to 
uranium dioxide dust.  Additionally, no alterations in body weight gain or hematology, serum clinical 
chemistry, or urinalysis parameters were noted.  Histopathological alterations were limited to the kidneys; 
“very slight” renal tubular degeneration was observed in two of six dogs at 8.2 mg U/m3.  No alterations 
were observed in two dogs examined from the 9.2 mg U/m3 group.  The results of this study are supported 
by the findings of slight to mild tubular degeneration in dogs exposed to 10 mg U/m3 as uranium dioxide 
for 1 year; no effects were observed at 1 mg U/m3 (Stokinger et al. 1953). 
 
Benchmark dose (BMD) modeling was not used to estimate the point of departure due to the limited 
reporting of incidence data.  The no-observed-adverse-effect level (NOAEL) of 1.1 mg U/m3 was used to 
derive the MRL.  This value was adjusted for intermittent exposure (6 hours/24 hours, 6 days/7 days) 
resulting in a NOAELADJ of 0.24 mg U/m3.  Because regional deposited dose ratios (RDDRs) are not 
available for dogs, dosimetric adjustments could not be made; thus, the NOAELADJ was used as the point 
of departure.  The NOAELADJ was divided by an uncertainty factor of 100 (10 for extrapolation from 
animals to humans and 10 for human variability), resulting in an intermediate-duration inhalation MRL of 
0.002 mg U/m3 for insoluble uranium compounds. 
 
• An MRL of 0.0001 mg U/m3 has been derived for intermediate-duration inhalation exposure (15–
364 days) to soluble compounds of uranium. 
 
Intermediate-duration inhalation studies in animals have identified the kidney and lung as the most 
sensitive targets of toxicity following inhalation exposure to soluble or poorly soluble uranium 
compounds.  The renal toxicity of various uranium compounds in several animal species is summarized in 
Table 2-2.  These data demonstrate that the soluble uranium compounds are more toxic than the poorly 
soluble compounds, dogs, rabbits, and possibly rats are the most sensitive species tested, and guinea pigs 
are the least sensitive. 
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Table 2-2.  Renal Effects Following Intermediate-Duration Inhalation Exposure to 






(mg U/m3) Effect Reference 
Uranium hexafluoride 
 Rat 30 days 0.05 0.2 Mild tubular damage Spiegl 1949 
 Mouse 30 days 2 13.3 Severe degeneration, 
necrosis 
Spiegl 1949 
 Rabbit 9 months  0.2 Very mild tubular injury Stokinger et al. 1953 
 Guinea pig 30 days  13.3 Severe degeneration, 
necrosis 
Spiegl 1949 
 Guinea pig 9 months 0.05   Stokinger et al. 1953 
 Dog 30 days 0.05 0.2 Mild tubular regeneration Spiegl 1949 
Uranyl fluoride 
 Rat 5 weeks 0.5 2.2 Minimal degeneration Rothstein 1949a 
 Guinea pig 5 weeks 2.2 9.2 Severe degeneration Rothstein 1949a 
 Dog 5 weeks  0.15 Very slight degeneration Rothstein 1949a 
Uranyl nitrate 
 Rat 30 days  0.13 Slight degeneration Roberts 1949 
 Rabbit 6.5 months  0.25 Mild tubular atrophy Stokinger et al. 1953 
 Guinea pig 6.5 months 2   Stokinger et al. 1953 
 Dog 30 days  0.13 Proteinuria Roberts 1949 
Uranium tetrachloride 
 Rabbit 7.5 months 0.2   Stokinger et al. 1953 
 Guinea pig 7.5 months 0.2   Stokinger et al. 1953 
Sodium diuranate 
 Rat 5 weeks  15 Moderate degeneration, 
necrosis 
Rothermel 1949 
 Rabbit 5 weeks  15 Degeneration, necrosis Rothermel 1949 
Ammonium diuranate 
 Rat 30 days  6.8 Minimal necrosis Dygert 1949b 
 Rabbit 30 days  6.8 Severe necrosis Dygert 1949b 
Uranium tetrafluoride 
 Rat 30 days 4 18 Slight azotemia Dygert 1949a 
 Rabbit 9 months 3   Stokinger et al. 1953 
 Guinea pig 30 days 4 18 Moderate-severe 
necrosis 
Dygert 1949a 
 Guinea pig 9 months 3   Stokinger et al. 1953 
 Dog 30 days 0.5 3 Very slight degeneration Dygert 1949a 
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In addition to the renal effects, pulmonary toxicity has been observed in animals particularly after 
exposure to uranium hexafluoride.  Exposure to 2 mg U/m3 for 30 days resulted in severe pulmonary 
edema in rabbits and slight pneumonia in dogs (Spiegl 1949).  At higher concentrations (13.3 mg U/m3), 
lung edema, hemorrhage, and emphysema were observed in rats, rabbits, and guinea pigs (Spiegl 1949).  
Since uranium hexafluoride is readily hydrolyzed to uranyl fluoride and hydrogen fluoride and hydrogen 
fluoride is a strong respiratory irritant resulting in pulmonary edema, it is likely that the observed 
respiratory effects are due to the hydrogen fluoride exposure.  Respiratory effects have also been observed 
in rabbits and rats exposed to 6.8 mg U/m3 as ammonium diuranate (Dygert 1949b).  In rabbits, 
ammonium diuranate exposure (6.8 mg U/m3) resulted in extensive respiratory tract irritation, evidence 
by nasal bleeding and pulmonary edema, hemorrhage, and necrosis.  Respiratory irritation (nasal bleeding 
and interstitial bronchopneumonia) was also observed in rats exposed to 6.8 mg U/m3.  It is possible that 
these effects were secondary to the release of the ammonium ion, rather than uranium toxicity.  
Respiratory effects have not been consistently observed following exposure to other uranium compounds. 
 
As presented in Table 2-2, dogs are the most sensitive species to the renal toxicity of uranium 
compounds.  The lowest LOAEL values identified in dogs are 0.13 mg U/m3 as uranyl nitrate for 
proteinuria (Roberts 1949) and 0.15 mg U/m3 as uranyl fluoride for tubular damage (Rothstein 1949a).  In 
the Roberts (1949) study, an increase in urinary protein excretion was observed between days 9 and 12 
and then returned to normal; very mild histological changes, which the investigator noted were not of 
sufficient severity to be of concern, were observed in the renal cortex in two dogs exposed for 10 days.  
Since the two LOAEL values are almost identical, the Rothstein (1949a) study was selected as the basis 
of the MRL because it included histological examination of dogs exposed for an intermediate duration 
(the one dog examined at the end of the Roberts study had severe chronic nephritis, which precluded 
observing any possible uranium-induced renal effects).  Although the lowest LOAEL value in rats 
(0.13 mg U/m3) was similar to the lowest LOAEL values in dogs, the intermediate and chronic databases 
for soluble uranium compounds provide strong evidence that dogs are more sensitive than rats.  In the 
Rothstein (1949a) study, groups of 2–6 dogs (strain and gender not specified) were exposed to 0.19, 2.8, 
or 12.2 mg/m3 of uranyl fluoride dust (0.15, 2.2, or 9.2 mg U/m3) for 6 hours/day, 6 days/week for 
5 weeks.  Clinical signs of toxicity, mortality, body weight changes, hematology, and blood and urine 
chemistries were monitored.  At the termination of the study, the animals were sacrificed, selected organs 
were histopathologically examined, and uranium levels were determined.  Anorexia, rhinitis, and 
polydipsia were observed in the two dogs exposed to 9.2 mg U/m3; prior to death, vomiting blood, severe 
muscle weakness, and exhibited lassitude were observed.  No deaths or clinical signs were observed at 
0.15 or 2.2 mg U/m3.  Severe weight loss was also observed at 9.2 mg U/m3; no alterations in body weight 
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gain were observed at 0.15 or 2.2 mg U/m3.  At 9.2 mg U/m3, both dogs had increased blood nonprotein 
nitrogen (NPN) levels with the maximum value over 200 mg%.  At 2.2 mg U/m3, blood NPN and urinary 
amino acid levels were normal while one of three dogs had increased urinary protein levels.  At 9.2 mg 
U/m3, severe renal damage was seen in dogs.  Moderate renal damage (no additional information 
provided) was observed at 2.2 mg U/m3 and very slight damage was observed in about 50% of the dogs at 
0.15 mg U/m3. 
 
A NOAEL/LOAEL approach was used to identify the point of departure for the MRL; BMD modeling 
was not used because incidence data were not available for all groups.  The LOAEL of 0.15 mg U/m3 for 
minimal renal lesions was used to derive the MRL.  This value was adjusted for intermittent exposure 
(6 hours/24 hours, 6 days/7 days) resulting in a LOAELADJ of 0.032 mg U/m3.  Because RDDRs are not 
available for dogs, dosimetric adjustments could not be made; thus, the LOAELADJ was used as the point 
of departure.  The LOAELADJ was divided by an uncertainty factor of 300 (3 for the use of a minimal 
LOAEL, 10 for extrapolation from animals to humans, and 10 for human variability), resulting in an 
intermediate-duration inhalation MRL of 0.0001 mg U/m3 for soluble uranium compounds. 
 
Chronic-Duration Inhalation MRL 
 
• An MRL of 0.0008 mg U/m3 has been derived for chronic-duration inhalation exposure (365 days 
or more) to insoluble compounds of uranium. 
 
There are limited data available to assess the toxicity of chronic exposure to insoluble uranium 
compounds.  Slight to mild renal tubular degeneration was observed in dogs exposed to 10 mg U/m3 as 
uranium dioxide for 1 year (Stokinger et al. 1953); no alterations were observed at 1 mg U/m3.  Although 
several tissues were examined histologically, significant alterations were only noted for the kidneys.  
Stokinger et al. (1953) also exposed rats to 1 or 10 mg U/m3 as uranium dioxide, but no uranium-related 
alterations were observed.  In a second chronic-duration study, no adverse effects were observed in rats or 
dogs exposed to 5.1 mg U/m3 as uranium dioxide for 1–5 years (Leach et al. 1970).  However, fibrosis in 
the tracheobronchial lymph nodes and fibrosis and metaplasia in the lungs were observed in dogs during a 
6.5-year postexposure period (Leach et al. 1973).  In monkeys, exposure to 5.1 mg U/m3 resulted in lung 
fibrosis beginning after 3.6 years of exposure (Leach et al. 1970); the severity of the fibrosis increased 
with exposure duration.  Fibrosis was also present in the lungs and tracheobronchial lymph nodes in 
monkeys sacrificed during the 6.5-year postexposure period (Leach et al. 1973).  The investigators noted 
that the fibrosis may have been a radiotoxic effect based on the magnitude of the radiation dose, the 
absence of renal effects, and the similarity of the lesions to those observed following exposure to 
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plutonium dioxide; the alpha-radiation tissue doses were >500 rad (5 Gy) for the lungs and 7,000 rad 
(70 Gy) for the lymph nodes.  However, it is unclear whether the damage was chemically or 
radiologically induced (or both); similar degenerative effects in the lungs have also been observed 
following prolonged exposure to diverse inorganic dusts.  An elevation of blood NPN level was also 
observed in the monkeys during the postexposure period, but no histological alterations were observed in 
the kidneys (Leach et al. 1973). 
 
Rhesus monkeys (5 males, 20 females) were exposed to 5.8 mg/m3 uranium dioxide (5.1 mg U/m3) 
5.4 hours/day, 5 days/week for 5 years; the mass median particle diameter was 1.03 µm with a geometric 
standard deviation of 2.40.  Another group of one male and five female monkeys served as controls.  
Groups of 1–2 monkeys were sacrificed after 1 day, 4 days, 15 days, 1 month, 2 months, 3 months, 
5 months, 1 year, 1.5 years, 1.8 years, 1.9 years, 3.6 years, 4.1 years, or 4.7 years; two monkeys were 
sacrificed at 5 years.  Six monkeys were observed for 6.5 years after exposure termination; two were 
sacrificed after 12 months, one after 6 years, and three after 6.5 years; the results of the recovery period 
examinations were reported in Leach et al. (1973).  The following parameters were used to assess 
toxicity:  general health, body weight, peripheral hematology, blood NPN levels, and histopathology of 
major tissues and organs.  No uranium dioxide-related deaths were observed.  No alterations in body 
weight, hematological parameters, or blood NPN levels were found.  Histological alterations were limited 
to the lungs and tracheobronchial lymph nodes.  After 2–3 months of exposure, granular black pigment 
accumulations were found in the lungs and tracheobronchial lymph nodes.  After 3.6 years of exposure, 
slight fibrosis was observed in the lungs and hyaline fibrosis was observed in the tracheobronchial lymph 
nodes; the severity of the fibrosis increased with exposure duration and was not observed in the controls.  
Fibrosis was still present in the lungs and tracheobronchial lymph nodes 6.5 years postexposure. 
 
The LOAEL of 5.1 mg U/m3 was selected as the point of departure for the MRL; BMD modeling was not 
used due to the small number of animals sacrificed at each time period.  The LOAEL was adjusted for 
intermittent exposure (5.4 hours/24 hours, 5 days/7 days) resulting in a LOAELADJ of 0.82 mg U/m3.  
Because RDDRs are not available for monkeys, dosimetric adjustments could not be made; thus, the 
LOAELADJ was used as the point of departure.  The LOAELADJ was divided by an uncertainty factor of 
1,000 (10 for the use of a LOAEL, 10 for extrapolation from animals to humans, and 10 for human 
variability), resulting in a chronic-duration inhalation MRL of 0.0008 mg U/m3 for insoluble uranium 
compounds.  A full uncertainty factor of 10 was used for extrapolation from monkeys to humans because 
no data were available to make dosimetric adjustments (pharmacokinetic component of uncertainty 
factor) and there are inadequate human data to assess potential differences in sensitivity between monkeys 
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and humans (pharmacodynamic component of uncertainty factor).  A wide range of sensitivity has been 
found in animal species, but it is not known where humans would fall in the range of sensitivity. 
 
• An MRL of 0.00004 mg U/m3 has been derived for chronic-duration inhalation exposure 
(365 days or more) to soluble compounds of uranium. 
 
There are limited human data on the chronic toxicity of soluble uranium.  Thun et al. (1985) examined 
uranium mill workers exposed to yellowcake (26–86% ammonium diuranate), which was considered 
biologically soluble, for at least 1 year.  Significant increases in urinary excretion of β2-microglobulin and 
amino acids were observed in the uranium workers suggesting impaired renal tubular function.  Clearance 
of β-2-microglobulin relative to that of creatinine was significantly associated with the length of time that 
the uranium workers had spent in the yellowcake area.  Although urinary uranium levels were reported, 
atmospheric concentrations were not reported. 
 
Stokinger et al. (1953) examined the chronic toxicity of uranium hexafluoride, uranium tetrachloride, and 
uranyl nitrate in dogs and rats following a 1-year exposure.  Slight to mild renal tubular atrophy was 
observed in dogs and rats exposed to 0.2 mg U/m3 as uranium hexafluoride or uranium tetrachloride; no 
effects were observed at 0.05 mg U/m3.  Exposure to uranyl nitrate resulted in mild to moderate tubular 
atrophy in dogs exposed to 0.25 mg U/m3 (NOAEL of 0.15 mg U/m3) and mild to marked tubular atrophy 
in rats exposed to 2 mg U/m3 (NOAEL of 0.25 mg U/m3). 
 
The chronic-duration inhalation MRL for soluble uranium compounds was based on a 1-year dog study 
involving exposure to uranium tetrachloride (Stokinger et al. 1953).  In this study, dogs of both sexes 
(11–12 males, 9–10 females) were exposed to uranium tetrachloride in inhalation chambers for 
33 hours/week for 1 year at concentrations of 0.05, and 0.20 mg U/m3.  The animals were monitored for 
body weight alterations, clinical signs of toxicity, and biochemical alterations in the blood and urine.  At 
the termination of the study, the animals were sacrificed and selected organs were histopathologically 
examined.  All dogs survived the 1-year exposure period.  No alterations in body weight gain, 
hematological parameters, or blood NPN levels were observed.  Urinary protein levels were elevated, as 
compared to controls; however, pre-exposure levels were also elevated, precluding evaluating the clinical 
significance of the effect.  Alterations in bromsulfalein retention test, indicating impaired liver function, 
were observed in the four dogs tested (0.2 mg U/m3 group); no alterations in blood clotting times were 
observed.  In the absence of histological evidence of liver damage, the change was not considered 
clinically significant.  Renal tubular atrophy was observed in 2/16 dogs exposed to 0.05 mg U/m3 (not 
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statistically significant using Fisher Exact test).  Slight tubular atrophy in the inner cortex was observed in 
7/14 dogs exposed to 0.2 mg U/m3. 
 
Data for the incidence of renal tubular atrophy were analyzed using all available dichotomous models in 
the EPA Benchmark Dose Software (BMDS, version 2.1.2) using the extra risk option; details of the 
BMD modeling are presented in Appendix A.  The benchmark concentrations (BMCs) ranged from 
0.032 to 0.082 mg U/m3 and the 95% lower confidence limits on the BMCs (BMCLs) ranged from 
0.019 to 0.054 mg U/m3.  A BMCL10 of 0.019 mg U/m3 was selected as a point of departure because it 
was estimated from the model providing the best fit to the incidence data.  The BMCL10 was adjusted for 
intermittent exposure (33 hours/168 hours) resulting in a BMCLADJ of 0.0037 mg U/m3.  Because RDDRs 
are not available for dogs, dosimetric adjustments could not be made; thus, the BMCLADJ was used as the 
point of departure.  The BMCLADJ was divided by an uncertainty factor of 100 (10 for extrapolation from 
animals to humans and 10 for human variability), resulting in a chronic-duration inhalation MRL of 




Acute-Duration Oral MRL 
 
• An MRL of 0.002 mg U/kg/day has been derived for acute-duration oral exposure (≤15 days) to 
soluble compounds of uranium. 
 
There are limited human data on the oral toxicity of uranium.  Signs of gastrointestinal irritation (nausea, 
vomiting, diarrhea) were observed in a subject ingesting 14.3 mg U/kg as uranyl nitrate in drinking water 
(Butterworth 1955); other potential targets of toxicity were not examined.  Acute oral exposure studies in 
rats and mice have examined the lethality, systemic toxicity, neurotoxicity, and developmental toxicity of 
uranium.  Information on the systemic toxicity is limited to two single-exposure toxicity study in rats 
(Domingo et al. 1987) and mice (Martinez et al. 2003) administered lethal doses and a repeated exposure 
study in mice (Ozmen and Yurekli 1998).  In the 2 weeks following administration of a single gavage 
dose of 118 mg U/kg as uranyl acetate to rats, significant increases in urine volume (in the absence of 
changes in water consumption), plasma creatinine and urea, and urinary total protein and creatinine were 
observed; hyperemia and microhemorrhagic foci were also observed in the liver and kidneys at the end of 
the 2-week observation period (Domingo et al. 1987).  In mice, administration of 166 mg U/kg as uranyl 
nitrate resulted in increases in blood urea and creatinine levels and proximal tubular necrosis (Martinez et 
al. 2003).  Similarly, significant increases in BUN and creatinine levels were observed in mice exposed to 
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508 mg U/kg/day as uranyl acetate in the diet for 5 days (Ozmen and Yurekli 1998); the study did not 
include a histological examination of the kidney or other tissues.  Neurological effects consisted of 
increased open field activity (line crossing and/or rearing) (Briner 2009; Briner and Murray 2005) in mice 
administered 28 or 6 mg U/kg/day as depleted uranyl acetate in drinking water for 2 weeks; exposure to 
28 mg U/kg/day also resulted in a 53% decrease in body weight gain.  Gestational exposure to ≥2.8 mg 
U/kg/day as uranyl acetate resulted in significant decreases in fetal body weights and increases in the 
occurrence hematomas in the fetuses of mice exposed on gestation days 6–15 (Domingo et al. 1989c); 
increases in the incidence of cleft palate were observed at ≥5.6 mg U/kg/day.  Decreases in maternal body 
weight gain were observed at ≥2.8 mg U/kg/day.  Exposure of neonatal rats (1 or 7 days of age) to 
42.7 mg U/kg/day as uranyl nitrate administered via gavage in water, resulted in significant reductions in 
bone formation, increases in bone resorption, and diminished tooth development (Pujadas Bigi et al. 
2003). 
 
The available data provide evidence that the gastrointestinal tract, kidney, and developing organisms are 
target of uranium toxicity following acute oral exposure.  Longer duration oral studies and inhalation 
studies identify the kidney as the most sensitive target of toxicity.  The Domingo et al. (1989c) 
developmental toxicity study identified the lowest LOAEL (2.8 mg U/kg/day) and was selected as the 
basis of acute-duration oral MRL.  In this study, groups of 20 pregnant Swiss mice were administered via 
gavage 0, 5, 10, 25, or 50 mg/kg/day uranyl acetate dihydrate (0, 2.8, 5.6, 14, or 28 mg U/kg/day) on 
gestation days 6–15.  Body weights, food consumption, and general appearance were monitored daily.  At 
termination, maternal liver and kidney weights were measured and uterine contents (number of 
implantation sites, resorptions, dead fetuses, and live fetuses) were evaluated.  Live fetuses were 
evaluated for body weight, body length, sex, gross morphological abnormalities, visceral malformations, 
visceral anomalies, and skeletal defects.  Significant decreases in maternal body weight were observed in 
all uranium groups; during the exposure period, the dams in the 2.6, 5.6, 14, and 28 mg U/kg/day groups 
weighed 33, 53, 75, and 88% less than controls, respectively.  Significant decreases in food intake were 
also observed in the dams exposed to 5.6 mg U/kg/day and higher.  A significant decrease in the number 
of live fetuses was observed at 5.6 mg U/kg/day, but was not observed at the two higher dose levels.  No 
significant alterations in the number of early or late resorptions, number of dead fetuses, or sex ratio were 
observed.  Significant decreases in fetal body weight were observed at ≥2.8 mg U/kg/day and decreases in 
fetal length were observed at ≥5.6 mg U/kg/day.  Significant increases in the incidences of external 
defects were observed at 2.8 mg U/kg/day.  The external alterations included cleft palate (significant at 
≥5.6 mg U/kg/day) and hematomas (significant at 2.8 and 28 mg U/kg/day).  The total number of skeletal 
defects was significantly increased at 14 and 28 mg U/kg/day; skeletal defects included bipartite 
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sternebrae (significant at 2.8, 14, and 28 mg U/kg/day), some metatarsal of hindlimb poorly ossified 
(significant at 14 and 28 mg U/kg/day), delayed ossification of skull (significant at 14 and 28 mg 
U/kg/day), and caudal reduced ossification (significant at 14 and 28 mg U/kg/day). 
 
The results of the Domingo et al. (1989c) study suggest maternal body weight gain and fetal body weight 
and external and skeletal alterations as sensitive end points of uranium toxicity.  It is possible that the 
developmental effects were secondary to the maternal toxicity; however, some of these effects may also 
be primary effects of uranium on the developing fetus.  Thus, maternal and fetal end points were 
considered as the basis of possible points of departure for the acute-duration MRL.  BMD modeling was 
used to identify potential points of departure for maternal and fetal effects.  As described in greater detail 
in Appendix A, the number of litters with cleft palate, bipartite sternebrae, and total skeletal defects were 
analyzed using all available dichotomous models in the EPA BMDS (version 2.1.2) using the extra risk 
option and a benchmark response rate of 5%.  The results of the BMD modeling are presented in 
Appendix A.  The fetal body weight data and maternal body weight gain data were fit to all available 
continuous models in EPA’s BMDS (version 2.1.2); however, none of the models provided an adequate 
fit to either data set. 
 
The BMDL05 values for cleft palate, bipartite sternebrae, and total skeletal defects were 0.20, 0.42, and 
0.25 mg U/kg/day, respectively.  The BMDL05 of 0.20 mg U/kg/day for cleft palate was selected as the 
point of departure; this point of departure is lower than the BMDL05 values for other fetal effects and is 
approximately 10-fold lower than the LOAEL for maternal and fetal body weight effects.  Thus, it is 
likely to be protective of the other effects.  The 0.2 mg U/kg/day point of departure was divided by an 
uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability) 
resulting in an acute-duration oral MRL of 0.002 mg U/kg/day. 
 
Intermediate-Duration Oral MRL 
 
• An MRL of 0.0002 mg U/kg/day has been derived for intermediate-duration oral exposure (15–
364 days) to soluble compounds of uranium. 
 
No studies have been identified that examined the toxicity of uranium in humans following an 
intermediate-duration oral exposure.  A number of studies have examined the intermediate-duration oral 
toxicity of uranium in laboratory animals.  Most of these studies involved exposure to soluble uranium 
compounds such as uranyl nitrate and uranyl acetate; there are limited data on poorly soluble or insoluble 
uranium compounds.  The available data suggest that the kidney is the most sensitive target of uranium 
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toxicity; at higher dose levels, neurological, reproductive, and developmental effects have been reported.  
At lower concentrations, histological alterations have been observed in the proximal tubules, glomerulus, 
and/or renal interstitium in rats and mice exposed to uranyl nitrate in drinking water (Gilman et al. 1998a, 
1998b, 1998c; McDonald-Taylor et al. 1992, 1997).  At higher concentrations (40.38 mg U/kg/day), 
evidence of renal dysfunction (e.g., glycosuria, proteinuria) have also been observed (Gilman et al. 
1998c).  The Gilman et al. (1998a, 1998b) studies identified LOAELs of 0.06 and 0.05 mg U/kg/day for 
renal effects in rats and rabbits, respectively; neither study identified NOAEL values. 
 
The LOAELs for neurological, reproductive, and developmental effects are similar and are about 50-fold 
higher than the LOAEL for renal effects.  Neurological effects such as sleep and behavior alterations and 
decreased spatial memory were observed in rats exposed to 2.5–2.7 mg U/kg/day as enriched uranyl 
nitrate (Houpert et al. 2005, 2007b).  However, no neurological effects were observed in rats similarly 
exposed to the same dose of depleted uranyl nitrate (Houpert et al. 2005).  The investigators suggest that 
the observed effects may have been related to radiation toxicity.  The reproductive effects consisted of 
decreases in male fertility in rats and mice following exposure to ≥5.6 mg U/kg/day as uranyl acetate 
(Linares et al. 2005; Llobet et al. 1991) and alterations in ovarian folliculogenesis in mice at ≥1.25 mg 
U/kg/day as uranyl nitrate (Arnault et al. 2008; Feugier et al. 2008; Kundt et al. 2009).  A recent study by 
Raymond-Whish et al. (2007) also reported alterations in ovarian folliculogenesis in mice, but the effects 
were at an extremely low dose (0.00039 mg U/kg/day).  Additional data are needed to support whether 
reproductive effects occur at this dose level and to evaluate the toxicological significance of the observed 
effect (reduced number of small primary follicles, but no effect on primordial, secondary/growing, 
healthy, or atretic follicle populations).  Developmental effects have been observed in rats and mice; most 
effects occurred at maternally toxic doses.  The observed effects included neurobehavioral effects in the 
offspring of rats exposed premating and during gestation and lactation to 4.3 mg U/kg/day as enriched 
uranyl nitrate (Houpert et al. 2007a), decreases in pup body weight at ≥2.8 mg U/kg/day as uranyl acetate 
(Paternain et al. 1989; Sánchez et al. 2006), decreases in litter size, live fetuses, or viability at ≥14 mg 
U/kg/day as uranyl acetate (Domingo et al. 1989b; Paternain et al. 1989), and altered ovarian 
folliculogenesis in 3-month-old pups of dams exposed to 1.25 mg U/kg/day as uranyl nitrate (Arnault et 
al. 2008). 
 
The LOAELs of 0.05 and 0.06 mg U/kg/day for kidney effects in rats and rabbits (Gilman et al. 1998a, 
1998b) were considered as possible points of departure for an intermediate-duration oral MRL for soluble 
uranium compounds.  Although the rabbit study identified the slightly lower LOAEL, the rat LOAEL was 
selected as the point of departure for the MRL due to possible subclinical infection in the rabbits.  Gilman 
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et al. (1998b, 1998c) conducted two 91-day studies in rabbits.  The kidney uranium levels for the two 
studies were not comparable; rabbits in the first study (Gilman et al. 1998b) had higher kidney uranium 
levels than in the second study (Gilman et al. 1998c) even though the dose was lower in the first study 
(28.70 mg U/kg/day dose and 4.98 µg U/g kidney level in the Gilman et al. 1998b study compared to 
40.98 mg U/kg/day dose and 3.48 µg U/g kidney level in the Gilman et al. 1998c study).  In the Gilman et 
al. (1998b) study, the male rabbits were not SPF derived and four animals developed Pasteurella 
multocida infections during the study; Gilman et al. (1998c) suggested that even though the affected 
rabbits were removed from the study, it is possible that other animals had a subclinical infection and that 
this may have increased sensitivity.  Thus, the rat study was selected as the basis of the MRL; the rats 
used in the Gilman et al. (1998a) study were SPF derived.  The Raymond-Whish et al. (2007) study was 
not selected as the point of departure because there are no other data to support this extremely low value 
and the toxicological significance of this slight change in one follicle population is not known. 
 
In the Gilman et al. (1998a) study, five groups of Sprague-Dawley rats (15/sex/dose, 60 g) were exposed 
to uranium as uranyl nitrate in drinking water (0, 0.96, 4.8, 24, 120, and 600 mg/L) for 91 days.  Time-
weighted average doses (as mg U/kg/day) calculated by the authors from fluid intake data were 
<0.0001 (control group), 0.06, 0.31, 1.52, 7.54, and 36.73 mg U/kg/day in males and <0.0001 (controls), 
0.09, 0.42, 2.01, 9.98, and 53.56 mg U/kg/day in females.  Clinical signs were monitored daily and body 
weights were measured weekly; fluid intake and feed consumption were also measured, but the frequency 
was not reported.  Hematological and serum clinical chemistry parameters, organ weights, and 
histopathology examination of major tissues and organs were assessed at termination.  Hematological and 
biochemical parameters were not affected in a significant exposure-related manner.  Statistically 
significant increases in renal lesions included cytoplasmic vacuolization, tubular dilation, and lymphoid 
cuffing in males at ≥0.06 mg U/kg/day; capsular sclerosis, tubular anisokaryosis, and interstitial reticulin 
sclerosis in females at ≥0.09 mg U/kg/day; nuclear vesiculation in males and females at ≥0.06/0.09 mg 
U/kg/day; and glomerular adhesions and cytoplasmic degeneration in males at ≥0.31 mg U/kg/day.  
Lesions were also observed in the liver at all doses including anisokaryosis, vesiculation, increased portal 
density, perivenous vacuolation, and homogeneity; the investigators considered these adaptive and likely 
reversible.  Thyroid lesions were observed in both sexes (multifocal reduction of follicular size, increased 
epithelial height in males at 0.31 mg/kg/day and females at 2.01 mg/kg/day).  A decreased amount and 
density of colloid in the thyroid was observed in males only.  Sinus hyperplasia of the spleen was 
observed in males and females at 36.73/53.56 mg/kg/day. 
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An attempt was made to fit the incidence data to BMD models; however, none of the models provided an 
adequate fit.  Thus, a NOAEL/LOAEL approach was used to derive the MRL.  The LOAEL value of 
0.06 mg U/kg/day for renal effects in rats (Gilman et al. 1998a) was divided by an uncertainty factor of 
300 (3 for the use of a minimal LOAEL, 10 for animals to human extrapolation, and 10 for human 
variability) resulting in an intermediate-duration oral MRL of 0.0002 mg U/kg/day for soluble uranium 
compounds.  A partial uncertainty factor was used to extrapolate from a LOAEL because the histological 
alterations observed at 0.06 mg U/kg/day were considered minimally adverse. 
 
There are inadequate data to derive an MRL for insoluble uranium compounds (e.g., uranium 
tetrafluoride, uranium trioxide, uranium dioxide, uranium peroxide, triuranium octaoxide).  The toxicity 
of insoluble uranium compounds were tested in a series of 30-day studies conducted by Maynard and 
Hodge (1949).  No histological alterations were observed at the highest uranium dioxide, uranium 
trioxide, uranyl octaoxide, or uranium tetrafluoride doses (11,000–12,000 mg U/kg/day).  By comparison,  
renal lesions were observed following exposure to 200 mg U/kg/day as uranyl nitrate.  These data suggest 
that the toxicity of soluble uranium compounds are at least an order of magnitude higher than for insoluble 
uranium compounds. 
 
Chronic-Duration Oral MRL 
 
Available data on the chronic oral toxicity of uranium comes from several ecological studies examining 
the possible association between elevated levels of uranium in drinking water and alterations in kidney 
function (Kurttio et al. 2002, 2006a; Limson Zamora et al. 1998, 2009; Mao et al. 1995; Seldén et al. 
2009).  Associations between parameters of renal dysfunction (e.g., urine levels of albumin, β2-micro-
globulin, glucose, and protein HC) and elevated uranium levels in drinking water were observed in some 
of the studies (Kurttio et al. 2002; Limson Zamora et al. 1998, 2009; Mao et al. 1995; Seldén et al. 2009).  
These studies did not find overt signs of toxicity and in many cases, the biomarkers of renal dysfunction 
were within the normal range.  Although most of the epidemiology studies provided information on 
uranium levels in the drinking water, there was often a large range of exposure levels; thus, the human 
oral exposure studies do not provide reliable dose-response data. 
 
Chronic-duration oral studies have been conducted in rats exposed to uranyl fluoride, uranyl nitrate, 
uranium dioxide, or uranium tetrafluoride in the diet for 2 years (Maynard and Hodge 1949; Maynard et 
al. 1953) and in dogs exposed to uranyl fluoride, uranyl nitrate, uranium tetrachloride, uranium 
tetrafluoride, or uranium dioxide in the diet for 1 year (Maynard and Hodge 1949; Maynard et al. 1953).  
URANIUM  36 
 








As with shorter durations of exposure, these studies identify the kidney as the most sensitive target of 
uranium toxicity.  In rats, minimal tubular damage primarily consisting of regeneration of tubular 
epithelium was observed at the lower doses of soluble uranium compounds, 81 mg U/kg/day as uranyl 
fluoride and 170 mg U/kg/day as uranyl nitrate.  At higher doses (140 mg U/kg/day as uranyl fluoride and 
330 mg U/kg/day as uranyl nitrate), tubular atrophy was observed; the severity of the atrophy and extent 
of the damage increased with dose.  For the less soluble uranium tetrafluoride, minimal tubular 
degeneration was observed at the highest dose tested, 11,000 mg U/kg/day; no adverse effects were 
observed in rats exposed to 12,000 mg U/kg/day as uranium dioxide (Maynard and Hodge 1949; Maynard 
et al. 1953).  In dogs, renal tubular atrophy was observed following a 1-year exposure to 7.7 mg U/kg/day 
as uranyl fluoride, 9.5 mg U/kg/day as uranyl nitrate, 31 mg U/kg/day as uranium tetrachloride, 150 mg 
U/kg/day as uranium tetrafluoride, or 900 mg U/kg/day as uranium dioxide; the uranyl fluoride study also 
found slight renal damage in dogs exposed to 1.9 mg U/kg/day for 1 year.  As with the rat studies, the dog 
studies showed that the severity and extent of the renal damage increased with dose.  The highest 
NOAELs in the dog study were 0.77 mg U/kg/day as uranyl fluoride and 6.2 mg U/kg/day as uranium 
tetrachloride; NOAELs were not identified in the uranyl nitrate, uranium tetrafluoride, or uranium dioxide 
studies.   
 
The dog study of uranyl fluoride identified the lowest LOAEL (1.9 mg U/kg/day); however, the dog 
studies are not a suitable basis for an MRL because only two dogs of unknown strain and gender were 
tested at each dose level.  The rat studies of uranyl fluoride and uranyl nitrate appear to be the most 
suitable basis for a chronic-duration oral MRL.  A NOAEL of 0.54 mg U/kg/day and a LOAEL of 81 mg 
U/kg/day were identified for uranyl fluoride and a NOAEL of 33 mg U/kg/day and a LOAEL of 170 mg 
U/kg/day were identified for uranyl nitrate (Maynard and Hodge 1949; Maynard et al. 1953).  In the 
uranyl fluoride study, which identified the lowest LOAEL, groups of 15–25 male and 15–25 female rats 
(strain not specified) were exposed to diets containing 0, 0.01, 0.05, 0.1, 0.15, 0.25, 0.5, or 0.75% uranyl 
fluoride (0, 5.4, 27, 54, 81, 140, 270, or 400 mg U/kg/day) for 2 years.  The animals were monitored for 
body weight alterations, clinical signs of toxicity, hematology, and biochemical alterations in the blood 
and urine.  At the termination of the study, the surviving animals were sacrificed and selected organs were 
histopathologically examined.  All rats in the 400 mg U/kg/day group died within the first 2 months of the 
study.  At 270 mg U/kg/day, increased mortality was observed, with only 50% of the animals surviving 
the first year of exposure.  At the end of the first year, decreases in body weight gain of >10% were 
observed at 270 mg U/kg/day in males (30%) and females (18%); at the end of 2 years, >10% decreases 
in body weight gain were observed at 140 mg U/kg/day in males (11%) and females (15%) and at 270 mg 
U/kg/day in males (20%) and females (28%).  Decreases in red blood cell counts and hemoglobin levels 
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and increases in white blood cell counts were observed in males at 140 and 270 mg U/kg/day.  
Histopathological alterations were observed in the kidneys at doses of ≥81 mg U/kg/day.  Marked renal 
tubular atrophy was observed at 140 and 270 mg U/kg/day, with a dose-related increase in severity of the 
lesions.  At 81 mg U/kg/day, 2/5 rats examined showed traces of renal tubular alterations.  No other 
uranium-related effects were noted. 
 
Derivation of an MRL using the NOAEL of 54 mg U/kg/day identified in the 2-year uranyl fluoride rat 
study (Maynard and Hodge 1949; Maynard et al. 1953) as the point of departure was considered; the 
NOAEL/LOAEL approach was used because the lack of incidence data for most exposure groups 
precluded using benchmark dose analysis to identify a point of departure.  Using this point of departure 
would result in an MRL that is higher than the intermediate-duration oral MRL for uranium; thus, a 
chronic-duration oral MRL has not been derived. 
 
The results of a serial study in which rats were exposed to several doses of uranyl nitrate in the diet for up 
to 1 year (Maynard et al. 1953) coupled with the rat 2-year study (Maynard and Hodge 1949; Maynard et 
al. 1953) suggest that at low exposures, the renal tubular epithelium is regenerated and continued 
exposure does not result in more severe effects.  However, at higher doses, the capacity to regenerate the 
renal tubular epithelium is exceeded and tubular atrophy is observed.  In the serial study (Maynard et al. 
1953), exposure to 170 mg U/kg/day as uranyl nitrate in the diet resulted in regeneration of the renal 
tubular epithelium after 2 weeks of exposure; there was no progression of renal damage with continued 
exposure and the renal tubules in rats exposed for 2 weeks were similar to those exposed for 1 year.  
Additionally, a 2-year exposure to 170 mg U/kg/day did not result in any further damage to the kidneys 
(Maynard and Hodge 1949; Maynard et al. 1953).  In contrast, regeneration was observed in the first 
month of the exposure to 660 mg U/kg/day; however, with continued exposure, tubular atrophy was 
observed at 6–8 weeks.  The severity of the atrophy and the areas of the kidney affected by uranium 
increased with duration.  Given these data on the ability of the kidney to repair renal damage at low doses, 
the intermediate-duration oral MRL may be protective for chronic exposures. 
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3.  HEALTH EFFECTS 
 
3.1   INTRODUCTION  
 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of uranium.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
 
The health effects associated with oral or dermal exposure to natural and depleted uranium appear to be 
primarily chemical in nature and not radiological, while those from inhalation exposure may also include 
a slight radiological component, especially if the exposure involves prolonged exposure to insoluble 
uranium compounds.  This profile is primarily concerned with the effects of exposure to natural and 
depleted uranium, but does include limited discussion regarding enriched uranium, which is considered to 
be more of a radiological than a chemical hazard.  Also, whenever the term Aradiation@ is used, it applies 
to ionizing radiation and not to non-ionizing radiation. 
 
Although natural and depleted uranium are primarily chemical hazards, the next several paragraphs 
describe the radiological nature of the toxicologically-important uranium isotopes, because individual 
isotopes are addressed in some of the health effects studies.  Uranium is a naturally occurring radioactive 
element and a member of the actinide series.  Radioactive elements are those that undergo spontaneous 
transformation (decay), in which energy is released (emitted) either in the form of particles, such as alpha 
or beta particles, or electromagnetic radiation with energies sufficient to cause ionization, such as gamma 
rays or x-rays.  This transformation or decay results in the formation of different elements, some of which 
may themselves be radioactive, in which case they will also decay.  The process continues until a stable 
(nonradioactive) state is reached (see Appendix D for more information). 
 
Uranium is naturally occurring or has been produced in nuclear reactors and in high energy physics 
experiments.  It exists in a number of isotopic forms (NNDC 2011), all of which are radioactive.  The 
most toxicologically important of the 22 currently recognized uranium isotopes are anthropogenic 
uranium-232 (232U) and uranium-233 (233U) and naturally occurring uranium-234 (234U), uranium-235 
(235U), and uranium-238 (238U).  When an atom of any of these five isotopes decays, it emits an alpha 
particle (the nucleus of a helium atom) and transforms into a radioactive isotope of another element.  The 
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process continues through a series of radionuclides until reaching a stable, non-radioactive isotope of lead 
(or bismuth in the case of 233U).  The radionuclides in these transformation series (such as isotopes of 
radium and radon), emit alpha or beta particles, as well as gamma and x-rays, with energies and 
intensities that are unique to the individual radionuclide. 
 
There are three basic categories of uranium isotope mixtures (based on the mass percentage of 235U 
relative to that of the earth’s crust): natural uranium, enriched uranium, and depleted uranium.  Natural 
uranium in the earth’s crust is comprised of 99.2742% 238U, 0.7204% 235U, and 0.0054% 234U by mass.  
Combining these mass percentages with the unique half-life of each isotope converts mass into 
radioactivity units and shows that crustal uranium contains 48.7% 234U, 2.27% 235U, and 49.0% 238U by 
radioactivity, and has a very low specific activity of 0.69 μCi/g based on data compiled by the National 
Nuclear Data Center (NNDC 2011).  Natural uranium in the environment can vary somewhat from these 
ratios due to physical and environmental factors, as shown by the varying ratios of natural uranium in air 
(EPA 2008).  Enriched and depleted uranium are the products of a process, which increases (or enriches) 
the percentages of 234U and 235U in one portion of a uranium sample and decreases (or depletes) their 
percentages in the remaining portion.  Enriched uranium is quantified by its 235U mass percentage.  
Uranium enrichment for nuclear energy produces uranium that typically contains 3% 235U.  Uranium 
enrichment for a number of other purposes, including nuclear weapons, can produce uranium that 
contains as much as 97.3% 235U and has a higher specific activity (~50 μCi/g).  The residual uranium after 
the enrichment process is called “depleted uranium,” which possesses even less radioactivity (0.36 μCi/g) 
than natural uranium.  The USNRC considers the specific activity of depleted uranium to be 0.36 μCi/g 
(10 CFR 20), but more aggressive enrichment processes can drive this value slightly lower (0.33 μCi/g).  
In this profile, both natural and depleted uranium are referred to as “uranium,” although depleted uranium 
is specified when this use benefits the text.  The higher specific-activity mixtures and isotopes are 
described in the profile as “enriched uranium” or as 232U, 233U, or 234U, as applicable, in the summary of 
the studies in which these mixtures and isotopes were used. 
 
Uranium is a heavy metal that forms compounds and complexes of different varieties and solubilities.  
The chemical action of all isotopes and isotopic mixtures of uranium is identical, regardless of the 
specific activity (i.e., enrichment), because chemical action depends only on chemical properties.  Thus, 
the chemical toxicity of a given amount or weight of natural, depleted, and enriched uranium is identical. 
 
The toxicity of uranium varies according to its chemical form and route of exposure.  On the basis of the 
toxicity of different uranium compounds in animals, it was concluded that the relatively more water-
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soluble compounds (uranyl nitrate, uranium hexafluoride, uranyl fluoride, uranium tetrachloride) were the 
most potent systemic toxicants.  The poorly water-soluble compounds (uranium tetrafluoride, sodium 
diuranate, ammonium diuranate) were of moderate-to-low systemic toxicity, and the insoluble compounds 
(uranium trioxide, uranium dioxide, uranium peroxide, triuranium octaoxide) had a much lower potential 
to cause systemic toxicity but could cause pulmonary toxicity when exposure was by inhalation.  The 
terms soluble, poorly soluble, and insoluble are often used in this profile without relisting the specific 
compounds.  Generally, hexavalent uranium, which tends to form relatively soluble compounds, is more 
likely to be a systemic toxicant than tetravalent uranium, which forms relatively insoluble compounds.  
Ingested uranium is less toxic than inhaled uranium, which may be partly attributable to the relatively low 
gastrointestinal absorption of uranium compounds. 
 
Because natural uranium produces very little radioactivity per mass of uranium, the renal and respiratory 
effects from exposure of humans and animals to uranium are usually attributed to the chemical properties 
of uranium.  However, in exposures to more radioactive uranium isotopes (e.g., 232U and 233U, and 
combined 234U and 235U in enriched uranium), it has been suggested that the chemical and radiological 
toxicity may be additive or may potentiate in some instances.  In these instances, this dual mode of 
uranium toxicity may not be distinguishable by end point because of the overlap of etiology and 
manifested effects.  Although the mechanism of this interaction is as yet unclear, it is not necessary to 
know it in order to identify critical targets of toxicity or evaluate the dose-response relationships. 
 
3.2   DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
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or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and the general public alike. 
 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of uranium are 
indicated in Table 3-1 and Figure 3-1. 
 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
 
3.2.1   Inhalation Exposure  
 
The toxicity of uranium compounds to the lungs and distal organs varies when exposed by the inhalation 
route.  In general, the more soluble compounds (uranyl fluoride,1 uranium tetrachloride, uranyl nitrate 
hexahydrate) are less toxic to the lungs but more toxic systemically by the inhalation route due to easier 
absorption from the lungs into the blood and transportation to distal organs (Tannenbaum et al. 1951).  A 
study summary of the data for inhalation toxicity (lethality) studies in mice exposed to equivalent 
                                                           
1Uranium hexafluoride is hydrolyzed to uranyl fluoride and hydrogen fluoride.  Hydrogen fluoride is highly toxic in 
acute exposures and causes pulmonary edema, which may be immediately life-threatening. 
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uranium concentrations of uranium tetrafluoride, uranyl fluoride, uranium tetrachloride, uranyl nitrate 
hexahydrate, or triuranium octaoxide concluded that the order of decreasing systemic toxicity for these 
compounds may be as follows:  very toxic, uranyl fluoride; toxic, uranyl nitrate hexahydrate; and 
nontoxic (at the levels tested in companion studies), uranium tetrachloride, uranium tetrafluoride, and 
triuranium octaoxide (Stokinger et al. 1953; Tannenbaum et al. 1951).  Although uranium tetrachloride is 
highly soluble in water, it is easily hydrolyzed and oxidized into less soluble uranyl chloride and insoluble 
uranium dioxide.  For this reason, inhaled uranium tetrachloride tends not to behave as if it is a highly 
soluble uranium compound.  Conversely, the more common insoluble salts and oxides (uranium 
tetrafluoride, uranium dioxide, uranium trioxide, triuranium octaoxide) are generally more toxic to the 
lungs through inhalation exposure because of the longer retention time in the lung tissue but they are less 
toxic to distal organs. 
 
3.2.1.1   Death  
 
The lethal effects of inhalation exposure to uranium have been investigated in humans in epidemiological 
studies and in animal studies under controlled conditions.  Epidemiological studies indicate that routine 
exposure of humans (in the workplace and the environment at large) to airborne uranium is not associated 
with increased mortality.  Brief accidental exposures to very high concentrations of uranium hexafluoride 
have caused fatalities in humans, most likely due to the resulting exposure to hydrogen fluoride.  
Laboratory studies in animals indicate that inhalation exposure to certain uranium compounds can be 
fatal.  These deaths are believed to result from renal failure caused by absorbed uranium.  The low 
specific activity of uranium precludes the possibility of absorbing enough uranium to deliver a lethal dose 
of radiation. 
 
No definitive evidence has been found in epidemiologic studies that links human deaths to uranium 
exposure.  Uranium miners have higher-than-expected rates of death from lung cancer; however, this 
finding is attributed to the radiological effects of radon and its decay products, which are progeny of 
uranium and, therefore, present in uranium mines.  In addition, the role of tobacco smoking was not 
evaluated in some of the studies (Archer et al. 1973a; Gottlieb and Husen 1982; Lundin et al. 1969; Samet 
et al. 1984a, 1986); additionally, the contributions of crystalline silica and diesel engine exhaust to the 
cancer rate ascribed to radon have not been evaluated.  Epidemiologic studies of workers at uranium mill 
and metal processing plants (where there is little or no exposure to radon in excess of normal 
environmental levels) showed no significant increase in overall deaths attributable to exposure to uranium 
(Archer et al. 1973b; Boice et al. 2008; Checkoway et al. 1988; Cragle et al. 1988; Hadjimichael et al. 
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1983; NIOSH 1987; Pinkerton et al. 2004; Polednak and Frome 1981; Scott et al. 1972; Waxweiler et al. 
1983).  Results of several mortality assessments of populations living near uranium mining and milling 
operations have not demonstrated significant associations between mortality and exposure to uranium 
(Boice et al. 2003, 2007a, 2007b, 2010). 
 
Deaths occurred after accidental releases of uranium hexafluoride at uranium-processing facilities in 1944 
and 1986, but these deaths were not attributed to the uranium component of this compound (Kathren and 
Moore 1986; Moore and Kathren 1985; USNRC 1986).  These releases resulted in the generation of 
concentrated aerosols of highly toxic hydrofluoric acid2.  In the 1944 incident, exposure time was 
estimated to be only 17 seconds; deaths occurred in 2 of 20 workers within an hour and were attributed to 
severe chemical burns of the lungs.  In the 1986 incident, 1 of 23 workers died from massive pulmonary 
edema.  Estimated airborne concentrations were 20 mg uranium hexafluoride/m3 for a 1-minute exposure 
and 120 mg uranium hexafluoride/m3 for a 60-minute exposure (15.2 and 91 mg U/m3, respectively).  For 
both accidents, the observed effects are suggestive that inhalation of hydrofluoric acid was responsible for 
death. 
 
A study of U.K. Gulf War veterans (>50,000 veterans) did not find a significant increase in the risk of 
dying in a 13-year follow-up period, as compared to >50,000 veterans not deployed to the Gulf.  Among 
the 7% of Gulf War veterans who self reported exposure to depleted uranium, a non-statistically 
significant increase in the risk of disease-related deaths was found (mortality rate ratio of 1.99, 95% 
confidence interval [CI] of 0.98–4.04) (Macfarlane et al. 2005). 
 
Mortality can be induced in animals exposed to sufficiently high concentrations of pure uranium 
compounds.  The acute-duration LC50 (lethal concentration, 50% death) for uranium hexafluoride has 
been calculated for Long-Evans rats and Hartley guinea pigs (Leach et al. 1984).  The animals were 
exposed to uranium hexafluoride in a nose-only exposure apparatus for periods of up to 10 minutes and 
then observed for 14 days.  The 2-minute LC50 values (95% CIs) for the rats and guinea pigs were 
120,290 mg U/m3 (99,270–145,750 mg U/m3) and 62,080 mg U/m3 (43,380–88,830 mg U/m3), 
respectively.  For a 5-minute inhalation exposure, the LC50 in rats was estimated as 38,600 mg U/m3 
(26,760–55,720 mg U/m3); the LC50 for a 10-minute inhalation was estimated as 12,010 mg U/m3 
(10,090–14,290 mg U/m3). 
 
                                                           
2Uranium hexafluoride rapidly dissociates into hydrofluoric acid and uranyl fluoride on contact with moisture in the 
air. 
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The animals that died showed some damage to the respiratory tract, probably due to hydrofluoric acid, but 
this damage was not judged to be the cause of death, at least in the animals that died more than 2 days 
postexposure.  Urinalysis and histopathological examination indicated that renal injury was the primary 
cause of death (Leach et al. 1984).  In other acute lethality studies, rats, mice, and guinea pigs suffered 10, 
20, and 13% mortality, respectively, following a 10-minute inhalation of uranium hexafluoride 
corresponding to 637 mg U/m3 (Spiegl 1949). 
 
In intermediate-duration studies, rabbits and cats were generally the most sensitive species to uranium 
lethality.  Deaths in these studies generally occurred beginning 2 weeks after exposure started and 
continued to the end of the experiment.  Exposure to 2 mg U/m3 (as uranium hexafluoride) 6 hours/day 
for 30 days caused 5, 20, and 80% mortality in guinea pigs, dogs, and rabbits, respectively (Spiegl 1949).  
An exposure to 9.5 mg U/m3 (as uranyl nitrate hexahydrate) for 8 hours/day, 5 days/week for 30 days 
caused 10% mortality in rats and guinea pigs, and 75% mortality in dogs.  Exposure to 2 mg U/m3 killed 
all four cats tested (Roberts 1949).  Exposure to 9.2 mg U/m3 (as uranyl fluoride) 6 hours/day, 
5.5 days/week for 5 weeks caused 0, 100, 83, and 55% mortality in rats, mice, rabbits and guinea pigs, 
and deaths in two dogs and two cats tested at this concentration (Rothstein 1949a).  The lowest exposure 
causing death with uranyl fluoride was 0.15 mg U/m3 in mice and rabbits and 2.2 mg U/m3 in guinea pigs.  
Exposure to 15.4 mg U/m3 (as uranium peroxide) 5 hours/day, 5 days/week for 23 days caused 10, 63, 40, 
80, and 100% mortality in rats, mice, guinea pigs, rabbits, and cats, respectively, while 9.2 mg U/m3 
killed all of the dogs tested (Dygert 1949d).  Inhalation of air containing 15 mg U/m3 (as sodium 
diuranate) for 6 hours/day, 5.5 days/week for 5 weeks caused 13 and 28% mortality in guinea pigs and 
rabbits, respectively (Rothermel 1949). 
 
Insoluble uranium compounds were also lethal to animals by the inhalation route, but at higher 
concentrations than soluble compounds.  Exposure to 15.8 mg U/m3 (as uranium trioxide) 6 hours/day, 
5.5 days/week for 4 weeks caused 10, 9, 17, and 67% mortality in rats, guinea pigs, dogs, and rabbits, 
respectively (Rothstein 1949c).  Inhalation of air containing 19.4 mg U/m3 (as uranium dioxide) for 
6 hours/day, 5.5 days/week for 5 weeks, caused 60% mortality in rabbits but no mortality in rats, mice, 
guinea pigs, or dogs (Rothstein 1949b).  Inhalation of air containing 18 mg U/m3 (as uranium 
tetrafluoride) for 5 hours/day for 30 days caused 15, 32, 33, and 100% mortality in guinea pigs, rats, 
rabbits, and cats, respectively, and death in a single dog tested at this concentration.  Inhalation at 
4 mg U/m3 caused no deaths in a group of 18 dogs, and one death in a group of 30 rats (Dygert 1949a).  A 
mortality of 4% was observed among rabbits given 3 mg U/m3 (Stokinger et al. 1953).  Exposure to 
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6.8 mg U/m3 (as ammonium diuranate) 6 hours/day for 30 days caused 20 and 100% mortality in guinea 
pigs and rabbits, respectively (Dygert 1949b). 
 
In chronic-duration experiments, inhalation of 2 mg U/m3 as uranyl nitrate hexahydrate for 6 hours/day, 
5.5 days/week for 92–100 weeks resulted in 1% mortality in rats (Stokinger et al. 1953).  This is not an 
unusual mortality rate for rats, so it is unlikely that these deaths can be attributed to uranium exposure.  
Dogs exposed to uranyl nitrate hexahydrate for 2 years suffered 4% mortality (Stokinger et al. 1953).  Out 
of 25 exposed dogs, 1 dog died at 0.25 mg U/m3 and another died at 2 mg U/m3.  Death may or may not 
have been attributable to uranium, according to the study investigators. 
 
In several other inhalation-exposure animal studies, no deaths were observed when either soluble or 
insoluble uranium compounds were administered.  In one of these animal studies, no mortality was 
observed in monkeys exposed by inhalation to uranium dioxide dust at a concentration of 5 mg U/m3 for 
5 years.  The death of Beagle dogs similarly exposed could not be attributed to uranium by the 
investigators (Leach et al. 1970). 
 
The percent mortality values for each species and other LOAEL values for mortality from exposure to 
uranium by the inhalation route are presented in Table 3-1 and plotted in Figure 3-1. 
 
3.2.1.2   Systemic Effects  
 
No human studies were located regarding the cardiovascular, musculoskeletal, endocrine, metabolic, 
dermal, ocular, body weight, or other systemic effects of elemental uranium following acute-duration 
inhalation exposure.  Nor were any human studies located regarding the respiratory, hematological, 
cardiovascular, gastrointestinal, musculoskeletal, hepatic, renal, endocrine, metabolic, dermal, ocular, 
body weight, or other systemic effects of uranium following intermediate-duration inhalation exposure.  
No studies were found regarding the cardiovascular, gastrointestinal, musculoskeletal, renal, endocrine, 
metabolic, dermal, ocular, body weight, or other systemic effects in humans following chronic-duration 
inhalation exposure.  The existing human data on the respiratory and hepatic effects of uranium are 
limited to acute- and chronic-duration inhalation exposures, hematological effects are limited to chronic-
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a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate-duration inhalation minimal risk level (MRL) of 0.0001 mg U/m3 for soluble uranium compounds based on a LOAELADJ of 0.032 mg/m3 and an
uncertainty factor of 300 (3 for used of a minimal LOAEL, 10 for extrapolation from animals to humans, and 10 for human variability).
c Used to derive an intermediate-duration inhalation minimal risk level (MRL) of 0.002 mg U/m3 for insoluble uranium compounds based on a NOAELADJ of 0.24 mg/m3 and an
uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).
d Used to derive a chronic-duration inhalation minimal risk level (MRL) of 0.0008 mg U/m3 for insoluble uranium compounds based on a LOAELADJ of 0.82 mg/m3 and an
uncertainty factor of 1000 (10 for use of LOAEL, 10 for extrapolation from animals to humans and 10 for human variability).
e Used to derive a chronic-duration inhalation minimal risk level (MRL) of 0.00004 mg U/m3 for soluble uranium compounds based on a BMCLADJ of 0.0037 mg/m3 and an
uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).
Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; Gastro = gastrointestinal; Gn Pig = guinea pig; Hemato = hematological; hr
= hour(s); LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); NOAEL = no-observed-adverse-effect level; NS = not specified; occup = occupational; Resp =
respiratory; wk = week(s); yr = year(s)
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No animal studies were located regarding the endocrine, metabolic, dermal, or ocular effects of uranium 
in animals following acute-duration inhalation exposures to uranium.  Nor were any studies located 
regarding the metabolic, dermal, ocular, or other systemic effects in animals following intermediate-
duration inhalation exposure to uranium.  There are animal data for acute-, intermediate-, and chronic-
duration inhalation exposures to uranium for respiratory, hematological, cardiovascular, gastrointestinal, 
renal, or body weight effects.  However, animal data on hepatic effects are limited to acute- and chronic-
duration inhalation exposures to uranium. 
 
The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
systemic effects from chemical exposure to uranium by the inhalation route are presented in Table 3-1 
and plotted in Figure 3-1. 
 
Respiratory Effects.    The hazard from inhaled uranium aerosols, or from any noxious agent, is the 
likelihood that the agent will reach the site of its toxic action.  Two of the main factors that influence the 
degree of hazard from toxic airborne particles are:  (1) the site of deposition in the respiratory tract of the 
particles and (2) the fate of the particles within the lungs.  The deposition site within the lungs depends 
mainly on the particle size of the inhaled aerosol, while the subsequent fate of the particle depends mainly 
on the physical and chemical properties of the inhaled particles and the physiological status of the lungs. 
 
Small particles (about 2 micrometers [μm] or smaller in size) are primarily deposited in the alveoli.  The 
alveoli, frequently called the “deep respiratory tract,” form the functional part of the lungs where gas 
exchange occurs.  As the particle size increases, progressively fewer particles penetrate into the deep 
respiratory tract, and increasingly greater fractions of the inhaled particles are deposited in the upper 
respiratory tract.  The respiratory tract is a system of ducts that starts at the nares and includes the 
pharynx, larynx, trachea, and a complex series of bronchi and bronchioles that terminate in several 
thousand alveoli.  Three different mechanisms are involved in the removal of particles from the 
respiratory tract.  The first is mucociliary action in the upper respiratory tract (trachea, bronchi, 
bronchioles, and terminal bronchioles), which sweeps particles deposited there into the throat, where they 
are either swallowed into the gastrointestinal tract or spat out.  The two other clearance mechanisms, 
dissolution (which leads to absorption into the bloodstream) and phagocytosis (removal by specialized 
cells in the process), deal mainly with the particles deposited in the deep respiratory tract (respiratory 
bronchioles, alveolar ducts, and alveolar sacs) (ICRP 1994a; NCRP 1997).  The less soluble uranium 
particles may remain in the lungs and in the regional lymph nodes for weeks (uranium trioxide, uranium 
tetrafluoride, uranium tetrachloride) to years (uranium dioxide, triuranium octaoxide). 
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Human and animal studies have shown that long-term retention in the lungs of large quantities of inhaled 
insoluble uranium particles (e.g., carnotite dust [4% uranium as uranium dioxide and triuranium 
octaoxide, 80–90% quartz, and <10% feldspar]) can lead to serious respiratory effects.  However, animals 
exposed to high doses of purified uranium (as uranyl nitrate hexahydrate, uranium tetrachloride, uranium 
dioxide, uranium trioxide, uranium tetraoxide, uranium fluoride, or uranium acetate) through the 
inhalation or oral route in acute-, intermediate-, or chronic-duration exposures failed to develop these 
respiratory ailments.  The lack of significant pulmonary injury in animal studies with insoluble 
compounds indicates that other factors, such as diverse inorganic particle abrasion or chemical reactions, 
may contribute to these effects. 
 
In acute exposures, respiratory disease may be limited to interstitial inflammation of the alveolar 
epithelium, leading eventually to pulmonary fibrosis (Clayton and Clayton 1981; Cooper et al. 1982; 
Dungworth 1989; Wedeen 1992).  In studies of the pulmonary effects of airborne uranium dust in 
uranium miners and in animals, the respiratory diseases reported are probably aggravated by the inhalable 
dust particles’ (the form in which uranium is inhaled) toxicity.  In some of these instances, additional data 
from the studies show that the workers were exposed to even more potent respiratory tract irritants, such 
as silica and vanadium pentaoxide (Waxweiler et al. 1983). 
 
The effects of massive acute exposures to uranium in humans, as well as epidemiologic or clinical studies 
of uranium mine workers chronically exposed to mine atmospheres (containing other noxious agents that 
include silica, diesel engine exhaust, cigarette smoke, and radon and its daughters), have been 
investigated.  Several epidemiologic studies have reported respiratory diseases in uranium mine and mill 
workers, who were also exposed to significant amounts of dust and other pulmonary irritants, but not in 
uranium-processing workers, who were not exposed to these potential aggravants. 
 
Accidental exposure of workers to estimated airborne concentrations of 20 mg uranium hexafluoride/m3 
for a 1-minute exposure and 120 mg uranium hexafluoride/m3 for a 60-minute exposure (15.2 and 
91 mg U/m3, respectively) resulted in acute respiratory irritation, which is attributed to the hydrofluoric 
acid decomposition product.  One worker died of pulmonary edema a few hours after the accident 
(USNRC 1986, 1990).  In another report, 20 men who were seriously injured following accidental 
exposure to a stream of uranium hexafluoride when a transportation cask ruptured showed signs of 
pulmonary edema, which also was attributed to hydrofluoric acid.  After 3 weeks, most had normal 
clinical findings and were considered to be in excellent health.  A follow-up examination 38 years later on 
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three of the injured workers showed no detectable uranium deposition and no respiratory findings 
attributable to the exposure (Kathren and Moore 1986).  No clinical signs of pulmonary toxicity were 
found in about 100 uranium-processing workers exposed to insoluble uranium dust at levels of 0.5–
2.5 mg U/m3 for about 5 years (Eisenbud and Quigley 1956).  Other reports of workers in the uranium 
processing industry did not show increased deaths due to diseases of the respiratory system related to 
exposure to uranium (Cragle et al. 1988; NIOSH 1987; Polednak and Frome 1981; Scott et al. 1972). 
 
A 30-year follow-up study (Dupree et al. 1987) in which ionizing radiation hazard was assessed for a 
study cohort consisting of 995 workers in a uranium-processing facility that operated between 1943 and 
1949 found statistically significant increases in death from all causes.  Significantly increased mortality 
was observed for cancer of the larynx and for pneumonia, but not for lung cancer.  The workers were 
exposed to internal radiation from the inhaled uranium dust, with an upper limit of 1,000 mSv.  The data 
(external radiation badge) for the last 24 months of operation indicated that the highest cumulative 
external gamma dose for a worker was about 20 mSv.  Long-term occupational exposure was evaluated in 
a subcohort that received 150 mSv/year or more.  Because the workers were also exposed to radon-222 
(222Ra), chlorine, hydrofluoric acid, lead sulfate, nickel, nitric acid and nitrogen oxides, silicon dioxide, 
and sulfuric acid, the etiology of the reported laryngeal disease is uncertain (Dupree et al. 1987).  An 
increased incidence of deaths (standard mortality ratios [SMRs]=2.29) from obstructive pulmonary 
disease was found in 4,106 workers in a nuclear fuels fabrication plant who were employed for >6 months 
from 1956 to 1978 (Hadjimichael et al. 1983).  However, the overall death rate and the rate of all cancers 
combined were lower than expected.  The association of disease with exposure to uranium was not 
confirmed. 
 
Pinkerton et al. (2004) reported significantly increased mortality from nonmalignant respiratory disease 
(100 observed vs. 70.16 expected; SMR 1.43, 95% CI 1.16–1.73) within a cohort of 1,485 workers 
employed in uranium mills in the Colorado Plateau region (Arizona, Colorado, New Mexico) when 
worker mortality was compared to mortality within the U.S. population.  The workers were employed for 
at least 1 year; 37% were employed for 3–9 years and 20% for ≥10 years.  The latency period (time from 
first employment to evaluation) was at least 20 years for 86% of the cohort.  Mortality rates were not 
significantly elevated among the mill workers when compared to Colorado Plateau regional population 
mortality rates.  This region is noted for relatively high chronic obstructive pulmonary disease compared 
to other states. 
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Boice et al. (2008) examined mortality in a cohort of mining (1,867 males and females) and milling 
(759 males and females) workers at Grants, New Mexico, compared to mortality rates for the U.S. 
population.  All workers were employed for at least 6 months; 47 and 12% of the miners were employed 
for 0.5–1.9 and ≥10 years and 42 and 15% of the millers were employed for 0.5–1.9 and ≥10 years.  For 
both groups, the latency period was ≥20 years.  After separating the cohort according to type of 
employment (mining, milling), only the group that reported having worked in underground uranium 
mines exhibited significant excess mortality from nonmalignant respiratory disease (55 observed vs. 
33.6 expected; SMR 1.64, 95% CI 1.23–2.13); the mortality ratio for the millers was 1.07 (25 observed 
vs. 23.4 expected; 95% CI 0.69–1.58).  The increased mortality from nonmalignant respiratory disease 
among the workers with uranium mining experience is attributable to exposure to mining dusts, radon 
decay products, diesel exhaust, and excessive tobacco use, rather than exposure to uranium. 
 
The pulmonary toxicity of uranium compounds varies in animals.  Reports of pulmonary toxicity in 
animals after acute-duration exposure to uranium are limited to experiments with uranium hexafluoride.  
Gasping and severe irritation to the nasal passages were reported after 10-minute exposures at 637 mg 
U/mg3 in rats and mice (Spiegl 1949) and nasal hemorrhage in rats after a 5-minute exposure to 
54,503 mg/m3 (Leach et al. 1984).  Uranium hexafluoride promptly hydrolyzes on contact with water to 
uranyl fluoride and hydrofluoric acid.  Thus, the animals were potentially exposed to hydrofluoric acid, a 
potent toxicant to respiratory tract epithelium, which probably contributed to pulmonary tissue destruction 
(Leach et al. 1984; Spiegl 1949; Stokinger et al. 1953).  In addition, exposure to fluoride ions can result in 
hypocalcemia, hypomagnesemia, pulmonary edema, metabolic acidosis, ventricular arrhythmia, and death 
(Meditext 1998). 
 
Intermediate-duration exposure to uranium compounds also caused pulmonary toxicity, particularly when 
exposure was to uranium hexafluoride.  Exposure of rats, mice, and guinea pigs to this compound for 
6 hours/day for 30 days at 13.3 mg U/m3 resulted in pulmonary edema, hemorrhage, emphysema, and 
inflammation of the bronchi and alveoli (Spiegl 1949).  Exposure to 2.0 mg U/m3 resulted in pulmonary 
edema, hemorrhage, and emphysema in rabbits and slight pneumonia in dogs (Spiegl 1949).  Milder 
effects were observed with other uranium compounds in a series of experiments where exposure 
conditions were similar to those found in the workplace (i.e., 5–6 hours/day, 5–6 days/week).  For 
example, rhinitis was observed in cats and dogs after 30 days of exposure to 18 mg U/m3 as uranium 
tetrafluoride (Dygert 1949a) and after 5 weeks of exposure to 9.2 mg U/m3 as uranyl fluoride (Rothstein 
1949a); the rhinitis was observed in animals dying early and were associated with other signs of 
morbidity.  Histopathological evidence of toxicity was observed in several studies, including slight 
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degenerative changes in the lungs of rats and dogs exposed to 16 mg U/m3 as uranium trioxide (Rothstein 
1949c) and dogs exposed to 9.5 mg U/m3 as uranyl nitrate (Roberts 1949).  Uranium dioxide and 
triuranium octaoxide did not cause toxicity (Dygert 1949c; Rothstein 1949b).  Carnotite uranium ore did 
not cause toxicity in mice or guinea pigs, but hemorrhagic lungs were observed in dogs (Pozzani 1949).  
The species differences may reflect deeper penetration of this material into the dog respiratory tract.  
Rabbits were more sensitive to respiratory effects of uranium compounds than other species.  Severe 
respiratory effects (pulmonary edema, hemorrhage) were observed in this species with exposure to 6.8 mg 
U/m3 as ammonium diuranate (Dygert 1949b), 15.4 mg U/m3 as uranium peroxide (Dygert 1949d), 16 mg 
U/m3 as uranium trioxide (Rothstein 1949c), and 22 mg U/m3 as carnotite uranium ore (Pozzani 1949).  
Uranium dioxide at 19.4 mg U/m3 did not cause respiratory effects in rabbits (Rothstein 1949b). 
 
In chronic-duration exposure tests, a total of 3,100 test animals, including rats, rabbits, guinea pigs, and 
dogs were exposed to aerosols containing 0.05–10 mg U/m3 of various uranium compounds for 7–
13 months.  No histological damage attributable to uranium exposure were observed in the lungs.  There 
was an absence of any other type of histological damage outside the kidneys (Cross et al. 1981a, 1981b; 
Stokinger et al. 1953).  Dogs exposed to 15 mg/m3 of carnotite ore dust containing 0.6 mg U/m3 with a 
particle size activity median aerodynamic diameter (AMAD) of 1.5–2.1 μm 4 hours/day, 5 days/week for 
1–4 years showed very slightly increased pulmonary resistance, which may not have been statistically 
significant.  Histological findings included vesicular emphysema, which was present to a lesser degree in 
control animals.  Fibrosis was not noted at this concentration (Cross et al. 1981a, 1982).  Exposure of rats 
to 5.1 mg U/m3 as uranium dioxide dust 5.4 hours/day, 5 days/week for 1 year did not result in 
histological damage in the lungs (Leach et al. 1970). 
 
Because particles containing insoluble uranium compounds can reside in the lung for years, it is likely 
that radiotoxicity as well as chemical toxicity can result from inhalation exposure to highly enriched 
uranium compounds.  Radiation effects on tissues from the alveolar regions of the lungs were examined 
in Albino HMT (F344) male rats exposed, nose-only, for 100 minutes to an aerosol of to 92.8% 
235U-enriched uranium dioxide with a concentration ranging from 2,273 nCi/m3 (84.1 kBq/m3) to 
5,458 nCi/m3 (202 kBq/m3).  Increases in the sizes and numbers of lung macrophages and type II3 cells 
and the numbers of macrophages and type I cells, and a significant increase in the size of lysosomal 
granules within the macrophages were reported 8 days postexposure.  At 7 days postexposure, 35 of the 
                                                           
3Type I cells are alveolar lining cells that are involved with the transfer of oxygen and other substances between the 
alveolus and the blood.  Type II cells are alveolar cells involved in production and secretion of the surfactant coating 
the alveolar surface. 
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rats were further exposed to thermal neutrons at a fluence of 1.0x1012 neutrons/cm2 over 2.5 minutes in 
order to study the combined effects of radiation and chemical toxicity.  The radiation dose due to the 
neutrons and the fission fragments was about 600 rad, which is about 300 times greater than the radiation 
dose from the uranium dioxide alpha particles.  No significant difference was found between the uranium 
dioxide-only group and those that were subsequently irradiated with neutrons, indicating that the extra 
radiation exposure caused no immediate pulmonary cellular reaction above that produced by uranium 
dioxide alone.  This finding implies that the observed acute pulmonary effects were due to the 
metallotoxicity of the uranium dioxide rather than to the alpha radiation from the uranium (Morris et al. 
1989). 
 
However, another study (Morris et al. 1990) reported severe alveolar fibrosis or metaplasia in the lungs of 
three F344 rats nose-only exposed to an aerosol of 111–220 mg/m3 92.8% enriched uranium dioxide for 
100 minutes; AMAD of the particles ranged from 2.7 to 3.2 μm.  The lung damage was observed only in 
animals sacrificed at 720 days postexposure; no effects were observed in animals examined ≤540 days 
postexposure.  The α-particle radioactivity concentration was estimated as 1.91 kBq/g (51.6 nCi/mg) 
(Morris et al. 1990). 
 
In other animal studies, changes suggestive of damage from either radiation or diverse inorganic dust 
(fibrosis) were reported in lungs and tracheobronchial lymph nodes in Rhesus monkeys exposed by 
inhalation to 5.1 mg/m3 (as uranium dioxide) corresponding to a radioactivity concentration of 3.4 nCi/m3 
(126 Bq/m3) for periods >3 years.  Estimated cumulative alpha-radiation tissue doses were >500 rad 
(5 Gy) for the lungs and 7,000 rad (70 Gy) for the lymph nodes.  Similarly exposed dogs also developed 
slight interstitial and vascular fibrosis of the lungs at lung following exposure to 5.1 mg U/m3 with an 
estimated alpha-radiation tissue dose of 760–1,280 rad (7.6–12.8 Gy) (Leach et al. 1970).  The effect on 
the tracheobronchial lymph nodes in animals exposed for an additional 2 years ranged from involvement 
of a single node to complete destruction of all nodes, was dose-dependent and showed a similarity to 
changes seen after inhalation exposure to plutonium as 238Pu or 239Pu dioxide (Leach et al. 1973).  Renal 
damage was not observed in either dogs or monkeys, but fibrosis was found in monkey lung and both 
necrosis and fibrosis were found in dog and monkey lymph nodes.  It was not clear whether the damage 
was chemically or radiologically induced, but the magnitude of the radiation doses and the presence of 
lung and lymph node damage in the absence of renal effects was suggestive to the authors of long-term 
radiation damage (Leach et al. 1970).  However, such degenerative changes in the lungs have also been 
observed following prolonged exposure to diverse inorganic dust. 
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For a review of the hazards associated with alpha-emitting radionuclide exposure, see Appendix D of this 
profile. 
 
Cardiovascular Effects.    No cardiovascular effects have been reported in humans after inhalation 
exposure to uranium.  No effect on blood pressure or pulse rate was observed in a man accidentally 
exposed to powdered uranium tetrafluoride for 5 minutes (Lu and Zhao 1990).  Air concentration and 
mean particle size of the powder were not determined.  Electrocardiograms and chest x-rays were normal 
shortly after the accident and over a 7.5-year follow-up period. 
 
No cardiovascular effects were seen in rats exposed to 0.2 mg U/m3 (0.13 nCi U/m3) as uranium 
hexafluoride for 1 year (Stokinger et al. 1953) or in rats, mice, guinea pigs, and rabbits exposed to 
4.8 mg U/m3 (3.2 nCi U/m3) triuranium octaoxide for 26 days (Dygert 1949c). 
 
Gastrointestinal Effects.    Inhalation exposure to uranium has generally not resulted in 
gastrointestinal effects in humans although transient effects occurred after one accidental exposure (Lu 
and Zhao 1990).  On the sixth day after a male worker at a uranium-enrichment plant was accidentally 
exposed for about 5 minutes in a closed room by inhalation to a high concentration of uranium 
tetrafluoride (natural uranium) powder, the patient reported nausea and loss of appetite.  Air concentration 
and mean particle size of the powder were not determined.  On postaccident day 8, the clinical findings 
were loss of appetite, abdominal pain, diarrhea, tenesmus, and pus and blood in the stool.  On 
postaccident day 9, all parameters returned to normal.  The study gave no indication of particle size for 
assessing deposition in the upper lung and no indication of whether fecal uranium analysis was 
undertaken to determine if the noted effects may have been mediated by the mucocilliary clearance of the 
uranium tetrafluoride from the lung and its subsequent swallowing to the gastrointestinal tract in 
accordance with the current International Commission on Radiological Protection (ICRP) lung model 
(ICRP 1994a) or whether the signs were the result of another intestinal irritant.  Gastrointestinal 
symptoms were not among the clinical signs reported for other workers accidentally exposed to uranium 
hexafluoride (Eisenbud and Quigley 1956; Moore and Kathren 1985; USNRC 1986). 
 
Dogs, but not other species, appear susceptible to gastrointestinal effects after inhalation exposure to high 
concentrations of uranium compounds.  Vomiting was observed during intermediate-duration exposure to 
9.5 mg U/m3 uranyl nitrate (Roberts 1949), 18 mg U/m3 uranium tetrafluoride (Dygert 1949a), and 9.2 mg 
U/m3 uranyl fluoride (Rothstein 1949a).  It is possible that irritation of the gastrointestinal tract occurred 
either from clearance of uranium particles from the lungs or ingestion of uranium from grooming of 
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uranium particulates deposited on the fur during the whole-body exposures.  Histopathological 
examination of rat gastrointestinal tissues revealed no changes after 1-year exposures to 0.2 mg U/m3 
uranium hexafluoride or uranium tetrachloride (Stokinger et al. 1953). 
 
Hematological Effects.    Inhalation exposure to uranium compounds has generally had no effect, or 
only minor effects, on hematological parameters in both humans and animals.  In human studies, no 
hematological effects were found in a man who was accidentally exposed to powdered uranium 
tetrafluoride for 5 minutes (Lu and Zhao 1990).  Air concentration and mean particle size of the powder 
were not determined.  Small but significant decreases in the hemoglobin concentration and the mean 
corpuscular hemoglobin concentration and significant increases in red blood cells counts and mean 
corpuscular volume were found in uranium miners who had worked for <5–20 years.  All values 
measured were well within the normal range, such that values for individual miners could not be used as 
an estimate of exposure.  No evidence of damage to red blood cell formation was found.  The ambient 
concentration to which these workers had been exposed was not provided in the study (Vich and Kriklava 
1970). 
 
A study on the mortality among uranium mill workers found four deaths from lymphatic and 
hematopoietic tissue effects other than leukemia, while only one was statistically expected among these 
workers, who were occupationally exposed to uranium dust at airborne levels corresponding to a 
radioactivity concentration of 0.07 nCi/m3 (0.1 mg/m3).  However, the authors of this study suggest that 
this excess may be due to irradiation of the lymph nodes by thorium-230 (230Th) (Archer et al. 1973b).  
No changes in hematological parameters were observed in humans occupationally exposed to insoluble 
uranium dust at 0.5–10 mg U/m3 (Eisenbud and Quigley 1956). 
 
Some intermediate-duration animal studies observed a range of hematological changes.  Rats exposed to 
dusts of ammonium diuranate containing 6.8 mg U/m3 for 6 hours/day for 30 days showed a decrease of 
1 million in red blood cell counts and a loss of 4 g of hemoglobin/100 mL of blood (Dygert 1949b).  It 
was not stated whether exposure was for 30 consecutive days or on weekdays only.  Rats exposed to 
airborne uranyl nitrate hexahydrate containing 9.5 mg U/m3 for 8 hours/day, 5 days/week for 30 exposure 
days showed decreased numbers of erythrocytes and hemoglobin (measured at 24 hours postexposure and 
weekly thereafter) (Roberts 1949).  Increased percentages of lymphoid cells and myeloblasts in bone 
marrow were reported at termination in rats exposed to airborne uranium peroxide containing 
15.4 mg U/m3 5 hours/day 5 days/week for 23 days (Dygert 1949d).  A 4-week study in rats exposed to 
airborne uranium as uranium trioxide at a concentration corresponding to 16 mg U/m3 6 hours/day 
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6 days/week reported similar findings (significant increases in myeloblasts and lymphoid cells of bone 
marrow) (Rothstein 1949c).  Rabbits and rats exposed to airborne uranium at a level corresponding to a 
uranium concentration of 0.13 mg/m3 as uranyl nitrate hexahydrate for 30 days exhibited altered blood 
function as indicated by decreased fibrinogen during the final week of exposure (Roberts 1949). 
 
In contrast to the above findings, most other intermediate-duration animal inhalation studies with soluble 
and insoluble uranium compounds found no adverse effects on the blood.  In intermediate-duration 
inhalation studies lasting 23–40 days, exposure to various uranium compounds at the following 
concentrations produced no harmful effects on hematological parameters:  22 mg U/m3 as high-grade 
carnotite uranium ore to rats; 2.8 mg U/m3 as uranium dioxide or triuranium octaoxide to dogs; 
22 mg U/m3 as uranium dioxide or triuranium octaoxide to rabbits; 11 mg U/m3 as uranium tetrachloride 
to rats; 2 mg U/m3 as uranium tetrachloride to rabbits; 1 mg U/m3 as uranium tetrachloride to dogs; 
13.2 mg U/m3 as uranium hexafluoride to rabbits and dogs; 0.1 mg U/m3 as uranium hexafluoride to dogs; 
14.5 mg U/m3 as triuranium octaoxide to mice; 14.5 mg U/m3 as uranium dioxide or triuranium octaoxide 
to rabbits; 14.5 mg U/m3 as triuranium octaoxide to guinea pigs and rabbits; 15.4 mg U/m3 as uranium 
peroxide to dogs, rabbits, and cats; or 4.8 mg/m3 as triuranium octaoxide to rats, mice, guinea pigs, and 
rabbits (Dygert 1949c, 1949d; Pozzani 1949; Rothermel 1949; Spiegl 1949). 
 
In other intermediate-duration studies, inhalation exposures to uranium dioxide dusts containing 
1 mg U/m3 for 30 weeks and 2 mg U/m3 for 26 weeks in rabbits and guinea pigs, respectively (Stokinger 
et al. 1953), 19.4 mg U/m3 for 5 weeks in mice, and 9.2 mg U/m3 for 5 weeks in dogs and rats had no 
adverse effects on hematological parameters (Rothstein 1949b).  Similarly, exposures to 9.2 mg U/m3 for 
5 weeks to rats and dogs (Rothstein 1949a); 16 mg U/m3 for 4 weeks to rats, rabbits, cats, and dogs 
(Rothstein 1949c); and 15 mg U/m3 as sodium diuranate to rats had no harmful effects on hematological 
parameters (Rothermel 1949). 
 
In chronic-duration exposures, dogs exposed to an airborne uranium concentration of 0.2 mg U/m3 as 
uranium hexafluoride for 1 year exhibited a lengthening in blood clotting time with a decrease in blood 
fibrinogen levels (Stokinger et al. 1953).  However, hamsters exposed to airborne carnotite uranium ore 
dust containing 0.7 mg U/m3 for 16–27 months exhibited no adverse hematological effects (Cross et al. 
1981b).  Similarly, no changes in hematological parameters were observed in rats, dogs, rabbits, and 
monkeys exposed to airborne uranium at concentrations ranging from 1 to 5.1 mg U/m3 for 1–5 years 
(Leach et al. 1970, 1973; Rothstein 1949b; Stokinger et al. 1953). 
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Musculoskeletal Effects.    No studies were located regarding the chemical or radiation effects of 
uranium on the musculoskeletal system in humans or animals following inhalation exposure for any 
duration. 
 
Hepatic Effects.    No hepatic effects were found in a man accidentally exposed to powdered uranium 
tetrafluoride for 5 minutes (Lu and Zhao 1990).  Air concentration and mean particle size of the powder 
were not determined.  Serum hepatic enzyme levels and liver function tests were within normal limits 
from the time of the incident through a 3-year follow-up period. 
 
Data from the available studies provide equivocal evidence that exposure of animals to uranium has 
effects on the liver, although the etiology for this effect is not clear.  Urinary catalase, a measure of 
hepatic injury, was significantly increased in rabbits exposed to 0.13 mg U/m3 as uranyl nitrate 
8 hours/day, 5 days/week for 30 days (Roberts 1949).  A slight decrease in hepatic lactate content was 
observed in rabbits following exposure to 15 mg U/m3 as sodium diuranate dust (Rothermel 1949).  
Rabbits exposed to 16 mg U/m3 as uranium trioxide dust for 4 weeks suffered moderate fatty livers in 
63% of the animals that died (Rothstein 1949c).  Focal necrosis of the liver was observed in rats exposed 
to 0.4 mg U/m3 as uranium tetrafluoride for 30 days (Dygert 1949a).  In other studies, no changes were 
found in the liver morphology, histology, or function in the following animals:  rabbits exposed to 0.15 or 
2 mg U/m3 as uranyl nitrate hexahydrate for 26 weeks; rats exposed to 14.5 mg U/m3 as triuranium 
octaoxide dust for 26 days; rats exposed to 16 mg U/m3 as uranium trioxide for 4 weeks; mice and guinea 
pigs exposed to 3 mg U/m3 as high-grade uranium ore dust for 30 days; and rabbits exposed for 30 days to 
22 mg U/m3 as high-grade uranium ore dust (contains uranium dioxide, triuranium octaoxide, and other 
potentially toxic contaminants) (Dygert 1949c; Pozzani 1949; Rothstein 1949c; Stokinger et al. 1953). 
 
In chronic-duration exposure studies with animals, an unspecified strain of dogs exposed to ambient air 
concentrations of 0.05–0.2 mg U/m3 as uranium hexafluoride for 1 year exhibited increased and persistent 
bromosulfalein retention, indicative of impaired biliary function, at the 0.2 mg U/m3 concentration level 
(Stokinger et al. 1953). 
 
Renal Effects.    Uranium has been identified as a nephrotoxic metal, exerting its toxic effect by 
chemical action mostly in the proximal tubules in humans and animals.  However, it has been suggested 
that the renal damage from exposure to high-linear energy transfer coefficient (LET) alpha-emitting 
heavy metals, such as uranium, may be the complementary effect of both the chemical toxicity and the 
radiotoxicity of these metals (Wrenn et al. 1987). 
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Several epidemiologic studies found no increased mortality in uranium workers due to renal disease 
(Archer et al. 1973a, 1973b; Checkoway et al. 1988; NIOSH 1987; Pinkerton et al. 2004; Polednak and 
Frome 1981).  Also, case studies showed that workers accidentally exposed to high levels of uranium did 
not suffer renal damage, even up to 38 years postexposure (Eisenbud and Quigley 1956; Kathren and 
Moore 1986), although the tests for renal damage used in these studies were not very sensitive.  A 
comparison of kidney tissue obtained at autopsy from seven uranium workers and six referents with no 
known exposure to uranium showed that the groups were indistinguishable by pathologists experienced in 
uranium-induced renal pathology (Russell et al. 1996).  Three of seven workers and four of six referents 
were categorized as abnormal.  Uranium levels in the workers kidney tissue (estimated by alpha particle 
emission) ranged from 0.4 to 249 μg/kg.  As reviewed by Eisenbud and Quigley (1956), no evidence of 
renal toxicity was observed in workers exposed to insoluble uranium compounds; 100 workers were 
exposed to 0.5–2.5 mg U/m3 and another 50 workers were exposed to 2.5–10 mg U/m3.  Eisenbud and 
Quigley (1956) did not provide information on the parameters used to assess renal toxicity.  A study on 
the kidney function of uranium mill workers chronically exposed to biologically soluble ammonium 
diuranate revealed renal tubular dysfunction as manifested by mild proteinuria, aminoaciduria, and a 
concentration-related clearance of β2-microglobulin relative to that of creatinine when compared to a 
referent group of cement workers.  Air levels of uranium dioxide were not reported; the mean (and 
median) urinary uranium levels were 65.2 µg/L (20 µg/L) in 1975 and 7.2 µg/L (6 µg/L) in 1981 after a 
new facility was built.  The incidence and severity of these nephrotoxic signs correlated with the length of 
time that the uranium workers had spent in the area where yellowcake was dried and packaged in the old 
mill (prior to mid-1979) (Thun et al. 1985), which is typically the second dustiest area of the uranium mill 
following the ore crushing and grinding station.  The data from this study are indicative of reduced 
reabsorption in the proximal renal tubules. 
 
Delayed renal effects were observed after a male worker at a uranium enrichment plant was accidentally 
exposed to a high concentration of uranium tetrafluoride powder for about 5 minutes in a closed room.  
While renal parameters were normal during an initial 30-day observation period, the patient showed signs 
of nephrotoxicity beginning at postaccident day 68 as indicated by significantly elevated levels of urinary 
proteins, nonprotein nitrogen (NPN), and amino acid nitrogen/creatinine, and decreased phenol-
sulfonpthalein excretion rate.  These abnormalities persisted through day 1,065, but gradually returned to 
normal (Lu and Zhao 1990).  The authors used uranium urinalysis data and a pharmacokinetic model 
(ICRP 1979) to estimate a kidney dose of 2.6 μg U/g kidney on postaccident day 1. 
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Renal effects were not observed in another accidental exposure (USNRC 1990) in which 24 of 31 initially 
exposed workers were followed for 2 years.  Estimated airborne concentrations were 20 mg uranium 
hexafluoride/m3 for a 1-minute exposure and 120 mg uranium hexafluoride/m3 for a 60-minute exposure 
(15.2 and 91 mg U/m3, respectively) (USNRC 1986).  Initial intakes of workers involved in the accident 
were estimated from uranium excretion data and ranged from 470 to 24,000 μg uranium.  Maximum 
uranium concentrations in the kidney were estimated by a kinetic model to be 0.048–2.5 μg U/g kidney 
tissue (Fisher et al. 1991). 
 
The pathogenesis of the kidney damage in animals indicates that regeneration of the tubular epithelium 
occurs upon discontinuation of exposure to uranium (Bentley et al. 1985; Dygert 1949b; Maynard and 
Hodge 1949; Pozzani 1949; Rothermel 1949; Rothstein 1949b, 1949c; Spiegl 1949; Stokinger et al. 
1953).  The magnitude of uranium intake that causes kidney damage depends on the type of uranium 
compound to which the animal has been exposed, appearing to depend on its solubility and oxidation 
state.  For example, in dogs and monkeys, exposure to 5 mg U/m3 as uranium dioxide (insoluble) dust for 
up to 5 years produced no damage to the kidneys, even 6.5 years after the exposure ceased (Leach et al. 
1970, 1973).  Similarly, rats and guinea pigs were exposed to ≤10 mg U/m3 as uranium dioxide for 1 year 
without noticeable kidney pathology (Stokinger et al. 1953).  Uranium dioxide is relatively insoluble in 
water and is retained in the lungs longer than the other more soluble uranium compounds (uranium 
tetrafluoride, uranyl fluoride, uranium tetrachloride, uranium peroxide, uranyl acetate, and uranyl nitrate 
hexahydrate), thereby causing higher toxicity to the lungs and lower toxicity to distal organs such as the 
kidney.  In contrast, relatively soluble uranium compounds have been shown to cause renal tubular 
damage in dogs, guinea pigs, rabbits, and rats (Leach et al. 1984; Morrow et al. 1982a; Roberts 1949; 
Stokinger et al. 1953).  Apparently, the difference in effect is due to the extent of absorption of uranium 
deposited in the lungs and, thus, the fraction that eventually gets into the blood.  Differences in species 
susceptibility have also been suggested to be an additional factor. 
 
Renal effects can be produced in animals after acute-duration inhalation exposures to uranium.  A 
10-minute exposure to 637 mg U/m3 as uranium hexafluoride produced severe degeneration of the 
cortical tubules 5–8 days later in rats (Spiegl 1949).  These same effects were observed in dogs 1–3 days 
after a 1-hour exposure to 250 mg U/m3 as uranyl fluoride (Morrow et al. 1982a).  Proteinuria and 
glucosuria were also observed in rats after 2–10-minute exposures to uranium hexafluoride (Leach et al. 
1984). 
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In intermediate-duration studies with guinea pigs, mice, rats, cats, rabbits, and dogs, inhalation exposures 
to a variety of uranium compounds were damaging to the kidneys.  The effects were compound- and 
concentration-dependent and ranged from minimal microscopic lesions in tubular epithelium, increased 
urinary catalase, decreased diodrast (iodopyracet) clearance to severe necrosis of the tubular epithelium 
(for high concentrations) in several species (Dygert 1949a, 1949b, 1949c; Pozzani 1949; Roberts 1949; 
Rothermel 1949; Rothstein 1949a, 1949c; Spiegl 1949; Stokinger et al. 1953).  Soluble uranium 
compounds were more toxic, as evidenced by much lower LOAEL values, than the insoluble compounds.  
In an intermediate-duration inhalation exposure study, mice were exposed to uranium tetrachloride dust at 
ambient air concentrations of 0.1, 2.1, or 11 mg U/m3 for 3–7 hours/day 6 days/week for approximately 
30 days.  The exposure resulted in severe degeneration and necrosis of the renal-cortical tubular 
epithelium, as well as mortality, in the 11 mg U/m3 group by the third day.  At the end of the study, 
moderate tubular degeneration was observed in the 2.1 mg U/m3 group and minimal degeneration was 
noted in the 0.1 mg U/m3 group (Rothermel 1949).  In another intermediate-duration study, rats suffered 
renal injury (of inconsistent severity), which became apparent on or about the 7th day and pronounced by 
the 25th or 26th day, following inhalation exposure to uranyl nitrate hexahydrate at 0.13, 0.2, 0.9, 2.1, or 
9.5 mg U/m3 daily for 8 hours/day, 5 days/week for 30 days.  At 0.9 mg U/m3, the rats showed significant 
degenerative changes only in the renal tubules and no changes to the glomeruli.  Rats exposed to 
0.2 mg U/m3 exhibited only slight damage to the tubular epithelium of the kidneys.  At 0.13 mg U/m3, 
slight renal tubular degeneration was observed in one of the three animals sacrificed after 28 days of 
exposure.  Except for the group receiving no dietary supplement, no significant difference in blood CO2 
values was seen at 14 days of exposure to uranium.  Thirty days after the start of exposure, all groups 
exhibited increased blood NPN levels over 14-day values (maximum 111 mg/mL blood for the 
unsupplemented diet group).  No clinical signs of toxicity were observed at any concentration level 
(Roberts 1949). 
 
Dogs (of both sexes) exposed to 0.13 mg U/m3 as uranyl nitrate hexahydrate showed mild inner cortex 
changes after 10 days of exposure.  The dogs were given full-body exposures to aerosols with an AMAD 
assumed to be 1.5–2.1 μm; the average was 1.8 μm (Pozzani 1949).  Severe nephritis masked any damage 
from uranium in one dog sacrificed after 10 days of exposure.  The dogs showed a transient elevation in 
protein excretion between days 9 and 12 of exposure.  Increased bromosulfalein retention was observed 
during the second and fourth weeks of exposure.  No alterations to blood NPN or total blood CO2 were 
observed.  Chloride clearance values, which were initially elevated and then became depressed in 
one dog, returned to normal 37 days after the beginning of exposure.  Catalase and protein excretion 
increased significantly, but returned to normal at the end of exposure.  No significant changes in diodrast 
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clearance, inulin clearance, or blood NPN levels were observed.  Dogs exposed to 0.9 mg U/m3 exhibited 
mild inner cortex and medullary ray degeneration and necrosis with moderate epithelial regeneration.  
Two of the four animals showed a steady rise in NPN from the beginning of the experiment until they 
were sacrificed 12 days later, at which time NPN values were 252 and 356 mg%, respectively.  Urinary 
protein in the dogs significantly increased between the 5th and 24th days.  The mean NPN level in a 
control study performed in the same lab was approximately 32 mg% (Sprague 1949).  The dogs showed a 
decrease in inulin clearance during the third week of exposure, with a return toward normal values during 
the fifth week.  There was decreased diodrast clearance throughout the observation period, indicating a 
severe reduction of the excretory capability for diodrast after 1 week (one dog showed a decrease of 
69%).  Diodrast clearances returned to normal by days 35–37.  Two dogs showed a transient decrease in 
inulin clearance during the third week, lasting until the fifth week.  All four dogs showed a drop in total 
blood CO2, attaining a minimum value between the first and seventh days.  The minimum value was 
generally less than half that of controls, indicating severe acidosis.  Glucose tolerance was significantly 
decreased.  Large quantities of protein (400–800 mg%) and sugar were excreted.  The greatest excretion 
occurred during the first 6 days of exposure and decreased thereafter.  There was also a decrease in 
urinary creatinine excretion during the exposure.  At the 2 mg U/m3 exposure level, the dogs did not show 
highly elevated NPN and BUN values during exposure.  There were no increases in blood NPN or BUN.  
All dogs exposed to 9.5 mg U/m3 had severe renal tubular damage.  Four dogs showed renal injury 
followed by repair when they were sacrificed at the end of the exposure (Roberts 1949). 
 
No treatment-related renal effects were seen in other studies when animals were exposed to uranium 
compounds by inhalation at concentrations as high as 10 mg U/m3 (as uranium dioxide) in guinea pigs for 
28 weeks, 2 mg U/m3 (as uranyl nitrate hexahydrate) in guinea pigs for 26 weeks, and 16 mg U/m3 (as 
uranyl nitrate hexahydrate) in rats for 4 weeks (Rothstein 1949c; Stokinger et al. 1953). 
 
The nephrotoxic effects of uranium in animals may also include damage to the glomerulus as evidenced 
by histopathological signs in the kidneys of rats and rabbits exposed to 15.4 mg U/m3 as uranium dioxide 
for 23 days (Dygert 1949d) and of dogs exposed to 15 mg U/m3 as uranyl fluoride for 5 weeks 
(Rothermel 1949) and to 16 mg U/m3 as uranium trioxide for 4 weeks (Rothstein 1949c). 
 
In chronic-duration inhalation studies with rats and dogs, uranium (as uranium tetrachloride, uranium 
tetrafluoride, uranyl nitrate hexahydrate, or uranium dioxide) exposures as low as 0.05 mg U/m3 and as 
high as 10 mg U/m3 for 1–5 years were damaging to the kidneys.  Nephrotoxic effects found in these 
animals ranged from minimal microscopic lesions in tubular epithelium (for low concentrations) to acute 
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tubular necrosis (for high concentrations) (Leach et al. 1970; Stokinger et al. 1953).  In one of these 
chronic-duration studies, dogs were exposed to ambient air concentrations of 0.05 or 0.2 mg U/m3 as 
uranium hexafluoride for 1 year for a total of 1,680 exposure hours.  The UF6 was rapidly hydrolyzed to 
HF gas and UO2F2 fumes, whose AMAD was 0.1 μm.  After 10 days in the study, there was evidence of 
mild tubular injury, which was characterized by desquamation of the epithelium and active regeneration 
in the proximal convoluted tubule in the inner cortex of the kidneys in 86% of animals exposed to 
0.2 mg U/m3.  From the 16th week to the end of the study, regeneration of the tubular epithelium was 
almost complete, with a few flattened atrophic tubules in the inner zone of the cortex.  These mild 
nephrotoxic effects were also observed in 12% of the 0.05 mg U/m3 exposed animals.  Blood NPN levels 
were normal (elevated blood NPN levels indicate a decrease in renal filtration capacity, similarly to 
elevated BUN).  Observed changes in urinary protein were inconsistent and insignificant (Stokinger et al. 
1953). 
 
In another study, dogs of both sexes (9–12 males, 9–13 females) were exposed to concentrations of 0.04, 
0.15, 0.25, or 2 mg U/m3 as uranyl nitrate for 6 hours/day, 5.5 days/week for 1 year.  The AMAD of the 
aerosols was given as 2–5 μm.  At the termination of the study, histological and biochemical 
examinations revealed minimal microscopic lesions in the renal tubules and transient increases in blood 
NPN in the 0.25 mg U/m3 concentration-level dogs.  Transient increases in blood NPN were also 
observed at higher concentration levels (Stokinger et al. 1953). 
 
No treatment-related renal effects were seen in dogs exposed to uranium dioxide by inhalation at airborne 
concentrations as high as 5.1 mg U/m3 for 1–5 years (Leach et al. 1973).  In similarly exposed Rhesus 
monkeys, blood NPN levels were consistently elevated; however, no renal histopathology was evident 
(Leach et al. 1973). 
 
Endocrine Effects.    A single study was found that reported on possible effects of uranium on the 
endocrine system.  In this study, no histopathology was seen in the endocrine organs (adrenal, pancreas) 
in rats exposed to 0.2 mg U/m3 as uranium tetrachloride for 1 year (Stokinger et al. 1953). 
 
Dermal Effects.    No dermal effects were found in a man accidentally exposed to powdered uranium 
tetrafluoride for 5 minutes (Lu and Zhao 1990).  Histopathologic examination of the skin was normal in 
rats exposed to 0.2 mg U/m3 as uranium tetrachloride for 1 year (Stokinger et al. 1953). 
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Ocular Effects.    Chemical burns to the eyes were reported in humans after accidental exposure to 
uranium hexafluoride (Kathren and Moore 1986).  Conjunctivitis and eye irritation have also been 
reported in animals after exposure to uranium hexafluoride (Spiegl 1949) and uranium tetrachloride 
(Dygert 1949a).  Ocular effects were due to direct contact of the eye with vapor or aerosols; because 
uranyl fluoride and hydrogen fluoride (a highly irritating chemical) are produced when uranium 
hexafluoride comes in contact with moisture, it is possible that uranium was not the causative agent for 
the ocular effects. 
 
Body Weight Effects.    In general, inhalation of insoluble uranium compounds did not significantly 
affect body weight in animals.  Decreased body weight was observed with the more water-soluble 
compounds.  A 30% decrease in body weight was reported for rabbits exposed to 11 mg U/m3 as uranium 
tetrachloride dust for 35–40 days.  Mice and guinea pigs experienced unspecified weight loss and 13% 
weight loss, respectively, following exposure to 13 mg U/m3 as uranium hexafluoride for 30 days.  
Rabbits suffered 12% weight loss following exposure to 0.2 mg U/m3 as airborne uranium hexafluoride 
for 30 days (Spiegl 1949).  Mild to severe weight loss was observed in several species during exposure to 
uranyl nitrate hexahydrate (Roberts 1949).  Rabbits lost 22% of their body weight during a 30-day 
exposure to 0.9 mg U/m3, dogs and cats lost approximately 25% of their body weight during a similar 
exposure to 9.5 mg U/m3.  Similar effects were observed with uranium tetrafluoride (Dygert 1949a).  
Rabbits, rat, cats, and dogs all experienced a greater than 20% weight loss during 30 days exposure to 
18 mg U/m3. 
 
Several intermediate-duration animal inhalation studies with soluble and insoluble uranium compounds 
found no significant adverse effects on body weight.  In short-term intermediate-duration studies lasting 
23–40 days, exposure to concentrations at the following levels were without significant effects on body 
weight:  22 mg U/m3 as high-grade or carnotite uranium ore to rats, 2.9 mg U/m3 as uranium dioxide or 
triuranium octaoxide to dogs, 22 mg U/m3 as uranium dioxide or triuranium octaoxide to rabbits, 
11 mg U/m3 as uranium tetrachloride to rats, 2.1 mg U/m3 as uranium tetrachloride to rabbits, 
1.1 mg U/m3 as uranium tetrachloride to dogs, 13 mg U/m3 as uranium hexafluoride to rabbits and dogs, 
0.2 mg U/m3 as uranium hexafluoride to dogs and guinea pigs, 14.5 mg U/m3 as triuranium octaoxide to 
mice, and 4.8 mg U/m3 as triuranium octaoxide to guinea pigs and rabbits (Dygert 1949c; Spiegl 1949); 
15 mg U/m3 as uranium peroxide to cats and rabbits (Dygert 1949d); 15 mg U/m3 as carnotite ore (mostly 
uranium dioxide, triuranium octaoxide) to dogs or 22 mg U/m3 as carnotite ore to rabbits for 30 days 
(Pozzani 1949); and 1 mg U/m3 for 30 weeks to rabbits or 2 mg U/m3 for 26 weeks to rabbits and guinea 
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pigs (Stokinger et al. 1953).  Exposures of rats to 13 mg U/m3 or of rabbits to 0.1 mg U/m3 as uranium 
hexafluoride for 30 days also were without harmful effects (Spiegl 1949). 
 
No effects on body weight were observed after several intermediate-duration dosing studies that lasted 4–
5 weeks.  These studies researched exposures by the inhalation route as follows:  16 mg U/m3 as uranium 
trioxide to rats, rabbits, dogs, and cats; 19 mg U/m3 as uranium dioxide to mice; 16 mg U/m3 as uranium 
dioxide to guinea pigs; 9.2 mg U/m3 as uranyl fluoride to dogs and rabbits; 2.2 mg U/m3 as uranyl 
fluoride to rats; 9.2 mg U/m3 as uranium dioxide to dogs; 19.2 mg U/m3 as uranium dioxide to rabbits; 
15 mg U/m3 as sodium diuranate to rats and dogs; and 12 mg U/m3 as ammonium diuranate to rats for 
30 days (8 hours/day, 5 days/week for 6 weeks) (Rothermel 1949; Rothstein 1949a, 1949b, 1949c; 
Stokinger et al. 1953).  Hamsters exposed to 0.8 mg U/m3 as carnotite uranium ore by inhalation for 16–
27 months also exhibited no adverse body weight effects (Cross et al. 1981b).  Similarly, no changes in 
body weight were observed in rats, dogs, rabbits, and monkeys exposed to airborne uranium dioxide at 
0.1–5 mg U/m3 for 1–5 years (Leach et al. 1970, 1973; Stokinger et al. 1953). 
 
In chronic-duration studies, exposure of monkeys to concentrations of 3 mg U/m3 as uranium dioxide for 
5 years produced no significant body weight changes (Leach et al. 1970). 
 
Other Systemic Effects.    Several general effects have been attributed to uranium inhalation 
exposure.  In animal studies, dogs exposed to 13 mg U/m3 as uranium hexafluoride for 30 days exhibited 
decreased water intake (Spiegl 1949).  Reduced food intake was also observed in a 4-week study of rats 
and mice exposed to 16 mg U/m3 as uranium trioxide (Rothstein 1949c) and in a 5-week study of rats and 
mice exposed to 15 mg U/m3 as sodium diuranate for 6 hours/day, 5.5 days/week (Rothermel 1949). 
 
3.2.1.3   Immunological and Lymphoreticular Effects  
 
Although no studies were located that specifically tested immunological effects in humans following 
inhalation exposure to uranium, none of the epidemiologic studies of workers in uranium mines and fuel 
fabrication plants showed increased incidence of death due to diseases of the immune system (Checkoway 
et al. 1988; Keane and Polednak 1983; NIOSH 1987; Polednak and Frome 1981). 
 
Human studies that assessed damage to cellular immune components following inhalation exposure to 
uranium found no clear evidence of an immunotoxic potential for uranium.  No association was found 
between the uranium exposure and the development of abnormal leukocytes in workers employed for 12–
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18 years at a nuclear fuels production facility (Cragle et al. 1988).  Increases in the number of fatal 
malignant disease of the lymphatic and hematopoietic tissue reported among uranium mill workers may 
have been caused by other carcinogens in the work environment such as 230Th.  The study investigators 
estimated that the workers were exposed to 8–5,100 mg/m3 (median 110 mg/m3) uranium mill dust, which 
contains 230Th as a natural component (Archer et al. 1973b). 
 
In animal studies, rats exposed to dusts of ammonium diuranate containing 6.8 mg U/m3 for 6 hours/day, 
5 days/week for 30 days developed a rise in neutrophils, a decrease in lymphocytes, a moderate fall in the 
white blood cell count, and a rise in the number of eosinophils (Dygert 1949b).  Rats exposed to airborne 
uranyl nitrate hexahydrate containing 9.5 mg U/m3 8 hours/day, 5 days/week for 30 exposure days 
showed an initial increase and a subsequent decrease in the absolute number of lymphocytes and 
neutrophils (Roberts 1949).  Focal necrosis of the spleen and edematous cecal lymph nodes were 
observed in some rats exposed for 30 days for 6 hours/day to 0.4 and 4 mg U/m3 uranium tetrafluoride 
(Dygert 1949a).  However, these effects were not observed at 18 mg U/m3, so the significance of this 
finding is unclear. 
 
No histopathological changes or accumulation of uranium were evident in the spleens of 110 dogs and 
25 monkeys exposed to uranium dioxide dusts (5 mg U/m3) for 6 hours/day, 5 days/week for 1–5 years 
and then monitored for up to 6.5 more years.  Similar results were seen for rats similarly exposed for 
1 year (Leach et al. 1970, 1973).  Rats, rabbits, guinea pigs, and dogs exposed to dusts of various uranium 
compounds for 7–12 months showed no significant histological changes in the lymph nodes and marrow 
(Stokinger et al. 1953). 
 
There is some evidence from animal studies that exposure to ≥90% enriched uranium may affect the 
immune system.  Increased macrophage activity, associated with localized alpha tracks in all five lobes of 
the lungs, was seen in F344 rats exposed to 6,825.5 nCi/m3 through inhalation exposure to enriched 
uranium dioxide for 100 minutes (Morris et al. 1992).  The radioactive material concentration of the 
mixture was estimated as 1.91 kBq/mg (51.6 nCi/mg); the degree of enrichment was calculated based on 
this specific activity.  The increased activity was evident from days 1–7, 180, 360, 540, and 720 with 
increases in percent activity of 0.44, 2.15, 19.70, 6.54, and 37.84, respectively.  The number and size of 
macrophage clusters in the lung increased with time postexposure. 
 
Albino HMT (F344) male rats were exposed to 92.8% enriched uranium dioxide with a concentration 
ranging from 2,274.2 nCi/m3 (84.1 kBq/m3) to 5,458 nCi/m3 (202 kBq/m3).  Increases in the sizes and 
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numbers of lung macrophages, with a significant increase in the size of lysosomal granules within the 
macrophages, were reported 8 days postexposure (Morris et al. 1989). 
 
Dogs exposed to airborne uranium dioxide concentrations of 5.1 mg/m3 for 1–5 years showed lymph node 
fibrosis in the lungs.  Rhesus monkeys similarly exposed for 5 years showed fibrotic changes in the 
tracheobronchial lymph nodes.  The investigators of these studies concluded that although these effects 
could not be extrapolated to humans because of the absence of squamous cell carcinomas in the lungs, the 
changes were suggestive of radiation injury (Leach et al. 1973).  However, the morphological changes 
observed in these studies were similar to observations in humans and animals as a result of exposure to 
diverse inorganic dust (Dockery et al. 1993). 
 
The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
immunological effects from chemical exposures by the inhalation route to uranium are presented in 
Table 3-1 and plotted in Figure 3-1. 
 
3.2.1.4   Neurological Effects  
 
A limited number of studies have examined the potential of uranium to induce neurological effects in 
humans or animals following inhalation exposure.  In the available studies, uranium has not been shown 
to cause damage to the nervous system of humans by metallotoxic or radiotoxic action following 
inhalation exposures for any duration.  Although no studies were located that specifically tested 
neurological effects in animals following inhalation exposure to uranium, none of the available studies 
reported any neurological deficits, such as narcosis, ataxia, or cholinergic signs.  Clinical signs in humans 
following acute exposure to enriched uranium included dizziness and anorexia in one man 6 days after 
being exposed for 5 minutes to uranium tetrafluoride by inhalation (Lu and Zhao 1990), but did not 
include neurological effects in others similarly exposed to uranium hexafluoride (Kathren and Moore 
1986; USNRC 1986).  Some of the victims were evaluated for as long as 38 years after exposure (Kathren 
and Moore 1986).  In longer-term exposures, epidemiologic studies found no increase in deaths from 
brain tumors or other neurological diseases that could be attributed to uranium in workers at uranium-
processing plants (Carpenter et al. 1988; Cragle et al. 1988; NIOSH 1987; Polednak and Frome 1981; 
Reyes et al. 1984).  The autopsy reports also did not reveal any other structural pathology of the central 
nervous system.  In a retrospective study, more deaths than expected were found from central and 
peripheral nervous system diseases (SMR=2.98) in employees in a nuclear fuels fabrication plant.  
However, the employees were also concurrently exposed to other radiological and chemical agents.  The 
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investigators of this study concluded that there was no etiology associated with uranium for the central 
nervous system and peripheral nervous system diseases (Hadjimichael et al. 1983). 
 
In intermediate-duration animal studies, neurological signs were observed in dogs and cats following 
inhalation exposure to uranium.  On the 13th day of a 30-day study, dogs exposed to 0.5, 3, 4, or 
18 mg U/m3 as uranium hexafluoride gas by inhalation exhibited muscular weakness followed by 
instability of gait indicative of neurological dysfunction at the highest concentration tested (Dygert 
1949a).  Anorexia observed in of dogs exposed 8 hours/day, 5 days/week for 30 days to 9.5 mg U/m3 as 
uranyl nitrate hexahydrate may also have had its origin in neurological dysfunction (Roberts 1949).  
Similarly, cats exposed to 18 mg U/m3 as uranium tetrafluoride exhibited unsteady gait on the seventh 
day in a 30-day study (Dygert 1949a).  In 5-week studies (8 hours/day, 5 days/week), dogs and cats 
exposed to 0.15, 2.2, or 9.2 mg U/m3 as uranyl fluoride suffered anorexia, severe muscle weakness, and 
lassitude at the highest concentration tested (Rothstein 1949a).  These neurological effects were observed 
in animals exposed to lethal concentrations. 
 
In 12 rats exposed to 190 mg U/m3 as depleted uranium dioxide 30 minutes/day, 4 days/week for 3 weeks, 
a significant increase in spontaneous activity (both locomotor and rearing behaviors) was observed on day 
1 postexposure, but not on day 5 postexposure (Monleau et al. 2005).  This appeared to correlate with a 
rapid reduction in uranium concentration in the hippocampus, frontal cortex, cerebellum, and olfactory 
bulb; with the exception of the hippocampus, brain uranium levels reached control levels by the 3rd 
postexposure day.  A depression of spatial working memory was also observed on day 6 postexposure, 
but not on day 1 postexposure; no alterations in exploratory activity were observed. 
 
The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
neurological effects by the inhalation route to uranium are presented in Table 3-1 and plotted in 
Figure 3-1. 
 
3.2.1.5   Reproductive Effects  
 
It is unlikely that inhalation of uranium produces a significant effect on reproductive health.  Studies of 
one human population group (miners) were located that identified a reproductive effect associated with 
the inhalation exposure of mine air, but the association with uranium compounds was unclear, and the 
other miner studies observed no reproductive effects. 
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Three studies of one mining population were located that equivocally associated reproductive effects in 
humans following inhalation exposure to uranium.  The studies reported that male uranium miners were 
found to have more first-born female children than expected (Muller et al. 1967; Waxweiler et al. 1981b; 
Wiese and Skipper 1986).  In addition, it is not certain if the effect described is from exposure to uranium 
because the workers were also exposed to 222Rn, chlorine, hydrofluoric acid, lead sulfate, nickel, nitric 
acid and nitrogen oxides, silicon dioxide, and sulfuric acid (Dupree et al. 1987). 
 
No animal studies were located that described reproductive effects following inhalation exposure to 
uranium for any duration of exposure. 
 
3.2.1.6   Developmental Effects  
 
No studies were located that specifically reported effects of uranium on development in humans or 
animals following inhalation exposures for any duration.  However, the issue of teratogenicity of depleted 
uranium aerosols in humans was reviewed by Hindin et al. (2005).  The investigators examined a series of 
reports that included groups of Gulf War veterans from the United States, the United Kingdom, Canada, 
and Australia; reports from Iraqi hospitals and clinics during and after the war; reports of birth defects in a 
New Mexico community living near a depleted uranium weapons testing facility; reports of birth defects 
in infants born in Bosnia and Herzegovina after the Bosnia War or in Kuwait after the Gulf War; and 
other reports.  Most of the data from these reports have not been published in peer-reviewed journals; 
some have been published in newspapers or presented at Iraqi conferences.  Lacking from all reports was 
documentation of individual depleted uranium exposure and other wartime-generated substances, as well 
as nutritional and environmental factors.  Some reports lacked methodologically rigorous investigation, 
while in others, the incidences of birth defects between purportedly exposed and nonexposed groups were 
not statistically significant.  Of particular interest is a report from three major maternity hospitals in 
Basra, Iraq, which noted a dramatic increase in the incidence of total congenital malformations since the 
1991 war.  However, Hindin et al. (2005) note that very low incidence reported prewar often reached 
baseline Western levels by 1999–2000.  Of note is the case of hydrocephalus, which the report of data 
through 2000 indicates no diagnosed cases of hydrocephalus between 1990 and 1998.  This would mean 
that there were no cases of hydrocephalus among about 100,000 births, which was considered 
implausible.  Hindin et al. (2005) raised the question of whether the detection of birth defects at the Basra 
study was less than complete, and if so, whether the omissions could have been systematic or random.  In 
studies of Gulf War veterans, comparisons were made between deployed versus non-deployed, not 
necessarily between depleted uranium-exposed and non-depleted uranium-exposed; as such, the studies 
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are not very informative regarding the potential role of depleted uranium in inducing congenital 
malformations.  Hindin et al. (2005) concluded that, overall, the epidemiological evidence is consistent 
with increased risk of birth defects in offspring from persons exposed to depleted uranium.  However, 
given the limitations of the data described by the reviewers and confounders that were not addressed, the 
conclusion regarding birth defects may have overlooked other causes for the increase and overstated the 
data. 
 
Similarly, Busby et al. (2010) examined the incidence of infant mortality and alterations in sex ratio in 
children living in Fallujah, Iraq using data collected from questionnaires completed by 711 households 
with 4,843 persons.  An 18% reduction in male:female ratio from the expected ratio (1,055 boys to 
1,000 girls) was found among children aged 0–4 years.  In older children, the ratio was close to the 
expected level.  An infant mortality (deaths between 0 and 1 year of age) ratio of 80 deaths per 1,000 was 
estimated.  The authors state that this is significantly higher than infant mortality ratios in Egypt, Jordan, 
and Kuwait.  However, the investigators did not evaluate the potential exposure for depleted uranium or 
have a comparable reference group (i.e., Iraqi households without the potential for exposure to depleted 
uranium), used a questionnaire to collect information on infant mortality and birth defects without 
confirmation from medical records, and collected data for a 10-year period but only used the last 5 years 
for the analysis; additionally, the investigators did not provide demographic data to support using infant 
mortality data from Egypt, Jordan, and Kuwait as an appropriate reference.  The limitations of this study 
preclude using it to establish a causal relationship between exposure to depleted uranium and 
developmental toxicity. 
 
3.2.1.7   Cancer  
 
Human and animal studies have examined the potential carcinogenicity of uranium.  Because uranium 
emits predominantly high-LET alpha particles, current theories on gene mutation and apoptotic 
mechanisms of cancer promotion by high-LET alpha radiation suggest a concern for carcinogenesis from 
uranium’s radioactivity (BEIR 1980, 1988, 1990; Otake and Schull 1984; Sanders 1986; UNSCEAR 
1982, 1986, 1988) (see Appendix D for a review of the hazards associated with radionuclide exposure).  
As discussed below, some studies have found significant increases in the risk of lung cancer, although it 
is not clear whether uranium is the causative agent and whether the cancer is due to chemical toxicity or 
radiotoxicity.  In general, human and animal studies have not found increases in the risk of cancer in other 
tissues, including the kidney and bone. 
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Increased deaths from cancers of the respiratory tract (predominantly lung cancer) have been reported in 
numerous studies of uranium miners (Archer et al. 1973a; Auerbach et al. 1978; Band et al. 1982; Boice 
et al. 2008; Chovil and Chir 1981; Gottlieb and Husen 1982; Grace et al. 1980; Hornung and Meinhardt 
1987; Hornung et al. 1998; Howe and Stager 1996; Howe et al. 1986, 1987; Kusiak et al. 1993; Lundin et 
al. 1969; Moolgavkar et al. 1993; Saccomanno et al. 1971, 1976, 1986, 1988, 1996; Samet et al. 1984a, 
1984b, 1986, 1989, 1991, 1994; Ševc et al. 1993; Tirmarche et al. 1992, 1993; Tomášek et al. 2008; 
Waxweiler et al. 1981a; Whittemore and McMillan 1983; Woodward et al. 1991).  However, the miners 
were exposed to cancer-inducing agents such as radon and its decay products, silica dust, arsenic, and 
diesel engine exhaust fumes.  As discussed in the ATSDR Toxicological Profile for Radon (Agency for 
Toxic Substances and Disease Registry 2012), the increased lung cancer in uranium miners is attributable 
to exposure to radon and the additive effect of cigarette smoking, crystalline silica, and/or diesel engine 
exhaust rather than exposure to uranium.  No alterations in deaths from bone or kidney cancer were 
observed in studies of uranium miners (Boice et al. 2008; Tirmarche et al. 1993; Waxweiler et al. 1981a). 
 
Mortality has also been assessed in uranium mill workers without reported employment in uranium 
mining operations.  A study of 662 male uranium mill workers employed at one of six uranium mills in 
the Colorado Plateau states (Colorado, Utah, New Mexico, Arizona) found a significant increase in death 
from tumors of the lymphatic and hematopoietic tissue (other than leukemia) during the period of 1950–
1967 (4 observed vs. 1.02 expected; SMR 392; 95% CI not reported); the study authors noted that none of 
the four men worked near the fusion furnaces where exposure to concentrated uranium dust or fume was 
greatest (Archer et al. 1973b).  Waxweiler et al. (1983) performed a study that included 2,002 uranium 
millers employed at one of seven uranium mills in the Colorado Plateau states for at least 1 year after 
January 1, 1940; a nonsignificant excess of deaths from lymphatic malignancies other than leukemia 
(7 deaths vs. 5.6 expected) was reported for the period through 1977.  When divided by latency period, 
excess risk (6 deaths vs. 2.6 expected) was only found at >20 years.  No significant alterations in lung 
cancer risk was found.  Pinkerton et al. (2004) reevaluated the cohort described by Waxweiler et al. 
(1983) and determined that a total of 1,484 men fit the criteria for inclusion; most of the workers were 
employed for <9 years, 42.7% were employed for 1–2 years.  Nonsignificant excesses of mortality from 
lymphatic and hematopoietic malignancies other than leukemia (16 observed vs. 11.08 expected; SMR 
1.44; 95% CI 0.83–2.35) and from respiratory cancers that included trachea, bronchus, and lung 
(78 observed vs. 68.93 expected; SMR 1.13; 95% CI 0.89–1.41) and a significant decrease in digestive 
systems cancers (33 observed vs. 53.18 expected; SMR 0.62; 95% CI 0.43–0.87) were reported through 
1998.  Mortality from these diseases did not increase with length of employment, and mortality from lung 
cancer was higher among workers hired prior to 1955 when exposures to uranium, silica, and vanadium 
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were presumably higher.  Interpretation of the results of these studies of uranium mill workers is limited 
due to relatively small cohort sizes, inability to estimate individual exposures, and lack of smoking data. 
 
Boice et al. (2008) conducted a cohort mortality study of workers engaged in uranium mining and milling 
activities near Grants, New Mexico between 1955 and 1990.  Vital status was determined through 2004 
and SMRs were calculated for 2,745 workers (2,500 males, 245 females) alive after 1978 who were 
employed for at least 6 months.  No significant increases in cancer mortality were observed in 
904 uranium milling workers who were not known to have worked at a mine or 106 workers whose 
mining experience was not known.  Based on national mortality rates, mortality from respiratory cancers 
(bronchus, trachea, lung) was significantly higher than expected among the uranium mining and milling 
workers known to have been employed in an underground uranium mine (n=1,735) (SMR 2.17; 95% CI 
1.75–2.65).  Therefore, the observed increased cancer mortality was considered attributable to historically 
high levels of radon in the mines combined with heavy use of tobacco products and co-exposure to 
crystalline silica and diesel exhaust.  Deaths from other types of cancer were not significantly increased in 
the whole cohort or either subcohort. 
 
Cancer mortality has been assessed in studies of populations living near uranium mining and milling 
facilities in Uravan, Colorado (Boice et al. 2007a), Montrose County, Colorado (Boice et al. 2007b), 
Karnes County, Texas (Boice et al. 2008), Grants, New Mexico (Boice et al. 2010), and Monticello, Utah 
(UDOH 2007).  Compared to U.S. mortality rates, no significant increase in mortality from cancers was 
observed among the residents of Uravan, Colorado, or among 622 of the residents who had been 
employed in uranium mills.  A significant increase in lung cancer (SMR 2.00; 95% CI 1.39–2.78) was 
found among 459 residents who had worked in underground uranium mines and was attributed to 
historically high levels of radon in the mines coupled with heavy use of tobacco products.  Similarly, 
increased mortality from lung cancer was noted in males living in Montrose County, Colorado, and 
Grants, New Mexico, but not in females.  Occupational exposure to radon and smoking among 
underground uranium mine workers was considered to be the cause of the increased mortality from lung 
cancer within the population of male residents.  The female population of Grants, New Mexico exhibited 
a significant excess of mortality from stomach cancer (SMR 1.30; 95% CI 1.03–1.63), which declined 
over the 55-year observation period; the stomach cancer increase was highest before the uranium mining 
and milling operations began and then decreased to normal levels, indicating that these operations were 
not the source of the increased mortality from stomach cancer.  No unusual patterns of cancer mortality 
were observed in residents of Karnes County, Texas from 1950 to 2001 (Boice et al. 2003).  Among 
residents of Monticello, Utah, a significant increase in the incidence of lung and bronchial cancer was 
URANIUM  106 
 








found for three analytical periods (1973–2004, 1998–2004, and 1993–1997); the standardized incidence 
ratio (SIR) for the 1973–2004 period was 1.94 (95% CI 1.24–2.79) (UDOH 2007).  An increase in 
stomach cancer risk (SIR 6.14; 95% CI 1.60–13.63) was also found for the 1998–2004 evaluation period; 
however, the small number of observed cases reduces the reliability of the significant SIR.  Interpretation 
of the results of this study is limited by the small number of subjects and the lack of control for potential 
risk factors such as smoking and family history.  In addition to potential uranium exposure, past 
monitoring data of on- and off-site soil samples and off-site air samples have found elevated levels of 
radium, radon, beryllium, chromium, lead, nickel, and thallium. 
 
The issue of cancer risk in nuclear workers occupationally exposed to uranium has recently been 
reviewed by Canu et al. (2008).  The authors reviewed 23 epidemiological studies: 18 cohort studies and 
5 nested case-control studies published since 1980.  The overall conclusion was that the epidemiological 
studies provide limited evidence of a relationship between site-specific cancer mortality and internal 
exposure to uranium and mixed fission products.  The authors identified three main limitations common 
to almost all studies:  limited statistical power, relatively low radiation doses, and inaccurate exposure 
assessment.  A more recent study of gaseous diffusion workers (Chan et al. 2010) did not find a 
significant increase in deaths from all cancers or a specific type of cancer when all workers were 
combined.  The investigators used a surrogate measure (µg/year) estimated from urine data to represent 
cumulative dose of internally deposited radionuclides; however, since this is not a unit of measure for 
radiation, it is unclear what was actually measured.  The workers were exposed to arsenic, beryllium, 
chromium, nickel, and uranium.  A significant increase in the risk of non-Hodgkin’s lymphoma were 
observed in workers with cumulative internal radiation exposures of 21–50 or 51–125 µg/year, but not in 
workers with the highest cumulative exposure (>125 µg/year).  No significant increases in the risk of non-
Hodgkin’s lymphoma were found when the workers were divided by cumulative external radiation 
quartiles.  When workers were divided by the levels of individual metal exposures, a near significant 
increase in lung cancer (standardized rate ratio [SRR] 1.17; 95% CI 0.99–1.38) was noted in workers with 
medium exposure to uranium.  An increase in lung cancer risk was also observed in workers with medium 
exposure to nickel.  Interpretation of the results of this study is limited by the lack of exposure 
information and due to co-exposure to other metals including arsenic, beryllium, chromium, and nickel 
and co-exposure to radiation.  Another study of gaseous diffusion workers (Yiin et al. 2009), found a 
marginally increased risk of multiple myeloma among the workers (odds ratio of 1.04; 95% CIs 1.00–
1.09; with adjustment for age, combined x-ray and external radiation exposures, and chemical exposures) 
at a radiation dose of 10 µGy to bone marrow estimated from uranium urinalysis measurements. 
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Busby et al. (2010) examined the relative risk of cancer among residents living in Fallujah, Iraq between 
2005 and 2010; data were collected from questionnaire completed by 711 households with 4,843 persons.  
As compared to cancer rates from Egypt in 1999, significant increases in the risk of several cancers, 
including childhood cancers, breast cancer, leukemia, lymphoma, and brain cancer, were observed.  As 
with the developmental toxicity portion of this study, the investigators did not provide uranium exposure 
level or support for the assumption that the residents were exposed to uranium.  Additionally, the study 
did not involve a comparison between cancer incidences in Fallujah with other Iraqi populations not 
exposed to uranium and cancer incidences were based on self-reported data without confirmation from 
medical records.  These limitations preclude establishing a causal relationship between increased cancer 
risk and uranium exposure. 
 
A study of groups of 102 male golden Syrian hamsters exposed to carnotite uranium ore dust 
(AMAD=1.5–2.1 μm) at a concentration of 19 mg U/m3 by inhalation for 16 months failed to show signs 
of cancer development upon examination of selected tissues including lungs, trachea, liver, kidneys, 
spleen, heart, and any abnormal tissue (Cross et al. 1981b).  In the same study, the results of exposure of 
golden Syrian hamsters for 16–27 months to concentrations of radon progeny, uranium ore dust 
(0.5 nCi/m3 [18.5 Bq/m3]), or a combination of uranium and radon progeny provided evidence that, while 
prolonged exposure to uranium dust causes inflammation and proliferative pulmonary changes, inhalation 
of radon progeny produced bronchiolar epithelial hyperplasia and changes in the alveolar epithelium in 
hamsters.  The authors also concluded that exposure to radon progeny and development of squamous 
metaplasia and carcinoma were related.  The animals had cumulative radon progeny exposures 
>8,000 WLMs.  Pulmonary neoplasms occurred in the three radon-progeny-exposed hamsters and in 
one hamster exposed to a combination of uranium, radon, and radon progeny.  Both the hamsters exposed 
to radon progeny and those exposed to a combination of uranium and radon progeny had a significantly 
greater incidence of adenomatous proliferative changes in the alveolar epithelium.  No significant 
alterations in the incidence on nonpulmonary neoplasms were observed in any exposure group, as 
compared to the unexposed controls.   
 
Pulmonary adenomas or adenocarcinomas were observed in 4/13 Beagle dogs exposed to 5.1 mg U/m3 as 
uranium dioxide for 5 years (Leach et al. 1973).  The neoplasms were observed 22–67 months after 
exposure termination.  The lung dose was estimated as 600–700 rad (6–7 Gy).  Spontaneous tumors are 
rarely found in dogs, and the incidence found in this study was 50–100 times higher than the expected 
rate of spontaneous tumors.  No pulmonary neoplasms were observed in six monkeys similarly exposed 
to 5.1 mg U/m3 as uranium dioxide for 5 years (Leach et al. 1973). 
URANIUM  108 
 









A study was conducted with uranium ore dust in male Sprague-Dawley rats (Mitchel et al. 1999).  The 
rats were exposed nose-only to uranium ore dust that was delivered to the rats as an aerosol under positive 
pressure.  The ore was without significant radon content.  The rats were exposed to 0, 8.4, or 22 mg U/m3 
4.2 hours/day, 5 days/week for 65 weeks and were allowed to live for their natural lifetime.  Exposure to 
uranium significantly increased the incidence of malignant and nonmalignant lung tumors.  The frequency 
of primary malignant lung tumors was 0.016, 0.175, and 0.328 and the frequency of nonmalignant lung 
tumors was 0.016, 0.135, and 0.131 in the control, low- and high-dose groups, respectively.  The main 
malignant tumor was bronchioalveolar carcinoma.  No bronchial lymph node tumors were detected even 
though the lymph node specific burdens were considerably higher than in the lung in the same animal.  
The average absorbed doses for the low- and high-dose groups were 0.87 and 1.64 Gy, respectively, 
resulting in an average risk of malignant lung tumors of about 0.20 tumors per animal per Gy in both 
exposed groups.  Lung tumor frequency was not directly proportional to dose, but exhibited a direct linear 
relationship with dose rate (as measured by the lung burden at the end of dust inhalation).  Mitchel et al. 
(1999) noted that this suggested that lung burden may be the more important determinant of lung cancer 
risk. 
 
Cancer Effect Levels (CELs) for chemical and radiation inhalation exposure to uranium are shown in 
Table 3-1 and plotted in Figure 3-1. 
 
3.2.2   Oral Exposure  
 
The oral toxicity of uranium compounds has been evaluated in several animal species following exposure 
in drinking water or via gavage.  The oral exposure studies did not report baseline uranium levels in the 
diet or drinking water; thus, baseline exposures were not included in the estimated doses.  The levels of 
uranium in the drinking water may vary according to the source of the water (e.g., tap water, mineral 
water) and some sources may have naturally high levels of uranium; if provided, the source of the 
drinking water was included in the discussion of individual studies.  The maximal dosage just failing to 
be lethal for rats in a 30-day feeding test was about 0.5% uranium compound in the diet for the 
three soluble compounds (uranyl nitrate hexahydrate, uranyl tetrafluoride, and uranium tetrachloride) and 
20% uranium compound for the three insoluble uranium compounds (uranium dioxide, uranium trioxide, 
and triuranium octaoxide) tested.  Some of these studies sweetened the feed to make it edible.  No amount 
of insoluble uranium compounds acceptable to the rat was lethal.  Dietary levels of 1–4% soluble uranium 
compound produced 50% mortality in 30 days.  The marked difference in the toxicity of soluble and 
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insoluble uranium compounds is attributable to the ease of absorption and, thus, the dose that reaches the 
target organs.  In general, the water-soluble compounds are more toxic by the oral route because of the 
greater ease of absorption in the gastrointestinal tract (Domingo et al. 1987, 1989a, 1989b; Goel et al. 
1980; Maynard and Hodge 1949; Paternain et al. 1989).  In a summary of the oral toxicity in both rats and 
dogs, several uranium compounds were ordered by relative toxicity as follows:  very toxic compounds 
included uranium tetrachloride, uranium peroxide, and uranyl fluoride; toxic compounds included 
uranium nitrate hexahydrate, uranyl acetate, ammonium diuranate, sodium diuranate, uranium trioxide, 
and high-grade uranium ore (carnotite); and practically nontoxic compounds were uranium tetrafluoride, 
triuranium octaoxide, and uranium dioxide (Maynard and Hodge 1949). 
 
3.2.2.1   Death  
 
There are no reports of human deaths from oral exposure to uranium compounds.  However, data from 
animal studies demonstrate that soluble uranium compounds, at very high intake levels, can be lethal to 
animals through the oral route for all durations of exposure.  Uranium compounds at these concentrations 
are not palatable to animals and require sweetening. 
 
Oral LD50 (lethal dose, 50% mortality rate) values of 114 and 136 mg U/kg have been estimated for male 
Sprague-Dawley rats and male Swiss-Webster mice, respectively, following single gavage 
administrations of uranyl acetate dihydrate (Domingo et al. 1987).  Mortality occurred in pregnant Swiss 
mice exposed to 0.028, 0.28, 2.8, and 28 mg U/kg/day uranium as uranyl acetate dihydrate by gavage in 
water from gestation day 13 through postnatal day 21.  Two dams in the 2.8 mg U/kg/day group and three 
in the 28 mg U/kg/day group died before delivery (Domingo et al. 1989b).  Deaths were also reported in 
mice during the first 10 days of feeding studies with uranyl nitrate (8 of 25 at 925 mg U/kg/day) and with 
uranyl fluoride (2 of 25 at 452 mg/kg/day) (Tannenbaum et al. 1951). 
 
In 30-day oral studies, oral LD50 values for both sexes of rats of an unspecified strain given uranyl 
fluoride or uranyl nitrate hexahydrate have been estimated as 540 and 1,579 mg U/kg/day, respectively.  
Oral LD50 values were 658 and 1,096 mg U/kg/day as uranium tetrachloride for male and female rats, 
respectively, in a similar 30-day study (Maynard and Hodge 1949).  Another 30-day study, in which male 
and female rats of an unspecified strain were exposed to oral uranium peroxide doses, oral LD50 values 
were estimated as 827 and 1,103 mg U/kg/day, respectively (Maynard and Hodge 1949).  In other 
intermediate-duration feeding studies with rats, 16% mortality was reported in the animals following 
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dietary administration of 664 mg U/kg/day for 30 days.  Most of the animals died from complications of 
chemically induced kidney damage (Maynard et al. 1953). 
 
Two-year feeding studies with uranyl fluoride, uranyl nitrate hexahydrate, uranium tetrafluoride, and 
uranium dioxide showed that chronic intake of large amounts of uranium can lead to a decrease in 
lifespan.  The largest daily intake that did not affect longevity in the rat was 81 mg U/kg/day as uranyl 
fluoride.  For the other uranium compounds studied, the maximum daily intakes that did not affect 
longevity were 1,130 mg U/kg/day as uranyl nitrate, 1,390 mg U/kg/day as uranium tetrafluoride, and 
1,630 mg U/kg/day as uranium dioxide.  About 18% of the experimental rats survived for the entire 
2-year duration of the study, while about 38% of the control animals survived (Maynard and Hodge 
1949).  Most of the deaths in the available animal studies resulted from chemically induced renal damage. 
 
The LD50 values for each species and other LOAEL values for mortality from exposure to uranium by the 
oral route are presented in Table 3-2 and plotted in Figure 3-2. 
 
3.2.2.2   Systemic Effects  
 
No human studies were located regarding respiratory, endocrine, dermal, ocular, body weight, or other 
systemic effects in humans following acute-, intermediate-, or chronic-duration oral exposure to uranium 
compounds. 
 
Animal data are lacking regarding musculoskeletal, metabolic, dermal, or ocular effects following oral 
exposure to uranium and its compounds for all durations.  Similarly, no animal studies were located on 
the hematological effects of uranium in animals following acute-duration oral exposure or on the 
cardiovascular, endocrine, or other systemic effects following acute- or chronic-duration oral exposure.  
Data exist for the respiratory, renal, and body weight effects following oral exposure of animals to 
uranium for all durations.  However, the existing data on the hematological, cardiovascular, hepatic, and 
other systemic effects of uranium in animals are limited to acute- or chronic-duration inhalation exposure; 
data on the gastrointestinal effects are limited to acute-duration exposure. 
 
The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
systemic effects from chemical exposures to uranium by the oral route are presented in Table 3-2 and 
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a The number corresponds to entries in Figure 3-2.
b Used to derive an acute-duration oral minimal risk level (MRL) of 0.002 mg/kg/day for soluble uranium compounds based on a BMDL0.05 of 0.20 mg/kg/day and an uncertainty
factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).
c Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.0002 mg/kg/day for soluble uranium compounds based on a LOAEL of 0.06 mg/kg/day and an
uncertainty factor of 300 (3 for use of a minimal LOAEL, 10 for extrapolation from animals to humans and 10 for human variability).
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd = gestation
day; (GW) = gavage in water; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; Metab =  metabolic; mo = month(s);
Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; PND = post-natal day; Resp = respiratory; (W) = drinking water; wk = week(s); x =
time(s); yr = year(s)
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Respiratory Effects.    Respiratory effects from oral exposure to uranium are unlikely.  In an acute-
duration animal study, no adverse effects on the respiratory system were reported in rats given single oral 
doses of 118 mg uranium/kg body weight/day (U/kg/day) as uranyl acetate dihydrate (Domingo et al. 
1987). 
 
In intermediate-duration exposures, Sprague-Dawley rats (10/sex/dose) were exposed to uranium as 
uranyl nitrate in the drinking water (males:  up to 35.3 mg/kg/day; females:  up to 40.0 mg/kg/day) for 
28 days and then sacrificed.  No treatment-related histopathological changes were found, and no changes 
in lung weights were noted (Gilman et al. 1998a).  In several 30-day dietary studies using much higher 
doses, no adverse effects on the respiratory system were reported in rats exposed to 6,637 mg U/kg/day as 
uranyl nitrate hexahydrate, 8,769 mg U/kg/day as uranium tetrachloride, 11,033 mg U/kg/day as uranium 
peroxide, 10,611 mg U/kg/day as uranium tetrafluoride, 10,818 mg U/kg/day as uranyl fluoride, 
12,342 mg U/kg/day as uranium dioxide, 8.167 mg U/kg/day as uranyl acetate dihydrate, or 
11,650 mg U/kg/day as uranium trioxide (Maynard and Hodge 1949; Maynard et al. 1953; Stokinger et al. 
1953).  Lengthening the duration of exposure to uranium failed to produce detectable lesions in lungs of 
laboratory animals.  Sprague-Dawley rats (15/sex/dose) were exposed to uranium as uranyl nitrate in 
drinking water (males:  up to 36.73 mg/kg/day; females:  up to 53.56 mg/kg/day) for 91 days and were 
sacrificed.  No treatment-related histopathological changes were found in the lungs, and no changes in 
lung weights were noted (Gilman et al. 1998a).  In addition, New Zealand rabbits were exposed to 
uranium as uranyl nitrate in the drinking water (males:  up to 28.70 mg/kg/day; females:  up to 
43.02 mg/kg/day) for 91 days.  No treatment-related histopathological changes were found, and no 
changes in lung weights were noted (Gilman et al. 1998b).  Male New Zealand rabbits were also exposed 
to uranium as uranyl nitrate in drinking water (1.36 and 40.98 mg/kg/day) for 91 days, again with no 
histopathological or organ weight changes found (Gilman et al. 1998c). 
 
In chronic-duration feeding studies, no adverse effects on the respiratory system were reported in 1-year 
studies of dogs given oral doses of 31 mg U/kg/day as uranium tetrachloride, 3,790 mg U/kg/day as 
uranium hexachloride, 8 mg U/kg/day as uranyl fluoride, or 4,407 mg U/kg/day as uranium dioxide 
(Maynard and Hodge 1949; Maynard et al. 1953).  In 2-year studies, the respiratory system was 
unaffected in dogs and rats given 2 mg U/kg/day as uranyl nitrate hexahydrate and in rats given 
12,141 mg U/kg/day as uranium dioxide, 664 mg U/kg/day as uranyl nitrate hexahydrate, 
10,611 mg U/kg/day as uranium tetrafluoride, or 405 mg U/kg/day as uranyl fluoride (Maynard and 
Hodge 1949; Maynard et al. 1953; Stokinger et al. 1953). 
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No histological alterations were observed in the lungs of rats exposed to 400 mg U/kg/day as uranyl 
fluoride, 660 mg U/kg/day as uranyl nitrate, 11,000 mg U/kg/day as uranium tetrafluoride, or 12,000 mg 
U/kg/day as uranium dioxide in the diet for 2 years (Maynard and Hodge 1949; Maynard et al. 1953). 
 
Cardiovascular Effects.    Cardiovascular effects following intake of uranium are unlikely.  One case 
report documented a cardiovascular effect that was possibly related to uranium exposure in a male 
admitted to the hospital following deliberate ingestion of 15 g of uranyl acetate, along with an unknown 
quantity of benzodiazepine, in a failed suicide attempt.  While body weight was not reported, the dose 
would be approximately 131 mg U/kg for a 70-kg reference man.  Initial blood chemistry was 
unremarkable, and decreased cardiac output was consistent with ingestion of benzodiazepam.  The patient 
was reported to have suffered from myocarditis resulting from the uranium ingestion, resolving 6 months 
after the ingestion (Pavlakis et al. 1996). 
 
A significant association between urinary uranium levels and increases in diastolic and systolic blood 
pressure were observed among adults living in households with uranium in the drinking water at levels of 
0.03–1,500 µg/L (31% >100 µg/L and 55% >15 µg/L; the median daily intake was 36 µg/day) (Kurttio et 
al. 2006a); however, the increases in blood pressure were small and did not appear until urine uranium 
levels were at least 1 µg/L.  A urinary uranium level of 1 µg/L is approximately 25 times higher than the 
95% percentile level for the U.S. population (CDC 2012).  This is consistent with the findings of Kurttio 
et al. (2002) that a 1 mg/L increase in uranium levels in drinking water would be associated with 7.4 and 
5.0 mm Hg increases in systolic and diastolic blood pressure, respectively.  Kurttio et al. (2006a) noted 
that the increases in blood pressure were expectedly greater in older individuals than younger individuals. 
 
The available studies in animals have found no adverse cardiovascular effects following oral exposures 
for up to 30 days to uranium compounds.  In one study, Sprague-Dawley rats (10/sex/dose) were exposed 
to uranium as uranyl nitrate in drinking water (males:  up to 35.3 mg/kg/day; females:  up to 
40.0 mg/kg/day) for 28 days and sacrificed.  No cardiac histopathological changes were found, and no 
changes in heart weights were noted (Gilman et al. 1998a).  No changes in the heart or blood vessels were 
observed in rats following oral exposure to doses as high as 9,393 mg U/kg/day as uranyl nitrate 
hexahydrate, 8,769 mg U/kg/day as uranium tetrachloride, 11,033 mg U/kg/day as uranium peroxide, 
10,611 mg U/kg/day as uranium tetrafluoride, 10,819 mg U/kg/day as uranyl fluoride, 
12,342 mg U/kg/day as uranium dioxide, 11,650 mg U/kg/day as uranium trioxide, or 7,859 mg U/kg/day 
as uranyl acetate dihydrate (Maynard and Hodge 1949).  Sprague-Dawley rats (15/sex/dose) were 
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exposed to uranium as uranyl nitrate in drinking water (males:  up to 36.73 mg/kg/day; females:  up to 
53.56 mg/kg/day) for 91 days and sacrificed.  No uranium-related histopathological changes were found 
in the heart, and no changes in heart weights were noted (Gilman et al. 1998a).  In addition, New Zealand 
rabbits were exposed to uranium as uranyl nitrate in the drinking water (males:  up to 28.70 mg/kg/day; 
females:  up to 43.02 mg/kg/day) for 91 days.  No treatment-related cardiac histopathological changes 
were noted, and no changes in heart weights were detected (Gilman et al. 1998b).  Male New Zealand 
rabbits also were exposed to uranium as uranyl nitrate in drinking water (1.36 and 40.98 mg/kg/day) for 
91 days, with no histopathological or organ weight changes (Gilman et al. 1998c). 
 
No histological alterations were observed in the heart of rats exposed to 400 mg U/kg/day as uranyl 
fluoride, 660 mg U/kg/day as uranyl nitrate, 11,000 mg U/kg/day as uranium tetrafluoride, or 12,000 mg 
U/kg/day as uranium dioxide in the diet for 2 years (Maynard and Hodge 1949; Maynard et al. 1953). 
 
Gastrointestinal Effects.    A volunteer given a single dose of 1 g uranyl nitrate (14.3 mg/kg) and 
observed for clinical signs and symptoms within 24 hours after intake suffered acute nausea, vomiting, 
and diarrhea within a few hours of administration.  All clinical signs returned to normal within 24 hours 
after administration of the oral uranyl nitrate dose (Butterworth 1955).  Paralytic ileus was reported in a 
male after the deliberate ingestion of 15 g uranyl acetate (Pavlakis et al. 1996).  While body weight was 
not reported, the dose would be approximately 131 mg U/kg for a 70-kg reference man.  No other reports 
of gastrointestinal effects after acute-duration exposure to uranium in either humans or laboratory animals 
were available. 
 
Studies of intermediate-duration exposure to uranium compounds were available for laboratory animals.  
In one study, Sprague-Dawley rats (10/sex/dose) were exposed to uranium as uranyl nitrate in the 
drinking water (males:  up to 35.3 mg/kg/day; females:  up to 40.0 mg/kg/day) for 28 days and sacrificed.  
No treatment-related histopathological changes were found, and no changes in organ weights were noted 
(Gilman et al. 1998a).  In a study of longer duration, Sprague-Dawley rats (15/sex/dose) were exposed to 
uranium as uranyl nitrate in drinking water (males:  up to 36.73 mg/kg/day; females:  up to 
53.56 mg/kg/day) for 91 days and then sacrificed.  No treatment-related histopathological changes were 
found in the gastrointestinal tract, and no changes in stomach and intestinal weights were noted (Gilman 
et al. 1998a).  In addition, New Zealand rabbits were exposed to uranium as uranyl nitrate in the drinking 
water (males:  up to 28.70 mg/kg/day; females:  up to 43.02 mg/kg/day) for 91 days.  No treatment-
related histopathological changes were found, and no changes in organ weights (i.e., colon, duodenum, 
stomach [gastric cardia, fundus, and pylorus]) were noted (Gilman et al. 1998b).  Male New Zealand 
URANIUM  139 
 








rabbits were exposed to uranium as uranyl nitrate in drinking water (1.36 and 40.98 mg/kg/day) for 
91 days, with no histopathological or organ weight changes found (Gilman et al. 1998c). 
 
No histological alterations were observed in the stomach, small intestine, or large intestine of rats exposed 
to 400 mg U/kg/day as uranyl fluoride, 660 mg U/kg/day as uranyl nitrate, 11,000 mg U/kg/day as 
uranium tetrafluoride, or 12,000 mg U/kg/day as uranium dioxide in the diet for 2 years (Maynard and 
Hodge 1949; Maynard et al. 1953). 
 
Hematological Effects.    In one case report, a male (no age or weight given) was admitted to hospital 
following the deliberate ingestion of 15 g of uranyl acetate, along with an unknown quantity of 
benzodiazepine, in a failed suicide attempt.  While body weight was not reported, the dose would be 
approximately 131 mg U/kg for a 70-kg reference man.  Initial blood chemistry was unremarkable; 
however, an anemia developed and continued to progress over the next 8 weeks, along with persistent 
renal dysfunction (Pavlakis et al. 1996).  While the authors attributed the renal dysfunction to uranium 
ingestion, the etiology of the anemia was unknown.  The patient also suffered from peptic ulcer disease, 
which may have been related to the anemia. 
 
The majority of animal studies show no effect of uranium on hematological parameters after oral 
exposure.  Exposure to uranium as uranyl nitrate in drinking water had no hematological effects in 
Sprague-Dawley rats after 28 days (up to 40 mg U/kg/day) or 91 days (up to 53 mg U/kg/day) (Gilman et 
al. 1998a), or in New Zealand rabbits after 91 days (up to 43 mg U/kg/day) (Gilman et al. 1998b, 1998c).  
Exposure to a variety of uranium compounds in feed had no effect on hematological parameters in 
intermediate- and chronic-duration studies (Maynard and Hodge 1949).  One study reported a significant 
increase in the hematocrit and hemoglobin values, the mean corpuscular hemoglobin concentration, and 
the number of erythrocytes at 9 mg U/kg/day as uranyl acetate in drinking water for 4 weeks, but not at 
4.5 mg U/kg/day and lower doses (Ortega et al. 1989a).  In contrast, a 20% reduction in erythrocyte levels 
was observed in male Sprague-Dawley rats exposed to 2.4 mg U/kg/day as depleted uranyl nitrate 
hexahydrate in mineral water for 9 months (Berradi et al. 2008).  The study did not find reductions in 
erythrocyte production in the spleen or bone marrow or evidence of alterations in spleen iron recycling.  
The investigators suggested that the observed hematological effect may be secondary to observed kidney 
damage. 
 
In a 2-year feeding study, decreases in erythrocyte levels and/or hemoglobin levels were observed in rats 
exposed to ≥330 mg U/kg/day as uranyl nitrate or ≥140 mg U/kg/day as uranyl fluoride; an increase in 
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leukocyte levels was also observed at ≥140 mg U/kg/day as uranyl fluoride (Maynard and Hodge 1949; 
Maynard et al. 1953).  No hematological alterations were observed in rats similarly exposed to 11,000 mg 
U/kg/day as uranium tetrafluoride or 12,000 mg U/kg/day as uranium dioxide (Maynard and Hodge 1949; 
Maynard et al. 1953). 
 
Musculoskeletal Effects.    In one human case report, a male (no age or weight given) was admitted 
to the hospital following the deliberate ingestion of 15 g of uranyl acetate, along with an unknown 
quantity of benzodiazepine, in a failed suicide attempt.  While body weight was not reported, the dose 
would be approximately 131 mg U/kg for a 70-kg reference man.  The patient suffered from increasing 
rhabdomyolysis (biochemically characterized by increased creatine kinase).  At 6 months following the 
initial toxic insult, the rhabdomyolysis had resolved, and the subject showed no residual signs of muscle 
toxicity (Pavlakis et al. 1996).  The etiology of this effect is unknown. 
 
In a study of adults (146 men and 142 women) living in an area of Finland with elevated uranium levels 
in drinking water (0.002–1,920 µg/L with 27% of concentrations >100 µg/L and 59% >15 µg/L), a 
significant association between elevated serum type I collagen carboxy-terminal telopeptide (CTx) levels 
(biomarker of bone resorption) and levels of uranium in water was observed in males (Kurttio et al. 
2005).  A nonsignificant association between increased osteocalcin levels (biomarker of bone formation) 
and uranium levels in drinking water was also observed in males.  Other biomarkers of bone resorption 
and formation were not associated with uranium exposure.  No statistically significant associations were 
observed in females.  Daily uranium intakes ranged from 7 to 207 µg (0.0001–0.003 mg/kg/day, using a 
70-kg reference body weight) and the median intake was 36 µg (0.0005 mg/kg/day). 
 
There are limited data on the potential of uranium to induce bone or muscle damage following oral 
exposure.  A significant decrease in growth cartilage width, metaphyseal bone volume, and percent 
metaphyseal activity in bone formation area and a significant increase in metaphyseal activity in the bone 
resorption area were observed in male Balb/c mice administered a single gavage dose of 170 mg U/kg as 
uranyl nitrate hexahydrate and sacrificed 48 hours after dosing (Bozal et al. 2005). 
 
Histopathological examination of muscle after exposure to uranium in drinking water as uranyl nitrate 
showed no effects in Sprague-Dawley rats after 28 days (up to 40 mg U/kg/day) or 91 days (up to 53 mg 
U/kg/day) (Gilman et al. 1998a), or in New Zealand rabbits after 91 days (up to 43 mg U/kg/day) (Gilman 
et al. 1998b, 1998c). 
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Hepatic Effects.    Few human data are available on the hepatic effects of uranium.  In one case report, 
a male (no age or weight given) was admitted to the hospital following the deliberate ingestion of 15 g of 
uranyl acetate, along with an unknown quantity of benzodiazepine, in a failed suicide attempt.  While 
body weight was not reported, the dose would be approximately 131 mg U/kg for a 70-kg reference man.  
The patient suffered from increasing liver dysfunction, characterized by increased serum levels of alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT).  
Six months following the initial toxic insult, the patient had no residual signs of hepatic toxicity (Pavlakis 
et al. 1996).  The etiology of this effect is unknown, although histological signs of hepatic toxicity have 
been observed in animals after oral exposure to uranium. 
 
In the available animal studies, the existing data provide evidence that uranium exposure can damage the 
liver, although the etiology for this effect is not certain.  In an acute-duration study in which Sprague-
Dawley rats were given single gavage doses of 5.6 or 118 U/kg as uranyl acetate dihydrate, 
microhemorrhagic foci in the liver were observed at both doses tested (Domingo et al. 1987). 
 
Ingested uranium was also hepatotoxic to dogs in studies of intermediate-duration exposure.  When 
uranyl fluoride was tested at 7.7, 15.4, 77.3, 386.7, or 3,864 mg U/kg/day for 30 days, fatty infiltration 
was seen in dogs at the 15.4 mg U/kg/day dose level (Maynard and Hodge 1949).  In other tests, uranium 
tetrachloride induced minimal hepatic lesions at a dose level of 313 mg U/kg/day; uranium peroxide 
induced mild degeneration at a dose level of 386 mg U/kg/day; uranium dioxide induced mild 
degeneration at a dose level of 441 mg U/kg/day; uranium trioxide induced slight fatty infiltration at a 
dose level of 416 mg U/kg/day; triuranium octaoxide induced mild fatty changes at a dose level of 
5,653 mg U/kg/day; sodium diuranate induced mild degeneration at a dose level of 37.5 mg U/kg/day; 
uranium tetrafluoride caused degenerative fatty changes at a dose level of 15,159 mg U/kg/day; and 
uranyl nitrate hexahydrate induced minimal hepatic degeneration at a dose level of 237 mg U/kg/day 
(Maynard and Hodge 1949). 
 
Hepatic toxicity was also found in several other studies.  In one study, Sprague-Dawley rats (15/sex/dose) 
were exposed to uranium as uranyl nitrate in drinking water (males:  up to 36.73 mg/kg/day; females:  up 
to 53.56 mg/kg/day) for 91 days and then sacrificed.  Hepatic lesions, which included anisokaryosis, 
vesiculation, increased portal density, perivenous vacuolation, and homogeneity, were observed in the 
liver at all doses (Gilman et al. 1998a), although the dose ranging portion of this study found no effects at 
essentially the same doses as those discussed below (Gilman et al. 1998c).  However, in New Zealand 
rabbits exposed to uranium as uranyl nitrate in the drinking water (males:  0, 0.05, 0.20, 0.88, 4.82, and 
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28.70 mg/kg/day; females:  0, 0.49, 1.32, and 43.02 mg/kg/day) for 91 days, no treatment-related 
histopathological changes were found, and no changes in liver weights were noted (Gilman et al. 1998b).  
In contrast, another study by the same investigator in male New Zealand rabbits exposed to uranium as 
uranyl nitrate in drinking water (1.36 and 40.98 mg/kg/day) for 91 days found irregular accentuation of 
zonation in the liver, accompanied by increased variation in hepatocellular nuclear size, nuclear pyknosis, 
and extensive cytoplasmic vacuolization.  These changes were found to be treatment-related but not 
dose-related (Gilman et al. 1998c). 
 
In other intermediate-duration studies, no effects were seen on the liver of dogs given oral doses of 
9,393 mg U/kg/day as uranyl nitrate hexahydrate or 191 mg U/kg/day as ammonium diuranate for 30 days 
(Maynard and Hodge 1949).  Similarly, no effects were seen on the liver of rats given oral doses of 
8,769 mg U/kg/day as uranium tetrachloride, 11,033 mg U/kg/day as triuranium peroxide, 
10,818 mg U/kg/day as uranyl fluoride, 12,342 mg U/kg/day as uranium dioxide, 11,650 mg U/kg/day as 
triuranium trioxide, or 7,859 mg U/kg/day as uranium acetate dihydrate for 30 days (Maynard and Hodge 
1949).  Sprague-Dawley rats (10/sex/dose, 60 g) were exposed to uranium as uranyl nitrate in drinking 
water (males:  up to 35.3 mg/kg/day; females:  up to 40.0 mg/kg/day) for 28 days and then sacrificed.  No 
treatment-related histopathological changes were found, and no changes in liver weights were noted 
(Gilman et al. 1998a). 
 
Significant increases in plasma cholesterol (41%) were observed in rats exposed to approximately 2 mg 
U/kg/day as depleted uranyl nitrate in drinking water for 9 months (Souidi et al. 2005); the toxicological 
significance of this increase is not known.   
 
No histological alterations were observed in rats exposed via the diet for 2 years to 400 mg U/kg/day as 
uranyl fluoride, 660 mg U/kg/day as uranyl nitrate, 11,000 mg U/kg/day as uranium tetrafluoride, or 
12,000 mg U/kg/day as uranium dioxide (Maynard and Hodge 1949; Maynard et al. 1953). 
 
Renal Effects.    Uranium has been identified as a nephrotoxic metal, exerting its toxic effect by 
chemical action mostly in the renal proximal tubules of humans and animals.  Few human data are 
available that adequately describe the dose-response toxicity of uranium after an oral exposure.  In one 
human case report study (Pavlakis et al. 1996), acute nephrotoxicity was diagnosed in a male following 
the intentional ingestion of 15 g of uranyl acetate (approximately 131 mg/kg using a reference body 
weight of 70 kg), along with an unknown quantity of benzodiazepine, in a failed suicide attempt.  Initial 
blood chemistry was normal; however, 16 hours after admission, his blood urea levels had doubled and 
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creatinine levels had increased 3.5-fold, which suggested renal damage; the patient underwent chelation 
therapy and dialysis.  At 6 months following the initial toxic insult, the patient still suffered from an 
incomplete Fanconi syndrome (renal tubular acidosis).  A pre-existing peptic ulcer disease in this patient 
may have exacerbated toxicity by increased absorption of uranium through the damaged stomach mucosal 
layer. 
 
Several epidemiology studies (Kurttio et al. 2002, 2006a; Limson Zamora et al. 1998, 2009; Mao et al. 
1995; Seldén et al. 2009) examined the possible association between chronic exposure to elevated levels 
of uranium in drinking water and alterations in kidney function.  Mao et al. (1995) found a significant 
association between cumulative uranium exposure (product of uranium concentration in drinking water, 
reported average number of cups of water consumed per day, and the total years at the current residence) 
and urine albumin levels (expressed as mg/mmol creatinine) in adults living in households with elevated 
uranium levels in drinking water.  The mean uranium levels in the drinking water were 19.6 and 
14.7 µg/L in the exposed group and 0.71 µg/L in the control group.  Although a significant association 
between cumulative uranium exposure and urinary albumin levels was found, the albumin levels were 
within the normal range for most subjects. 
 
A significant association between uranium intake levels and urinary glucose, β2-microglobulin, and 
alkaline phosphatase levels were observed in males and females living in an area of high uranium levels 
in the drinking water; total uranium intake ranged from 3 to 570 µg/kg (0.00004–0.0085 mg/kg/day, 
assuming a reference body weight of 70 kg) (Limson Zamora et al. 1998). 
 
In a second study by this group (Limson Zamora et al. 2009), urine uranium levels (adjusted for fluid 
intake) were significant positively correlated with urine volume, specific gravity, γ-glutamyl transferase, 
and β2-microglobulin levels in a group of 54 residents exposed to various levels of uranium in drinking 
water.  The estimated average uranium intake for the group was 0.00065 mg/kg/day; however, uranium 
intake was estimated from data for all subjects, which included eight subjects with a uranium intake of 
<0.0000013 mg/kg/day (1.3 ng/kg/day). 
 
No significant differences in kidney function parameters were found in 301 residents consuming drinking 
water from wells drilled in bedrock areas and 153 consuming municipal water (Seldén et al. 2009).  When 
the two populations were combined, urinary uranium levels were significantly correlated with 
β2-microglobulin, kappa immunoglobulin light chains, and protein HC levels; however, there was no 
dose-response relationship.  Excluding 23 subjects with diabetes resulted in a tendency toward a dose-
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response relationship.  The median, mean, and range of uranium levels in the drinking water from wells 
were 6.7, 25.2, and <0.20–470 µg/L, respectively; the municipal water uranium levels were below the 
detection limit of 0.2 µg/L.  The respective median and geometric mean urine uranium levels were 
0.013 and 0.016 nmol/mmol creatinine in the well water group and 0.0019 and 0.0020 nmol/mmol 
creatinine in the municipal water group. 
 
A weak significant association between urinary uranium levels and fractional excretion of calcium and 
phosphate were observed in 325 Finnish residents exposed to uranium in drinking water from bored wells 
(Kurttio et al. 2002); a tendency for increased glucose excretion was also observed.  However, the lack of 
information on the presence of other possible contaminants in the drinking water confounds the 
interpretation of these results.  The investigators noted that calcium, phosphate, and glucose excretion 
levels were within the normal range.  Urinary uranium levels ranged from 1 to 5,650 µg/L (1.9–
955 ng/mmol creatinine) and the mean and median levels were 424 and 78 µg/L (73 and 13 ng/mmol 
creatinine), respectively.  The mean uranium intake was 3.2 mg/kg/day.  No significant associations were 
found for β2-microglobulin levels or indicators of glomerular dysfunction (creatinine clearance or urinary 
albumin).  Several years later, Kurttio et al. (2006a) examined a subset of these subjects (uranium 
drinking water levels ranged from 0.03 to 1,500 µg/L with 55% >15 µg/L and 31% >100 µg/L) and did 
not find significant associations between urinary uranium levels and calcium, phosphate, and glucose 
excretion.  However, a significant association between cumulative uranium intake and urinary glucose 
levels was found. 
 
There is sufficient information in animals with high exposures to both soluble and insoluble uranium to 
conclude that uranium is a renal toxicant.  The pathogenesis of the kidney damage in animals indicates 
that regeneration of the tubular epithelium occurs in survivors upon discontinuation of exposure to 
uranium (Bentley et al. 1985; Dygert 1949b; Maynard and Hodge 1949; Pozzani 1949; Rothermel 1949; 
Rothstein 1949c; Spiegl 1949; Stokinger et al. 1953). 
 
Two single exposure studies have reported renal damage.  Marked increases in blood urea and creatinine 
levels and tubular necrosis were observed after 2 days in Balb-c mice administered a lethal (animals died 
on day 3) gavage dose of 166 mg U/kg as uranyl nitrate hexahydrate (Martinez et al. 2003).  Evidence of 
renal dysfunction (increased urine volume, increased plasma urea and creatinine levels, and increased 
urinary total protein levels and creatinine clearance) and minimal microscopic lesions (moderate 
hyperemia and discrete microhemorrhagic foci) in the tubular epithelium were observed in male Sprague-
Dawley rats exposed to a single gavage dose of 5.6 mg U/kg as uranyl acetate dihydrate (Domingo et al. 
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1987).  In a repeated exposure acute-duration study, significant increases in BUN and serum creatinine 
levels were observed in Swiss albino mice exposed to 508 mg U/kg/day as uranyl acetate dihydrate in the 
diet for 5 days (Ozmen and Yurekli 1998). 
 
The renal toxicity of uranium compounds following intermediate-duration exposure has been examined in 
rats, rabbits, and dogs (Gilman et al. 1998a, 1998b, 1998c; Maynard and Hodge 1949; McDonald-Taylor 
et al. 1992, 1997; Rouas et al. 2011).  No histological alterations were observed in the kidneys of 
Sprague-Dawley rats exposed to doses as high as 35.3 mg U/kg/day (males) or 40.0 mg U/kg/day 
(females) as uranyl nitrate in drinking water for 28 days (Gilman et al. 1998a).  The only effect observed 
was a significant increase in serum uric acid in females at 40 mg U/kg/day (1.64 vs. 1.18 mg/dL in 
controls).  Similarly, no histological alterations were observed in Sprague-Dawley rats exposed to doses 
as high as 4.5 mg U/kg/day as uranyl acetate in drinking water for 4 weeks (Ortega et al. 1989a); small 
congestion of the kidney and a moderate increase in lysosomal content of the proximal convoluted tubule 
epithelial cells were observed at 9 mg U/kg/day.  In addition, a slight, non-dose-related increase in total 
plasma protein levels was observed at ≥1.1 mg U/kg/day. 
 
Extending the exposure duration to 91 days resulted in a number of kidney effects in Sprague-Dawley rats 
exposed to uranyl nitrate in drinking water (Gilman et al. 1998a).  At the lowest dose tested in males 
(0.06 mg U/kg/day), histological alterations were observed in the renal tubules (nuclear vesiculation, 
cytoplasmic vacuolation, and tubular dilation) and interstitium (lymphoid cuffing).  Exposure to ≥0.31 mg 
U/kg/day resulted in glomerular adhesions and tubular cytoplasmic degeneration.  Although female rats 
were equally susceptible to the renal toxicity of uranyl nitrate, the observed histological alterations 
differed from the males.  In the females exposed to ≥0.09 mg U/kg/day, capsular sclerosis, tubular 
anisokaryosis, tubular nuclear vesiculation, and interstitial reticulin sclerosis were observed.  The 
differences in renal effects between the male and female rats do not appear to be related to uranium levels 
in the kidney.  Although uranium levels were not measured at the lowest dose levels, exposure to 7.54 or 
9.98 mg U/kg/day resulted in kidney uranium levels of 0.42 and 0.42 µg/g in males and females, 
respectively. 
 
Gender-related differences in the renal toxicity of uranium were also observed in New Zealand rabbits 
exposed to uranyl nitrate in the drinking water for 91 days (Gilman et al. 1998b).  Histopathological 
alterations observed in males exposed to ≥0.05 mg U/kg/day included cytoplasmic vacuolation, 
anisokaryosis, and nuclear vesiculation in proximal tubular cells.  At the lowest dose tested in females 
(0.49 mg U/kg/day), anisokaryosis, nuclear vesiculation, and atrophy were observed in the proximal 
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tubules.  At higher doses, interstitial reticulin sclerosis (0.88 and 1.32 mg U/kg/day in males and females) 
and interstitial collagen sclerosis (4.82 and 43.02 mg U/kg/day in males and females) were also observed. 
 
In contrast to the results of this study, another 91-day study conducted by Gilman et al. (1998c) did not 
find statistically significant increases in the incidence of histological alterations in the kidneys of New 
Zealand rabbits exposed to 1.36 mg U/kg/day as uranyl nitrate in the drinking water for 91 days.  
Exposure to 40.98 mg U/kg/day resulted in increases in the incidence of cytoplasmic vacuolation, 
anisokaryosis, nuclear hyperchromicity, tubular dilation, tubular atrophy, and interstitial collagen and 
reticulum sclerosis.  Most of these histological alterations persisted throughout a 91-day recovery period.  
Electron micrographic examination of the glomeruli and proximal tubules were conducted by McDonald-
Taylor et al. (1992, 1997).  A dose-related increase in the thickness of the glomerular basement 
membrane was observed in the 1.36 and 40.98 mg U/kg/day groups; as compared to the control group, the 
glomerular basement membranes were 20 and 36% thicker in the 1.36 and 40.98 mg U/kg/day groups, 
respectively (McDonald-Taylor et al. 1992).  Observed effects in the proximal tubules included lumens 
filled with debris, a reduction in the height of epithelial cells, focal loss of brush border, splitting of the 
basal lamina, and renal interstitial fibrosis (McDonald-Taylor et al. 1997); these alterations were more 
common in the 40.98 mg U/kg/day group, but were also observed in some animals in the 1.36 mg 
U/kg/day group (incidence not reported).  At the end of the 91-day recovery period, there was an increase 
in the thickness of the glomerular basement membrane and an increase in the severity of the proximal 
tubule lesions, as compared to values in rabbits sacrificed at the end of the exposure period (McDonald-
Taylor et al. 1992, 1997).  The results of this study (Gilman et al. 1998c) conflict with the results of this 
group’s previous rabbit study (Gilman et al. 1998b).  The investigators suggested that there were 
differences in the ways that animals in the two studies handled the ingested uranium and that the animals 
in the Gilman et al. (1998c) study more effectively cleared the uranium resulting in lower uranium levels 
in the kidney and bone.  In this study (Gilman et al. 1998c), the uranium levels in the kidney and bone in 
rabbits ingesting a total intake of 3,557.25 mg U/kg/91 days were 3.48 and 2.89 µg/g, as compared to 
kidney and bone levels of 4.98 and 4.04 µg/g in rabbits ingesting 2,677.87 mg U/kg/91 days (Gilman et 
al. 1998b).  Additionally, the investigators noted that some of the rabbits in the Gilman et al. (1998b) 
study were infected with Pasteurella mutocida; although animals with known infections were excluded 
from the study, some of the remaining rabbits may have had subclinical infections that may have affected 
their response to administered uranium. 
 
In a longer exposure study, an increased incidence of tubule-interstitial lesions were observed in the 
kidneys of male Sprague-Dawley rats exposed to 2.4 mg U/kg/day as depleted uranyl nitrate hexahydrate 
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in mineral water for 9 months (Berradi et al. 2008).  However, in a similar study, no alterations in the 
incidence of renal lesions were observed in rats administered 2.3 mg U/kg/day as depleted uranyl nitrate 
hexahydrate in drinking water for 9 months (Rouas et al. 2011). 
 
Maynard and Hodge (1949) conducted a series of 30-day dietary exposure studies in rats and dogs using 
various uranium compounds.  Although the results were poorly reported, the rat studies provide useful 
information for comparing the relative renal toxicity of different uranium compounds.  No histological 
alterations were observed in the kidneys of rats exposed to 12,000 mg U/kg/day as uranium dioxide, 
uranium trioxide, or uranyl octaoxide or 11,000 mg U/kg/day as uranium tetrafluoride.  Mild to moderate 
renal lesions were found in rats exposed to 440 mg U/kg/day as uranium tetrachloride (NOAEL of 90 mg 
U/kg/day) or 790 mg U/kg/day as uranium acetate (NOAEL of 200 mg U/kg/day).  Mild histological 
alterations were observed in rats exposed to 200 mg U/kg/day as uranyl nitrate (NOAEL of 40 mg 
U/kg/day), 270 mg U/kg/day as uranyl fluoride (NOAEL of 140 mg U/kg/day), or 140 mg U/kg/day as 
uranium peroxide (NOAEL of 55 mg U/kg/day).  The relative toxicity of the various uranium compounds 
were similar in the dog studies; however, the use of one dog per dose level limits the interpretative value 
of this study. 
 
The chronic toxicity of uranium compounds was evaluated in a series of dietary exposure studies 
conducted by Maynard and associates (Maynard and Hodge 1949; Maynard et al. 1953) involving a 
1-year exposure of dogs to uranium dioxide, uranyl fluoride, uranium tetrafluoride, uranium tetrachloride, 
or uranyl nitrate and a 2-year exposure of rats to uranium dioxide, uranyl fluoride, uranium tetrafluoride, 
or uranyl nitrate.  A 2-year exposure of rats to uranyl fluoride or uranyl nitrate resulted in minimal tubular 
alterations at 81 and 170 mg U/kg/day, respectively; at higher doses (≥140 and ≥330 mg U/kg/day, 
respectively), the renal damage progressed to tubular atrophy (Maynard and Hodge 1949; Maynard et al. 
1953).  Exposure to the less soluble compound, uranium tetrafluoride, resulted in mild tubular 
degeneration at the highest dose tested (11,000 mg U/kg/day).  No renal effects were observed in rats 
exposed to uranium dioxide at doses as high as 12,000 mg U/kg/day for 2 years.  Although interpretation 
of the dog studies (Maynard and Hodge 1949; Maynard et al. 1953) is limited by the small number of 
dogs tested (typically two dogs per dose), the results are consistent with the chronic rat studies and with 
shorter duration studies.  Soluble uranium compounds, such as uranyl nitrate and uranyl fluoride, were 
more toxic than less soluble or insoluble compounds.  Renal tubular atrophy was observed in dogs 
exposed to 9.5 mg U/kg/day as uranyl nitrate, 7.7 mg U/kg/day as uranyl fluoride, 31 mg U/kg/day as 
uranium tetrachloride, 150 mg U/kg/day as uranium tetrafluoride, and 900 mg U/kg/day as uranium 
dioxide; the severity of the atrophy increased with dose.   
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The relationship between duration of exposure and the progression of renal lesions was evaluated in a 
serial exposure study in which rats were exposed to 33, 170, or 660 mg U/kg/day as uranyl nitrate 
hexahydrate in the diet (Maynard et al. 1953).  At 660 mg U/kg/day, slight degeneration and necrosis 
were observed after 1 day of exposure; the extent and severity of the degeneration and necrosis continued 
to progress during the first week of exposure.  At the end of the second week of exposure, there was less 
evidence of necrosis and more evidence of typical regeneration in the renal tubules.  Tubular atrophy was 
observed in rats exposed for 6–10 weeks, which progressed in severity and extent over the next 18 weeks 
with a concomitant decrease in tubular regeneration.  At 26 weeks, atrophy was the most prominent 
feature with dilation of atrophic tubules and narrowing of the cortex.  At the end of the 1-year study, 
moderate to moderately severe tubular atrophy was observed.  At the 170 mg U/kg/day dose, necrosis and 
degeneration were observed after 2 days of exposure and the severity continued to progress during the 
first week of exposure.  After 2 weeks of exposure, regeneration of the tubular epithelium was the 
prominent effect.  The severity of damage did not vary much during the first 30 weeks of exposure, with 
the exception of tubular atrophy detected in a small number of animals at 30 weeks.  After 1 year of 
exposure, the renal alterations were primarily regeneration with slight atrophy in some animals.  No 
uranium-related effects were observed in rats exposed to 33 mg U/kg/day.  The results of this study 
suggest that at low doses, the tubular epithelium is regenerated and further exposure does not result in 
more severe effects.  However, at higher doses, the capacity of the kidney to regenerate the damaged 
epithelium is exceeded, resulting in atrophy; continued exposure results in further damage to the kidney. 
 
Endocrine Effects.    No endocrine effects after oral intake of uranium have been reported in humans.  
Few endocrine effects have been reported after uranium exposure in laboratory animals.  In animal 
studies, a dose of 0.07 mg U/kg/day as uranyl nitrate hexahydrate for 16 weeks in drinking water resulted 
in degenerative changes in the thyroid epithelium and altered thyroid function in Wistar rats 
(Malenchenko et al. 1978).  Sprague-Dawley rats (10/sex/dose) were exposed to uranium as uranyl nitrate 
in drinking water (males:  up to 35.3 mg U/kg/day; females:  up to 40.0 mg U/kg/day) for 28 days and 
then sacrificed.  No treatment-related histopathological changes were found in any of the endocrine 
organs studied (adrenal, pancreas, parathyroid, pituitary, thymus, thyroid), and no treatment-related 
changes in these organ weights were noted (Gilman et al. 1998a).  In addition, New Zealand rabbits were 
exposed to uranium as uranyl nitrate in the drinking water (males:  up to 28.70 mg U/kg/day; females:  up 
to 43.02 mg U/kg/day) for 91 days.  No treatment-related histopathological changes were found, and no 
weight changes in the adrenal, pancreas, parathyroid, or pituitary glands were noted (Gilman et al. 
1998b).  Male New Zealand rabbits exposed to uranium as uranyl nitrate in drinking water (1.36 and 
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40.98 mg U/kg/day) for 91 days also failed to show any treatment-related histopathological or organ 
weight changes (Gilman et al. 1998c).  In another study, Sprague-Dawley rats (15/sex/dose) were exposed 
to uranium as uranyl nitrate in the drinking water (males:  up to 36.73 mg U/kg/day; females:  up to 
53.56 mg U/kg/day) for 91 days.  Thyroid lesions were observed in both sexes (multifocal reduction of 
follicular size, increased epithelial height in males at 0.31 mg U/kg/day and females at 2.01 mg 
U/kg/day).  A decreased amount and density of colloid in the thyroid was observed in males only. 
 
No histological alterations were observed in the thyroid, adrenals, or pancreas of rats exposed to 400 mg 
U/kg/day as uranyl fluoride, 660 mg U/kg/day as uranyl nitrate, 11,000 mg U/kg/day as uranium 
tetrafluoride, or 12,000 mg U/kg/day as uranium dioxide in the diet for 2 years (Maynard and Hodge 
1949; Maynard et al. 1953). 
 
Body Weight Effects.    No body weight effects after oral intake of uranium have been reported in 
humans. 
 
Oral exposure to uranium compounds has caused body weight effects in animals, but these effects are not 
necessarily the result of systemic toxicity.  The initial loss of body weight observed in animals exposed to 
high doses of uranium in the diet in acute-, intermediate-, and chronic-duration studies is usually 
accompanied by decreased food consumption in these animals.  The decreased food consumption could 
be due to the aversive taste of uranium compounds in food.  Subsequent acclimatization of the animals to 
the taste would normalize food intake and, consequently, reverse the initial loss of body weight.  Thus, 
the changes in body weight seen in such studies may be a result of reduction in food consumption due to 
distaste rather than of uranium-specific chemical or radiological toxicity.  Similarly, uranium in drinking 
water may influence palatability (some investigators have added sugar to the water to increase 
palatability), which may result in decreased water consumption and possibly influence body weight. 
 
In a 2-week drinking water study in rats, doses of 28 mg U/kg/day as depleted uranyl acetate dihydrate 
resulted in a 53% reduction in body weight gain in males; food consumption data were not provided 
(Briner and Murray 2005).  In the same study, exposure for 6 months reduced body weight gain by 
approximately 46% in males and 36% in females; no significant effects were reported at 14 mg U/kg/day 
either in the 2-week or the 6-month experiments.  In a developmental study in which rats were 
administered between 2.8 and 28 mg U/kg/day by gavage doses on gestation days 6–15, body weight gain 
during the treatment period was 33–88% lower than the control group (Domingo et al. 1989c); this was 
associated with significant reductions in food consumption.  Body weight losses of 18, 35, 27, 20, and 
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29%, respectively, were observed in rats given oral doses of 886 mg U/kg/day as uranium tetrachloride, 
1,081 mg U/kg/day as uranyl fluoride, or 664 mg U/kg/day as uranyl nitrate hexahydrate for 30 days 
(Maynard and Hodge 1949); rabbits given oral doses of 14.2 mg U/kg/day as uranyl nitrate hexahydrate 
for 30 days (Maynard and Hodge 1949); and rats given oral doses of 270 mg U/kg/day as uranyl fluoride 
for 2 years (Maynard and Hodge 1949; Maynard et al. 1953).   
 
No harmful effects on body weight were seen in rats given 12,342 mg U/kg as uranium dioxide or 
11,650 mg U/kg as uranium trioxide for 30 days (Maynard and Hodge 1949), mice given 1,100 mg U/kg 
as uranyl nitrate hexahydrate for 18 weeks or 462 mg U/kg as uranyl nitrate hexahydrate for 48 weeks 
(Tannenbaum et al. 1951), or Sprague-Dawley rats exposed to uranium as uranyl nitrate in drinking water 
at doses up to 35.3 mg U/kg/day (males) and 40 mg U/kg/day (females) for 28 days or up to 36.73 mg 
U/kg/day (males) and 53.56 mg U/kg/day (females) for 91 days (Gilman et al. 1998a).  No alterations in 
body weights were observed in rats given 12,341 mg U/kg as uranium dioxide or 10,611 mg U/kg as 
uranium hexafluoride for 2 years, or dogs given 8 mg U/kg as uranyl fluoride or 95 mg U/kg as uranyl 
nitrate hexahydrate for 1 year (Maynard and Hodge 1949; Maynard et al. 1953).  Reduced food intake 
was observed following a single oral dose of 5.6 mg U/kg as uranyl nitrate hexahydrate to rats (Domingo 
et al. 1987) and in a 48-week study in rats and mice at 1,100 mg U/kg/day as uranyl nitrate hexahydrate 
(Tannenbaum et al. 1951).  It has been suggested that this reduced food intake is a result of loss of 
appetite due to the unpalatability of the uranium compounds in the animals’ food (Dygert 1949e).  In two 
more recent drinking water studies in rats, doses of approximately 2–2.7 mg U/kg/day as uranyl nitrate 
hexahydrate in mineral water for up to 9 months did not significantly affect body weight or food or water 
consumption (Bensoussan et al. 2009; Bussy et al. 2006).  In mice, exposure via the drinking water to up 
to 100 mg U/kg/day as uranyl nitrate hexahydrate for 15 weeks had no significant effect on body weight 
(Arnault et al. 2008). 
 
In series of chronic rat dietary studies (Maynard and Hodge 1949; Maynard et al. 1953), decreases in 
body weight gain were observed in rats exposed to 330 mg U/kg/day as uranyl nitrate, 140 mg U/kg/day 
as uranyl fluoride, and 11,000 mg U/kg/day as uranium tetrafluoride; no alterations in body weight gain 
were observed in rats exposed to 12,000 mg U/kg/day as uranium dioxide.   
 
Metabolic Effects.    Tissandié et al. (2006, 2007) found alterations in 1,25(OH)2D3 (active form of 
vitamin D) levels in rats exposed to a single gavage dose of depleted uranyl nitrate or depleted uranyl 
nitrate in mineral water for 9 months.  One day after gavage administration of 97 mg U/kg, a significant 
62% increase in 1,25(OH)2D3 level was observed in male Sprague-Dawley rats; 3 days after 
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administration, there was a significant decrease (68% compared to controls) in the level (Tissandié et al. 
2006).  Significant decreases in serum inorganic phosphate levels (15% at day 1 and 28% at day 3) and 
parathyroid hormone (day 3 only) levels (90%) were also observed.  Intermediate-duration exposure to 
2.4 mg U/kg/day also resulted in significant decreases in 1,25(OH)2D3 levels; however, no alterations in 
25(OH)D3 (vitamin D metabolite), plasma calcium, inorganic phosphate, parathyroid hormone, or 
osteoclacin levels were found (Tissandié et al. 2007).  Alterations in mRNA expression levels of cyp24a1 
(encoding the enzyme that directs the catabolism of vitamin D) and vitamin D target genes involved in 
calcium homeostasis were also observed in the 9-month study. 
 
3.2.2.3   Immunological and Lymphoreticular Effects  
 
No information was located regarding the effects of uranium on the immune system in humans following 
oral exposure for any duration. 
 
In laboratory animals, oral exposure of rats, mice, and rabbits to uranium had no significant effect on 
immune system function.  In one study, Sprague-Dawley rats (10/sex/dose) were exposed to uranium as 
uranyl nitrate in drinking water (males:  up to 35.3 mg U/kg/day; females:  up to 40.0 mg U/kg/day) for 
28 days and then sacrificed.  No treatment-related effects were noted in the lymphoreticular tissues 
examined (bone marrow, mesenteric and mediastinal lymph nodes, spleen, and thymus) (Gilman et al. 
1998a).  In addition, New Zealand rabbits were exposed to uranium as uranyl nitrate in the drinking water 
(males:  up to 28.70 mg U/kg/day; females:  up to 43.02 mg U/kg/day) for 91 days.  No histopathological 
changes were found, and no changes in the bone marrow, mesenteric and mediastinal lymph nodes, or 
thymus were noted (Gilman et al. 1998b).  Rats exposed to oral doses of 0.07 mg U/kg as uranyl nitrate 
hexahydrate for 4 weeks showed an increase in spleen weight but the body weights of both the control 
and test animals were not provided, making it impossible to determine whether the net change in spleen 
weight had any toxicological significance (Malenchenko et al. 1978).  Sprague-Dawley rats exposed to 
uranium as uranyl nitrate in drinking water (males:  up to 36.73 mg U/kg/day; females:  up to 53.56 mg 
U/kg/day) for 91 days showed sinus hyperplasia of the spleen in both sexes at the highest dose (males:  
36.73 mg U/kg/day; females:  53.56 mg U/kg/day).  No lesions were observed in bone marrow, 
mesenteric and medistinal lymph nodes, or thymus (Gilman et al. 1998a).  In other studies with mice and 
rats, no histological changes in the spleen, lymph nodes, or bone marrow were seen in the animals 
following administration of up to 5,000 mg U/kg of various uranium compounds (uranyl nitrate 
hexahydrate, uranyl fluoride, uranium dioxide, uranium peroxide, uranium tetrafluoride, uranium 
tetrachloride, triuranium octaoxide, or uranium trioxide) in the diet for 48 weeks or 2 years.  No 
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consistent hematological changes were found in hematocrit, hemoglobin, or white blood cell counts 
(Maynard et al. 1953; Tannenbaum et al. 1951).  No other specific immunological tests were performed. 
 
3.2.2.4   Neurological Effects  
 
No studies were located for humans regarding neurological effects following oral exposure to uranium 
compounds. 
 
There is a limited number of reports of neurological effects in animals following acute oral exposure to 
uranium compounds.  A study aimed at determining an oral LD50 for uranyl acetate dihydrate in Sprague-
Dawley rats given single gavage doses ranging from 11 to 717 mg U/kg reported piloerection, tremors, 
hypothermia, pupillary size decreases, and exophthalmos (Domingo et al. 1987).  The signs became more 
severe as the number of days posttreatment increased; however, the study did not specify the dose levels 
at which the various clinical signs appeared. 
 
Two more recent acute-duration studies focused on the neurobehavioral effects of uranium and on effects 
on brain neurotransmitters.  Administration of 28 mg U/kg/day (depleted uranyl acetate dihydrate) to 
Long-Evans rats via the drinking water for 2 weeks significantly increased motor activity in males as 
judged by number of lines crossed and rearing frequency, no significant effect was reported at 14 mg 
U/kg/day (Briner and Murray 2005); similar but nonsignificant alterations in open-field behavior were 
observed in females.  Lipid oxidation in the brain was significantly increased in males and females dosed 
with 28 mg U/kg/day.  According to the investigators, lines crossing and rearing frequency exhibited 
significant correlations with brain lipid oxidation, but the correlation coefficients were only 0.21 and 0.23, 
respectively, indicating that only about 4% of the variance in the behavioral tests could be explained by 
changes in lipid oxidation.  Briner and Murray (2005) also exposed rats for 6 months to 14 or 28 mg 
U/kg/day and found increases in line crossing and rearing behavior in males at 14 and 29 mg U/kg/day 
and increased line crossing in females at 29 mg U/kg/day.  However, lipid oxidation did not correlate with 
line crossing or rearing behavior.  In a 2-week study in Swiss-Webster mice that also measured 
neurotransmitters and their metabolites in the midbrain, exposure to 6 mg U/kg/day (depleted uranyl 
acetate dihydrate; only dose level tested) significantly increased open-field line crossing in females, but 
not in males (Briner 2009).  Exposure to uranium significantly increased tyrosine and decreased 
3,4-dihydroxyphenylalanine (DOPA), norepinephrine (NE), and epinephrine (E); it had no significant 
effect on dopamine (DA) or homovanillic acid (HVA).  According to the investigator, levels of DOPA in 
the midbrain were inversely related to lines crossed in open field (r2=0.12).  Exposure to uranium 
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significantly increased brain lipid oxidation, but lipid oxidation did not correlate with levels of tyrosine, 
DOPA, NE, E, or HVA. 
 
Intermediate-duration oral studies that examined the gross and microscopic appearance of the brain of 
animals exposed to uranium have not reported compound-related alterations in male and female 
Sprague-Dawley rats exposed via drinking water to up to 40 mg U/kg/day as uranyl nitrate for 28 days or 
up to 54 mg U/kg/day for 91 days (Gilman et al. 1998a), and in male and female New Zealand rabbits 
similarly exposed to up to 43 mg U/kg/day for 91 days (Gilman et al. 1998b). 
 
Intermediate-duration studies have also examined the effects of uranium on behavior, transmitter levels in 
the brain, including genes involved in neurotransmitter metabolism, and oxidative stress in the brain. 
 
A study of neurotransmitter levels in the brain of male Sprague-Dawley rats following 1.5, 6, or 9 months 
of dosing with approximately 2.7 mg U/kg/day as depleted uranyl acetate dehydrate in mineral water; 
only dose level tested) reported that acetylcholinesterase activity was not significantly affected in the 
striatum, hippocampus, or frontal cortex at any time point, but it was significantly decreased in the 
cerebellum at 6 months (Bussy et al. 2006).  Of many biochemical measurements conducted, the only 
significant changes were as follows: increased dopamine in the hypothalamus at 1.5 months, decreased 
ratio (3,4-dihydroxyphenylacetic acid [DOPAC]+HVA)/DA in the frontal cortex at 6 months, decreased 
5HIAA and the ratio 5HIAA/5HT in the frontal cortex at 9 months, and decreased DOPAC and 
(DOPAC+HVA)/DA in the striatum at 9 months.  Uranium significantly increased in the striatum at 
1.5 months and to a lesser extent at 9 months (not measured at 6 months).  Bensoussan et al. (2009) 
examined alterations in cholinergic system in response to a 1.5- or 9-month exposure to 2 mg U/kg/day as 
uranyl nitrate in mineral water.  After 1.5 months of exposure, there were significant decreases in 
acetylcholine levels and acetylcholinesterase activity in the cortex; there were no alterations in the 
hippocampus.  At 9 months, there was a decrease in acetylcholinesterase activity in the cortex, but no 
changes in acetylcholine levels, and no alterations in the hippocampus.  Based on alterations in gene 
expression, the investigators noted that exposure to uranium seemed to induce transcriptional alterations 
in the hippocampus aimed at preserving acetylcholine levels, whereas in the cortex, exposure led mainly 
to translational alterations that increased acetylcholinesterase levels after 9 months of exposure.  The 
investigators also noted that the lack of correlation between the increase in genes expressing cortical 
acetylcholinesterase and the decrease in acetylcholinesterase activity in the cortex could be explained by 
the complex relation between mRNA and enzyme activity. 
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A 3-month drinking water study in male Sprague-Dawley rats dosed with up to 22.4 mg U/kg/day (uranyl 
acetate dihydrate) that conducted behavioral tests including open-field activity, passive avoidance, and 
Morris water maze reported that exposure to uranium did not significantly affect any of the behavioral 
tests (Belles et al. 2005).  A study that compared the effects of depleted and 4% enriched uranium (2.7 mg 
U/kg/day in mineral water for 1.5 months) in Sprague-Dawley rats reported that whole brain of controls 
had comparable amounts of uranium as brains of rats exposed to depleted or enriched uranium (Houpert 
et al. 2005).  However, uranium was 1.5–2 times higher in the hypothalamus and hippocampus from rats 
dosed with enriched uranium than in control rats or rats exposed to depleted uranium.  No significant 
increases in uranium levels were observed in the cortex, striatum, brainstem, or cerebellum were observed 
in the enriched or depleted uranium groups.  Rats exposed to enriched uranium had a significant increase 
in the amount of paradoxical sleep (37%) compared to controls.  In addition, exposure to enriched, but not 
depleted, uranium significantly decreased spatial working memory capacities and increased anxiety.  In 
an additional study by the same group of investigators, male Sprague-Dawley rats exposed to 2.5 mg 
U/kg/day as 5.26% enriched uranyl nitrate for 9 months via drinking water (Houpert et al. 2007b).  Four 
neurobehavioral tests (activity in open field, a two-object recognition task, a test for spatial working 
memory in a Y-maze, and a forced swimming test) were conducted before dosing started and at 3, 6, and 
9 months.  The only test that was affected by exposure to uranium was the spatial working memory test 
after 3 and 9 months of exposure, but not after 6 months.  The investigators suggested that the results may 
indicate that enriched uranium disrupts memory in a spatial task involving the hippocampus but does not 
affect memory in another task in which hippocampal functioning is less crucial. 
 
In a study examining the effects of uranium on the sleep cycle, Sprague-Dawley rats were exposed to 
uranium in drinking water for 90 days.  An increase in the amount of time spent in rapid eye movement 
(REM) sleep was observed in rats exposed to 3.7 mg U/kg/day as 4.92% enriched uranyl nitrate in 
mineral water for 30 or 60 days; a nonsignificant increase was observed after 90 days of exposure 
(Lestaevel et al. 2005b).  This increase in REM sleep was due to the number of REM sleep episodes 
rather than an increase in the duration of REM episodes.  The increases in the amount of REM sleep 
primarily occurred during the light period (normal sleeping period for rats), suggesting that the circadian 
rhythms were not affected by uranium exposure. 
 
The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
neurological effects from exposure to uranium by the oral route are presented in Table 3-2 and plotted in 
Figure 3-2. 
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3.2.2.5   Reproductive Effects  
 
No human studies were located regarding reproductive effects following oral exposure to uranium 
compounds. 
 
Some animal studies, mostly in rodents, have shown effects on some aspects of male and female 
reproductive function following exposure to uranium.  For the most part, general toxicity studies that 
conducted gross and microscopic examination of the reproductive organs did not report adverse effects.  
For example, no histopathology or changes in reproductive organ weight were reported in Sprague-
Dawley rats exposed to uranium as uranyl nitrate in the drinking water (males: up to 35.3 mg U/kg/day; 
females: up to 40.0 mg U/kg/day) for 28 days (Gilman et al. 1998a).  No reproductive effects or changes 
in reproductive organ weights were found in the epididymis, testes, ovary, or uterus of Sprague-Dawley 
rats (15/sex/dose) exposed to uranium as uranyl nitrate in drinking water (males: up to 36.73 mg 
U/kg/day; females:  up to 53.56 mg U/kg/day) for 91 days (Gilman et al. 1998a).  New Zealand rabbits 
exposed to uranium as uranyl nitrate in the drinking water (males: up to 28.70 mg U/kg/day; females: up 
to 43.02 mg U/kg/day) for 91 days showed no histopathological or organ weight changes in the 
epididymis, ovary, testes, or uterus (Gilman et al. 1998b).  In chronic-duration studies, male rats given 
high oral doses (331 mg U/kg/day) of uranyl nitrate hexahydrate in the diet for 2 years developed 
testicular degeneration (Maynard et al. 1953).   
 
Fertility has been assessed in a few studies.  Fertility was not significantly affected in a study in which 
male Swiss mice were given gavage doses of up to 14 mg U/kg/day as uranyl acetate dihydrate for 
60 days before mating with females that had received the same doses for 14 days (Paternain et al. 1989).  
In a 64-day drinking-water study with Swiss-Webster mice, treatment of males with ≥5.6 mg U/kg/day 
(uranyl acetate) followed by mating with untreated females resulted in significant reductions in pregnancy 
rates, which were associated with significant reductions in spermatozoa counts and reduced epididymal 
weights (Llobet et al. 1991).  Treatment of male Sprague-Dawley rats with 11.2 mg U/kg/day (uranyl 
acetate) in the drinking water for 3 months before mating with untreated females also resulted in a 
significant reduction in pregnancy rate; no significant effect was reported at 5.6 mg U/kg/day (Linares et 
al. 2005).  In this study, there were no significant effects on the number of total implants/litter or number 
of viable and nonviable implants/litter.  Neither the absolute nor relative weight of the testes and 
epididymis was significantly affected; a significant decrease in the number of spermatid/testis was 
observed at ≥11.2 mg U/kg/day.  Microscopic examination of the testes showed a progressive, but not 
significant, loss of Sertoli cells or germinal cells with cytoplasmic vacuolization.  Maynard and associates 
URANIUM  156 
 








conducted two continuous breeding studies to evaluate the effect of uranium on fertility.  In the first study 
(Maynard and Hodge 1949), pairs of male and female rats were exposed to 2% uranyl nitrate hexahydrate 
in the diet for 200 days (650 and 750 mg U/kg/day in males and females, respectively) followed by 
5 months on the control diet.  A dramatic decrease in the number of litters produced (46%) was observed 
in the uranium-exposed group; a decrease in the average number of offspring per litter was also observed.  
Irregular estrous cycles were observed in 14/44 of the uranium-exposed rats compared to 2/45 controls.  
The investigators suggested that the decreased fertility and irregular estrous cycle may have resulted from 
the marked decrease in body weight (after 200 days of exposure, the uranium group weighed 23% less 
than controls) and decreased food intake (no data provided).  In the second study (Maynard et al. 1953), 
pairs of male and female weaning rats were administered 2% uranyl nitrate hexahydrate in the diet for 
24 hours (1400 mg U/kg/day) and then fed a stock diet for 1 year.  A slight decrease (7%) in the total 
number of litters was observed in the uranium group; a 12% decrease in the total number of offspring was 
also observed.  No alterations in body weight gain were observed.  Interpretation of the study results to 
evaluate whether uranium affects reproduction (in the absence of marked decreases in body weight gain) 
is difficult because the Maynard et al. (1953) study did not conduct a statistical analysis of the data to 
determine whether the small decreases in number of litters and litter size were significant. 
 
The effects of uranium on ovarian function have also been studied.  Exposure of female C57Bl x CBA 
mice to ≥1.25 mg U/kg/day (uranyl nitrate hexahydrate) in drinking water for 15 weeks resulted in slight 
disturbance in ovarian folliculogenesis (Arnault et al. 2008).  In a similar study, exposure of female Swiss 
mice to up to 10 mg U/kg/day (uranyl nitrate hexahydrate) for 40 days in drinking water did not alter the 
mean number of oocytes ovulated per female (Kundt et al. 2009).  However, doses of ≥2.5 mg U/kg/day 
significantly increased (more than doubled) the percentage of dysmorphic oocytes; the increases consisted 
of increases in perivitaline space at ≥5 mg U/kg/day, lysed oocytes at 2.5 and 5 mg U/kg/day, fragmented 
oocytes at 10 mg U/kg/day, and nonspherical oocytes at ≥2.5 mg U/kg/day.  Exposure to uranium also 
significantly increased the incidence of micronuclei in cumulus cells (oocyte-supporting cells); a strong 
correlation between the number of micronuclei and dose was found.  The mitotic index in cumulus cells 
was significantly decreased in the mid- and high-dose groups in a dose-related fashion.  Uranium also 
increased the number of metaphase plate abnormalities in oocytes arrested in metaphase II.  In yet another 
study, exposure of hybrid female mice to up to 6.9 mg U/kg/day (uranyl nitrate hexahydrate) for 49 days 
in drinking water did not affect the number of ovulated oocytes (Feugier et al. 2008).  Oocyte quality was 
not affected by the lowest dose tested (1.9 mg U/kg/day), but the proportion of healthy oocytes was 
reduced by half at doses ≥3.9 mg U/kg/day.  Absence of the first polar body and abnormal perivitaline 
space were the main morphological alterations.  An increase from the 3.9 to 6.9 mg U/kg/day dose did not 
URANIUM  157 
 








increase the proportion of oocytes with abnormalities, but led to a diversification in oocyte abnormalities.  
Both Arnault et al. (2008) and Feugier et al. (2008) measured uranium in the ovaries and reported no 
significant accumulation of the chemical.  Effects of uranium on ovarian folliculogenesis were also 
studied by Raymond-Whish et al. (2007).  Administration of approximately 0.08 or 0.39 mg U/kg/day as 
depleted uranyl nitrate hexahydrate to 28-day-old B6C3F1 mice in tap water for 30 days significantly 
decreased the number of large primary follicles in the ovary, whereas a larger dose of 1.9 mg U/kg/day 
increased secondary or growing follicles.  No significant alterations were observed at 9.3 mg U/kg/day.  
In a different experiment, female mice were exposed to much smaller doses (0.00008–0.009 mg 
U/kg/day) of uranium for 30 days prior to mating with untreated males and then continued to be dosed 
during gestation.  Necropsy of dams on postnatal day 5 showed that doses ≥0.00039 mg U/kg/day 
significantly reduced the number of small primary follicles; however, all other follicle populations 
including primordial, secondary/growing, healthy, and atretic were unchanged. 
 
Raymond-Whish et al. (2007) also examined the potential estrogenic properties of uranium.  Exposure of 
ovariectomized (at 28-days of age) mice to 0.009 mg U/kg/day as depleted uranyl nitrate hexahydrate for 
30 days significantly increased proliferation of the epithelial cell lining of the uterus, and uterus weight 
increased 3-fold; however, significant effects were not observed at 0.09 or 0.9 mg U/kg/day.  In addition, 
mice exposed to 0.005 and 0.009 mg U/kg/day had significantly increased presence of cornified vaginal 
cells, indicative of estrogenic effects of uranium.  In a similar experiment, exposure of ovariectomized 
C57Bl/6J mice to 0.005 mg U/kg/day for 10 days beginning at 50 days of age significantly increased 
uterine weight and exposure to 0.009 mg U/kg/day significantly accelerated vaginal opening; both effects 
were blocked by intraperitoneal injections of an antiestrogenic drug.  These effects were observed at 
doses that are several orders of magnitude lower than the adverse effect levels of other studies and were 
not observed at higher uranium doses.  Additional research is needed to confirm these results; thus, the 
LOAEL values are not presented in Table 3-2 or plotted in Figure 3-2. 
 
A study was conducted to distinguish chemical versus radiological effects of uranium on the metabolism 
of steroids in rat testes (Grignard et al. 2008).  Sprague-Dawley rats were exposed to 0 or 1.9 mg depleted 
or 4.24% enriched U/kg/day (uranyl nitrate hexahydrate) in the drinking water for 9 months.  Exposure to 
depleted uranium did not significantly affect blood levels of testosterone or 17β-estradiol.  Exposure to 
depleted uranium also did not significantly affect the levels of genes encoding proteins regulating steroid 
synthesis.  In addition, depleted uranium did not significantly alter the expression levels of transcription 
factors regulating the expression of the genes that were monitored.  Exposure to enriched uranium did not 
significantly affect blood levels of 17β-estradiol, but significantly increased testosterone levels and the 
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expression of genes involved in steroidogenesis.  In addition, enriched uranium significantly increased the 
expression of transcription factors involved in the regulation of steroidogenic genes.  These results led the 
investigators to suggest that the adverse effects were mainly due to the radiological activity of the 
compounds. 
 
The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
reproductive effects from exposure to uranium by the oral route are presented in Table 3-2 and plotted in 
Figure 3-2. 
 
3.2.2.6   Developmental Effects  
 
No studies were located that reported developmental effects in humans following oral exposure to 
uranium for any duration.  Animal studies indicate that oral exposure to uranium can cause developmental 
effects, but only at relatively high doses. 
 
Pregnant Swiss mice were exposed to uranium as uranyl acetate dihydrate by gavage in water at a dose of 
0.028, 0.28, 2.8, or 28 mg U/kg/day from gestation day 13 through postnatal day 21 (Domingo et al. 
1989b).  Treatment had no significant effects on mean litter size at birth or on day 4, but litter size was 
significantly decreased at postnatal day 21 at 28 mg U/kg/day (5.5 vs. 8.8 in water-only controls).  The 
viability index (number of pups viable at day 21/number of pups born) and the lactation index (number of 
pups viable at day 21/number of pups retained at day 4) were significantly decreased in the 
28 mg U/kg/day group.  No significant differences were observed in developmental milestones (pinnae 
unfolding, lower incisor eruption, eye opening) or in pup weight or body length.  Structural variations 
were not assessed in this report.  Two dams in the 2.8 mg U/kg/day group and three in the 28 mg 
U/kg/day group died during the last period of gestation.  Although the cause of death was not determined, 
it was attributed to the administration of uranium.  Yet, the investigators stated that maternal toxicity was 
not evident from changes in body weight and/or food consumption. 
 
Increased late resorptions and decreased live fetuses were reported in Swiss mice administered 14 mg 
U/kg/day (uranyl acetate dihydrate) by gavage for 14 days before mating with males that received the 
same doses for 60 days; the females were sacrificed on gestation day 13 (Paternain et al. 1989).  No 
significant effects were reported at 5.6 mg U/kg/day.  In dams that were allowed to give birth and nurse 
the offspring until 21 days of age (dams’ exposure continued during gestation and lactation), doses of 
5.6 mg U/kg/day significantly increased neonatal death per litter, and the lowest dose tested, 2.8 mg 
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U/kg/day, significantly reduced pup weight on postnatal day 21 (Paternain et al. 1989).  No information 
was provided in this study regarding maternal effects.  Dose-related fetotoxicity, manifested as reduced 
fetal body weight and length, increased incidence of stunted fetuses and external and skeletal 
malformations, and increased incidence of developmental variations were reported in the offspring of 
20 pregnant Swiss mice given uranyl acetate dihydrate (2.8, 5.6, 14, and 28 mg U/kg/day) by gavage on 
gestation days 6–15 and sacrificed on gestation day 18 (Domingo et al. 1989c).  A significant increase in 
the number of external defects was observed at ≥2.8 mg U/kg/day.  The external malformations included 
a significant increase in the incidence of cleft palate (≥5.6 mg U/kg/day) and hematomas (at 2.8 and 
28 mg U/kg/day).  A significant increase in the incidence of skeletal abnormalities (bipartite sternebrae 
and reduced or delayed ossification of the hindlimb, forelimb, skull, and tail) was seen in the 14 and 
28 mg U/kg/day groups.  Embryolethality was not found at any of the dose levels tested.  Maternal 
toxicity was evident in all treated groups, as a dose-related significant reduction in maternal weight gain 
during exposure occurred (43% reduction in the lowest dose group, 82% in the highest dose group); this 
may have played a role in the observed developmental effects. 
 
More recent studies also provide information on the developmental effects of uranium.  Exposure of 
female Sprague-Dawley rats to doses of 0, 22.5, or 45 mg U/kg/day (uranyl acetate dihydrate) in the 
drinking water for 4 weeks before mating with untreated males and continued dosing during gestation and 
lactation had no significant effect on pup developmental landmarks such as pinna detachment, incisor 
eruption, and eye opening (Sánchez et al. 2006).  Neuromotor maturation was also not affected, but 
passive avoidance acquisition and retention time 24 hours after the test were significantly modified.  The 
lowest dose tested significantly reduced pup body weight on postnatal day 21, but not on postnatal day 1.  
The only maternal effects reported in this study were a significant dose-related increase in body weight 
gain on gestation days 0–14 and a significant increase in gravid uterine weight at 45 mg U/kg/day; no data 
were provided regarding food consumption.  Neurodevelopment was also examined by Houpert et al. 
(2007a) in offspring from Sprague-Dawley rats exposed to 0 or approximately 4.3 mg U/kg/day as 4.24% 
enriched uranyl nitrate hexahydrate in mineral water for 3 months before mating and during gestation and 
lactation.  Behavioral tests were performed in male offspring at 2, 5, and 9 months.  Rats were tested for 
locomotor activity and rearing indices, a spatial working memory test, and an elevated plus-maze test.  At 
2 months, when the tests began, exposed pups were comparable to control pups in body weight and organ 
weight (brain, kidneys, femur, and skull).  Uranium did not accumulate in the brain.  The results of the 
motor and behavioral tests showed that exposure to uranium induced hyperactivity in the offspring at 
5 months and was more evident at 9 months; the investigators considered this to be delayed hyperactivity.  
This was evidenced by increased rearing indices and activity in the open field (not statistically 
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significant), and increased activity in the two mazes.  The results also showed a reversible slight decrease 
in spatial working memory.  The only information regarding the dams in this study was that body weight 
gain during gestation was comparable between treated and control groups. 
 
Two studies reported effects on ovarian folliculogenesis in female offspring from exposed mice.  Arnault 
et al. (2008) exposed C57Bl x CBA mice to 0, 1.25, 12.5, or 100 mg U/kg/day (uranyl nitrate 
hexahydrate) in the drinking water for 15 weeks.  Mice were then mated to untreated males, and dams and 
female pups were sacrificed 3 months later.  Microscopic examination of the ovaries of the female pups 
showed that pups from exposed dams had a significantly decreased percentage of the largest follicles.  
The investigators noted that the effect could be due either to a direct effect of transplacental transfer of 
uranium or to an indirect effect resulting from uranium-induced physiological disturbances in the dams, 
or both.  In the other study, B6C3F1 mice were exposed via the tap water to low uranium doses ranging 
from approximately 0.00008 to 0.00093 mg U/kg/day as depleted uranyl nitrate hexahydrate for 30 days 
prior to breeding with untreated males (Raymond-Whish et al. 2007); treatment continued during 
gestation.  In female pups, sacrificed on postnatal day 5, exposure to 0.00008 or 0.00093 mg U/kg/day 
significantly reduced primordial follicles.  Nonsignificant decreases in primordial follicles were observed 
at 0.00039 and 0.00019 mg U/kg/day.  The investigators noted that neonatal mouse ovaries only have 
oogonia and primordial follicles.  These results in pups are analogous to the results in mouse dams, not-
mated mice, and immature mice. 
 
A study is available that examined the effect of a high dose of uranium on tooth eruption and 
development in young Wistar rats (Pujadas Bigi et al. 2003).  One- or 7-day-old rats were administered a 
single gavage dose of 0 or approximately 42.7 mg U/kg (uranyl nitrate hexahydrate) in water and were 
sacrificed on days 7 or 14, respectively.  Hemimandibles were resected and processed for microscopic 
examination.  Bone formation was significantly reduced in the bucal and lingual aspects of 7-day-old 
treated rats.  Bone resorption was significantly higher in the occlusal and lingual aspects of both 1- and 
7-day-old treated rats.  Tooth eruption was significantly lower in both treated groups compared with 
controls.  Tooth development was also found to be significantly diminished in both treated groups 
compared with controls.  The investigators suggested that the delay in tooth eruption may be due to 
decreased bone formation in the developing alveolar bone.  They further speculated that the diminished 
tooth development may be caused by a toxic effect on Hertwig's sheath cells, odontoblasts, and 
cementoblasts.  In a more recent study, the investigators showed that the delay in tooth eruption, dental 
development, and mandibular growth observed 7 days postdosing with uranium was no longer evident 
after day 27 (Pujadas Bigi and Ubios 2007). 
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The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
developmental effects from exposure to uranium by the oral route are presented in Table 3-2 and plotted 
in Figure 3-2. 
 
3.2.2.7   Cancer  
 
No evidence linking oral exposure to uranium to human cancer has been found.  Although natural, 
depleted, or enriched uranium and uranium compounds have not been evaluated in a cancer bioassay, 
there is potential for the carcinogenicity of uranium, since it emits primarily alpha radiation.  
Nevertheless, no evidence has been found to associate human exposure to uranium compounds and 
carcinogenesis.  The National Academy of Sciences has determined that bone sarcoma is the most likely 
cancer from oral exposure to uranium; however, their report noted that this cancer has not been observed 
in exposed humans and concluded that exposure to natural uranium may have no measurable effect (BEIR 
IV). 
 
No studies were located that provided evidence that oral exposure of humans to uranium as an 
alpha-emitting radiation source causes cancer.  The available human data on the relative potential of 
ingested radium and uranium isotopes to induce cancers in humans concluded that the cumulative lifetime 
risk to 1 million people, each ingesting 5 pCi of a radium isotope (226Ra, 228Ra, and 224Ra) per day, for the 
induction of skeletal cancers (bone sarcomas and carcinomas of the head sinuses) is 9 bone sarcomas and 
12 head carcinomas for 226Ra, 22 bone sarcomas for 228Ra, and 1.6 bone sarcomas for 224Ra.  Assuming 
that the risk per rad of the average skeletal dose is equal for 226Ra and uranium isotopes with half-lives 
exceeding 1,000 years, and that the equilibrium skeletal content is 25 times the daily ingestion of 226Ra 
but 11 times the daily ingestion of long-lived uranium, the cumulative lifespan risk to 1 million people, 
each ingesting 5 pCi/day of 234U (0.0008 μg), 235U (2.3 μg), or 238U (15 μg), is estimated to be about 
1.5 bone sarcomas.  However, no cancers would be expected if the incidence is found to vary with the 
square of the dose instead of linearly (Mays et al. 1985).  The BEIR IV report came to the same 
conclusion, but reserved the opinion that bone sarcomas might be caused by highly enriched uranium.  
The report estimated a lifetime risk of excess bone sarcomas per million people of 1.5 if soluble uranium 
isotopes were ingested at a constant daily rate of 1 pCi/day (0.037 Bq/day).  The number of bone 
sarcomas that occur naturally in a population of a million people is 750.  However, no quantitative risk 
coefficient estimates for developing human exposure protection benchmarks were provided in this report.  
In addition, the BEIR IV analysis was presumably based on generic short-lived alpha-emitting sources, 
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such as radon that have a higher potential for inducing cancer, and not on radionuclides with relatively 
longer radioactive half-lives like 238U, 235U, and 234U.  Perhaps more importantly, the BEIR IV report 
concluded that “...exposure to natural uranium is unlikely to be a significant health risk in the population 
and may well have no measurable effect” (BEIR IV 1988). 
 
There are limited data on the carcinogenicity of uranium compounds in animals.  Chronic oral exposure 
studies in rats and dogs have not reported neoplasms following ingestion of several uranium compounds 
(Maynard and Hodge 1949; Maynard et al. 1953).  The highest doses tested in 1-year dog studies were 
95 mg U/kg/day as uranyl nitrate, 8 mg/kg/day as uranyl fluoride, 31 mg U/kg/day as uranium 
tetrachloride, 3,790 mg U/kg/day as uranium tetrafluoride, and 8,815 mg U/kg/day as uranium dioxide.  
In the rat 1-year studies, the highest doses tested were 664 mg U/kg/day as uranyl nitrate, 10,611 mg 
U/kg/day as uranium tetrafluoride, and 12,341 mg U/kg/day as uranium dioxide. 
 
3.2.3   Dermal Exposure  
 
3.2.3.1   Death  
 
No deaths have been reported in humans as a result of dermal exposure to uranium. 
 
Deaths have occurred in animals after dermal exposure to uranium compounds from both single and 
repeated exposures.  Generally, the more water-soluble uranium compounds were the most toxic and the 
rabbit was the most sensitive species.  Deaths were due to renal failure. 
 
In a series of 4-hour exposures to uranium compounds followed by washing with detergent and a 30-day 
observation period, the lowest reported LD50 value was 28 mg U/kg as uranyl nitrate in an ethereal 
solution in New Zealand rabbits (Orcutt 1949).  Calculated LD50 values for identical exposures to uranyl 
nitrate were 1,190 mg U/kg for guinea pigs and 4,286 mg U/kg for mice.  Insufficient fatalities occurred 
to calculate an LD50 for rats, but the mortality curve fell between that of the rabbits and the guinea pigs.  
Deaths mainly occurred 5–7 days after exposure and were due to renal failure.  Similar experiments with 
other uranium compounds in rabbits using a lanolin vehicle showed that water-soluble compounds (uranyl 
fluoride, uranium tetrachloride, uranium pentachloride) were the most toxic; the slightly soluble 
compounds (uranium trioxide, sodium diuranate, ammonium diuranate) had intermediate toxicity; and the 
water-insoluble compounds (uranium tetrafluoride, uranium dioxide, uranium peroxide, triuranium 
octoxide) caused no deaths (Orcutt 1949). 
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Decreased survival was observed in female Wistar rats following dermal application of 280 mg U as 
uranyl nitrate hexahydrate diluted in an oil-water emulsion; survival was inversely related to the duration 
of exposure and the application area (Lopez et al. 2000).  A 24-hour application to 0.5, 1, 2, 4, 6, 8, or 
16 cm2 area resulted in survival rates of 80, 83, 67, 29, 33, 0, and 0%, respectively; application to 8 cm2 
for 1 minute, 7 minutes, 15 minutes, 30 minutes, 1 hour, 8 hours, or 24 hours resulted in survival rates of 
100, 100, 100, 67, 45, 43, 10, and 0%, respectively. 
 
Chemically induced renal failure caused 100% mortality in male Wistar rats after five daily exposures to 
237 or 1,928 mg U/kg/day as uranyl nitrate hexahydrate or ammonium uranyl tricarbonate, respectively, 
applied in a water-Vaseline® emulsion (De Rey et al. 1983).  A 60% mortality rate was also reported for 
other male Wistar rats that received daily applications of 1,965 mg U/kg as uranyl acetate dihydrate for 1–
11 days.  No deaths were reported for other Wistar rats similarly treated with 2,103 mg U/kg/day as 
ammonium diuranate or to an unspecified dose of uranium dioxide (De Rey et al. 1983). 
 
Intermediate-duration dermal exposure in guinea pigs indicated that smaller repeated doses were better 
tolerated than a large single dose when the total exposure was the same.  In a 4-week experiment where 
exposure was to 379 mg U/kg as uranyl nitrate for 3 days/week, 14% mortality was observed (Orcutt 
1949).  If the same cumulative dose (4,741 mg U/kg) had been given in a single application, 86% 
mortality would have been expected. 
 
The LD50 values for each species and other LOAEL values for mortality from exposure to uranium 
through the dermal route are presented in Table 3-3. 
 
3.2.3.2   Systemic Effects  
 
No studies were located regarding systemic effects in humans following dermal exposure to uranium 
compounds for acute, intermediate, or chronic durations. 
 
No studies were located regarding the respiratory, cardiovascular, gastrointestinal, hematological, hepatic, 
or endocrine effects of uranium in animals following acute-, intermediate-, or chronic-duration exposure.  
The existing animal data on musculoskeletal, renal, dermal, and body weight effects are limited to acute- 
and intermediate-duration exposures. 
 
 

































































































































































































1x/d Renal 237 M (renal failure)
mg/kg
mg/kg
De Rey et al. 1983
Uranyl Nitrate
1051

































1x/d Dermal 1928 M
mg/kg
mg/kg











1x/d Renal 1965 M (renal failure)
mg/kg
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1x/d Renal 2670 M (renal failure)
mg/kg
mg/kg
De Rey et al. 1983
Ammonium Diuranate
2017
Dermal 2670 M (mild lesions)
mg/kg
mg/kg
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Dermal 2.3 (severe dermal ulcers)
mg/kg/day
mg/kg/day
Bd Wt = body weight; d = day(s); Gn Pig = guinea pig; hr = hour(s); LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL =
no-observed-adverse-effect level; NS = not specified; wk = week(s); x = time(s)
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The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
adverse systemic effects from chemical exposure to uranium by the dermal route are presented in 
Table 3-3. 
 
Musculoskeletal Effects.    Statistically significant decreases in bone volumes were observed in 
female Wistar rats following an application of 280 mg U as uranyl nitrate hexahydrate diluted in an oil-
water emulsion to a 1 or 2 cm2 area for 24 hours or an 8 cm2 area for 24 hours, but not after 30 minutes, 
1 hour, or 8 hours (Lopez et al. 2000). 
 
Renal Effects.    Vascular congestion and vacuolization of the tubules in the corticomedullary boundary 
were observed in female Wistar rats following a 1–30-minute application of 280 mg U as uranyl nitrate 
hexahydrate diluted in an oil-water emulsion to an 8 cm2 area or following 24 hours of exposure to uranyl 
nitrate applied to a 0.5 or 1 cm2 area (Lopez et al. 2000).  Application of uranyl nitrate to an 8 cm2 area 
for 1–24 hours or to a 2–16 cm2 area for 24 hours resulted in formation of hyaline bodies and necrosis.  
Rabbits, guinea pigs, rats, and mice dermally exposed to uranyl nitrate hexahydrate for 1 day showed 
proteinuria for up to 10 days, followed by recovery to control values.  The degree of proteinuria did not 
correlate well with the applied dose of uranium.  Rabbits had elevated blood NPN at doses 
>270 mg U/kg.  The animals that died from dermal exposure to uranium had microscopic renal damage 
typical of uranium poisoning.  The kidneys of the animals that did not die were essentially normal, which 
may reflect repair of acute renal injury (Orcutt 1949).  Kidney lesions were also observed in female 
Wistar rats dermally exposed to 600 mg uranyl nitrate hexahydrate in an oil-water emulsion; the severity 
of the renal lesions increased with increasing exposure durations or increasing amount of exposed skin 
(Lopez et al. 2000).  Chemically induced renal failure caused 100% mortality in male Wistar rats after 
five daily exposures to 237 or 1,928 mg U/kg/day as uranyl nitrate hexahydrate or ammonium uranyl 
tricarbonate, respectively, applied in a water-Vaseline® emulsion (De Rey et al. 1983).  Deaths from renal 
failure were also reported in this study for male Wistar rats that received daily applications of 
1,965 mg U/kg as uranyl acetate dihydrate for 1–11 days. 
 
Dermal Effects.    Although no human studies were located regarding the dermal effects of uranium; no 
dermal effects were reported in studies of uranium miners, millers, and processors exposed to airborne 
uranium. 
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In animal studies, application of 41 mg U/kg as uranium pentachloride to the shaved backs of New 
Zealand white rabbits resulted in mild skin irritation (Orcutt 1949).  Dermally applied uranium was also 
damaging to the epidermis in other animal studies.  Application of 56.4 mg U/kg as uranyl nitrate 
hexahydrate to another group of rabbits resulted in superficial coagulation necrosis and inflammation of 
the epidermis, while a dose of 4.2 mg U/kg as uranyl nitrate hexahydrate applied in single or multiple 
sites for 5 weeks resulted in severe dermal ulcers.  No untreated controls were used in the 5-week study 
(Orcutt 1949).  Moderate erythema was observed in male and female New Zealand white rabbits after 
single applications of 1.4 mg U/kg as uranyl nitrate hexahydrate to their uncovered clipped skins (Orcutt 
1949).  An applied dose of 2,670 mg U/kg as ammonium diuranate for 1–10 daily applications to the 
shaved backs of a group of rats resulted in mild lesions on the skin of the rats, while a dose of 
237 mg U/kg as uranyl nitrate hexahydrate resulted in disrupted membranes in the cell, mitochondria, and 
cell nucleus, as revealed by transmission electron microscopy (TEM).  Light microscopy revealed swollen 
and vacuolated epidermal cells and damage to hair follicles and sebaceous glands in the uranyl nitrate 
hexahydrate-treated animals (De Rey et al. 1983). 
 
No dermal effects were seen following application of a single dose of 618 mg U/kg as uranyl fluoride, 
666 mg U/kg as uranium trioxide, 195 mg U/kg as sodium diuranate, 198 mg U/kg as ammonium 
diuranate, 410 mg U/kg as uranium peroxide, 458 mg U/kg as uranium dioxide, or 147 mg U/kg as 
triuranium octaoxide in 50% aqueous solution to the shaved skin of New Zealand white rabbits (Orcutt 
1949).  No dermal effects were observed on the shaved backs of New Zealand white rabbits to which a 
single dose of 98 mg U/kg as a 65% concentration of the uranium tetrafluoride in lanolin was applied 
(Orcutt 1949).  Similarly, application of 3,929 mg U/kg as uranyl acetate dihydrate or 2,103 mg U/kg as 
ammonium uranyl tricarbonate in water-Vaseline® emulsion to a 3 cm2 shaved area of the uncovered 
backs of 20 male Wistar rats in 1–10 daily applications had no effect on the skin of the rats (De Rey et al. 
1983). 
 
Body Weight Effects.    In animal studies, significant weight loss was reported in rats after the 
following dermal applications over a 3 cm2 area: 3,948 mg U/kg as uranyl nitrate hexahydrate, 
3,929 mg U/kg as uranyl acetate dihydrate, 2,103 mg U/kg as ammonium uranyl tricarbonate, or 
2,670 mg U/kg as ammonium uranate to rats for 1–10 days (De Rey et al. 1983).  Weight loss was also 
observed after single applications of 660 or 689 mg U/kg as uranium tetrachloride to guinea pigs, 616 or 
948 mg U/kg as uranyl nitrate hexahydrate to mice, 85 mg U/kg as uranyl nitrate hexahydrate to rats, and 
43 mg U/kg as uranyl nitrate hexahydrate to rabbits (Orcutt 1949). 
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Uranium (4.2 mg U/kg/day) applied as uranyl nitrate hexahydrate to the clipped backs of New Zealand 
white rabbits for 5 weeks also induced significant weight loss that peaked at 10–15 days after beginning 
treatment (Orcutt 1949).  However, in several other animal studies, no changes in body weight in New 
Zealand white rabbits were reported following single dermal applications of 618 or 804 mg U/kg as 
uranyl fluoride, 344 mg U/kg as uranium pentachloride, 666 mg U/kg as uranium trioxide or uranyl 
fluoride, 344 mg U/kg as uranyl pentachloride, 195 mg U/kg as sodium diuranate, 198 mg U/kg as 
ammonium diuranate, 410 mg U/kg as uranium peroxide, 458 mg U/kg as uranium dioxide, or 147 mg 
U/kg as triuranium octaoxide (Orcutt 1949). 
 
3.2.3.3   Immunological and Lymphoreticular Effects  
 
No information was located regarding the effects of uranium on the immunological and lymphoreticular 
system in humans and animals following dermal exposure for any duration. 
 
3.2.3.4   Neurological Effects  
 
No studies were located for humans regarding neurological effects following dermal exposure to uranium 
compounds. 
 
In animal studies, neurological signs including irritability, hyperactivity, upset equilibrium, limb rigidity, 
and respiratory arrest were observed in rabbits exposed to lethal doses of uranyl nitrate hexahydrate 
(Orcutt 1949); decreases in food and water intake and body weight were also observed in these animals. 
 
3.2.3.5   Reproductive Effects  
 
No studies were located for humans and animals that described reproductive effects following dermal 
exposure to uranium for any duration. 
 
3.2.3.6   Developmental Effects  
 
No studies were located regarding effects of uranium on development in humans or animals following 
dermal exposure for any duration. 
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3.2.3.7   Cancer  
 
No information on the cancer effects in humans or animals following dermal exposure to uranium for all 
durations of exposure was located; however, such effects have not been observed in studies involving 
uranium mining, milling, and production. 
 




A cohort of Gulf War I veterans exposed to depleted uranium were initially examined in 1994 (Hooper et 
al. 1999) and re-examined every 2 years beginning in 1997 (McDiarmid et al. 2000, 2001a, 2004b, 2006, 
2007, 2009, 2011b).  Over the years, additional soldiers with embedded metal fragments have been added 
to the original cohort.  The veterans were in or on armored tanks and fighting vehicles when they were 
fired upon by other U.S. forces using depleted uranium penetrators.  These veterans may have been 
exposed to depleted uranium via inhalation, ingestion, fragment penetration wounds, and wound exposure 
to dust; some of the soldiers who were injured were left with multiple tiny fragments of uranium and 
other substances in muscle and/or soft tissue.  However, not all of the embedded fragments contained 
depleted uranium (Squibb et al. 2012).  In a study of excised fragments from two veterans, no fragments 
contained depleted uranium; the fragments were primarily composed of copper, lead, iron, and zinc 
(Squibb et al. 2012).  Urinary uranium levels have been consistently elevated in the veterans with 
embedded depleted uranium fragments.  Urine uranium levels in the entire cohort ranged from 0.001 to 
60 µg/g creatinine (McDiarmid et al. 2000, 2001a, 2004b, 2006, 2007, 2009, 2011b); however, urinary 
uranium levels in the veterans with depleted uranium fragments were typically >0.1 µg/g creatinine.  In 
comparison, the geometric mean urine uranium levels in the U.S. males (National Health and Nutrition 
Examination Surveys [NHANES] sampling periods of 1999–2008) ranged from 0.005 to 0.008 µg/g 
creatinine (CDC 2012) and the 95th percentile values ranged from 0.026 to 0.040 µg/g creatinine.  A 
number of parameters were examined to evaluate potential adverse health effects associated with 
exposure to depleted uranium; potential targets included renal function, liver effects, hematological 
alterations, neuroendocrine hormone levels, semen characteristics, bone function, neurocogntive effects, 
and genotoxicity.  The effect of uranium exposure on these parameters was examined by dividing the 
veterans into two groups:  low exposure (urine uranium levels of <0.1 µg/g creatinine) and high exposure 
(urine uranium levels of ≥0.1 µg/g creatinine).  The results of these studies for each end point are 
discussed in the following sections.  Epidemiology studies of other war veterans exposed to depleted 
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uranium and animal studies involving exposure to uranium from implanted uranium are also discussed in 
the following sections. 
 
Hematological Effects.    As summarized in Table 3-4, no consistent alterations in hematological 
parameters were found in the Gulf War veterans (Hooper et al. 1999; McDiarmid et al. 2000, 2001a, 
2004b, 2006, 2007, 2009, 2011b). 
 
Potential hematological effects were observed in male and female Sprague-Dawley rats implanted with 
20 1x2 mm pellets of depleted uranium in the gastrocnemius muscle for up to 150 days.  A significant 
increase in the percentage of monocytes and decrease in platelet levels were observed, as compared to 
sham surgery controls (Arfsten et al. 2007).  However, when a group of rats with implanted tantalum 
pellets was used as the control, no significant hematological alterations were observed. 
 
Musculoskeletal Effects.    The two most recent studies of the Gulf War veterans cohort (McDiarmid 
et al. 2009, 2011b) examined biomarkers of bone turnover and bone metabolism.  A nonsignificant 
decrease in bone-specific serum alkaline phosphatase levels (measure of osteoblast function) was 
observed in the veterans with embedded fragments; however, no alteration in N-telopeptide levels 
(biomarker of collagen breakdown and bone resorption) was found (McDiarmid et al. 2009).  The 
investigators suggested that the increase in osteoblast activity without an alteration in osteoclast activity 
may be a clinically insignificant uncoupling of the bone turnover process.  A significant increase in 
1,25-dihydroxy vitamin D levels was observed in the veterans with embedded fragments; the increased 
1,25-dihydroxy vitamin D levels were within the normal range.  The increase in 1,25-dihydroxy vitamin 
D levels, in the absence of changes in parathyroid hormone levels, may be a due to an alteration in renal 
function rather than an alteration in bone metabolism.  In the most recent study, no significant alterations 
in bone biomarkers were found (McDiarmid et al. 2011b). 
 
Decreased tibia growth and impaired mandibular growth were observed in female Wistar rats 
administered 110 mg U/kg as uranium dioxide implanted directly into the subcutaneous tissue of dorsal 
skin for 30 days (Díaz Sylvester et al. 2002).  The decrease in bone growth was probably related to a 
marked decrease in active osteoblasts, which were replaced with a large increase in bone lining cells. 
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Table 3-4.  Summary of Significant Observations in Studies of a Cohort of Gulf 




1994b 1997c 1999d 2001e 2003f 2005g 2007h 2009i 
Renal function  
 Urine creatinine NS NS l>h (p=0.07) NS NS NS NS NS 
 Creatinine clearance – – – – – NS NS NS 
 Glomerular filtration 
rate 
– – – – –  NS NS 
 Urine glucose – – – – – NS NS NS 
 Urine calcium – – – NS NS NS NS NS 
 Urine phosphate – – – NS NS NS NS NS 
 Urine 
β2-microglobulin 
NS NS NS NS NS NS h>l 
(p=0.11) 
NS 
 Urine intestinal 
alkaline phosphatase 
– – NS NS NS NS NS NS 
 Urine NAG – – NS NS NS NS NS NS 




NS NS NS 
 Urine microalbumin – – – – NS NS NS NS 
 Retinol binding protein – NS NS h>l 
(p=0.06) 
h>l NS NS h>l 
(p=0.07) 
NS 
 Serum creatinine NS NS NS L>H NS NS NS L>H 
 Serum calcium NS NS H>L NS NS NS NS NS 
 Serum phosphate NS NS NS NS H>L NS NS NS 
 Serum uric acid NS NS NS NS NS NS NS NS 
Serum chemistry  
 Alanine 
aminotransferase  
NS NS NS NS NS NS NS NS 
 Aspartate 
aminotransferase 
NS NS NS NS h>l NS NS NS NS 
 Lactate 
dehydrogenase 
NS NS L>H L>H NS NS NS NS 
 Alkaline phosphatase NS NS NS NS NS NS NS NS 
Hematological parameters  
 Hematocrit NS NS NS L>H NS NS NS NS 
 Hemoglobin NS NS NS L>H NS NS NS NS 
 White blood cells H>L NS NS NS NS NS NS NS 
 Lymphocytes L>H NS L>H NS NS NS NS NS 
 Neutrophils H>L NS H>L NS NS NS NS NS 
 Basophils NS NS NS NS NS NS NS NS 
 Eosinophils NS H>L NS NS NS NS NS NS 
 Monocytes L>H NS L>H NS NS NS NS NS 
 Platelets NS NS NS NS NS NS NS NS 
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Table 3-4.  Summary of Significant Observations in Studies of a Cohort of Gulf 




 1994b  1997c  1999d   2001e 2003f  2005g  2007h 2009i 
Bone markers  
 Estradiol – – – – – – NS  
 Bone specific-alkaline – – – – – – NS NS 
phosphatase 
 1,25-Dihydroxy – – – – – – H>L NS 
vitamin D 
 25-Hydroxy vitamin D – – – – – – NS NS 
 Parathyroid hormone – – – – – – NS NS 
 Urine N-teleopeptide – – – – – – NS NS 
Neuroendocrine hormones  
 Follicle stimulating – NS NS NS NS NS NS NS 
hormone 
 Luteinizing hormone – NS NS l>h NS NS NS NS 
(p=0.06) 
 Testosterone – NS NS NS NS NS NS NS 
 Thyroid stimulating – – NS NS NS NS NS NS 
hormone 
 Free thyroxine – – NS L>H NS NS NS NS 
Semen characteristics  
 Semen volume – NS NS NS NS NS NS  
 Sperm concentration – H>L h>l (p=0.09) h>l NS h>l NS NS NS  
 Total sperm count – NS H>L h>l h>l NS NS NS  
(p=0.06) 
 Percent motile sperm – NS NS NS NS NS NS  
 Total progressive – NS H>L NS NS NS NS  
sperm 
 Percent progressive – NS NS NS NS NS NS  
sperm 
 Total rapid – NS H>L NS NS NS NS  
progressive sperm 
 Percent rapid – NS NS NS NS NS NS  
progressive sperm 
 
aTable modified from Squibb and McDiarmid (2006); lower case letters indicate nonsignificant findings; upper case 
letters indicate significant findings (p<0.05). 
bHooper et al. 1999. 
cMcDiarmid et al. 2000. 
dMcDiarmid et al. 2001a. 
eMcDiarmid et al. 2004b. 
fMcDiarmid et al. 2006. 
gMcDiarmid et al. 2007. 
hMcDiarmid et al. 2009. 
iMcDiarmid et al. 2011b. 
 
h,H = high urine uranium (≥0.1 µg/g creatinine); l, L = low urine uranium group (<0.1 µg/g creatinine);  
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Hepatic Effects.    There are limited data on the potential hepatotoxicity of embedded depleted 
uranium; no consistent alterations in several clinical chemistry parameters (ALT, AST, lactate 
dehydrogenase, alkaline phosphatase) were found in Gulf War veterans (Hooper et al. 1999; McDiarmid 
et al. 2000, 2001a, 2004b, 2006, 2007, 2009, 2011b). 
 
Renal Effects.    In general, no significant alterations in parameters of kidney function were observed 
among Gulf War veterans (Hooper et al. 1999; McDiarmid et al. 2000, 2001a, 2004b, 2006, 2007, 2009, 
2011b); a summary of these data are presented in Table 3-4.  However, the increases in several 
parameters, including urinary retinol binding protein and β-2-microglobulin levels approached statistical 
significance in the veterans with embedded fragments.  No alterations in N-acetyl-β-glucosaminidase 
levels (a biomarker of renal proximal tubule cell cytotoxicity) were found (McDiarmid et al. 2009, 
2011b).  Of the biomarkers of renal function, only urine retinol binding protein and β-2-microglobulin 
levels were in the direction that would be indicative of renal damage (McDiarmid et al. 2009), and retinol 
binding protein levels were altered at several examination periods.  During the period of 2001–2009, 
increases in retinol binding protein excretion were observed in the high exposure group at three of the 
four examinations.  Urine retinol binding protein levels at the 2001, 2003, 2007, and 2009 examinations 
were 46.13, 27.33, 31.00, and 28.49 µg/g creatinine in the low exposure group and 65.68, 80.51, 48.11, 
and 40.12 µg/g creatinine in the high exposure group.  The difference between the two groups did not 
reach statistical significance and the levels are within the normal range (<610 µg/g creatinine, McDiarmid 
et al. 2009).  Although the difference was not statistically significant and values were within the normal 
range, there is concern (Squibb and McDiarmid 2006) because retinol binding protein may be a potential 
sentinel marker of proximal tubular effects from uranium. 
 
Alterations in renal function and histopathology were observed in rats 90, 180, or 360 days after 0.1, 0.2, 
or 0.3 g of depleted uranium fragments (each 8x2x1 mm weighing 0.1 g) were embedded in the 
gastrocnemius muscle (Zhu et al. 2009b).  Rats in each group were implanted with 0 fragments (sham 
surgery controls), 1 depleted uranium and 2 tantalum fragments, 2 depleted uranium and 1 tantalum 
fragment, 3 depleted uranium fragments, or 3 tantalum fragments.  The histological alterations included 
swollen glomeruli with infiltrated inflammatory cells, turgidity and epithelial necrosis in the tubules, and 
interstitial fibrosis (360 days after fragment implantation).  Significant increases in urinary 
β2-microglobulin levels were observed in the 0.3 g group 180 and 360 days after implantation, and an 
increase in urinary albumin levels was observed in the 0.3 g group after 90 days (but not after the longer 
exposure durations); however, there were large standard deviations for these measurements.  
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Additionally, significant increases in serum creatinine levels were observed in all three exposed groups at 
90 days, in the 0.3 g group at 180 days, and in the 0.2 and 0.3 g groups at 360 days; BUN levels were 
significantly increased in the 0.3 g group at 90 days and 0.2 and 0.3 g groups at 360 days (no significant 
alterations were observed at 180 days).  Another study by this group also found significant decreases in 
1-α-hydroxylase activity (responsible for the hydroxylation of 25(OH)D3 to 1α,25(OH)2D3 the active form 
of vitamin D) in the kidneys of rats exposed to 0.2 or 0.3 g depleted uranium embedded in the 
gastrocnemius muscle for 3 months (Yan et al. 2010); no significant alterations were observed at 6 or 
12 months or in the 1 g group at any time period. 
 
Endocrine Effects.    As summarized in Table 3-4, no consistent alterations in neuroendocrine 
hormone levels have been found in the Gulf War veterans with embedded uranium (Hooper et al. 1999; 
McDiarmid et al. 2000, 2001a, 2004b, 2006, 2007, 2009, 2011b). 
 
Body Weight Effects.    Significant decreases in body weight gain were observed in rats 90 days 
following implantation of 0.1, 0.2, or 0.3 g of depleted uranium fragments (each 8x2x1 mm weighing 
0.1 g) in the gastrocnemius muscle (see discussion of study methods in Renal Effects section) (Zhu et al. 
2009b); the exposed rats weighed 11–21% less than controls with 0.3 g of biologically inert tantalum (Ta) 
fragments embedded in the gastrocnemius.  One year after implantation, decreases in body weight gain 
(10–11%) were only observed in the 0.2 and 0.3 g groups. 
 
A 25% decrease body weight gain was also observed in rats following implantation of 110 mg U/kg/day 
as uranium dioxide into the subcutaneous tissue of the dorsal skin for 30 days (Díaz Sylvester et al. 2002). 
 
Neurological Effects.    The results of neurocognitive tests in the Gulf War veterans cohort have not 
found significant differences between the high and low exposure groups (McDiarmid et al. 2000, 2001a, 
2004b, 2006, 2007, 2009, 2011b).  Significant associations between urine uranium levels and accuracy 
scores on neurocognitive tests were observed at several examinations; however, this association was 
strongly influenced by two subjects with extremely high uranium levels and severely complex co-morbid 
conditions due to combat injuries. 
 
An animal study examined the effects of implanted depleted uranium alloy pellets on neurobehavior in 
adult rats (Arfsten et al. 2007).  Groups of Sprague-Dawley rats (18–84 males and 17–42 females per 
group) were implanted with 1x2 mm pellets of depleted uranium in the gastrocnemius muscle for up to 
150 days.  Males received 12 or 20 pellets and females received 4, 8, 12, or 20 pellets.  Controls were 
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implanted with 12 or 20 tantalum pellets.  Beginning on postimplantation day 150, a portion of males and 
females were evaluated for spontaneous locomotor activity in an open field, acoustic startle/prepulse 
inhibition, and conspecific social approach.  The results of the behavioral testing did not show definite 
evidence of neurobehavioral perturbations associated with depleted uranium implantation. 
 
In another study of rats with implanted depleted uranium pellets, 4, 10, or 20 pellets were implanted in the 
gastrocnemius muscle for 6, 12, or 18 months (Pellmar et al. 1999b).  Neurophysiological changes 
(impairment of ability of the synaptic potential to elicit the population spike, EPSP/spike coupling) were 
detected in the hippocampus 6 or 12 months after implantation; no effects were observed after 18 months, 
which may have been due to the effect of aging. 
 
Reproductive/Developmental Effects.    In the studies of the Gulf War veterans cohort (McDiarmid 
et al. 2000, 2001a, 2004b, 2006, 2007, 2009), differences in semen quality have been observed at a 
number of examinations (data summarized in Table 3-4); however, these data suggest improved quality in 
the high exposure group.  No significant alterations were found for follicle stimulating hormone, 
luteinizing hormone, or testosterone.  Although prolactin levels were elevated in the 1997 cohort, no 
differences were found in later evaluations. 
 
The reproductive/developmental effects of implanted depleted uranium pellets have been studied in rats 
(Arfsten et al. 2006, 2009).  Groups of Sprague-Dawley rats (6–18/sex/group) were implanted with 0, 4, 
8, 12, or 20 depleted uranium pellets (1x2 mm) in the gastrocnemius muscle.  Inert implant controls were 
implanted with 12 or 20 Ta pellets; sham-operated controls were also used.  Urine was collected from 
F0 rats on day 27 and 117 for uranium analysis.  Rats were mated on postimplantation day 120.  Body 
weight of pregnant females was checked throughout pregnancy.  F0 males were kept until necropsy on 
postnatal day 200.  The pups were counted and weighed immediately after birth; sex ratio was also 
determined; pups were also examined for gross malformations during postnatal days 1–20.  F0 females 
that did not deliver a litter were kept until necropsy on postnatal day 200.  On postnatal day 2, F0 females 
and their offspring underwent maternal retrieval testing.  On postnatal day 4, litters were culled to eight 
pups (four/sex); discarded pups were killed and the whole carcasses were analyzed for uranium.  The 
remaining pups were kept with their mothers through postnatal day 20.  On postnatal day 20, two 
pups/sex were killed and used for whole-body uranium analysis, gross examination of all major organs, 
and examination of the ribcage.  Subsets of F1 pups underwent neurobehavioral testing on postnatal 
days 4–63.  These tests assess developmental markers for basic proprioceptive coordination, social 
bonding, social interaction, and the developmental milestone of eye opening.  F0 dams were necropsied 
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on postnatal day 200.  Survival and body weight of F1 pups were monitored until postnatal day 120.  On 
postnatal day 120, F0 and F1 males were killed and sperm motility and concentration were examined.  
Major organs of males and females were examined and weighed.  The F2 generation was produced by 
mating F1 males with F1 females on postnatal day 70.  F2 pups were subjected to the same tests as F1 
except the maternal retrieval test.  F1 males and females were killed on postnatal day 120.  One male and 
one female per F2 litter were killed on postnatal day 90. 
 
No clinical signs of toxicity were seen in F0 rats during the postimplantation period.  Three male and 
4 female F0 rats died during the study, but necropsy did not show an obvious cause of death.  Depleted 
uranium had no significant effect on mating index.  There were no significant differences among the 
groups regarding gestational index, gestation duration, or gestation weight gain.  Viability of F1 pups to 
postnatal days 4 and 20 was similar across groups.  Pup body weight gain during postnatal days 4–20 also 
was similar across groups.  In F1 pups sacrificed on postnatal day 20, there were no gross abnormalities 
in the major organs and no alterations in the ribcage.  Results of the neurobehavioral tests showed no 
significant depleted uranium-related effects.  Evaluation of sperm parameters in F0 males on postnatal 
day 200 did not show compound-related effects.  Histological examination of major organs from controls 
and rats implanted with 20 depleted uranium pellets and 20 Ta pellets only showed tissue reactions to the 
foreign body; neither depleted uranium nor Ta pellet implantation sites showed evidence of proliferative 
of preneoplastic processes taking place in or around the site.  Body weight gain and body weight of F1 
pups during postnatal days 20–120 were comparable among all groups.  Eight of 414 F1 rats died before 
necropsy on postnatal day 120 of unknown causes.  No gross abnormalities were seen in the remaining 
F1 rats.  There did not seem to be compound-related effects on F1 organ weights or in histology of 
kidneys, spleen, thymus, bone marrow, ovaries, and testes.  An increase in mean relative heart weight was 
observed in the highest dose F1 females, when compared to the sham-operated controls; however, there 
was no change in absolute heart weight and no difference in absolute or relative heart weight when 
compared to the inert pellet control group.  Neither sperm motility nor concentration was significantly 
affected by depleted uranium in male F1 rats on postnatal day 120.  Overall mating success of F1 rats was 
lower than F0 rats, but was comparable among all groups.  No significant developmental effects were 
reported in F2 pups at birth or during postnatal days 0–20.  Gross necropsy of F2 pups on postnatal day 
20 showed no significant alterations; examination of the ribcage also showed no abnormalities.  Necropsy 
of F2 rats on postnatal day 90 did not show consistent depleted uranium-related effects on organ weights; 
an increase in relative heart weight was observed in the highest dosed F2 males, but there was no change 
in absolute heart weight.  Sperm motility parameters and sperm concentration were not significantly 
different among F2 groups. 
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A study was conducted in mice to determine whether paternal exposure to uranium could result in genetic 
damage to the offspring (Miller et al. 2010).  The authors used a transgenic mouse system that employs a 
λ shuttle vector that allows mutations to be analyzed in vitro.  Transgenic male mice were implanted with 
depleted uranium pellets (two, four, or six pellets) in the gastrocnemius muscle for 7 months and were 
then mated with untreated non-transgenic females to produce the F1 generation.  Controls received 
implants of biologically inert tantalum.  Litters from depleted uranium-implanted fathers were smaller in 
a dose-dependent manner than un-implanted or tantalum-implanted fathers.  Paternal exposure to depleted 
uranium did not result in fetal malformations and no significant increase in offspring hematopoietic 
malignancies in weaned offspring was observed.  At the age of 4–5 months, deoxyribonucleic acid (DNA) 
from bone marrow cells from F1 mice was screened for mutations.  A significantly higher mutation 
frequency relative to controls was observed in mid- and high-dose F1 mice, comparable to the frequency 
seen in offspring of male mice exposed to 4 Gy of 60Co gamma radiation delivered at 0.06 Gy/minute.  
Since the depleted uranium would have delivered a much lower radiation dose than the 60Co, the 
comparable results are supportive of uranium effects being primarily chemical in nature. 
 
Cancer.    A study of Danish military personnel deployed to the Balkans between 1992 and 2001 (most 
were deployed for at least 6 months) did not find significant increases in the risk of all cancers or a 
specific type of cancer (Storm et al. 2006).   
 
The carcinogenicity of implanted depleted uranium was studied in rats (Hahn et al. 2002).  Groups of 
male Wistar rats (50/group) were implanted in the thigh muscle with fragments of depleted uranium 
(alloyed with 0.75% titanium) of two different sizes (2.5x2.5x1 mm or 5.0x5.0x1.5 mm) or a pellet (2.0x1 
mm) for life.  A negative control group was implanted with Ta; a positive control group received an 
intramuscular injection of radioactive thorium dioxide (ThO2).  Depleted uranium and Ta implants were 
encapsulated with connective tissue at the time of death.  The capsules around depleted uranium were 
characterized histologically by fibrosis, inflammation, degeneration, and mineralization.  All implants 
(depleted uranium, ThO2, or Ta) had soft tissue tumors associated with the implants.  The most prevalent 
was malignant fibrous histiocytoma, which was significantly increased in the high-dose depleted uranium 
fragment rats (5.0x5.0x1.5 mm) and in the positive control.  There was no increase in tumors related to 
depleted uranium in tissues not associated with implant sites.  The results showed that depleted uranium 
fragments of sufficient size cause localized proliferative reactions and soft tissue sarcomas that can be 
detected with radiography.   
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A significant increase in the incidence of leukemia was observed within 210 days of surgically implanting 
6 depleted uranium pellets in the gastrocnemius muscle (3 pellets per leg) of DBA/2 mice, as compared to 
controls with or without Ta implants (Miller et al. 2005).  In another experiment in which mice were 
implanted with 2, 6, or 8 depleted uranium pellets and 6, 2, or 0 tantalum pellets for 60 days followed by 
an intravenous injection of FDC-P1 hematopoietic cells, a dose-related increase in the incidence of 
leukemia was observed (Miller et al. 2005). 
 
3.3   GENOTOXICITY  
 
Prospective evaluations of Gulf War veterans with retained depleted uranium metal fragments have 
provided inconsistent results (Bakhmutsky et al. 2011; McDiarmid et al. 2000, 2001a, 2004b, 2007, 2009, 
2011a).  Tests have been conducted in peripheral blood lymphocytes and included evaluations of sister 
chromatid exchanges (SCEs), chromosomal aberrations (traditional measures as well as those identified 
through fluorescent in situ hybridization [FISH]), micronuclei frequency, hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) mutation frequency, and phosphatidylinositol glycan class-A (PIG-A) 
gene mutant frequency.  No significant alterations in chromosomal aberrations were found when veterans 
with higher urine uranium levels were compared with veterans with lower urinary uranium levels 
(McDiarmid et al. 2000, 2001a, 2004b, 2006, 2007, 2009, 2011a), although a nonsignificant increase in 
chromosome aberrations, as measured by FISH, was found at one of the examination periods (McDiarmid 
et al. 2007).  Assessment of SCEs yielded inconsistent results as a function of urinary uranium levels; 
higher levels of SCEs were found in the low uranium group at two of the examination periods 
(McDiarmid et al. 2000, 2004a), higher levels were found in the high uranium group at one period 
(McDiarmid et al. 2004b), and no differences were found at another examination period (McDiarmid et 
al. 2006).  Nonsignificant increases in HPRT mutation frequencies were observed higher in the high 
uranium group at three examination periods (McDiarmid et al. 2004b, 2006, 2007); however, at the last 
two examinations, there were no differences between the high and low groups (McDiarmid et al. 2009, 
2011a).  A nonsignificant increase in PIG-A mutant frequency was observed in the high exposure group 
at the last examination period (McDiarmid et al. 2011a).  No significant alterations in the frequency of 
micronuclei were found between the two groups (Bakhmutsky et al. 2011; McDiarmid et al. 2011a).  
McDiarmid et al. (2009, 2011a) concluded that, overall, the body of evidence in this cohort shows 
relatively weak genotoxic effects from exposure to uranium. 
 
Schröder et al. (2003) examined 16 war veteran volunteers suspected of exposures to depleted uranium.  
Since a control group subjected to the same multiple-agent exposures except for depleted uranium was 
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not available, the investigators chose subjects from their own laboratory as controls.  Compared to the 
controls, there was a statistically significant increase in the frequency of dicentric chromosomes and 
centric ring chromosomes among veterans; SCEs were not increased.  The results suggested previous 
exposure to ionizing radiation, but the different sources of exposure could not be ascertained.  Four 
additional small studies from individuals in the former Republic of Yugoslavia who were exposed to 
depleted uranium either via consumption of contaminated food and/or clean-up operations reported 
increased frequencies of chromosomal aberrations in peripheral blood cells from the exposed subjects 
compared with unexposed controls (Krunić et al. 2005; Milačić 2008; Milačić and Simić 2009; Milačić et 
al. 2004).  A cytogenic study of men occupationally exposed to uranium in a fuel production plant and in 
a fuel enrichment plant found higher levels of chromosome aberrations in the exposed workers than in 
controls (Martin et al. 1991).  However, the possible role of smoking could not be assessed with certainty. 
 
In an early animal study, male BALB/c mice injected intraperitoneally with doses ranging from 0.05 to 
1.0 μg U/kg as 18.9% enriched uranyl fluoride showed a general tendency for an increase in chromosome 
breaks in sperm cells with an increasing dose of 18.9% enriched uranyl fluoride.  At high dose levels, the 
statistically significant difference of break frequencies between treated and control mice disappeared 
60 days after treatment (Hu and Zhu 1990).  More recently, Monleau et al. (2006a) exposed male 
Sprague-Dawley rats nose-only to an aerosol of uranium dioxide at concentrations of 0, 190 mg/m3 
(0.5 hours), or 375 mg/m3 (2 and 3 hours) and examined DNA damage in epithelial nasal cells, broncho-
alveolar lavage cells (BAL), and kidney cells at various times postexposure.  Groups of rats were also 
exposed repeatedly for 3 weeks to depleted uranium dioxide (190 mg/m3; insoluble depleted uranium) and 
to uranium peroxide (116 mg/m3; soluble depleted uranium) for 0.5 hours.  No DNA damage occurred in 
nasal epithelial cells under any exposure scenario.  BAL cells from rats exposed to 375 mg/m3 uranium 
dioxide for 3 hours showed significant DNA damage 1 and 8, but not 3, days postexposure.  A single 
0.5-hour exposure to uranium peroxide did cause DNA damage in BAL cells.  Repeated exposure to 
190 mg/m3 uranium dioxide produced DNA damage in BAL cells assessed 1, 4, 8, or 14 days 
postexposure.  Kidney cells showed DNA damage only after repeated exposures to uranium dioxide.  
DNA damage consisted partly of double strand breaks, suggesting that radiation could be a contributor to 
the effects.  These results suggested that there may be a threshold for effects of single exposure on BAL 
cells and that repeated inhalation exposure seemed to potentiate the effect of uranium in BAL and kidney 
cells.  Since uranium exposure also increased the expression of cytokines involved in inflammatory 
responses in lung tissue and of peroxides, the investigators suggested that DNA damage may have been 
partly a consequence of inflammatory processes and production of reactive oxygen species.  Another 
study from the same group of investigators reported that repeated exposure to uranium dioxide increased 
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the genotoxic effects of uranium peroxide inhalation in all three types of cells examined, when a single 
exposure to uranium peroxide had no significant effect (Monleau et al. 2006b).  The investigators 
suggested that pre-exposure to insoluble uranium could slightly disturb the biokinetics of subsequently 
inhaled soluble uranium in the kidneys, gastrointestinal tract, and excreta. 
 
In another study, groups of male and female Wistar rats were fed a diet that provided 0, 4, or 40 mg 
U/kg/day (depleted uranyl nitrate hexahydrate) for 4 months, at which time they were mated to produce 
the F1 generation (Hao et al. 2009).  The offspring were treated in the same manner for 4 months.  
Exposure to uranium induced a statistically significant dose-related increase in the incidence of 
micronuclei in bone marrow from both the parental and F1 generations.  It also induced DNA damage in 
the sperm from both generations in a dose-related manner.  The effects were more pronounced in the 
F1 generation than in the parental groups.  Analyses of uranium in urine and kidneys after the 4-month 
exposure period showed dose-related accumulation in the kidney, significantly higher in the F1 than in the 
parental generation.  Hao et al. (2009) did not elaborate as to why the effects were more pronounced in 
the F1 generation than in the parental rats.  One possible explanation could be that the F1 generation also 
could have been exposed during preweaning via the maternal milk. 
 
A study was conducted in mice to determine whether paternal exposure to uranium could result in genetic 
damage to the offspring (Miller et al. 2010).  The authors used a transgenic mouse system that employs a 
λ shuttle vector that allows mutations to be analyzed in vitro.  Transgenic male mice were implanted with 
depleted uranium pellets (two, four, or six pellets) in the gastrocnemius muscle for 7 months and were 
then mated with untreated females to produce the F1 generation.  At the age of 4–5 months, DNA from 
bone marrow cells from F1 mice was screened for mutations.  A significantly higher mutation frequency 
relative to controls was observed in mid- and high-dose F1 mice, comparable to the frequency seen in 
offspring of male mice exposed to 60Co gamma radiation.  To assess the role of radiation in the observed 
effects of depleted uranium, male mice were exposed to equal concentrations of depleted or enriched 
uranium in the drinking water (approximately 1 mg U/mouse) for 2 months.  Exposure to either form of 
uranium significantly increased the frequency of mutations compared with controls and also suggested 
that the increase was specific-activity dependent.  While this experiment showed that radiation can play a 
role in the observed effects of depleted uranium, the investigators noted that the mutation model used 
measures point mutations and cannot measure large deletions characteristic of radiation damage, the role 
of the chemical effects of depleted uranium may also be significant. 
 
Table 3-5 presents results of genotoxicity tests conducted in vivo. 
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Table 3-5.  Genotoxicity of Uranium In Vivo 
 
Species (test system) End point 
Exposure 
route Results Reference 
Mammalian systems:     
Human peripheral lymphocytes 
(DU) 
Chromosomal aberrations Inhalation + Schröder et al. 
2003 
Human peripheral lymphocytes 
(DU) 
Sister chromatid exchange Inhalation – Schröder et al. 
2003 
Human peripheral lymphocytes 
(DU) 
Chromosomal aberrations Oral + Milačić et al. 
2004 
Human peripheral lymphocytes 
(DU) 
Chromosomal aberrations Inhalation + Milačić 2008 
Human peripheral lymphocytes 
(DU) 
Chromosomal aberrations Inhalation + Milačić and Simić 
2009 
Human peripheral lymphocytes 
(DU) 
Chromosomal aberrations Inhalation + Krunić et al. 2005 
Human peripheral lymphocytes Chromosomal aberrations Inhalation + Martin et al. 1991 
Human peripheral lymphocytes Sister chromatid exchange Inhalation + Martin et al. 1991 
Human peripheral lymphocytes 
(DU) 
Chromosomal aberrations Retained metal 
fragment 
+ McDiarmid et al. 
2004a  
Human peripheral lymphocytes 
(DU) 
Chromosomal aberrations Retained metal 
fragment 




Human peripheral lymphocytes 
(DU) 
Sister chromatid exchange Retained metal 
fragment 
+ McDiarmid et al. 
2001a 
Human peripheral lymphocytes 
(DU) 
Sister chromatid exchange Retained metal 
fragment 
– McDiarmid et al. 
2000, 2004b, 
2006 
Human peripheral lymphocytes 
(DU) 
HPRT mutation frequency Retained metal 
fragment 
± McDiarmid et al. 
2004a, 2006, 
2007 
Human peripheral lymphocytes 
(DU) 
HPRT mutation frequency Retained metal 
fragment 
– McDiarmid et al. 
2009, 2011a 
Human peripheral lymphocytes 
(DU) 
Micronuclei frequency Retained metal 
fragment 
– Bakhmutsky et 
al. 2011 
Human peripheral lymphocytes 
(DU) 
PIG-A mutant frequency Retained metal 
fragment 
± McDiarmid et al. 
2011a 
Mouse (BALB/c) (EU) Sperm DNA damage Intraperitoneal + Hu and Zhu 1990 
Rat epithelial nasal cells (DU) DNA damage Inhalation – Monleau et al. 
2006a 
Rat broncho-alveolar lavage 
(BAL) cells (DU) 
DNA damage Inhalation + Monleau et al. 
2006a 
Rat kidney cells (DU) DNA damagea Inhalation – Monleau et al. 
2006a 
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Table 3-5.  Genotoxicity of Uranium In Vivo 
 
Species (test system) End point 
Exposure 
route Results Reference 
Rat kidney cells (DU) DNA damageb Inhalation + Monleau et al. 
2006a 
Rat bone marrow (DU) Micronuclei Oral + Hao et al. 2009 
Rat sperm cells (DU) DNA damage Oral + Hao et al. 2009 
Mouse bone marrow cellsc (DU) Point mutations Oral + Miller et al. 2010 
Mouse bone marrow cellsc (EU) Point mutations Oral + Miller et al. 2010 
Mouse bone marrow cellsc Point mutations Implanted DU 
pellets 




cFrom offspring of exposed males. 
 
+ = positive result; − = negative result; ± = weak or inconclusive result; DU = depleted uranium; EU = enriched 
uranium; PIG-A = phosphatidylinositol glycan class-A 
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With few exceptions, studies of genotoxicity of uranium in eukaryotic cells in vitro have yielded positive 
results (Table 3-6).  For example, incubation of Chinese hamster ovary (CHO) cells with uranyl nitrate 
hexahydrate resulted in significant dose-dependent increases in micronuclei, SCEs, and chromosomal 
aberrations (Lin et al. 1993).  Incubation of human osteosarcoma (HOS) cells with depleted uranium for 
24 hours resulted in cell transformation into a tumorigenic phenotype and in significant increases in 
micronuclei, SCEs, and chromosomal aberrations in the form of dicentrics (Miller et al. 2002b).  The 
increase in dicentrics suggested that the radiological component may play a role in depleted uranium’s 
ability to induce both DNA damage and neoplastic transformation.  To further study the role of the 
radiological component in the genotoxicity of depleted uranium, the same group of investigators 
incubated HOS cells with one of three uranyl nitrate compounds (238U-uranyl nitrate, specific activity 
0.33 µCi/g; depleted uranyl nitrate, specific activity 0.44 µCi/g; 235U-uranyl nitrate, specific activity 
2.2 µCi/g) at the same concentration (50 µM) but varying in specific activity (Miller et al. 2002c).  The 
results showed a statistically significant difference in transformation frequency between the three uranyl 
nitrates that was specific activity-dependent, indicating that radiation can play a role in the genotoxicity of 
depleted uranium.  A subsequent report from these investigators showed that depleted uranium induced de 
novo genomic instability in HOS progeny cells, including delayed micronuclei expression and increased 
micronuclei frequency (Miller et al. 2003).  Delayed reproductive death was evident for many 
generations.  A similar effect was induced by nickel or gamma radiation.  Depleted uranium stimulated 
delayed production of micronuclei up to 26 days after exposure, longer than the 12 days it took the cells 
to return to normal after exposure to nickel or gamma radiation.  Miller et al. (2003) noted that the 
increase in micronuclei frequency is associated with cell lethality.  Although the precise mechanism by 
which depleted uranium induced genomic instability is unknown, the investigators noted that it might be 
similar to that for gamma radiation.  An additional study by Miller et al. (2002a), demonstrated that 
depleted uranium (15 nM), in the presence of hydrogen peroxide (2, 4, 6, 8, or 10 mM), can induce the 
formation of oxidative DNA damage in the absence of significant radioactive decay.  The  levels of 
hydrogen peroxide were 100 times higher than physiological levels; thus, the in vivo relevance of this 
finding is not known.  A more recent study by Darolles et al. (2010) found differences between the 
genotoxic mechanisms of depleted and 12% enriched uranium, which is 20 times more radioactive.  
Significant increases in micronuclei formation were found in mouse embryo fibroblast cells exposed to 
depleted uranium or enriched uranium; at a given uranium concentration, there were no differences in the 
number of micronuclei formed after exposure to depleted uranium as compared to enriched uranium.  
However, the origins of the micronuclei differed between depleted uranium and enriched uranium.  
Following exposure to depleted uranium, the increase in micronuclei induced by depleted uranium was 
due to chromosome loss.  In contrast, micronuclei formation following exposure to enriched uranium was  
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Table 3-6.  Genotoxicity of Uranium In Vitro 
 







Eukaryotic cells:    
 Human osteosarcoma 
(HOS) cells (DU) 
Micronucleus test ND + Miller et al. 2002b, 2002c, 
2003 
 HOS cell line (DU) Cell transformation ND + Miller et al. 1998b, 2002b, 
2002c 
 HOS cell line (DU) Sister chromatid 
exchange 
ND + Miller et al. 2002b 
 HOS cell line (DU) DNA damage ND + Miller et al. 2002b 





ND + Wise et al. 2007 
 Human bronchial 
fibroblasts 
(soluble DU)  
Chromosomal 
aberrations 
ND – Wise et al. 2007 





ND + LaCerte et al. 2010 
 Mouse embryo 
fibroblast cell line (DU) 
Micronucleus test ND + Darolles et al. 2010 
 CHO cells Sister chromatid 
exchange 
ND                 + Lin et al. 1993 
 CHO cells Chromosomal 
aberrations 
ND                 + Lin et al. 1993 
 CHO cells Micronuclei        ND                + Lin et al. 1993 
 CHO EM9 cell line (DU) Mutation at hprt locus        ND ± Stearns et al. 2005; Coryell 
and Stearns 2006 
 CHO EM9 cell line (DU) DNA damage; DNA 
adducts 
       ND + Stearns et al. 2005 
 Rat kidney proximal 
cells (DU) 
DNA damage        ND + Thiébault et al. 2007 
 Rat kidney proximal 
cells (DU) 
Micronuclei        ND – Thiébault et al. 2007 
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Species (test system) End point activation activation Reference 
Prokaryotic organisms:    
pBluescript SK+ DNA damage        ND + Yazzie et al. 2003 
plasmid from E. coli 
TOP10F’ (DU)a 
Salmonella bReverse mutation         ND       + Miller et al. 1998a 
typhimurium TA98 (DU) 
Salmonella TA7001- bReverse mutation         ND       + Miller et al. 1998a 
7006 (DU) 
Salmonella TA98 (DU) cReverse mutation         ND       – Miller et al. 1998a 
Salmonella TA7001- cReverse mutation         ND       – Miller et al. 1998a 
7006 (DU) 
 
aIncubated with ascorbate. 
bUrine from rats implanted DU was tested. 
cSerum from rats implanted DU was tested. 
 
+ = positive result; ± = weakly positive; CHO = Chinese hamster ovary; DU = depleted uranium; ND = no data 
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primarily due to chromosome breakage.  Thus, depleted uranium primarily acted as an aneugenic agent 
and enriched uranium as a clastogenic agent. 
 
Studies conducted with depleted uranium trioxide partially dissolved in acetone and depleted uranyl 
acetate fully dissolved in water showed that while both forms were cytotoxic to human bronchial cells in 
vitro, only the partially dissolved depleted uranium trioxide induced chromosome aberrations above 
background levels (LaCerte et al. 2010; Wise et al. 2007).  Wise et al. (2007) speculated that the different 
results may be related to different uptake mechanisms by the cell.  Particulate depleted uranium would be 
able to enter the cell by phagocytosis, whereas soluble uranium would not.  Wise et al. (2007) suggested 
that if depleted uranium were to be carcinogenic in vivo, it would require a high dose or involve a non-
genotoxic mechanism.   
 
In addition to causing DNA strand breaks in CHO cells, depleted uranium also produced uranium-DNA 
adducts.  Incubation of CHO cells with depleted uranyl acetate showed the presence of DNA adducts on 
the order of a few uranium atoms per thousand nucleotides (Stearns et al. 2005).  The formation of 
adducts was concentration- and time-dependent.  Characterization of the uranium-induced mutation in 
CHO cells showed the mutation spectrum to be different from the spectra generated spontaneously or by 
exposure to hydrogen peroxide or alpha and beta particles (Coryell and Stearns 2006).  This suggested 
that depleted uranyl acetate had distinct effects on cells that result in a mutagenic response.  A study that 
assessed DNA damage in rat kidney (NRK-52E) proximal cells using several methods reported DNA 
damage and apoptosis occurring in a concentration-dependent manner (Thiébault et al. 2007).  Apoptosis 
cell death was caspase-dependent and activated via the intrinsic pathway of the cells. 
 
Implantation of depleted uranium pellets in rats resulted in an increase in the mutagenic potential of urine 
towards the Salmonella tester strain TA98 (Miller et al. 1998a).  Responses were dose- and time-
dependent and strongly correlated with levels of uranium in the urine.  In contrast to urine, tests 
conducted with rats’ serum showed no significant increase in mutations, which was consistent with the 
low levels of uranium in blood.  In support of the view that uranium in the urine and no other factor was 
responsible for the urine mutagenicity was the fact that the urine from controls, both non-surgical and 
implanted with an inert tantalum pellet, did not show an increase in mutagenic activity. 
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3.4   TOXICOKINETICS  
 
Overview.    Absorption of uranium is low by all exposure routes (inhalation, oral, and dermal).  
Absorption of inhaled uranium compounds takes place in the respiratory tract via transfer across cell 
membranes.  The deposition of inhalable uranium dust particles in the lungs depends on the particle size, 
and its absorption depends on its solubility in biological fluids (ICRP 1994a, 1996).  Estimates of 
systemic absorption from inhaled uranium-containing dusts in occupational settings based on urinary 
excretion of uranium range from 0.76 to 5%.  A comprehensive review of the available data for a 
pharmacokinetic model used lung absorption factors of 2–4% for 3-month-old children and 0.2–2% for 
adults, based on compound absorbability (ICRP 1996).  Gastrointestinal absorption of uranium can vary 
from <0.1 to 6%, depending on the solubility of the uranium compound.  Studies in volunteers indicate 
that approximately 2% of the uranium from drinking water and dietary sources is absorbed in humans 
(Leggett and Harrison 1995; Spencer et al. 1990; Wrenn et al. 1989), while a comprehensive review 
indicates that the absorption is 0.2% for insoluble compounds and 2% for soluble hexavalent compounds 
(ICRP 1996).  There are limited data on the dermal absorption of uranium.  In hairless rats, dermal 
exposure to uranyl nitrate resulted in 0.4% of the dose being absorbed (Petitot et al. 2007a); damage to the 
skin resulted in higher absorption efficiencies.  Once in the blood, uranium is distributed to the organs of 
the body.  Uranium in body fluids generally exists as the uranyl ion (UO2)2+ complexed with anions such 
as citrate and bicarbonate.  Approximately 67% of uranium in the blood is filtered in the kidneys and 
leaves the body in urine within 24 hours; the remainder distributes to tissues.  Uranium preferentially 
distributes to bone, liver, and kidney.  Half-times for retention of uranium are estimated to be 11 days in 
bone and 2–6 days in the kidney.  The human body burden of uranium is approximately 90 μg; it is 
estimated that 66% of this total is in the skeleton, 16% is in the liver, 8% is in the kidneys, and 10% is in 
other tissues.  The large majority of uranium (>95%) that enters the body is not absorbed and is 
eliminated from the body via the feces.  Excretion of absorbed uranium is mainly via the kidney.  The 
case of Gulf War veterans who were exposed to depleted uranium from inhalation, ingestion, and wounds, 
showed average urinary excretion, 7 years postexposure, of 0.08 μg U/g creatinine, with the highest rates 
around 30 μg/g (McDiarmid et al. 1999b). 
 
3.4.1   Absorption  
 
3.4.1.1   Inhalation Exposure  
 
The deposition of inhalable uranium dust particles in the various regions of the lungs (extrathoracic, 
tracheobronchial, and deep pulmonary or alveolar) depends on the size of the particles.  Particles >10 μm 
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are likely to be transported out of the tracheobronchial region by mucocilliary action and swallowed.  
Particles that are sufficiently small to reach the alveolar region (≤10 μm AMAD) may transfer rapidly or 
slowly into the blood, depending on the solubility of the uranium compound.  According to the ICRP 
(1996), a more soluble compound (uranium hexafluoride, uranyl fluoride, uranium tetrachloride, uranyl 
nitrate hexahydrate) is likely to be absorbed into the blood from the alveoli within days and is designated 
inhalation Type F (fast dissolution).  A less soluble compound (uranium tetrafluoride, uranium dioxide, 
uranium trioxide, triuranium octaoxide) is likely to remain in the lung tissue and associated lymph glands 
for weeks and is designated Type M (medium dissolution).  A relatively insoluble compound (uranium 
dioxide, triuranium octaoxide) may remain in the lungs for years and is designated Type S (slow 
dissolution).  The dissolution parameters estimated in an in vitro study of uranium oxide at a fuel factory 
differed from the ICRP default values (Dias da Cunha et al. 2011).  The rapid dissolution rat was 0.47/day 
and the slow dissolution rate was 0.0019/day. 
 
Analysis of excreta of active uranium mill crushermen exposed to ore dust indicated that 1–5% of 
uranium entering the lungs was absorbed systemically and excreted in the urine and 95–99% was 
eliminated in the feces.  Absorption could have taken place in the lungs or in the gastrointestinal tract 
from swallowed particles cleared from the lungs (Fisher et al. 1983).  Uranium workers exposed to high 
levels of uranium dust had a very low lung burden of uranium, indicating that only a small fraction 
penetrates into the alveolar region (West and Scott 1969) and remains there without being cleared (or 
being very slowly cleared) via retrograde tracheobronchial mucus transport to the gastrointestinal tract, 
into lymph nodes, or dissolved into the circulating blood. 
 
Estimates of absorption into the blood were derived from the excretion data of uranium mill workers 
(Wrenn et al. 1985).  The authors’ estimated daily mean absorption of inhaled uranium by mill workers 
was 24 μg U/day (0.34 μg U/kg for 70-kg reference man) based on measured excretion in feces and 
workplace ambient air concentrations.  The absorption of uranium by these workers was estimated as 
0.76% (range, 0.4–1.6%).  Control subjects in a study of differential metabolism of 230Th, 234U, and 
238U inhaled in uranium ore dust included three retired uranium mill workers (4–14 years since last 
employment as uranium ore crushermen), and three volunteers who lived in uranium milling communities 
but had no uranium work history.  Two consecutive 24-hour urine and fecal collections were obtained and 
analyzed for 234U and 238U.  The apparent total intakes of uranium of these individuals ranged from 11 to 
18 μg U/day for the controls and from 5.3 to 71 μg U/day for the retirees.  Although large compared to 
uranium intakes estimated for city dwellers, the uranium intakes of these individuals are not unreasonable 
because uranium in potable waters and locally grown foods tends to be higher in uranium mining and 
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milling communities.  The mean uranium absorption calculated for the controls (0.82%; range, 0.6–1%) 
was not significantly different from that calculated for the retired uranium workers (0.94%; range, 0.55–
1.6%) (Wrenn et al. 1985). 
 
Urinary excretion data were used to estimate the absorption of uranium by workers accidentally exposed 
to uranium hexafluoride (USNRC 1990).  Estimated airborne concentrations were 20 mg uranium 
hexafluoride/m3 for a 1-minute exposure and 120 mg uranium hexafluoride/m3 for a 60-minute exposure 
(15.2 and 91 mg U/m3, respectively) (USNRC 1986).  Initial intakes of workers involved in the accident 
ranged from 470 to 24,000 μg uranium. 
 
Higher absorption of uranium occurred in animal studies using aerosols of purified uranium compounds.  
In these studies, as in human studies, the solubility of the uranium compound and the size of the inhaled 
particles determined absorption.  Reported absorption of the inhaled dose was 18–40% in rats and 20–
31% in guinea pigs for uranium hexafluoride (Leach et al. 1984) and 23% for uranium trioxide in dogs 
(Morrow et al. 1972).  One month following a single intratracheal instillation, the percentage of the dose 
transferred to the blood from the lungs was 73.7–74.8% for uranium peroxide (7.6 or 195 µg 
administered) and 38.8–43.9% for uranium tetrafluoride (32 or 301 µg administered); the percent 
absorbed was not influenced by the instillation concentration (Houpert et al. 1999). 
 
In addition to the uptake of uranium from the lungs, there is some evidence from a study of rats exposed 
via nose-only exposure to 190 mg/m3 depleted uranium dioxide 30 minutes/day, 4 days/week for 
30 weeks (Houpert et al. 2007c) that uranium may be taken up by the olfactory epithelial pathway and 
travel along the olfactory neuron to the olfactory bulb. 
 
3.4.1.2   Oral Exposure  
 
Experimental studies in humans consistently show that absorption of uranium by the oral route is <5%.  
Reported fractional absorptions include a range of 0.005–0.05 (0.5–5%) in a group of 4 males ingesting 
10.8 mg uranium in a soft drink (Hursh et al. 1969), 0.001–0.06 (median of 0.009) in 50 males and 
females exposed to uranium in the diet and drinking water (Limson Zamora et al. 2002, 2003), 0.001–
0.005 in 4 subjects ingesting a single dose of 100 mg uranium as depleted uranyl nitrate dissolved in a 
grapefruit drink (Karpas et al. 1998), <0.0025–0.04 in a group of 12 volunteers given drinking water high 
in uranium (Wrenn et al. 1989), and 0.005–0.05 in another drinking water study (Harduin et al. 1994).  
Measuring uranium levels in bone ash, Chen et al. (2011) estimated fractional absorption values in several 
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age groups.  The estimated fractional absorption values were 0.030±0.022, 0.030±0.023, and 0.021±0.015 
for children aged 7–12 years, children aged 12–18 years, and adults aged 18–25 years.  Similar results 
were obtained in dietary balance studies (Leggett and Harrison 1995; Spencer et al. 1990; Wrenn et al. 
1989).  A study comparing uranium absorption between subjects primarily exposed to uranium in the diet 
and subjects exposed to elevated levels of uranium in the drinking water (Limson Zamora et al. 2002, 
2003) did not find significant differences in fractional absorption between the two subroutes.  This study 
also found no significant differences in uranium fractional absorption related to gender or age (subjects 
<25 years compared to those >25 years).  A review of human data conducted by the ICRP determined that 
a fractional absorption of 0.02 for soluble compounds and 0.002 for insoluble compounds should be used 
in modeling the kinetics of dietary uranium in humans (ICRP 1995).  A rapid absorption rate (5–15 hours) 
was estimated in four individuals ingesting a single dose of depleted uranyl nitrate (Karpas et al. 1998). 
 
In animal studies, absorption generally increases with increasing solubility of the compound, being 
greatest for uranium ingested as uranyl nitrate hexahydrate, uranium hexafluoride or uranyl fluoride, 
about half as great for uranium tetroxide or uranium trioxide, and 1–2 orders of magnitude lower for 
uranium tetrachloride, triuranium octaoxide, and uranium tetrafluoride (ICRP 1995).  Increased 
absorption of uranium has been demonstrated in neonatal rats and pigs (ICRP 1995).  Fractional 
absorption in 2-day-old rats given uranyl nitrate was estimated as 0.01–0.07, 2 orders of magnitude 
greater than for adults (ICRP 1995). 
 
Evidence from several animal studies showed that the amount of uranium absorbed from the 
gastrointestinal tract was about 1% (Harrison and Stather 1981; Houpert et al. 2001; Larsen et al. 1984; 
La Touche et al. 1987; Maynard et al. 1953; Sullivan 1980a), although other studies have reported lower 
absorption efficiencies.  Frelon et al. (2005) estimated that 0.43% of the depleted uranyl nitrate in 
drinking water was absorbed by rats.  A range of gastrointestinal absorption rates of 0.038–0.078% has 
been estimated by others based on data from a 2-year study in which rats were fed diets containing 0.05–
0.5% of soluble uranium compounds (uranyl fluoride or 0.5–2% of uranyl nitrate).  The rate of absorption 
appeared to be independent of concentration of uranium in the diet (Wrenn et al. 1985).  Absorption 
factors in rats that were exposed by gavage to doses of 233U-uranyl nitrate hexahydrate (where this 
anthropogenic radionuclide provided increased sensitivity without competition with natural isotopes) 
increased 3.4 times over normal in rats that were iron-deficient (Sullivan and Ruemmler 1988), doubled 
in rats that were fasted (Sullivan et al. 1986), and increased 3.6 times in neonates as compared to adults 
(Sullivan 1980b).  Adult baboons (fed normally) absorbed about 0.5%, whereas fasted baboons absorbed 
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an average of 4.5% (Bhattacharyya et al. 1989).  Consistent with the results in baboons, fed and 24-hour 
fasted male B6CF1/ANL mice absorbed 0.069 and 0.80%, respectively (Bhattacharyya et al. 1989). 
 
Studies in rats suggest that the primary pathway for gastrointestinal absorption of soluble uranium as 
depleted uranyl nitrate is through the small intestinal epithelium (Dublineau et al. 2005, 2006) via the 
transcellular pathway (Dublineau et al. 2005).  Uranium was not absorbed from the buccal cavity, 
stomach, or large intestine (Dublineau et al. 2005).  Ex vivo experiments provide evidence that uranium is 
equally absorbed in all regions of the small intestine (Dublineau et al. 2005). 
 
3.4.1.3   Dermal Exposure  
 
Absorption of uranium through the skin has not been characterized in humans.  Dermal absorption in 
animal models can be inferred from the appearance of toxicity in mice, rats, rabbits, and guinea pigs after 
dermal exposure to uranium compounds (Orcutt 1949).   
 
Electron microscopy and x-ray microanalytical methods showed that uranium as uranyl nitrate 
hexahydrate penetrated the stratum corneum within 15 minutes and accumulated in the intracellular space 
between the viable epidermis and the stratum corneum (De Rey et al. 1983).  As is the case with 
inhalation and oral absorption, water solubility is an important determinant of absorption, and no 
penetration was observed with the insoluble compounds uranium dioxide, uranyl acetate, or ammonium 
diuranate.  After 48 hours, uranium applied as uranyl nitrate was no longer found in the skin and toxicity 
developed, indicating that the uranium had been absorbed into the blood. 
 
A series of in vitro and in vivo studies conducted by Petitot et al. (2004, 2007a, 2007b) demonstrated that 
uranyl nitrate is absorbed through the skin.  In vitro, the first transfer of uranium across hairless rat skin 
and pig ear skin occurred 3 or 4 hours, respectively, after application of uranyl nitrate (Petitot et al. 2004).  
However, uranium was transferred across excoriated skin (stratum corneum removed to simulate a 
wound) in 30 minutes for both rat and pig skin.  Application of depleted uranium to the skin of hairless 
rats in vivo resulted in significant increases in uranium levels in muscle at the contamination site 6 hours 
after application to intact skin and within 30 minutes after application on excoriated skin (Petitot et al. 
2007a).  Twenty-four hours after application, 0.4% of the dose was absorbed through intact skin (Petitot 
et al. 2007a).  A higher percentage of uranium was absorbed through wounded skin; 38% absorbed 
through excoriated skin and 2–4% through skin damaged from application of a mild acid solution.  In 
URANIUM  198 
 








contrast, severely damaged skin from exposure to a strong acid or base solution, resulted in lower 
absorption efficiencies than intact skin. 
 
3.4.2   Distribution  
 
Absorbed uranium is found in all human tissues, but preferentially deposits in bone and kidney, regardless 
of the route of exposure (ICRP 1995, 1996).  Although uranium also distributes significantly to liver, this 
organ is not a major repository for uranium; however, for modeling purposes, tissue contents are often 
normalized to liver concentration because the latter is reported in almost all studies of uranium 
biokinetics.  The normal adult body burden is considered to be approximately 90 μg.  It is estimated that 
about 66% of this total is in bone, 16% is in the liver, 8% is in the kidneys, and 10% is in other tissues 
(ICRP 1979, 1995, 1996).  It is not known if maternal bone stores of uranium (like those of calcium and 
lead) are mobilized during pregnancy and lactation.  Uranium can cross the placenta after parenteral 
administration in animals; no information was located on distribution of uranium in breast milk for either 
humans or animals.   
 
3.4.2.1   Inhalation Exposure  
 
Autopsy data from individuals occupationally exposed to uranium indicates that bone is the primary site 
of long term retention of absorbed uranium (ICRP 1995).  Inhalation exposure may also result in some 
retention of insoluble uranium particles in the lungs.  An evaluation of the postmortem data from a 
uranium worker who had inhaled a total of 220 mg (147 pCi) uranium over a 3-year period found 11 μg 
(7 pCi) uranium in the lungs 13 years after the end of exposure.  The total calculated dose equivalent from 
the inhaled uranium was 35 rem (0.35 Sv) (Keane and Polednak 1983). 
 
In a comprehensive study of tissues from two long-time residents of New Mexico without known 
occupational exposure, the skeleton was the primary depot for uranium (Kathren 1997).  Approximately 
80 soft tissue samples and 90 bone samples were analyzed from each subject.  The mean uranium 
concentrations in bone were 4.8 and 5.8 ng/g wet weight for the two subjects, respectively.  Highest 
concentrations of uranium in soft tissues were in the tracheobronchial and other pulmonary related lymph 
nodes indicating uranium-bearing particulate clearance from the lungs.  Concentrations in pulmonary 
lymph nodes ranged from 16–28 ng/g in one individual to 29–259 ng/g wet weight in the other.  In 
another comprehensive autopsy study of a worker at a facility involved in the processing and handling of 
radioactive material, the highest levels of uranium in soft tissues was found in the respiratory tract, 
particularly the tracheobronchial lymph nodes (Russell and Kathren 2004).  The relative amounts of 
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uranium in the body were lung > skeleton > spleen > liver > kidney.  Relatively high levels of uranium 
were also found in the urinary bladder, blood, and thyroid.  A study of uranium process workers and 
nearby residents chronically exposed to depleted uranium aerosols detected depleted uranium levels in the 
urine in 2 of the 18 subjects 20 years after exposure (Parrish et al. 2008).  Although the investigators 
suggest that this finding indicates long-term storage and distribution of depleted uranium, the small 
number of positive findings and the lack of monitoring data on other potential sources of depleted 
uranium limit the interpretation of the results. 
 
Urinary excretion data were used in a kinetic model to estimate the maximum uranium kidney 
concentrations of workers accidentally exposed to uranium hexafluoride (USNRC 1990).  Initial intakes 
of workers involved in the accident ranged from 470 to 24,000 μg uranium.  The model estimated the 
maximum kidney concentrations in the workers as ranging from 0.048 to 2.5 μg U/g in kidney tissue; 
renal toxicity was not observed in any of the workers (USNRC 1990). 
 
In animals, uranium that has been absorbed from the lungs leaves the blood very quickly for distribution 
to body tissues.  Following a single intratracheal instillation, uranium was removed from the lung with 
retention half-times of 0.6–1.3 (63.6–71.6% absorbed) and 30–35 days (36.4–29.4% absorbed) following 
instillation of 32 or 301 µg uranium tetrafluoride, and 0.5–1.2 (96.6–90.3% absorbed) and 27–38 days 
(3.4–9.7% absorbed) following instillation of 7.6 or 195 µg uranium peroxide (Houpert et al. 1999).  One 
month after instillation of either uranium compound, 11.3–20.4% of the uranium dose remained in the 
carcass, 1.5–4.4% was found in the kidney, and 75.9–84.3% was excreted in the urine.  The amount of 
uranium found in the bones of dogs and rats exposed to uranium for 1 year was related to the solubility of 
the uranium solubility (Stokinger et al. 1953).  The concentrations of uranium in bone were 2.0 and 
2.7 µg/g in rats exposed to uranyl nitrate (0.25 mg U/m3) and uranyl fluoride (0.2 mg U/m3), respectively; 
however, exposure to a similar concentration of uranium tetrachloride (0.2 mg U/m3) resulted in a 10-fold 
reduction in uranium bone levels (0.2 µg/g).  Uranium has also been shown to accumulate in the 
tracheobronchial lymph nodes, lungs, bones, and kidneys of rats, dogs, and monkeys exposed to uranium 
dioxide at 5.1 mg U/m3 for 1–5 years (Leach et al. 1970, 1973).  In rats exposed to yellowcake, the U3O8 
portion of the yellowcake cleared from the lung with a half-time of 110–240 days (Damon et al. 1984).  
Mice given inhaled doses of U3O8 equivalent to about 0.2 mg U/kg exhibited uranium tissue distribution 
(in μg/g tissue) as follows:  lung, 6.05; liver, 0.051; spleen, 1.45; kidney, 0.536; tibia, 0.731; urine, 0.519; 
and feces, 2.20 (Walinder 1989).  In an inhalation study using highly enriched uranium dioxide particles 
(92.8% 235U), rat lungs were found to clear the uranium particles at a rate of 0.28% per day over a period 
of 720 days.  At 720 days postexposure, 82% of the uranium remained in the lungs and thoracic lymph 
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nodes of the rats.  The highest mass of extrapulmonary uranium dioxide was detected in rats sacrificed up 
to 11 days postexposure.  This was mainly found in the intestinal tract and the carcass.  The authors found 
that the pulmonary clearance rate of highly enriched uranium dioxide particles was about the same as the 
clearance rate for natural or unenriched uranium dioxide particles (Morris et al. 1990), as would be 
expected since they are the same chemical compound. 
 
One site of deposition for the soluble compounds (uranyl nitrate, uranium tetrachloride, uranium 
hexafluoride) in animals was the skeleton, but accumulation was not seen in bone at levels below 
0.25 mg U/m3 over a period of 2 years in rats exposed to soluble compounds (uranyl nitrate, uranium 
tetrachloride, uranium hexafluoride) in one study.  The insoluble compounds (uranium hexafluoride, 
uranium dioxide) were found to accumulate in the lungs and lymph nodes after the inhalation exposure.  
For uranyl nitrate exposure, no retention was found in the soft tissues.  Accumulation of uranium was also 
found in the skeleton (Stokinger et al. 1953).  The amount distributed in the skeleton has been reported to 
be 23–45% of the intake in dogs (Morrow et al. 1972); 28–78% in rats (Leach et al. 1984); and 34–43% in 
guinea pigs (Leach et al. 1984).  A biological half-time of 150–200 days (Ballou et al. 1986) or 70 days 
(Morrow et al. 1982a) in the skeleton has been reported following inhalation exposure to soluble uranium 
compounds (e.g., uranium hexafluoride). 
 
A 5-year exposure of Beagle dogs and monkeys, and a 1-year exposure of rats, to 5.8 mg uranium 
dioxide/m3 (5.1 mg U/m3) as uranium dioxide dust (AMAD=1 μm) resulted in rapid lung buildup during 
the first few months, which approached maximal values of 2, 3.6, and 0.8 mg U/g in dogs, monkeys, and 
rats, respectively, at the end of year 1.  Buildup in the tracheobronchial lymph nodes reached peak values 
in year 4 of 50–70 mg U/g in both dogs and monkeys.  For each, the peak radiation dose rates reached 
1.8 and 3.3 rad/week (0.018 and 0.033 Gy/week) to lungs and 55 and 64 rad/week (0.55 and 
0.65 Gy/week) to lymph nodes, while the total radiation dose for the 5 years approached 500 and 900 rad 
(5 and 9 Gy) to lungs and 10,000 rad (10 Gy) to lymph nodes.  A reevaluation of the study data also 
showed a rapid accumulation of uranium in the lungs and tracheobronchial lymph nodes during the first 
few months of exposure.  The accumulation in these organs was highest (0.8 mg/g in lungs and 1.5 mg/g 
in lymph nodes) at the end of 1 year of exposure.  The uranium content in the lungs decreased with a half-
time of approximately 480 days.  In the lymph nodes, uranium depletion showed a trend similar to the 
lungs in dogs exposed for 2 and 5 years and a biphasic pattern in dogs exposed for 1 year.  Comparatively 
low levels of uranium were found in the kidney, femur, liver, and spleen, and these decreased with time 
(Leach et al. 1973). 
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In other studies, no significant accumulation was found in the spleen or liver of rats, dogs, or guinea pigs 
(Ballou et al. 1986; Diamond et al. 1989; Leach et al. 1973, 1984; Morrow et al. 1972; Wrenn et al. 
1987).  Uranium has been shown to increase in the brain following intermediate-duration inhalation 
exposure to depleted uranium dioxide; however, the levels rapidly decrease following exposure 
termination and returned to control levels within 3–8 days (Monleau et al. 2005).  Uranium is unequally 
distributed in the brain, with the highest levels found in the olfactory bulbs, followed by the hippocampus, 
cortex, and cerebellum. 
 
3.4.2.2   Oral Exposure  
 
Uranium levels have been measured in tissues from humans, with no occupational exposure where the 
source of uranium was assumed to be dietary and environmental. 
 
In a comprehensive study of tissues from two long-time residents of New Mexico, the skeleton was the 
primary depot for uranium (Kathren 1997).  Approximately 80 soft tissue samples and 90 bone samples 
were analyzed from each subject.  The mean uranium concentrations in bone were 4.8 and 5.8 ng/g wet 
weight for the two subjects, respectively.  Highest concentrations of uranium in soft tissues were in the 
tracheobronchial and other pulmonary related lymph nodes, indicating uranium-bearing particulate 
clearance from the lungs.  Concentrations in pulmonary lymph nodes ranged from 16 to 28 ng/g in one 
individual to 29–259 ng/g wet weight in the other.  An unexpectedly high concentration was found in the 
thyroid of one subject.  In both subjects, uranium was widely distributed among the soft tissues; liver 
concentrations were lower than those in the kidney (approximately 0.1 and 0.9 ng/g wet weight, 
respectively). 
 
The concentrations of uranium in human blood from New York City donors averaged 0.14 mg U/kg in 
both whole blood and red cells, compared to values ranging from <0.04 to 86 mg U/kg globally (Fisenne 
and Perry 1985).  The median concentrations of uranium in the lungs, liver, kidneys, and vertebra from 
New York City residents among all age groups were reported to be 0.33, 0.13, 0.32, and 0.29 mg U/kg, 
respectively (Fisenne and Welford 1986). 
 
In an evaluation of two human skeletal tissues, it was observed that the sacrum contained the highest 
concentrations of 238U and 234U (4.9 mBq/g ash; 0.13 pCi/g ash; 0.20 μg/g ash).  The concentration of 238U 
was lowest (0.1 mBq/g ash; 0.0027 pCi/g ash; 0.004 μg/g ash) in the right femur (Singh et al. 1987b).  In 
URANIUM  202 
 








the United Kingdom, the mean uranium concentration in wet bone was reported to be 0.33 µg U/kg 
(Fisenne and Welford 1986). 
 
Data on laboratory animals indicate that a substantial portion of uranium leaving the blood may initially 
distribute throughout soft tissues, but a few days after absorption or injection into the blood, most of the 
systemic content is found in the kidneys and skeleton (Bhattacharyya et al. 1989; ICRP 1995). 
 
In animals, a substantial fraction of plasma uranium is associated with the ultrafilterable low-molecular-
weight fraction, and the remainder is weakly associated with transferrin and other plasma proteins.  Data 
on baboons indicate that ≥50% of the uranium in blood is associated with the red blood cells during the 
period 10–1,000 hours after injection.  These data have been interpreted to mean that about 0.7% of the 
uranium leaving the plasma attaches to red blood cells and is returned to plasma with a half-time slightly 
greater than 1 day (ICRP 1995). 
 
In animals, absorbed uranium is osteotropic, accumulating largely on the surface of all types of bone of 
the animals.  Eventually, the uranium on the bone surface diffuses into the mineral portion of the bone.  
Autoradiography provides confirming evidence that, in the long-term, uranium is a bone volume seeker 
(Wrenn et al. 1987).  Kinetic models of uranium distribution predict that, for the short-term, uranium 
distributes to the bone surface and bone marrow, while the deep bone is the long-term depot (Sontag 
1986).  These results suggest that the macro distribution of uranium in the human skeleton is not uniform. 
 
In some ways, the skeletal behavior of uranium is quantitatively similar to that of alkaline earths.  It is 
known that the uranyl ion (UO22+) exchanges with Ca2+ on the surfaces of bone mineral crystals, although 
it does not participate in crystal formation or enter existing crystals.  The early distribution of uranium in 
different parts of the skeleton is similar to that of calcium.  Uranium initially deposits on all bone surfaces 
but is most highly concentrated in areas of growth.  Depending on the microscopic structure of the bone 
of each species, uranium on bone surfaces may gradually diffuse into bone volume; such diffusion has 
been observed in dogs but not in rats or mice.  As with calcium, a substantial portion of uranium 
deposited in bone is lost to plasma by processes that occur more rapidly than bone resorption (see 
Section 3.4.5).  In human subjects injected with uranium, an estimated 80–90% of the original skeletal 
deposition was lost from bone over the first 1.5 years (ICRP 1995). 
 
In a study with female mice exposed orally in feed to uranyl nitrate hexahydrate at a dosage of 462 mg 
U/kg/day for 36–44 weeks, average uranium accumulations were 6 μg per pair of kidneys, 46 μg/g bone, 
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and 0–0.5 μg in whole liver, respectively.  No significant organ accumulation was found for the lower 
dose levels (Tannenbaum et al. 1951).  Maximal concentrations of 77 μg per pair of kidneys and 216 μg/g 
in bone were estimated at 50 weeks in male mice that were orally exposed to uranyl nitrate hexahydrate at 
925 mg U/kg/day for 48 weeks.  One mouse with small kidneys showed levels of 395 μg/pair of kidneys 
and 1,440 μg/g bone (Tannenbaum et al. 1951).  Average uranium accumulations in the kidneys and bone 
of male mice exposed to uranyl fluoride orally at 452 mg U/kg/day for 28 weeks were 33 μg/pair of 
kidneys and 145 μg/g bone at 20 weeks (Tannenbaum et al. 1951).  Maximal concentrations of 6 μg/pair 
of kidneys at 50 weeks and 29 μg/g bone at 14 weeks were found in female mice given oral uranium 
tetrachloride at 978 mg U/kg/day for 48 weeks (Tannenbaum et al. 1951). 
 
Paquet et al. (2006) examined the distribution of depleted uranium in rats following chronic ingestion of 
2.0–2.9 mg U/kg/day as depleted uranyl nitrate in mineral water.  In addition to the elevated levels of 
uranium found in the kidney and bones, uranium accumulated in the teeth and brain.  Uranium 
concentrations in teeth were higher than in the skeleton, suggesting that uranium was deposited on the 
enamel.  Accumulation of uranium in the whole body and individual tissues followed a nonmonotonous 
pattern that was not predictable by biokinetic models.  In the whole body, peak levels were found after 3, 
10, and 19 months of exposure.  Total uranium levels in the whole body were 51.0, 182, 42.2, 134, 3.8, 
and 200 ng/g tissue after 1, 3, 6, 10, 12, and 19 months of exposure, respectively.  Different patterns of 
uranium accumulation were found in the lumbar vertebrae and femur (diaphysis and epiphysis regions).  
In the vertebrae, uranium levels did not significantly change until 570 days of exposure; in contrast, 
uranium levels in the femur peaked at day 95, decreased at day 186, and increased at days 312 and 570.  
In the kidneys, uranium levels decreased between months 1 and 12 (220 ng/g tissue to 72.4 ng/g) and then 
increased again (311 ng/g) at 19 months.  The investigators noted that the results could not be adequately 
explained and that further studies should be conducted.  Elevated levels of uranium in the brain were also 
observed in rats exposed to 3.7 mg U/kg/day as 4.92% enriched uranyl nitrate in mineral water for 90 
days (Lestaevel et al. 2005b).  The levels of uranium in the brain increased from 75.4 to 86.1 ng; the 
levels of uranium in the kidneys were also significantly increased from 101.9 to 579.0 ng. 
 
The insoluble compounds of uranium accumulated to a lesser extent in tissues.  Only small amounts of 
uranium were found in the kidneys (3–9 μg/pair of kidneys) of female mice that were exposed orally to 
uranium tetrafluoride at 4,437 mg U/kg/day for 48 weeks.  No uranium was found in the bone 
(Tannenbaum et al. 1951).  Only small amounts of uranium were found in kidney (1–3 μg/pair of 
kidneys) of female mice that were exposed orally to triuranium octaoxide at 1,655 mg U/kg/day for 
48 weeks.  No uranium was found in the bone (Tannenbaum et al. 1951). 
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Arruda-Neto et al. (2004a) examined the accumulation of uranium in bones as a function of uranium dose 
in young rats exposed to uranyl nitrate in the diet at doses of 0.1–26 mg U/kg/day for 60 days and found a 
biphasic relationship.  The inflexion point was at approximately 6 mg/kg/day and accumulation of 
uranium in the bone increased linearly at doses higher than 6 mg/kg/day.  Another study by this group 
(Arruda-Neto et al. 2004b) found that uranium was equally distributed in the bone and bone marrow in 
dogs following a long-term exposure to uranyl nitrate in the diet. 
 
Oral exposure to uranyl nitrate in mineral water for 9 months resulted in significant increases in uranium 
concentration in the hippocampus and cortex; a 1.5-month exposure resulted in nonsignificant increases in 
uranium in these brain areas (Bensoussan et al. 2009).  Bellés et al. (2005) also reported significant 
increases in brain uranium levels, as compared to controls, following a 3-month exposure to uranyl 
acetate; however, there was no statistical relationship between dose and brain uranium levels. 
 
The uranium blood:tissue transfer coefficients were estimated in Wistar rats exposed to 0.5–26 mg 
U/kg/day as uranyl nitrate in the diet for 60 days (Arruda-Neto et al. 2001).  The highest transfer 
coefficients were found in the kidneys and liver.  A plot of the transfer coefficients for skin, brain, 
intestine, heart, liver, and kidneys exhibited concave shapes with the point of deflection occurring at the 
5 mg U/kg/day dose level in all tissues except the intestines.  The investigators suggested that this may 
indicate that similar mechanisms are involved in the uptake of uranium by different tissues.  Additionally, 
the slope of the uranium tissue concentration versus dietary concentration increased gradually at the lower 
doses (<5 mg U/kg/day) and steeply at doses of 5–26 mg U/kg/day.  This could be due to an enhanced 
absorption at uranium doses >20 mg U/kg/day.  However, increases in occult blood levels in the urine 
were also observed at the higher doses, suggesting that the sharp increase in tissue uranium levels may be 
due to renal damage resulting in an increased concentration of uranium in blood and consequently in 
organs and tissues. 
 
3.4.2.3   Dermal Exposure  
 
No studies were located regarding distribution of uranium after dermal exposure in humans.  In hairless 
rats dermally exposed to depleted uranium in a nitric acid solution, increased levels of uranium were 
detected in the kidneys and bone 6 hours after application to intact skin; the highest concentrations were 
found in the kidney (Petitot et al. 2007a).  Application to wounded skin (via mechanical abrasion or 
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exposure to weak acids) resulted in significant increases in uranium levels in the kidneys and bone within 
30 minutes of exposure. 
 
3.4.2.4   Other Routes of Exposure 
 
Intravenously injected uranium is rapidly taken up by the tissues or excreted in the urine (ICRP 1995).  
Typically, 25% of intravenously injected uranium (as uranyl nitrate) remained in blood of human subjects 
after 5 minutes, 5% after 5 hours, 1% after 20 hours, and <0.5% after 100 hours although inter-subject 
variation was high (AEC 1948, 1957).  Measurements of systemic distribution of uranium made at 
autopsy in one terminally ill human given a single intravenous injection of uranium indicated that the 
skeleton, kidneys, and other soft tissues after 2.5 hours contained about 10, 14, and 6%, respectively, of 
the dose.  Distribution data taken from another human subject 18 hours after a single intravenous injection 
uranium showed that the bones, kidneys, and other soft tissues contained about 4–13, 6, and 4%, 
respectively, of the amount injected.  At 566 days postinjection, uranium distribution in the skeleton, 
kidneys, and other soft tissues declined to about 1.4, 0.3, and 0.3%, respectively. 
 
The distribution of uranium following implantation of depleted uranium pellets into the gastrocnemius 
muscle has been investigated in rats (Pellmar et al. 1999a; Zhu et al. 2009a).  Within 1 day of 
implantation, uranium was measurable in kidney and bone but not in the other tissues.  At later time 
points, significant amounts of uranium were found in the other tissues, especially the spleen, liver, and 
lung; the levels were always highest in the kidney and bone.  The amount of uranium in the kidney and 
bone was significantly correlated with the uranium dose.  Tissue uranium levels peaked 90 days after 
implantation and gradually decreased; however, the levels were still elevated 360 days postimplantation 
(Zhu et al. 2009a). 
 
3.4.3   Metabolism  
 
Uranium is usually found in compounds that can be metabolized and recomplexed to form other 
compounds.  In body fluids, tetravalent uranium is likely to oxidize to the hexavalent form followed by 
formation of uranyl ion.  Uranium generally complexes with citrate, bicarbonates, or protein in plasma 
(Cooper et al. 1982; Dounce and Flagg 1949; Stevens et al. 1980).  The stability of the carbonate complex 
depends on the pH of the solution, which will differ in different parts of the body (BEIR IV 1988).  The 
low-molecular-weight bicarbonate complex can be filtered at the renal glomerulus and be excreted in 
urine at levels dependent on the pH of the urine.  The uranium bound to the protein (primarily transferrin) 
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is less easily filtered and is more likely to remain in blood.  In the blood, the uranyl ion binds to 
circulating transferrin, and to proteins and phospholipids in the proximal tubule (Wedeen 1992). 
 
3.4.4   Elimination and Excretion  
 
Two-thirds of uranium, intravenously injected as uranyl nitrate in human subjects was typically excreted 
in urine in the first 24 hours.  Approximately 10% more was excreted over a period of 5 days.  Fecal 
excretion accounted for <1% of the excretion (ICRP 1995). 
 
3.4.4.1   Inhalation Exposure  
 
In a study of 7,231 uranium workers, the urinary concentration of uranium ranged from 5 μg/L in 
4,556 workers to >100 μg/L in 32 workers.  Samples were taken weekly over a 6-year period.  Among a 
control group of 600 non-uranium workers, none had urinary uranium concentrations that exceeded 
40 μg/L.  The author concluded that urinary uranium concentrations >100 μg/L are definitely indicative of 
recent absorption, and that pathological albuminuria is rare, except when the urinary uranium 
concentration exceeds 1,000 μg/L.  Albuminuria, when seen, was transient, and did not persist 
(Butterworth 1955). 
 
Urinary excretion in crushermen (about 0.2 nCi/day [7 Bq/day; 0.3 mg/day]) is about 1/100th of fecal 
excretion (about 13.5 nCi/day [500 Bq/day; 20 mg/day]).  The activity of 234U in urine was slightly higher 
than that of 238U.  Active crushermen excreted higher levels of 234U, 238U, and 230Th than retired 
crushermen or controls (Fisher et al. 1983).  Most of the inhalation doses of female employees at the Oak 
Ridge plant were excreted in the feces, indicating that ciliary action in the lungs, followed by fecal 
excretion, was an important mechanism of body clearance (West and Scott 1969). 
 
Lu and Zhao (1990) reported on the excretion of uranium in an occupationally exposed worker.  A 
23-year-old man who weighed 60 kg, dressed in protective clothing, mask, and gloves, was accidentally 
exposed to pure uranium tetrafluoride powder for 5 minutes.  The uranium tetrafluoride powder cloud was 
reported to contain natural uranium.  Urinary excretion was reported as 112 μg/L or 156.8 μg in the first 
24 hours, gradually increasing through postaccident day 60 and returning to normal at about postaccident 
day 1,065.  The total urinary excretion of uranium through day 1,065 was calculated to be 86.7 mg.  The 
excretion data was used to calculate total absorption and kidney content by use of a kinetic model (ICRP 
1979).  The kidney content on postaccident day 1 was reported as 804.2 μg or approximately 2.6 μg/g of 
kidney. 
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Depleted uranium was detected in the urine of uranium process workers and nearby residents 20 years 
after chronic exposure to depleted uranium aerosols (Parrish et al. 2008).  The biological half-time of 
uranium dioxide in human lungs (occupational exposure) at German fuel fabrication facilities was 
estimated to be 109 days.  Body burden measurements of uranium taken from 12 people who handled 
uranium oxides for 5–15 years were used for this determination.  Twice a year for 6 years, urinalysis was 
conducted on workers exposed to uranium.  In vivo lung counting was performed on the last day before 
and the first day after a holiday period.  Levels of uranium in feces were measured during the first 3 days 
and the last 3 days of a holiday period and the first 3 days after the restart of work.  For some employees, 
the levels of uranium in feces were measured during 3–4 days one-half year after the holiday period 
(Schieferdecker et al. 1985). 
 
In animals, most of absorbed uranium is excreted in urine.  Inhaled larger particles (≥10 μm) are 
transported out of the respiratory system by mucocilliary action, then swallowed, and eliminated in the 
feces (Ballou et al. 1986; Downs et al. 1967; Morrow et al. 1982a).  Deposition sites of inhaled aerosols, 
and hence the clearance kinetics, are determined in part by particle size of the inhaled particles.  As the 
AMAD increases, the amount deposited in the upper respiratory tract increases, and the amount deposited 
in the deep respiratory tracts of the lungs decreases.  This study used both 232U and 233U dusts.  The 
233U dust deposition in the upper respiratory tract increased from 21 to 62% of the total amount of dust 
deposited with increasing particle size; deposition in the deep lung decreased from 22 to 7% with 
increasing particle size.  The 232U dust deposition in the upper respiratory tract increased from 10 to 32% 
with increasing particle size; deposition in the deep lung decreased from 23 to 9% with increasing particle 
size.  The differences were less marked for 232U dust, presumably because the particle size was much 
more uniform than that for the 233U dust.  A large amount of the initial lung burden was preferentially 
cleared via the feces following clearance from the upper respiratory tract to the gastrointestinal tract 
(higher fecal excretion with higher AMAD) by mucocilliary action.  Urinary excretion was 25–50% of 
initial lung burden on day 1 and less with larger particles.  By day 7, 25–80% of the uranium uptake was 
cleared in urine; most of the uranium was eliminated in the feces (Ballou et al. 1986).  In one study with 
rats, most of the inhaled uranium, as uranium dioxide, was excreted in the urine.  In dogs, <10% was 
excreted in feces (presumably cleared by mucocilliary action) (Cooper et al. 1982).  About 60% of the 
retained uranium, as uranyl nitrate hexahydrate (Ballou et al. 1986), uranium hexafluoride (Leach et al. 
1984), and uranium trioxide (Morrow et al. 1982a), was excreted in urine within 1 day in other studies 
with rats, dogs, and guinea pigs.  Most of the retained uranium in rats exposed via intratracheal intubation 
with uranium dioxide or uranyl nitrate hexahydrate was excreted in the urine.  Less than 10% was 
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excreted in feces (presumably cleared by mucocilliary action) (Cooper et al. 1982).  The fraction of 
insoluble compounds (uranium tetrafluoride, uranium dioxide) retained in the lungs and lymph nodes was 
independent of the exposure concentration.  More than 90% of the uranium retained at the end of the first 
year of exposure to uranium dioxide was cleared by the end of the second year despite continued 
exposure to uranyl nitrate hexahydrate.  All of the uranium retained following 1 year of exposure to 
uranium tetrafluoride was cleared by the end of the second year.  For uranyl nitrate hexahydrate exposure, 
no retention was found in the soft tissues (Stokinger et al. 1953). 
 
Once deposited in the lungs, uranium compounds clear from the various biological compartments by 
solubility.  The ICRP lung model recognizes three clearance classification types:  F, M, and S.  Type F 
compounds (uranium hexafluoride, uranyl fluoride, uranium trioxide, possibly uranium tetrafluoride, 
possibly triuranium octaoxide) show 100% absorption with a half-time of 10 minutes.  Type M compounds 
(uranyl nitrate, ammonium diuranate, possibly uranium tetrafluoride, possibly triuranium octaoxide) show 
10% absorption with a half-time of 10 minutes, 90% with a half-time of 140 days, and about 70% of the 
material in the alveoli eventually reached body fluid.  Type S compounds (uranium dioxide) show 0.1% 
absorption with a half-time of 1 minute, 99.9% with a half-time of 7,000 days, and 10% of that deposited 
in the alveoli reaches body fluid (ICRP 1996).  The half-time of uranium in the lungs has also been 
calculated to be 1–5 days for soluble compounds like uranyl nitrate hexahydrate in rats (Ballou et al. 
1986), ammonium diuranate in hamsters (Stradling et al. 1984), and uranyl fluoride in dogs (Morrow et al. 
1982a).  It is longer for the less soluble uranium dioxide:  141–289 days in rats (Downs et al. 1967) and 
480 days in dogs (Leach et al. 1973).  In the kidney, uranium selectively accumulates in the proximal 
tubule with a biological half-time of about 1 week (Wedeen 1992).  The half-time of uranyl fluoride in the 
kidneys has been reported to be 2–5 days in rats (Diamond et al. 1989) and 9 days in dogs.  In dogs, 
<1% of the uranium remained in the kidneys after 30 days (Morrow et al. 1982a). 
 
In rats receiving an intratracheal instillation of uranium tetrafluoride or uranium peroxide, urinary 
excretion of uranium steadily increased during the first 8 days after instillation and then remained 
constant until the end of the study (postexposure day 30) (Houpert et al. 1999).  Two dose levels were 
administered for each compound, and despite signs of renal toxicity at the high dose level, there were no 
difference in the K/K+U ratio (K is the percent of uranium retained in the kidneys and U is the percent 
excreted in urine) between the groups. 
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3.4.4.2   Oral Exposure  
 
The available evidence on the excretion of ingested uranium suggests that most (≥95%) is excreted in the 
feces, and the remainder in urine (Wrenn et al. 1985).  Urinary uranium excretion rates from 
nonoccupationally exposed persons in three villages near uranium mining and refining facilities and a 
control village in Japan were <0.02–0.24 and <0.02–0.04 mg U/day per person, respectively (Masuda 
1971).  The half-time in the kidneys has been estimated to be 1–6 days for 99% of the uranium in the 
kidneys and 1,500 days for the remainder (ICRP 1979).  Most of the uranium doses, given as 900 mL of 
water containing 90 pCi (3.3 Bq) 234U and 90 pCi (3.3 Bq) 238U (180 pCi or 6.6 Bq uranium) to drink over 
a period of 6 hours, was excreted in feces within 2 days (Singh and Wrenn 1987).  Four volunteers who 
ingested 10.8 mg of uranium mixed with Coca-Cola excreted the uranium in both feces and urine over a 
25-day period (Hursh et al. 1969).  Urinary excretion after oral exposure is generally low and has been 
estimated as 2% of total excretion (Spencer et al. 1990). 
 
Animal studies have shown that most ingested uranium (99%) is not absorbed in rats, but is eliminated in 
the feces without being cycled through the bile.  In rats, most of the absorbed uranium leaves the body 
within a few days in urine; half is excreted in 2–6 days (Durbin and Wrenn 1975) and 98% is excreted 
within 7 days (Sullivan et al. 1986).  About 95% of the uranium in the kidneys of rats is excreted in urine 
within 1 week, and very little remains in any other organ (La Touche et al. 1987; Sullivan 1980a; Sullivan 
et al. 1986). 
 
Data from parenteral studies provide further indication that uranium retention in animal kidneys is 
described by a two-compartment exponential curve.  Reported biological half-times for the compartments 
are 2 and 50–60 days (Diamond et al. 1989), 2 and 13 days (Bentley et al. 1985), or 3 and 103 days (DOE 
1986b). 
 
A nonmonotonous pattern of uranium excretion was observed in rats chronically exposed to 2.0–2.9 mg 
U/kg/day as depleted uranyl nitrate in drinking water (Paquet et al. 2006).  The highest excretion levels 
were observed after 6 months of exposure (200 ng U/mL), after which time the levels steadily declined.  
At approximately 13 months of exposure, the levels remained constant at 30 ng U/mL for the last 6 
months of the study. 
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3.4.4.3   Dermal Exposure  
 
No studies were located describing the excretion of uranium following dermal exposure in humans.  
Application of depleted uranium or uranium in a nitric acid solution resulted in significant increases in the 
urinary excretion of uranium within 24 hours of exposure in hairless rats (Petitot et al. 2007a, 2007b).  
Application to intact skin resulted in increases in urinary uranium within 2 hours of exposure; application 
to wounded skin (via mechanical abrasion or exposure to low concentration of an acid solution) resulted 
in increases in urinary uranium within 30 minutes of exposure.  In contrast, severe damage to the skin 
resulted in low levels of uranium in the urine, first detected 6 hours after exposure. 
 
3.4.4.4   Other Routes of Exposure  
 
One day after depleted uranium pellets were implanted in the gastrocnemius muscle of rats, increased 
levels of uranium were measured in the urine (Zhu et al. 2009a).  Urinary excretion peaked 90 days after 
implantation and remained elevated 360 days after implantation. 
 
3.4.5   Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points. 
 
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between:  (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
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The PBPK model for a chemical substance is developed in four interconnected steps:  (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figures 3-3 through 3-9 show models for radionuclides in general or specifically for uranium. 
 
If PBPK models for uranium exist, the overall results and individual models are discussed in this section 
in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations. 
 
The ICRP (1994a, 1996) developed a Human Respiratory Tract Model (HRTM) for Radiological 
Protection, which contains respiratory tract deposition and clearance compartmental models for inhalation 
exposure that may be applied to uranium.  The ICRP (1995) also developed a biokinetic model for human 
oral exposure that applies to uranium.  Several more recent enhancements to the oral exposure model  
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Figure 3-3.  Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a  











































Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
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have been reported.  A multicompartmental gastrointestinal tract model was developed to replace what 
was originally a single parameter model (Human Alimentary Tract Model, HATM; ICRP, 2006a).  A hair 
compartment was developed to support biomonitoring of ingestion intakes (e.g., drinking water 
exposures, Li et al. 2009a).  Drinking water and dietary exposure models and Bayesian approaches have 
been developed to improve uranium dose assessments made with the ICRP model (Little et al. 2003, 
2007).  A biokinetics model for embedded uranium has been developed based on studies of uranium 
kinetics in rats that received implants of depleted uranium pellets (Leggett and Pellmar 2002; Squibb et 
al. 2005).  An adaptation of the ICRP human model for simulating biokinetics of inhaled uranium in rats 
has been reported (Monleau et al. 2006b) and the rat model was used to evaluate the general assumption 
of linear kinetics in the ICRP model (i.e., kinetics are independent of the dose history).  Several 
quantitative uncertainty analyses of the ICRP model have been reported (Davesne et al. 2009; Farfan et al. 
2003; Puncher et al. 2008).  The ICRP model performance has been evaluated against data on urinary 
excretion of uranium and data on uranium levels in tissues obtained from autopsy studies (Li et al. 2005, 
2006, 2009a; Russell and Kathren 2004).  Several recent applications of the ICRP model to exposure and 
risk assessment have been reported.  The model has been applied to simulate uranium body burdens and 
radiation doses associated with exposure scenarios of releases of depleted uranium in vehicles impacted 
by depleted uranium munitions (Guilmette et al. 2009).  The embedded uranium model developed by 
Leggett and Pellmar (2002) has been extended to humans and has been applied to predicting kidney 
uranium burdens in military veterans who received embedded fragment wounds resulting from vehicles 
impacted with depleted uranium munitions (Squibb et al. 2005).  A wound biokinetic model developed by 
NCRP (2008) has been coupled with the ICRP model to calculate predicted urinary excretion patterns and 
uranium kidney retention for different categories of uranium exposure (NCRP 2008).  An extension of the 
ICRP model that includes simulation of the transfer of uranium to hair has been used to estimate uranium 
dose coefficients for ingestion of uranium in drinking water (Li et al. 2009a).  The model has been used to 
predict radiation doses associated with exposures to uranium in drinking water and uranium body burdens 
associated with ingestion and inhalation exposures (Chen et al. 2004; Li et al. 2009b). 
 
The NCRP has also developed a respiratory tract and biokinetics model for inhaled radionuclides (NCRP 
1997).  Four other compartmental models (Fisher et al. 1991; Sontag 1986; Valdés 2009; Wrenn et al. 
1994) are also described below. 
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Human Respiratory Tract Model for Radiological Protection (ICRP 1994a, 1996) 
 
Deposition.  The ICRP has developed a deposition model for behavior of aerosols and vapors in the 
respiratory tract.  It was developed to estimate the fractions of radioactivity in breathing air that are 
deposited in each anatomical region.  ICRP provides inhalation dose coefficients that can be used to 
estimate the committed equivalent and effective doses to organs and tissues throughout the body based on 
a unit intake of radioactive material.  The model applies to three levels of particle solubility, a wide range 
of particle sizes (approximately 0.0005–100 μm in diameter), and parameter values can be adjusted for 
various segments of the population (e.g., sex, age, level of physical exertion).  This model also allows one 
to evaluate the bounds of uncertainty in deposition estimates.  Uncertainties arise from natural biological 
variability among individuals and the need to interpret some experimental evidence that remains 
inconclusive.  It is applicable to particles containing uranium, but was developed for a wide variety of 
radionuclides and their chemical forms. 
 
The ICRP deposition model estimates the amount of inhaled material that initially enters each 
compartment (see Figure 3-4).  The model was developed with five compartments:  (1) the anterior nasal 
passages (ET1); (2) all other extrathoracic airways (ET2) (posterior nasal passages, the naso- and 
oropharynx, and the larynx); (3) the bronchi (BB); (4) the bronchioles (bb); and (5) the alveolar 
interstitium (AI).  Particles deposited in each of the regions may be removed from each region and 
redistributed either upward into the respiratory tree or to the lymphatic system and blood by different 
particle removal mechanisms. 
 
For extrathoracic deposition, the model uses experimental data, where deposition is related to particle size 
and airflow parameters, and scales deposition for women and children from adult male data.  Similarly to 
the extrathoracic region, experimental data served as the basis for lung (bronchi, bronchioles, and alveoli) 
aerosol transport and deposition.  A theoretical model of gas transport and particle deposition was used to 
interpret data and to predict deposition for compartments and subpopulations other than adult males.  
Table 3-7 provides reference respiratory values for the general Caucasian population under several levels 
of activity. 
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*Compartment numbers shown in lower right corners are used to define clearance pathways.  The clearance rates, 
half-lives, and fractions by compartment, as well as the compartment abbreviations are presented in Table 3-8. 
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Table 3-7.  Reference Respiratory Values for a General Caucasian Population at 
Different Levels of Activity 
 
Breathing 
parameters: 3 Months 1 Year 5 Years 
10 Years 15 Years Adult 
Male Female Both Male Female Male Female 
Resting (sleeping); maximal workload 8% 
Breathing parameters: 
 VT (L) 0.04 0.07 0.17 – – 0.3 0.500 0.417 0.625 0.444 
 B (m3hour-1) 0.09 0.15 0.24 – – 0.31 0.42 0.35 0.45 0.32 
 fR (minute-1) 38 34 23 – – 17 14 14 12 12 
Sitting awake; maximal workload 12% 
Breathing parameters: 
 VT (L) NA 0.1 0.21 – – 0.33 0.533 0.417 0.750 0.464 
 B (m3hour-1) NA 0.22 0.32 – – 0.38 0.48 0.40 0.54 0.39 
 fR (minute-1) NA 36 25 – – 19 15 16 12 14 
Light exercise; maximal workload 32% 
Breathing parameters: 
 VT (L) 0.07 0.13 0.24 – – 0.58 1.0 0.903 1.25 0.992 
 B (m3hour-1) 0.19 0.35 0.57 – – 1.12 1.38 1.30 1.5 1.25 
 fR (minute-1) 48 46 39 – – 32 23 24 20 21 
Heavy exercise; maximal workload 64% 
Breathing parameters: 
 VT (L) NA NA NA 0.841 0.667 – 1.352 1.127 1.923 1.364 
 B (m3hour-1) NA NA NA 2.22 1.84 – 2.92 2.57 3.0 2.7 
 fR (minute-1) NA NA NA 44 46 – 36 38 26 33 
 
B = ventilation rate; fR = respiration frequency; NA = not applicable; VT = tidal volume 
 
Source:  See Annex B (ICRP 1994a) for data from which these reference values were derived. 
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Respiratory Tract Clearance.  This portion of the model identifies the principal clearance pathways 
within the respiratory tract.  The model was developed to predict the retention of various radioactive 
materials.  Figure 3-5 presents the compartmental model and is linked to the deposition model 
(Figure 3-4) and to reference values presented in Table 3-8.  Table 3-8 provides clearance rates and 
deposition fractions for each compartment for insoluble particles.  The table provides rates of insoluble 
particle transport for each of the compartments, expressed as a fraction per day and also as half-time.  
ICRP also developed modifying factors for some of the parameters, such as age, smoking, and disease 
status.  Parameters of the clearance model are based on human evidence for the most part, although 
particle retention in airway walls is based on experimental data from animal experiments. 
 
The clearance of particles from the respiratory tract is a dynamic process.  The rate of clearance generally 
changes with time from each region and by each route.  Following deposition of large numbers of 
particles (acute exposure), transport rates change as particles are cleared from the various regions.  
Physical and chemical properties of deposited material determine the rate of dissolution and as particles 
dissolve, absorption rates tend to change over time.  By creating a model with compartments of different 
clearance rates within each region (e.g., BB1, BB2, BBseq), the ICRP model overcomes problems 
associated with time-dependent functions.  Each compartment clears to other compartments by constant 
rates for each pathway. 
 
Particle transport from all regions is toward both the lymph nodes and the pharynx, and a majority of 
deposited particles end up being swallowed.  In the front part of the nasal passages (ET1), nose blowing, 
sneezing, and wiping remove most of the deposited particles.  Particles remain here for about a day.  For 
particles with AMADs a few micrometers or greater, the ET1 compartment is probably the largest 
deposition site.  A majority of particles deposited at the back of the nasal passages and in the larynx (ET2) 
are removed quickly by the fluids that cover the airways.  In this region particle clearance is completed 
within 15 minutes. 
 
Ciliary action removes deposited particles from both the bronchi and bronchioles.  Though it is generally 
thought that mucocilliary action rapidly transports most particles deposited here toward the pharynx, a 
fraction of these particles are cleared more slowly.  Evidence for this is found in human studies.  For 
humans, retention of particles deposited in the lungs (BB and bb) is apparently biphasic.  The “slow” 
action of the cilia may remove as many as half of the bronchi- and bronchiole-deposited particles.  In 
human bronchi and bronchiole regions, mucus moves more slowly the closer to the alveoli it is.  For the  
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See Table 3-8 for rates, half-lives, and fractions by compartment. 
 
Source:  ICRP 1994a 
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Table 3-8.  Reference Values of Parameters for the Compartment Model to 
Represent Time-dependent Particle Transport from the 
 Human Respiratory Tract 
 
Part A 
Clearance rates for insoluble particles 
Pathway From To Rate (d-1)  Half-lifea 
m1,4 AI1 bb1 0.02  35 days 
m2,4 AI2 bb1 0.001  700 days 
m3,4 AI3 bb1 1x10-4  7,000 days 
m3,10 AI3 LNTH 2x10-5  No data 
m4,7 bb1 BB1 2  8 hours 
m5,7 bb2 BB1 0.03  23 days 
m6,10 bbseq LNTH 0.01  70 days 
m7,11 BB1 ET2 10  100 minutes 
m8,11 BB2 ET2 0.03  23 days 
m9,10 BBseq LNTH 0.01  70 days 
m11,15 ET2 GI tract 100  10 minutes 
m12,13 ETseq LNET 0.001  700 days 
m14,16 ET1 Environment 1  17 hours 
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Table 3-8.  Reference Values of Parameters for the Compartment Model to 
Represent Time-dependent Particle Transport from the  
Human Respiratory Tract 
 
Part B 
Partition of deposit in each region between compartmentsb 
Region or deposition site Compartment 
Fraction of deposit in region 
assigned to compartmentc 
ET2 ET2 0.9995 
 ETseq 0.0005 
BB BB1 0.993-fs 
 BB2 fs 
 BBseq 0.007 
bb bb1 0.993-fs 
 bb2 fs 
 bbseq 0.007 
AI AI1 0.3 
 AI2 0.6 
 AI3 0.1 
 
aThe half-lives are approximate since the reference values are specified for the particle transport rates and are 
rounded in units of days-1.  A half-life is not given for the transport rate from Al3 to LNTH, since this rate was chosen to 
direct the required amount of material to the lymph nodes.  The clearance half-life of compartment Al3 is determined 
by the sum of the clearance rates. 
bSee paragraph 181, Chapter 5  (ICRP 1994a) for default values used for relating fs to dae. 
cIt is assumed that fs is size-dependent.  For modeling purposes, fs is taken to be: 
 
  
f for d m and









05 2 50 63 2 5
. . /
. . /. ( / . )
ρ χ µ
ρ χ µχ ρ  
 
where 
fs = fraction subject to slow clearance 
dae  = aerodynamic particle diameter/(μm) 
ρ = particle density (g/cm3) 
χ = particle shape factor 
 
AI = alveolar-interstitial region; BB = bronchial region; bb = bronchiolar region; BBseq = compartment representing 
prolonged retention in airway walls of small fraction of particles deposited in the bronchial region; 
bbseq = compartment representing prolonged retention in airway walls of small fraction of particles deposited in the 
bronchiolar region; ET = extrathoracic region; ETseq = compartment representing prolonged retention in airway tissue 
of small fraction of particles deposited in the nasal passages; GI = gastrointestinal; LNET = lymphatics and lymph 
nodes that drain the extrathoracic region; LNTH = lymphatics and lymph nodes that drain the thoracic region 
 
Source:  ICRP 1994b 
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faster compartment it has been estimated that it takes about 2 days for particles to travel from the 
bronchioles to the bronchi and 10 days from the bronchi to the pharynx.  The second (slower) 
compartment is assumed to have approximately equal fractions deposited between BB2 and bb2 and both 
with clearance half-times estimated at 20 days.  Particle size is a primary determinant of the fraction 
deposited in this slow thoracic compartment.  A small fraction of particles deposited in the BB and bb 
regions is retained in the airway wall for even longer periods (BBseq and bbseq). 
 
If particles reach and become deposited in the alveoli, they tend to stay imbedded in the fluid on the 
alveolar surface or move into the lymph nodes.  The one mechanism by which particles are physically 
resuspended and removed from the AI region is coughing.  For modeling purposes, the AI region is 
divided into three subcompartments to represent different clearance rates, all of which are slow. 
 
In the alveolar-interstitial region, human lung clearance has been measured.  The ICRP model uses 2 half-
times to represent clearance:  about 30% of the particles have a 30-day half-time and the remaining 70% 
are given a half-time of several hundred days.  Over time, AI particle transport falls and some compounds 
have been found in lungs 10–50 years after exposure. 
 
Absorption into Blood.  The ICRP model assumes that absorption into blood occurs at equivalent rates in 
all parts of the respiratory tract, except in the anterior nasal passages (ET1), where no absorption occurs.  
It is essentially a two-stage process, as shown in Figure 3-6.  First, there is a dissociation (dissolution) of 
particles; then the dissolved molecules or ions diffuse across capillary walls and are taken up by the 
blood.  Immediately following dissolution, rapid absorption is observed.  For some elements, rapid 
absorption does not occur because of binding to respiratory-tract components.  In the absence of specific 
data for specific compounds, the model uses the following default absorption rate values for those specific 
compounds that are classified as Types F (fast), M (medium), and S (slow): 
 
• For Type F, there is rapid 100% absorption within 10 minutes of the material deposited in the BB, 
bb, and AI regions, and 50% of material deposited in ET2.  Thus, for nose breathing, there is rapid 
absorption of approximately 25% of the deposit in ET and 50% for mouth breathing.  Type F 
uranium compounds include uranium hexafluoride, its mixture with uranyl fluoride, uranyl nitrate 
(which can behave as Type M), pure uranium trioxide, and uranium tetrafluoride (which can 
behave at Type M). 
 
For Type M, about 70% of the deposit in AI reaches the blood eventually.  There is rapid 
absorption of about 10% of the deposit in BB and bb, and 5% of material deposited in ET2.  Thus, 
there is rapid absorption of approximately 2.5% of the deposit in ET for nose breathing, and 5% 
for mouth breathing.  Type M compounds include unpure uranium trioxide, uranyl nitrate (which  
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can behave as Type F), ammonium diuranate, uranium oxtaoxide (which can behave as Type S), 
and uranium tetrafluoride (which can behave as Type F). 
 
• For Type S, 0.1% is absorbed within 10 minutes and 99.9% is absorbed within 7,000 days, so 
there is little absorption from ET, BB, or bb, and about 10% of the deposit in AI reaches the 
blood eventually.  Type S compounds include uranium dioxide and uranium octaoxide (which can 
behave as Type M). 
 
Human Alimentary Tract Model for Radiological Protection (ICRP 2006a) 
 
The ICRP HATM is a generic multicompartment gastrointestinal tract model that was developed for 
applications to radiation risk assessments of radionuclides.  The model replaced an earlier gastrointestinal 
absorption model that consisted of single compartment and single parameter representation of absorption 
of radionuclides into the central plasma compartment from the small intestine.  The structure of the 
multicompartment model is shown in Figure 3-7.  The model simulates the following major processes that 
can contribute to absorption of radionuclides from the gastrointestinal tract and contact and retention 
radionuclides in the gastrointestinal tract tissues (i.e., which could contribute to radiation dose to these 
tissues): 
 
• Entry of a radionuclide into the mouth by ingestion, or into the esophagus after mechanical 
clearance from the respiratory tract; sequential transfer of the radionuclide through the contents of 
the oral cavity, esophagus, stomach, small intestine, and segments of the colon, followed by 
excretion in feces. 
 
• Deposition and retention on or between the teeth and return to the oral cavity. 
 
• Deposition and retention in the oral mucosa or walls of the stomach and intestines. 
 
• Transfer from the oral mucosa or walls of the stomach and intestines back into the luminal 
contents or into blood (absorption). 
 
• Transfer from various secretary organs or blood into the contents of certain segments of the 
alimentary tract (secretion). 
 
Biokinetic Model for Uranium (ICRP 1995, 2006a) 
 
The ICRP biokinetic model for uranium is based on the generic model structure for alkaline earth 
elements described in Publication 67 (ICRP 1994b, 1995) linked to a generic multicompartmental 
alimentary tract model (HATM) described in Publication 100 (ICRP 2006a).  The structure of the model 
is shown in Figure 3-8.  Uranium (as the UO22+ ion) is similar to calcium (Ca2+) with regard to skeletal 
kinetics. 
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Some transfer rates in the biokinetic model for uranium are equated with bone formation rates.  The early 
behavior of uranium in human circulation is represented reasonably well by treating plasma as a 
uniformly mixed pool, where uranium is removed at a rate of 35 d-1 (ICRP 1995) and where a soft tissue 
compartment (ST0) is in relatively rapid exchange with plasma.  Compartment ST0 is assumed to receive 
30% of uranium leaving plasma and to have a removal half-time of 2 hours (from ST0 to plasma).  ICRP 
assumed that 1% of uranium leaving the circulation (or 0.7% leaving plasma) deposits in red blood cells 
(ICRP 1995).  The removal half-time from red blood cells to plasma is assumed to be 2 days. 
 
Urinary excretion of uranium is assumed to arise from uranium moving directly from plasma to the 
urinary bladder contents.  Approximately 60% of uranium leaves the blood directly to the bladder and 
another 12% is retained temporarily in the renal tubules before excretion.  The liver is assumed to consist 
of two compartments:  Liver 1 and Liver 2.  The liver receives an estimated 1.5% of uranium leaving the 
blood, with over 90% returning to circulation. 
 
Little direct information on the kinetics of uranium in children exists.  Age-specific deposition of uranium 
in the skeleton is assumed to be proportional to the deposition of the alkaline earth elements.  The rate of 
removal from deep bone is assumed to be the same as the age-specific bone turnover rate.  Because 
children have higher amounts of uranium taken up by bone, deposition in soft tissues and excreta are 
likely lower in children than for adults. 
 
Valdés (2009) Lung Model 
 
A multicompartment model for predicting lung burdens of uranium resulting for exposure to depleted 
uranium aerosols was proposed by Valdés (2009).  Clearance of uranium particles deposited in the lung is 
assumed to occur by mechanical clearance by the mucociliary escalator and by cellular transport of 
uranium particles to lymph nodes after phagocytosis by macrophages.  The model assumes that 
phagocytosis is sufficiently rapid that essentially all absorption of uranium can be assumed to occur from 
macrophages after intracellular dissolution of uranium oxides to uranyl ion in macrophage lysosomes.  
The macrophage plasma membrane is assumed to be transparent to uranyl ion (i.e., absorption to the 
systemic circulation is considered to be essentially instantaneous).  Therefore, the rate of absorption of 
uranium into the systemic circulation is determined by the dissolution rate, which is assumed to have fast 
and slow rate components.  This representation of fast and slow dissolution kinetics and essentially 
instantaneous absorption of dissolved uranium is conceptually similar to the ICRP HRTM (ICRP 1995, 
URANIUM  227 
 








1996).  A competing process within macrophages is precipitation of uranyl phosphates within lysosomes.  
Uranyl phosphate precipitates are assumed to be kinetically inert and are stored permanently in lymph 
nodes.  Uranium absorbed into the systemic circulation is distributed and excreted according to the 
systemic biokinetics model based on the model developed by Wrenn et al. (1994). 
 
The lung model is implemented as a series of first-order differential equations, the core of which are as 
follows.  The amounts of uranium oxides in lungs (L) and lymph nodes (N) at time, t, following initial 
deposition in the lung of amount A0 are given by: 
 
L(t) =A0(0.0142e-2.1512t + 0.3042e-0.00201t + 0.0261e-0.2812t + 0.0107e-0.0023t) 
 
N(t) =A0[0.0024(e-2.15t - e-2.1512t) + 0.0018(e-0.0011t - e-0.0023t) +  
0.0567(e-0.00081t - e-0.00201t) + 0.0044(e-0.28t - e-0.2812t)] 
 
A similar set of expressions represents the amount of insoluble uranyl phosphates in lungs (PL) and lymph 
nodes (PN) at time, t, following initial deposition in the lung of amount A0: 
 
PL(t) =A0(1.460e-0.0012t - 1.419e-0.00201t - 0.0238e-2.1512t - 0.0094e-0.2812t - 0.008e-0.0023t) 
 
PN(t) =A0(0.1015 + 2.2164x10-6e-2.1512t + 0.1412e-0.00201t + 6.6816x10-6e-0.2812t +  
0.0007e-0.0023t - 0.2434e-0.0012t)  
 
The Valdés (2009) model has been applied to estimating initial and current body burdens of uranium in 
military veterans who were exposed to depleted uranium aerosols, based on time history of urinary 
uranium measurements. 
 
Wrenn et al. (1994) Pharmacokinetic Model 
 
A multicompartment model of distribution and excretion of absorbed uranium was proposed by Wrenn et 
al. (1994), based on data collected in studies conducted in nonhuman primates and in other animal models 
and data on tissue levels and urinary excretion of uranium in humans.  The model includes a central 
compartment consisting of plasma and extracellular fluid (ECF), which exchanges uranium with the 
skeleton, kidney, and a lumped compartment representing all other soft tissues (see Figure 3-9).  The 
skeleton is represented as a single compartment, unlike the ICRP model (ICRP, 1995), which 
subsequently adopted a multicompartment representation for the skeleton.  The kidney includes slow and 
fast kinetics compartments, both of which contribute to urinary uranium.  Uranium is also transferred to 
urine directly from plasma. 
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Sontag (1986) Pharmacokinetic Model 
 
An extended multicompartmental model (see Figure 3-10) describing the kinetic behavior of uranium 
(absorption, distribution, and excretion as a function of time) in the organs of male and female rats was 
developed using data taken from experiments performed on 13-month-old male and female Sprague-
Dawley rats intravenously injected with 1.54 mCi/kg (57 kBq/kg) 233U-uranyl citrate and sacrificed at 7, 
28, 84, 168, or 336 days after injection. 
 
The model is composed of 10 compartments.  These 10 compartments are connected by 17 linear transfer 
coefficients using 21 parameters.  The whole system describes the flux of compounds between a central 
compartment (the blood) and outer compartments which connect with the central compartment only.  The 
10 compartments are labeled blood, bone 1, bone 2, liver 1, liver 2, kidney 1, kidney 2, residual 1, 
residual 2, and excretion.  The organs are divided into two compartments: one compartment represents the 
short term and one represents the long term.  For example, the short-term compartment for the bone is the 
bone surface and bone marrow, and the long-term compartment is the deep bone.  In the liver, the short-
term compartment is assumed to be the lysosomes, and the long-term compartment is assumed to be the 
telolysosomes.  Separation of these organs into two components helps to account for the reabsorption and 
rapid excretion.  Using the symbols BP=blood, EC=excretion, B1=bone 1, L1=liver 1, K1=kidney 1, 
R1=residual 1, B2=bone 2, L2=liver 2, K2=kidney, and R2=residual 2, the calculated transfer coefficients 
for this model are shown in Table 3-9. 
 
Parallel evaluations produced two different values (ranges) for each of the 21 parameters.  The maximum 
fractions of uranium in various compartments were as follows:  bone, 0.0710 or 0.0735; liver, 0.0160 or 
0.0146; kidney, 0.1777 or 0.4789; residual compartment, 0.0358 or 0.0481; and excretion compartment, 
0.6995 or 0.3849 (if no back transfer to the blood compartment occurred).  The time at which the 
maximum amount of the uranium in the organ is reduced to one-half is 0.0009 or 0.0013 days in the 
blood, 165 or 93 days in the bone, 6 or 7 days in the liver, 11 or 5 days in the kidney, and 5 or 6 days in 
the residual compartment.  The cumulative radiation absorbed dose in the organ 365 days after injection 
of 56.6 kBq/kg body weight was 0.0002 or 0.0004 Gy to blood, 0.730 or 1.29 Gy to bone, 0.0268 or 
0.0308 Gy to liver, 1.32 or 1.77 Gy to kidney, and 0.0061 or 0.0076 Gy to residual compartment.  The 
ratio of single injection/continuous intake calculated for the same dose 1 year after the first injection was 
0.018 or 0.003 to blood, 0.619 or 0.812 to bone, 0.422 or 0.355 to liver, 0.256 or 0.231 to kidney, 
0.726 or 0.585 to residual compartment, and 1.024 or 1.023 to excretion compartment (Sontag 1986). 
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Table 3-9.  Sensitivity and Calculated Transfer Coefficients (d-1) 
 
Transfer from-to  Symbol Experimental value 1 Experimental value 2 Sensitivity 
BP-EC f10 555 209 0.2 
BP-B1 f12 56.3 39.9 5.9 
BP-L1 f13 12.7 7.94 3.3 
BP-K1 f14 141 2.60 1.5 
BP-R1 f15 28.4 26.1 17.5 
B1-BP f21 0.00979 0.0184 1.9 
L1-BP f31 0.187 0.270 5.6 
K1-BP f41 0.0948 0.365 0.5 
R1-BP f51 0.225 0.341 3.4 
B1-B2 f26 0.00565 0.00649 2.2 
L1-L2 f37 0.00863 0.00940 2.7 
K1-K2 f48 0.00114 0.00122 2.2 
R1-R2 f59 0.0103 0.00860 6.1 
B2-B1 f62 0.00261 4.43x10-6 5.0 
L2-L1 f73 0.00284 0.00349 43.7 
K2-K1 f84 0.000972 0.00122 4.8 
R2-R1 f95 0.000716 0.00138 2.3 
Varinz V 0.00663 0.00465 Not applicable 
 
Source:  Sontag 1986 
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Fisher et al. (1991) Biokinetic Model 
 
A modified biokinetic model for uranium was developed for inhaled soluble uranium based on human 
data from an accidental release of uranium hexafluoride in Oklahoma.  Urinary excretion data from 
31 exposed workers were used to test two previously published compartmental models for inhalation 
exposure to uranium (ICRP 1979; Wrenn et al. 1989).  Urinary uranium was measured periodically for 
2 years following the accident.  Statistical analysis showed that the Wrenn et al. (1989) model produced a 
better fit to the excretion data than the ICRP (1979) model. 
 
Parameters of the (Wrenn et al. 1989) model were then modified to further improve the fit to the workers 
excretion data.  Changing the retention half-time in the kidney from 15 to 6 days and the clearance half-
time in the lung from 0.5 to 0.03 days optimized the fit of the model to the experimental data.  The model 
may be summarized with the following five-term exponential equation: 
 
yu(t) = 1.5e-2.77t + 0.028e-0.116t + 0.0069e-0.0347t + (4.8x10-7e-0.000462t) + 3.2x10-6e-0.000139t 
 
where, yu(t) is fractional daily uranium excretion rate at t days after intake; the excretion constants in the 
five exponents corresponding to compartments with retention half-times of 0.25, 6, 20, 1,500, and 
5,000 days. 
 
The model was used to estimate uranium intakes; uranium burdens in the lungs, kidneys, and bones; and 
effective dose equivalent for each worker in the accident.  Initial intakes of workers involved in the 
accident ranged from 470 to 24,000 μg uranium.  The model estimated the maximum kidney 
concentrations in the workers as ranging from 0.048 to 2.5 μg U/g kidney tissue; renal toxicity was not 
observed in any of the workers (Fisher et al. 1991; USNRC 1990). 
 
Based on this same data base, the USNRC determined that the maximum uranium dose equivalent of 
workers on-site was 28 mrem (0.28 mSv).  The maximum uranium dose equivalent of off-site individuals 
was 1.4 mrem (0.014 mSv).  However, these radiological doses were small compared to the background 
radiation level of 106 mrem/year (1.06 mSv/year), excluding radon, in the area from which the data were 
collected (USNRC 1986). 
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3.5   MECHANISMS OF ACTION  
 
3.5.1   Pharmacokinetic Mechanisms  
 
On the average, a given amount of an ingested uranium compound appears to be less toxic than the same 
amount of an inhaled uranium compound (Maynard and Hodge 1949; Stokinger et al. 1953).  This finding 
may be partly attributable to the relatively low gastrointestinal absorption of uranium compounds.  Only 
0.1–6% of even the more soluble uranium compounds are absorbed in the gastrointestinal tract (EPA 
1988d; Harrison and Stather 1981; Hursh et al. 1969; ICRP 1979; Larsen et al. 1984; La Touche et al. 
1987; Leggett and Harrison 1995; Maynard et al. 1953; Sullivan 1980a; Wrenn et al. 1985).  The ICRP 
(1995) recommends a gastrointestinal absorption reference fraction of 0.02 for uranium ingested in 
relatively soluble form and 0.002 for insoluble compounds.  On the basis of the toxicity of different 
uranium salts in animals, it was concluded that the relatively more soluble salts (uranyl nitrate 
hexahydrate, uranyl fluoride, uranium tetrachloride, uranium pentachloride) were most toxic, the slightly 
soluble compounds (uranium trioxide, sodium diuranate, ammonium diuranate) were of intermediate 
toxicity, and the insoluble compounds (uranium tetrafluoride, uranium dioxide, uranium tetrachloride, 
triuranium octaoxide) were nontoxic (Orcutt 1949). 
 
In inhalation exposures, uranium compounds are usually inhalable aerosols.  Thus, particle size plays a 
vital role in tissue dose.  Particles >5 μm AMAD are likely to be transported out of the tracheobronchial 
region by mucocilliary action and swallowed into the gastrointestinal tract, where absorption is minimal 
(ICRP 1979).  The less soluble compounds (uranium trioxide, uranium tetrafluoride), designated Type M 
by the ICRP (1995), are more likely to remain in the lung tissue and associated lymph glands for weeks.  
The relatively insoluble compounds (uranium dioxide, triuranium octaoxide), designated Type S by the 
(ICRP 1995), are likely to remain in the lungs for years (Eidson 1994).  This retention of uranium in the 
lung can lead to a significant pulmonary radiation dose. 
 
In addition, the sequestration patterns of the different uranium compounds are important determinants for 
the target organ chemical and radiological toxicities of these compounds.  The site of deposition for the 
soluble uranium compounds (uranyl nitrate, uranium tetrachloride, uranium hexafluoride) is the bone, 
while the insoluble compounds (uranium hexafluoride, uranium dioxide) accumulate in the lungs and 
lymph nodes (Stokinger et al. 1953). 
 
In an in vitro study by Vidaud et al. (2005), several uranium binding proteins were identified in human 
serum including haptoglobin, apolipoprotein A1, serum albumin, α-1-antitrypsin, IgG, α-1-acid 
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glycoprotein, holotransferrin, hemopexin, apotransferrin, complement C4, complement C3, and 
ceruloplasmin.  Uranium was not shown to bind with retinol binding protein, transthyretin, or 
tropomyosin.  It is not known if these proteins are involved in the distribution of uranium to other tissues. 
 
3.5.2   Mechanisms of Toxicity  
 
The dual modes of uranium chemical and radiological toxicity are not usually separately identifiable by 
end point.  The renal and respiratory effects from exposure of humans and animals to uranium are usually 
attributed to the chemical properties of uranium, while the theoretically potential excess cancers are 
usually attributed to the radiation properties of this substance.  Although the net effects on the lungs and 
kidneys have been suggested to be a cooperative action of the chemical and radiation properties, with a 
complementary mechanism of action, this relationship has not been demonstrated experimentally (Ballou 
et al. 1986; Dockery et al. 1993; Dungworth 1989; Filippova et al. 1978; Leach et al. 1984; Spoor and 
Hursh 1973; Spiegl 1949; Stokinger et al. 1953).   
 
The most sensitive target of uranium toxicity to mammals, and perhaps humans, is the kidney.  While 
acute, high-level exposure to uranium compounds can clearly cause nephrotoxicity in humans (Lu and 
Zhao 1990; Pavlakis et al. 1996), the evidence for similar toxicity as the result of long-term, lower-level 
occupational exposures is equivocal.  Epidemiologic studies have not noted an increase in deaths from 
urogenital or renal diseases (Checkoway et al. 1988; Dupree et al. 1987; Lundin et al. 1969; NIOSH 1987; 
Polednak and Frome 1981), and follow-up studies have failed to identify significant damage to human 
kidneys following occupational exposure to uranium (Eisenbud and Quigley 1956; Hursh and Spoor 
1973; Luessenhop et al. 1958), or after war-related exposures (McDiarmid et al. 2000, 2001a, 2004b, 
2006, 2007, 2009).  A comparison of autopsy kidney tissue samples revealed no differences between 
seven uranium workers and six referents with no known exposure to uranium (Russell et al. 1996).  One 
epidemiologic study provided evidence of nephrotoxicity following occupational exposure to uranium.  
Nephrotoxicity, indicated by β2-microglobulinuria and aminoaciduria due to decreased tubular 
reabsorption, was reported in a group of 39 male uranium mill workers exposed for >1 year to uranium 
concentrations exceeding the occupational standard of 3.7 Bq/m3 (currently 5 Bq/m3 [0.2 mg/m3]) by 
≤8-fold.  Cement workers were used as controls in this study (Thun et al. 1985). 
 
Many animal studies have shown that inhalation, oral, or dermal exposure to uranium results in kidney 
damage.  The damage was histologically manifested as glomerular and tubular wall degeneration.  
Ultrastructural analysis showed damage to the endothelial cells in the glomerulus, such as loss of cell 
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processes, and reduction in the density of the endothelial fenestrae (Avasthi et al. 1980; Haley 1982; 
Haley et al. 1982; Kobayashi et al. 1984).  In the terminal segments of the proximal convoluted tubules, 
there was a loss of the brush border, cellular vacuolization, and necrosis.  Tubular reabsorption of solutes 
was disrupted.  Functionally, this process led to a disruption of the tubular solute reabsorption and to a 
decrease in the filtration rate of the glomerulus, as assessed by creatinine or inulin clearance or by 
proteinuria (Bentley et al. 1985; Blantz 1975; Leach et al. 1973; Morrow et al. 1982a).  Excessive urinary 
excretion of protein, glucose, amino acids, or enzymes, such as catalase or alkaline phosphatase are 
additional indicators of uranium-induced renal pathology (Maynard et al. 1953) by inhalation exposure 
(Bentley et al. 1985; Diamond et al. 1989; Haley et al. 1982; Leach et al. 1984; Maynard et al. 1953; 
Morrow et al. 1982a). 
 
A mechanism involving bicarbonate activity in the kidneys has been proposed for uranium-induced renal 
toxicity.  Uranium is usually combined with either bicarbonate or a plasma protein in the blood.  In the 
kidneys, uranium is released from bicarbonate and is free to combine to form complexes with phosphate 
ligands and proteins in the tubular wall to cause damage.  Uranium is not tightly bound and is released 
again within a few days.  Within a week following exposure, uranium is largely cleared from the kidneys, 
and the tubules begin to regenerate.  Although the regenerated epithelium has histological differences 
from its normal state, it is often difficult to detect histological signs of kidney damage a month after 
exposure because all remaining functional damage is subtle.  An alternative mechanism through which 
uranium exerts its renal toxicity has been suggested by the results of a study conducted with rabbit kidney 
cells in vitro.  In this study, uranyl nitrate hexahydrate inhibited both sodium transport-dependent and 
-independent ATP utilization and mitochondrial oxidative phosphorylation in the renal proximal tubule.  
Ouabain-insensitive adenosine triphosphatase (ATPase) activity exhibited the greatest sensitivity to 
uranyl nitrate hexahydrate and was significantly inhibited at submillimolar concentrations (Brady et al. 
1989).  Perhaps both of these activities combine to cause renal damage.  In addition, because uranium is a 
predominantly alpha-emitting radionuclide, current theories on cellular necrosis by high-LET alpha 
radiation imply a contributory role to the cellular degenerative nephrotoxic changes (BEIR 1980, 1988, 
1990; Filippova et al. 1978; Sanders 1986; UNSCEAR 1982, 1986, 1988). 
 
Most studies of respiratory diseases reported for uranium involve noncancerous alveolar epithelium 
damage in type II cells.  These changes are characterized by interstitial inflammation of the alveolar 
epithelium leading eventually to pulmonary fibrosis in acute exposures or to hyperplasia, hypertrophy, 
and transdifferentiation (metaplasia) in chronic exposures (Clayton and Clayton 1981; Cooper et al. 1982; 
Dungworth 1989; Wedeen 1992).  However, the lack of significant pulmonary injury in most inhalation 
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animal studies indicates that other potentially toxic contaminants such as inhalable dust particles, radium, 
or radon may contribute to these effects. 
 
Large doses of ionizing radiation have the actual or theoretical potential of being carcinogenic, 
teratogenic, and mutagenic.  Since uranium has a low specific activity but emits high LET alpha particles 
that are densely ionizing along their track length, studies have been conducted to determine if uranium 
can produce these effects in humans and animals.  The 4–8 MeV alpha particles from uranium travel 
through 40–70 μm in soft tissue, incrementally transferring their kinetic energy to the series of atoms and 
molecules with which they interact along their short, straight paths.  Consequently, only structures within 
this range from the site of the deposition of uranium may be affected.  If a DNA molecule is intersected 
and damaged without resulting in cell death, a range of theoretical effects can result.  DNA has been 
found to be the most radiosensitive biological molecule, and ionizing radiation has been observed to 
damage individual chromosomes.  The main result from low level ionizing radiation exposure is DNA 
damage or fragmentation.  Viable cells repair the damage, but repair errors can result which produce gene 
mutations or chromosomal aberrations.  Such events may result in such highly rare events as 
carcinogenesis or teratogenesis, but there is currently no evidence for radiation mutagenesis in humans.  
Chromosomal aberrations following large radiation doses have been demonstrated in humans and in 
research animals, showing that ionizing radiation can both initiate and promote carcinogenesis, and 
interfere with reproduction and development. 
 
3.5.3   Animal-to-Human Extrapolations  
 
Kidney damage and respiratory disease are the most significant health effects in animals from the 
metallotoxicity of uranium.  Because the biological systems through which these effects are mediated are 
common to both animals and humans (Brady et al. 1989; Clayton and Clayton 1981; Cooper et al. 1982; 
Dungworth 1989; Wedeen 1992), it is reasonable that animals are appropriate surrogates for humans in 
this regard.  This assumption is consistent with evidence in humans for respiratory (Kathren and Moore 
1986, Waxweiler et al. 1981a) and renal (AEC 1957; Fisher et al. 1991; Kathren and Moore 1986; Lu and 
Zhao 1990; Luessenhop et al. 1958; Thun et al. 1985; USNRC 1986; Waxweiler et al. 1981a) effects.  
The data from these studies support the assumption of biological similarity in the renal toxicity of 
uranium in animals and humans.  Nevertheless, a considerable uncertainty is associated with animal-to-
human extrapolation regarding the renal toxicity of uranium exposure because the renal toxicity of 
animals varies with species. 
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3.6   TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
 
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors.  However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents.  The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997a).  Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992). 
 
Only one study was located that provided information regarding potential neuroendocrine effects of 
uranium (Raymond-Whish et al. 2007).  In that study, 28-day-old ovariectomized female mice received 
doses of approximately 0.005, 0.009, 0.09, or 0.9 mg U/kg/day in tap water for 30 days.  Ovariectomy 
was performed to remove the endogenous source of estrogen.  A group of mice was also exposed to 
diethylstilbestrol (DES) as a positive control.  Exposure to 0.009 mg U/kg/day significantly increased 
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uterine weight, but the higher doses were without significant effect.  In addition, mice exposed to 0.005 or 
0.009 mg U/kg/day had significantly increased presence of cornified vaginal cells relative to controls, 
which indicated an estrogenic effect of uranium.  In a different experimental series, the investigators 
studied the dependency of the estrogen-like effects of uranium on estrogen receptor (ER) activation.  
Ovariectomized mice received the same doses for 10 days beginning at 50 days of age.  A group of mice 
also received injections of an anti-estrogenic drug.  Doses of 0.005 mg U/kg/day, but not higher doses, 
significantly increased uterine weight and the effect could be blocked by the anti-estrogenic compound.  
Also, exposure to 0.009 mg U/kg/day significantly accelerated vaginal opening, which was also blocked 
by the anti-estrogenic drug.  A mechanism by which uranium evoked estrogenic responses was not 
defined. 
 
No in vitro studies were located regarding endocrine disruption of uranium. 
 
3.7   CHILDREN’S SUSCEPTIBILITY  
 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children. 
 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
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body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
 
Specific information is not available on whether children are more susceptible than adults to the effects of 
uranium.  No reports were located describing toxicity in children as the result of uranium exposure.  It is 
probable, however, that if exposure levels were high enough, signs of renal toxicity would be observed 
similar to those seen in adults exposed accidentally (Lu and Zhao 1990) or intentionally (Pavlakis et al. 
1996).  No reports are available of studies where toxic responses of young animals to uranium were 
directly compared to those of adults.  Three studies by Maynard et al. (1953) evaluated age-related 
differences in uranyl nitrate toxicity in rats aged 17 days to 6 months exposed to 2% uranyl nitrate in the 
diet for 30 days; in rats aged 1, 2, 3, or 6 months exposed to 2% uranyl nitrate in the diet for 24 hours 
followed by a 30-day observation period; and in rats aged 21 days to 6 months receiving a single 
intraperitoneal injection of 128 (males) or 200 (females) mg/kg uranyl nitrate hexahydrate.  Both studies 
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found age-related increases in mortality.  In the 30-day dietary exposure study, >75% of the 17- and 
21-day-old animals died during the study, <10% of the 28-day-old animals died, and >50% of the 2-, 3-, 
4-, 5-, and 6-month-old animals died.  Insufficient body weight and food intake data were provided; thus, 
daily doses cannot be calculated.  The 1-day dietary study found a similar pattern of mortality.  Mortality 
increased with age; 1% (males) and 3% (females) of the 1-month-old rats died compared to 8% (males) 
and 16% (females) of the 6-month-old rats.  Following a single intraperitoneal dose, the mortality rates 
were 36, 11, 8, 18, 24, and 19% males and 24, 18, 8, 23.5, 41, 22, and 52% of the females aged 21 days, 
1 month, 2 months, 3 months, 4 months, 5 months, and 6 months, respectively.  The differences in 
mortality may be due to age-related toxicokinetic differences, such as changes in absorption efficiency, 
skeletal development, or kidney development. 
 
Several investigators (as reviewed by Busby et al. 2010; Hindin et al. 2005) have examined the possible 
association between exposure to depleted uranium and birth defects.  Interpretation of these data is limited 
by the lack of adequate controls, monitoring data to determine whether the subjects were exposed to 
depleted uranium and at what level, potential exposure to other agents, and other possible confounding 
factors, such as poor nutrition.  Animal studies have examined the developmental toxicity of uranium 
compounds following oral exposure or intramuscular implantation.  Developmental effects (described in 
greater detail in Section 3.2.2.6) have been observed in rats and mice following oral exposure (gavage or 
drinking water administration) to soluble uranium compounds; the effects include decreases in viability or 
embryolethality (Domingo et al. 1989b, 1989c; Paternain et al. 1989), decreases in fetal body weight 
(Domingo et al. 1989c; Paternain et al. 1989), increases in the number of litters with visceral and skeletal 
defects (e.g., cleft palate, bipartite sternebrae, reduced ossification) (Domingo et al. 1989c), alterations in 
performance on neurobehavioral tests (Houpert et al. 2007a; Sánchez et al. 2006), alterations in ovarian 
folliculogenesis (Arnault et al. 2008; Raymond-Whish et al. 2007), and delayed tooth eruption (Pujadas 
Bigi and Ubios 2007; Pujadas Bigi et al. 2003).  No developmental effects were observed in offspring of 
rats following implantation of depleted uranium pellets in the gastrocnemius muscle (Arfsten et al. 2009). 
 
Information on the pharmacokinetics of uranium in children is very limited.  Since the skeletons of 
children are growing (higher rate of bone formation), it is possible that a higher fraction of circulating 
uranium will be deposited in bone than in adults.  A study of uranium content in bone from three age 
groups (<13, 13–20, 20–25 years old) reported somewhat higher uranium content in the youngest 
compared to the oldest age group (approximately 1.5–3 fold); however, there were only 2–4 subjects in 
each group and the differences were not statistically significant (Broadway and Strong 1983).  The 
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fractional absorption of uranium by the oral route was higher in neonatal swine and rats than in adult 
animals (Sullivan 1980b; Sullivan and Gorham 1982). 
 
Transfer of uranium across the placenta was investigated in an animal study, but no information is 
available for humans.  In the animal study, only 0.01–0.03% of an intravenous dose of uranium to rat 
dams crossed the placenta (Sikov and Mahlum 1968).  In contrast, another oral exposure study (Sánchez 
et al. 2006) found elevated uranium levels in the offspring of rats exposed to uranyl acetate prior to 
mating and throughout gestation and lactation, suggesting transplacental and/or lactational transfer of 
uranium.  No studies were located regarding uranium in breast milk.  Based on the chemical properties of 
uranium, it seems unlikely that there would be preferential distribution from the blood to this high-fat 
compartment.  It is not known if uranium has any effect on the active transport of calcium into breast 
milk.  Most of the adult body burden of uranium is stored in bone (ICRP 1979, 1995, 1996).  It is not 
known if maternal bone stores of uranium (like those of calcium and lead) are mobilized during 
pregnancy and lactation. 
 
Age-related differences in the pharmacokinetics of uranium have been incorporated into existing PBPK 
models (ICRP 1995, 1996) so that they can be applied to children.  Two adjustments were made: 
 
1. The value for the fractional absorption of ingested uranium (f1) was adjusted from the adult value 
of 0.02 (2%) to a value of 0.04 (4%) for children under the age of 1 year.  This adjustment was 
made based on animal data (Sullivan 1980b; Sullivan and Gorham 1982) and information on 
postnatal changes in the human gastrointestinal tract.  For ages over 1 year, the adult value for 
fractional absorption was used. 
 
2. Parameters for transfer of uranium into and out of bone were assumed to be proportional to those 
of alkaline earth elements such as calcium (the UO22+ ion can substitute for the Ca2+ ion at bone 
surfaces).  Age-specific bone turnover rates developed for a generic alkaline-earth model (ICRP 
1994b) were incorporated into the uranium model to predict distribution to the tissues.  As a 
result of this change, a greater proportion of uranium distributes to bone and a lesser proportion to 
soft tissues at ages under 25 years, compared to adults. 
 
The mechanism for the renal toxicity observed in cases of adult exposure to uranium is believed to be due 
to the retention of uranium in the kidney.  This is the result of the reabsorption of bicarbonate from the 
ultrafiltrate in the proximal tubule and the resulting release of the UO22+ ion from a bicarbonate complex.  
Newborn humans have relatively inefficient tubular secretion and reabsorption compared to older children 
or adults, and whether this would increase or decrease the susceptibility of newborns to uranium toxicity 
is not known. 
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3.8   BIOMARKERS OF EXPOSURE AND EFFECT  
 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
 
The National Report on Human Exposure to Environmental Chemicals provides an ongoing assessment 
of the exposure of the U.S. population to environmental chemicals using biomonitoring.  This report is 
available at http://www.cdc.gov/exposurereport/.  The biomonitoring data for uranium from this report is 
discussed in Section 6.5.  A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the 
product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is 
measured within a compartment of an organism (NAS/NRC 1989).  The preferred biomarkers of exposure 
are generally the substance itself, substance-specific metabolites in readily obtainable body fluid(s), or 
excreta.  However, several factors can confound the use and interpretation of biomarkers of exposure.  
The body burden of a substance may be the result of exposures from more than one source.  The 
substance being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels 
of phenol can result from exposure to several different aromatic compounds).  Depending on the 
properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route 
of exposure), the substance and all of its metabolites may have left the body by the time samples can be 
taken.  It may be difficult to identify individuals exposed to hazardous substances that are commonly 
found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium).  
Biomarkers of exposure to uranium are discussed in Section 3.9.1. 
 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by uranium are discussed in Section 3.9.2. 
 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
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other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.11, Populations That Are Unusually Susceptible. 
 
3.8.1   Biomarkers Used to Identify or Quantify Exposure to Uranium 
 
The primary biomarker of exposure to uranium is the chemical or radiological detection of total uranium 
or individual uranium isotopes in the urine because uranium absorbed through the oral, dermal, and 
inhalation routes is excreted in urine mostly as uranyl ions (Ballou et al. 1986; Cooper et al. 1982; Downs 
et al. 1967; Leach et al. 1984; Morrow et al. 1982a; Stradling et al. 1984, 1987; West and Scott 1969; 
Wrenn et al. 1985).  Uranium urinalysis data have been shown to correlate with airborne uranium 
exposures when averaged over a period of time when the ingested quantity is insignificant.  Uranium can 
also be measured in feces, nails, and hair (Karpas 2001; Karpas et al. 2005a, 2005b; Muikku et al. 2009).  
Although elevated uranium levels could only be measured in urine and fecal samples within days of acute 
exposure to uranium, elevated uranium levels could be measured in hair and nail samples weeks or 
months after the acute exposure (Karpas 2001; Karpas et al. 2005a, 2005b).  In humans chronically 
exposed to elevated uranium levels in drinking water, good correlations were found for daily uranium 
intake with hair uranium levels and with nail uranium levels (Karpas et al. 2005b).  Muikku et al. (2009) 
noted that in areas of high uranium in drinking water, a portion of the uranium content in hair may be due 
to external contamination and this proportion needed to be quantified before using hair uranium levels to 
estimate uranium ingestion.  Karpas et al. (2005a) also found that the isotopic ratio of 234U to 238U in hair 
and toenail samples correlated with that of drinking water (primary route of exposure for the study 
population) and could be used to identify the source of exposure. 
 
Twenty-four hour urine samples, corrected per gram creatinine concentration, are considered the “gold 
standard” for assessing uranium body burden.  To evaluate the accuracy of spot urine samples for 
assessing uranium body burden, McDiarmid et al. (1999b) examined 22 non-uranium exposed veterans 
and 29 veterans exposed to depleted uranium.  In both groups, the median and mean urine uranium levels 
were similar in the creatinine-corrected 24-hour samples and spot samples.  When both groups were 
combined, the 24-hour creatinine-corrected urine uranium levels were highly correlated (R2=0.97) with 
the creatinine-corrected spot urine uranium levels.  However, lower correlation coefficients were found in 
the non-exposed group (R2=0.44) and in exposed veterans with 24-hour urine uranium levels of <0.05 µg 
U/g creatinine (R2=0.48).  In contrast, the correlation coefficient was 0.99 in the veterans with 24-hour 
urine uranium levels of ≥0.05 µg/g creatinine.  Marco et al. (2008) also found that spot urine samples 
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normalized to creatinine concentration were representative of 24-hour uranium levels among workers at a 
nuclear research center. 
 
Uranium content in soft tissue and bone could also be used as biomarkers of exposure to uranium since 
uranium also distributes to these tissues and other organs (Ballou et al. 1986; Diamond et al. 1989; Leach 
et al. 1973, 1984; Morris et al. 1990; Morrow et al. 1972; Stokinger et al. 1953; Walinder 1989; Wrenn et 
al. 1987).  Although soft tissues and bone are the most frequently analyzed biological media after urine 
and feces, these tissues are usually available for analysis only at autopsy.  Therefore, this method is 
impractical and not used for routine screening purposes. 
 
3.8.2   Biomarkers Used to Characterize Effects Caused by Uranium 
 
Currently, there are no available biomarkers for specific exposure to the metallotoxic or radiotoxic effects 
of uranium. 
 
Functional damage to the kidneys has been documented in humans (Lu and Zhao 1990; Pavlakis et al. 
1996; Thun et al. 1985; Waxweiler et al. 1981a) and in animal (Leach et al. 1970, 1973, 1984; Morrow et 
al. 1982a; Stokinger et al. 1953) studies.  Increases in the urinary excretion of several biomarkers, 
including β2 microglobulin, protein HC, and retinol binding protein, have been observed in populations 
consuming elevated levels of uranium in drinking water (Kurttio et al. 2002; Limson Zamora et al. 1998, 
2009; Mao et al. 1995; Seldén et al. 2009).  These biomarkers, although not specific to uranium, could be 
used to as sensitive biomarkers of renal dysfunction.  In rats receiving a single intramuscular dose of 
depleted uranium nitrate, there was a high correlation between urinary N-acetyl-β-D-glucosamindase 
(NAG)/creatinine levels, depleted uranium concentration in the kidney, and the depleted uranium dose 
(Fukuda et al. 2006).  The investigators suggested that urinary NAG/creatinine levels are a useful 
biomarker to assess kidney damage and estimate depleted uranium intake.   
 
Toxicogenomic studies have sought to identify biomarkers that can be used to evaluate uranium-related 
kidney damage by examining alterations in gene or protein expression patterns in uranium-exposed renal 
cells and alterations in levels of urinary proteins (Malard et al. 2009; Prat et al. 2005, 2011).  Prat et al. 
(2005) identified a “transcriptomic fingerprint” of 18 genes that form the core mRNA response to 
uranium in renal cells.  Additionally, they identified a set of five modulated genes/proteins that could 
potentially be used as biomarkers of effects:  actin-β, tubulin-α, high mobility group protein 1 (HMGB1), 
protein 14-3-3, and heat shock protein (hsp) 90.  A subsequent in vitro study by this group (Prat et al. 
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2011) found repression of the SPP1 gene coding for osteopontin in human kidney HK2 cells; osteopontin 
levels were inversely related to the uranium level.  Urinary osteopontin levels were also decreased in 
uranium workers with urinary uranium levels >30 µg/L or individuals with chronic exposure to uranium 
in drinking water (Prat et al. 2011).  The investigators cautioned that it is not known if the decreased 
osteopontin levels are specific to uranium toxicity and noted that interindividual variability in urinary 
osteopontin levels is quite high.  In a study of rats injected with uranyl nitrate (Malard et al. 2009), 
14 proteins were shown to be modulated by uranium exposure.  A number of the proteins have been 
shown to be altered in response to kidney damage.  These protein alterations included increases in the 
urinary levels of albumin, α-1-antiproteinases, transthyretin, ceruloplasmin, and transferrin and decreases 
in urinary epidermal growth factor, contraspsin-like protease inhibitor 3, and pancreatic α-amylase. 
 
Very high doses of uranium may interfere with liver function in humans (Pavlakis et al. 1996), but renal 
effects are far more sensitive.  No specific biomarker is currently available for the liver as a target of 
uranium toxicity.  Because uranium has no appreciable effect on the nervous system, no biomarkers of 
effect are needed for this end point.  For more information on biomarkers for renal effects of chemicals, 
see ATSDR/CDC Subcommittee Report on Biological Indicators of Organ Damage (Agency for Toxic 
Substances and Disease Registry 1990).  Simultaneous analysis of multiple parameters, such as urinary 
glucose, alkaline phosphatase, and β2-microglobulin, which may be more specific to proximal tubular 
damage (Limson Zamora et al. 1998), should be considered for evaluating subjects in future studies. 
 
3.9   INTERACTIONS WITH OTHER CHEMICALS  
 
Co-administration of uranium (5 mg/kg uranyl acetate dehydrate administered via subcutaneous injection) 
and melatonin (10 or 20 mg/kg administered via intraperitoneal injection) resulted in a decrease in 
uranium-induced kidney damage (Bellés et al. 2007).  A significant reduction in the uranium-induced 
increase in urine volume and a reduction in the severity of renal tubular necrosis were observed.  No 
information was located regarding the modulation of the toxicity of uranium by other chemicals or vice 
versa.   
 
3.10   POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE  
 
A susceptible population will exhibit a different or enhanced response to uranium than will most persons 
exposed to the same level of uranium in the environment.  Reasons may include genetic makeup, age, 
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These 
parameters result in reduced detoxification or excretion of uranium, or compromised function of organs 
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affected by uranium.  Populations who are at greater risk due to their unusually high exposure to uranium 
are discussed in Section 6.7, Populations with Potentially High Exposures. 
 
Populations susceptible to uranium toxicosis would include people with impaired renal function or renal 
disease.  People with stomach ulcers are thought to have elevated absorption of some toxic metals and 
might be unusually susceptible to uranium toxicity.  The potential for children=s susceptibility is discussed 
in Section 3.6. 
 
3.11   METHODS FOR REDUCING TOXIC EFFECTS  
 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to uranium.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to uranium.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice.  The following texts provide specific information about treatment following exposures 
to uranium: 
 
Began D.  2002.  Dermatologic principles.  In:  Goldfrank LR, Flomenbaum NE, Lewin NA, et al., eds.  
Goldfrank’s toxicologic emergencies.  7th ed.  New York, NY:  McGraw-Hill, 432-440. 
 
Goans RE.  2007.  Medical management of radiation incidents.  In:  Shannon MW, Borron SW, Burns 
MJ, eds.  Haddad and Winchester's clinical management of poisoning and drug overdose.  4th ed.  
Philadelphia, PA:  Saunders, 1467-1485. 
 
NCRP.  2010.  Management of persons contaminated with radionuclides:  Handbook.  NCRP Report No. 
161.  National Council on Radiation Protection and Measurements, 128-137, 176-236.  
http://www.ncrponline.org/Publications/161press.html.  February 11, 2010. 
 
3.11.1   Reducing Peak Absorption Following Exposure  
 
No specific recommendations have been reported for reducing the peak absorption following acute 
inhalation or oral exposure to uranium.  The only specific recommendation reported regarding reducing 
absorption of uranium following exposure is to not wash the skin with water following dermal exposure 
to dusts of pure uranium because it will ignite or explode when contacted by water (Began 2002).  Thus, 
it is recommended that any residual metal should be removed with forceps, gauze, or towels and stored in 
mineral oil. 
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Houpert et al. (2001, 2004) investigated the use of chelating agents to decrease the transfer of uranium 
from a wound to blood.  Wound contamination with uranium was simulated by an intramuscular injection 
of 0.66 µg U as uranyl nitrate or 63 µg U as industrial-grade uranium peroxide in the hind leg of rats 
(Houpert et al. 2001).  Following exposure to uranium, the rats received an intramuscular or 
intraperitoneal injection or carballylic amido bis phosphonic acid (CAPBP).  A significant increase in the 
amount of uranium retained at the wound site was found following the intramuscular injection of CAPBP; 
significant reductions in uranium levels in the kidneys, femur, carcass, and urine were also observed.  
Intraperitoneal administration of CAPBP did not significantly reduce uranium absorption or alter uranium 
tissue levels.  In the second study (Houpert et al. 2004), the hind leg skin was incised and industrial-grade 
uranium peroxide was deposited in the underlying muscle; the wound was then covered for 1 hour with a 
dressing or paste composed of carboxymethylcellulose-based hydrocolloids, which are highly absorbant; 
in two groups, the paste was mixed with CAPBP or ethane-1-hydroxy-1,1-bisphosphonate.  Although the 
dressing and paste were effective in decreasing the amount uranium at the wound site and uranium levels 
in the kidneys, adding the chelating agent to the paste did not alter its efficiency. 
 
3.11.2   Reducing Body Burden  
 
Administration of bicarbonate is applicable to reducing uranium body burdens from acute exposures.  
Bicarbonate ions complex with uranium and alkalize the blood, both of which enhance the excretion from 
the kidneys by glomerular filtration (Cooper et al. 1982) and such an application was described in a case 
of prophylactic treatment (Fisher et al. 1991).  Experimental evidence in animals indicates that chelation 
therapy may reduce the body burden of uranium.  Several compounds were found to enhance the urinary 
and fecal excretion of uranium, if administered soon after uranium exposure.  When given immediately 
after exposure to uranium, Tiron® (sodium 4,5-dihydroxybenzene-1,3-disulphonate) resulted in the 
greatest reduction in renal and bone levels of uranium and acute lethal effects in animals (Domingo et al. 
1992; Ortega et al. 1989a).  None of the chelating agents affected bone levels of uranium when given 
≥24 hours after exposure to uranium (Domingo et al. 1992).  Bicarbonate treatment is also limited to very 
near-term exposures.  Another study that tested Tiron® alone and in conjunction with either DTPA or 
ethylenediamine-N,N=-bis(2-hydroxyphenylacetic acid) (EDHPA) found that it reduced the uranium body 
burden no more than about 35%, indicating that the administration of Tiron® is of limited practical value 
for the treatment of uranium exposures that do not greatly exceed the permitted intake level (Stradling et 
al. 1991). 
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Other studies have reported the efficiency of other chelating agents on reducing toxicity or tissue levels of 
uranium.  Administration of catechol-3,6-bis-(methyleiminodiacetic acid) (CBMIDA) or ethane-
1-hydroxy-1,1-bisphosphonate (EHBP) for 28 days after an intramuscular injection of 2 mg U/kg resulted 
in a reduction in mortality and decreases in uranium levels in the kidney, bone, and liver (Fukuda et al. 
2005).  Fukuda et al. (2009) also demonstrated that oral or intraperitoneal administration of CBMIDA for 
6 days significantly increased excretion of uranium and decreased tissue uranium levels in rats 
administered 8 mg/kg depleted uranium via intraperitoneal or intramuscular injection. 
 
Administration of bicarbonate for 3 days following an intramuscular injection of 4 mg/kg depleted 
uranium did not result in a significant reduction in uranium tissue levels or improvement in renal function 
in rats (Fukuda et al. 2008).  However, co-administration of bicarbonate with the chelating agent, 
deferiprone, resulted in decreased uranium tissue levels and increased urinary uranium excretion 
compared to groups of depleted uranium exposed rats administered bicarbonate only or deferiprone only.  
Co-administration of bicarbonate and 4,6-dimethyl-1-hydroxyprimidin-2(1H)-one resulted in an increase 
in uranium excretion but did not affect tissue levels or organ function.  Bicarbonate did not increase the 
efficiency of CBMIDA and was found to decrease the efficiency of EHBP. 
 
Administration of a 500 mg/kg oral dose or 50 mg/kg subcutaneous dose of bisodic etidronate 
immediately following administration of a 170 mg U/kg dose of uranyl nitrate hexahydrate resulted in a 
50% reduction in mortality and an improvement in the uranium-induced reduction in growth cartilage 
width, metaphyseal bone volume, and metaphyseal bone activity in male Balb/c mice (Bozal et al. 2005).  
Similarly, oral or subcutaneous administration of EHBP (Martinez et al. 2000, 2003) or bisodic etidronate 
(Martinez et al. 2003) immediately following administration of a single 170 mg U/kg as uranyl nitrate 
oral dose resulted in a decrease in mortality and a lessening of the severity of kidney lesions. 
 
3.11.3   Interfering with the Mechanism of Action for Toxic Effects  
 
No studies that examined methods for interfering with the mechanisms of action were identified. 
 
3.12   ADEQUACY OF THE DATABASE  
 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of uranium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
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initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of uranium. 
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
 
3.12.1   Existing Information on Health Effects of Uranium 
 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
uranium are summarized in Figure 3-11.  The purpose of this figure is to illustrate the existing 
information concerning the health effects of uranium.  Each dot in the figure indicates that one or more 
studies provide information associated with that particular effect.  The dot does not necessarily imply 
anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. 
 
Figure 3-11 depicts the existing health effects information on uranium for a specific route and duration of 
exposure.  There are limited data on uranium toxicity in humans following inhalation or oral exposure; no 
dermal exposure studies were identified.  Several available studies that investigated the health effects in 
humans of inhalation exposure to uranium are limited to occupational settings (miners, millers, 
processors).  The subjects of some of these studies were also concurrently exposed to other potentially 
toxic substances, rendering it difficult to establish the etiology for the effects reported in these studies; 
however, studies of processors who were not concurrently exposed to those toxicants are useful in this 
regard.  Although three human studies presented limited evidence of reproductive effects (damage to sex 
chromosomes) in uranium mine workers, no empirical evidence was presented for evaluation.  Oral 
studies are limited to several ecological studies of communities exposed to elevated uranium in drinking 
water.  Although the studies did find significant associations, particularly for biomarkers of renal  
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dysfunction, the studies do not provide reliable dose-response data.  Information on the systemic effects 
of uranium through the inhalation, oral, and dermal routes of exposure are available in a number of 
animal species.  Several studies have examined the neurological, reproductive, and developmental 
toxicity of uranium following oral exposure.  Reproductive and developmental end points have not been 
examined following inhalation or dermal exposure.  Non-specific neurological symptoms have been 
reported in animals exposed via the inhalation or dermal routes to lethal concentrations of uranium.  The 
carcinogenicity of uranium has been investigated in inhalation studies, but not in oral or dermal studies. 
  
3.12.2   Identification of Data Needs  
 
Acute-Duration Exposure.    Human fatalities from acute accidental exposure to airborne uranium 
hexafluoride have been reported, although the deaths were attributed to the sheer force of the explosions 
in the accident and the highly toxic hydrofluoric acid generated from the spontaneous decomposition of 
uranium hexafluoride upon contact with atmospheric moisture (Kathren and Moore 1986; Moore and 
Kathren 1985; USNRC 1986).  Two poisoning incidents, an inhalation exposure to powdered uranium 
tetrafluoride (Lu and Zhao 1990) and an intentional ingestion of approximately 131 mg U/kg as uranyl 
acetate (Pavlakis et al. 1996), resulted in renal toxicity.  Acute-duration studies in animals mainly 
examined lethality.  Inhalation acute-duration lethality studies in rats and guinea pigs are available for 
uranium hexafluoride for short durations (<2 hours) (Leach et al. 1984; Spiegl 1949); oral acute-duration 
lethality data are available for rats and rabbits (Domingo et al. 1987; Maynard and Hodge 1949; Orcutt 
1949); and dermal acute-duration lethality studies in rats, mice, guinea pigs, and rabbits (De Rey et al. 
1983; Orcutt 1949) are available.  Additionally, there are acute oral studies examining systemic toxicity 
(Ozmen and Yurekli 1998), neurological effects (Briner 2009; Briner and Murray 2005), and 
developmental toxicity (Domingo et al. 1989c; Pujadas Bigi et al. 2003).  The inhalation studies were 
inadequate for derivation of an MRL because the exposure durations were very short.  An acute oral MRL 
was derived based on a developmental toxicity study (Domingo et al. 1989c).  Acute-duration studies that 
define threshold values for renal toxicity by the inhalation and oral routes would be useful for assessment 
of brief exposures.  Dermal exposure to uranium-contaminated soil is also possible.  While dermal 
exposure to purified uranium compounds can cause toxicity in animals (De Rey et al. 1983; Orcutt 1949), 
the need for further dermal studies should be assessed after information is obtained on the bioavailability 
of uranium from uranium-contaminated soil. 
 
Intermediate-Duration Exposure.    No studies are available describing the effects of intermediate-
duration exposure to uranium in humans for any route.  However, an extensive animal database for this 
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duration for all routes demonstrates that renal toxicity is a concern for intermediate-duration human 
exposure.  A number of animal studies have evaluated the toxicity of various uranium compounds in a 
number of animal species (Dygert 1949a, 1949b, 1949d; Roberts 1949; Rothstein 1949a, 1949b, 1949c; 
Spiegl 1949; Stokinger et al. 1953).  Threshold values from these studies were used to derive inhalation 
MRLs for insoluble and soluble uranium compounds (see Chapter 2 and Appendix A); however, 
additional inhalation studies are needed to better define concentration-response relationships.  The animal 
database for intermediate-duration oral exposure is less extensive in terms of species and compounds 
examined.  Comprehensive studies are available for the effects of uranyl nitrate in rats and rabbits 
(Gilman et al. 1998a, 1998b, 1998c).  The severity of histopathological alterations in the kidney increased 
with dose, although tests of kidney function (dye clearance, urinalysis) were normal in all dosed groups.  
Additionally, histopathological effects were seen in the lower dose groups without a significant increase 
in kidney uranium content over controls.  Inconsistent results were found in the rabbit studies (Gilman et 
al. 1998b, 1998c), which the investigators attributed to a possible subclinical infection.  No threshold for 
the histopathological effects was observed; the lowest dose tested in the rats was considered a minimal 
effect and was used to derive an oral MRL for this duration (see Chapter 2 and Appendix A).  Further 
studies are needed to elucidate the time-course of the development of these histopathological effects; in 
rats, these changes were seen after 91 days, but not at 28 days, and to validate the results of the rabbit 
studies.  No reliable studies examining the oral toxicity of insoluble uranium compounds were identified; 
studies providing dose-response data would be useful for establishing an MRL for insoluble compounds.  
Dermal exposure to uranium-contaminated soil is also possible.  While dermal exposure to purified 
uranium compounds can cause toxicity in animals (De Rey et al. 1983; Lopez et al. 2000; Orcutt 1949), 
the need for further dermal studies should be assessed after information is obtained on the bioavailability 
of uranium from uranium-contaminated soil. 
 
Chronic-Duration Exposure and Cancer.    A small number of occupational exposure studies have 
examined renal toxicity.  No evidence of renal toxicity was reported in workers exposed to relatively low 
concentrations of insoluble uranium compounds (Eisenbud and Quigley 1956).  However, significant 
increases in urinary biomarkers of renal dysfunction were observed in workers exposed to ammonium 
diuranate (Thun et al. 1985).  Future studies of uranium workers should include exposure assessments and 
measurement of sensitive biomarkers of renal damage.  The available studies have linked respiratory 
diseases, fatal in some cases, in uranium miners to exposure to dust-containing uranium (and other 
noxious substances) (Waxweiler et al. 1981a).  In several of these studies, the investigators concluded 
that, although uranium mining may elevate the risk for nonmalignant respiratory disease, the etiology of 
the excess risk is not clearly identifiable because the miners were also concurrently exposed to known 
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potent respiratory tract irritants such as diverse inhalable dust particles, silica, nickel oxide, cobalt oxide, 
and vanadium pentaoxide (Waxweiler et al. 1983).  Studies of underground uranium miners have not yet 
accounted for confounding by diesel engine exhaust or crystalline silica dust, especially freshly cracked 
silica dust, which was in high concentrations in mine air; and have been identified as carcinogens.  A 
small number of studies have examined the chronic toxicity of inhaled uranium in animals.  Studies 
involving exposure to soluble uranium compounds have identified the kidney as the most sensitive target 
(Stokinger et al. 1953) and were used to derive a chronic-duration MRL for soluble compounds.  Data for 
insoluble compounds suggest that at low concentration and long exposure duration (≥3.5 years), the lung 
may be a more sensitive target than the kidney (Leach et al. 1970).  However, the lung effects may be due 
to radiotoxicity rather than chemical toxicity.  Additional mechanistic studies are needed to identify the 
causative agent.  The data were considered adequate for derivation of an MRL for insoluble uranium 
compounds; however, additional studies are needed to better define the concentration-response 
relationship for pulmonary and renal effects.  Several ecological studies have examined the possible 
association between elevated levels of uranium in drinking water and impaired kidney function (Kurttio et 
al. 2002, 2006a; Limson Zamora et al. 1998, 2009; Mao et al. 1995; Seldén et al. 2009).  Several studies 
have sound significant association.  A common limitation of the studies is a lack of accurate dose-
response data.  A series of studies in rats and dogs have examined the chronic toxicity of a variety of 
uranium compounds (Maynard and Hodge 1949; Maynard et al. 1953).  The dog studies were not 
considered suitable for MRL derivation because only two dogs were exposed to each dose level.  
Although the rat studies tested an adequate number of animals and included histopathological 
examination of major tissues and organs, including the kidneys, a chronic-duration oral MRL could not be 
derived for uranium.  Oral exposure studies examining a variety of end points, including sensitive end 
points of renal toxicity, are needed for soluble and insoluble uranium compounds.  No chronic-duration 
dermal toxicity studies were identified in humans or animals. 
 
A number of epidemiological studies are available for workers exposed to uranium (miners, millers, 
processors).  A number of studies reported death from lung cancers from occupational inhalation 
exposure of mine workers (Archer et al. 1973a; Gottlieb and Husen 1982; Lundin et al. 1969; Samet et al. 
1984a, 1986); however, the available studies document no lung cancers solely from inhaled uranium-
bearing dust.  It is generally accepted that lung cancers developed subsequent to inhalation of uranium-
containing dusts were principally due to radon daughters and long-term cigarette smoking, and not to 
uranium metallotoxicity or uranium radioactive emissions.  Existing epidemiologic studies that reported 
lung cancers in uranium miners, millers, and processors are inadequate for use in assessing the 
carcinogenic potential of uranium because the subjects were also concurrently exposed to other potential 
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carcinogens such as radon progeny and thorium (Archer et al. 1973a; Auerbach et al. 1978; Cookfair et al. 
1983; Howe et al. 1986; Polednak et al. 1982; Saccomanno et al. 1971, 1976, 1988; Samet et al. 1986; 
Wrenn et al. 1983).  There are limited animal data on the carcinogenicity of uranium following inhalation 
exposure and no oral or dermal exposure studies.  Pulmonary neoplasms were observed in dogs (Leach et 
al. 1973) and rats (Mitchel et al. 1999). 
 
Genotoxicity.    Limited data exist regarding in vivo genotoxicity in humans following exposure to 
uranium.  The only cases in which there were documented exposures to uranium are those of the Gulf 
War veterans who retained depleted uranium embedded fragments (McDiarmid et al. 2000, 2001a, 2004b, 
2007, 2009).  Prospective tests for clastogenicity and mutations in blood cells from this group yielded 
inconsistent results that led the investigators to conclude that the body of evidence in that cohort showed 
relatively weak genotoxic effects from uranium exposure.  Future assessments are unlikely to provide key 
new information.  Other assessments of small cohorts presumed to have been exposed to depleted 
uranium provided positive evidence of clastogenicity (Krunić et al. 2005; Milačić 2008; Milačić and 
Simić 2009; Milačić et al. 2004; Schröder et al. 2003).  Studies of populations in areas with high levels of 
uranium in drinking water or soil would be valuable.  In vivo studies in animals provided positive 
evidence of genotoxicity after inhalation and oral exposure to depleted uranium (Hao et al. 2009; Miller et 
al. 2010; Monleau et al. 2006a).  Miller et al. (2010) also showed that implantation of depleted uranium 
pellets in male mice for 7 months followed by mating with untreated females resulted in transmission of 
genetic damage to somatic cells of offspring; the exact mechanism by which this occurred is not known, 
so further studies in this area are warranted.  In addition, similar studies in mice exposed to uranium by 
routes relevant to general population exposure (contaminated drinking water or food) would be valuable.  
Studies of genotoxicity in vitro, both with mammalian cells (LaCerte et al. 2010; Lin et al. 1993; Miller et 
al. 2002a, 2002b, 2003; Stearns et al. 2005; Thiébault et al. 2007; Wise et al. 2007) and prokaryotic 
organisms (Miller et al. 1998a; Yazzie et al. 2003) have yielded positive results.  Studies with HOS cells 
showed that depleted uranium induced de novo genomic instability in the cells, which led to delayed 
reproductive death for many generations (Miller et al. 2003).  Further studies aimed at elucidating the 
mechanism by which this can occur are needed.  Some studies showed differences in genotoxic capacity 
between water-soluble and -insoluble uranium compounds (LaCerte et al. 2010; Wise et al. 2007).  The 
investigators speculated that the difference may be related to differences in kinetics between the two types 
of uranium compounds; research in this area would be helpful.  A study in CHO cells showed that 
uranium can form adducts with DNA (Stearns et al. 2005).  Further research in this area can provide 
information regarding possible sensitive biomarkers for uranium exposure.  There is an apparent 
knowledge gap between the positive findings of genotoxicity in in vitro and in vivo studies and the 
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predominantly negative findings of carcinogenicity studies.  Additional studies are needed to address this 
data deficiency. 
 
Reproductive Toxicity.    Existing human data from male uranium miners, millers, and processors 
(Muller et al. 1967; Waxweiler et al. 1981b; Wiese and Skipper 1986) and from men exposed to depleted 
uranium in the Gulf War via retained metal embedded fragments (McDiarmid et al. 2000, 2001a, 2004b, 
2007, 2009) have not suggested adverse uranium-induced reproductive effects.  The Gulf War veterans 
were subjected to longitudinal analyses of sex hormone levels in blood and sperm parameters; however, 
no assessments of fertility have been conducted.  It would be helpful to have that information, if available.  
Exposure to uranium reduced fertility in male mice (Llobet et al. 1991) and male rats (Linares et al. 2005) 
exposed via the drinking water.  In the former study, reduced fertility was associated with reduced 
spermatozoa counts; in the latter, there were morphological alterations in Sertoli or germinal cells.  
Fertility was not affected in mice dosed with uranium by gavage (Paternain et al. 1989) or in a 
2-generation reproductive toxicity study in rats implanted depleted uranium pellets (Arfsten et al. 2009).  
Differences in exposure routes may have played a role in the difference results obtained.  Clearly, 
drinking water studies are more relevant to potential exposures of the general population than exposures 
by gavage or through an embedded uranium pellet.  Of the four studies mentioned above (Arfsten et al. 
2009; Linares et al. 2005; Llobet et al. 1991; Paternain et al. 1989), urinary uranium, as a biomarker of 
exposure, was only monitored by Arfsten et al. (2009).  Studies are also available that reported that 
exposure to uranium altered ovarian folliculogenesis in mice (Arnault et al. 2008; Feugier et al. 2008; 
Kundt et al. 2009; Raymond-Whish et al. 2007).  The study conducted by Raymond-Whish et al. (2007) 
reported slight alterations in ovarian folliculogenesis in mice administered doses as low as 0.39 µg 
U/kg/day.  These authors also reported estrogenic effects in mice treated with 5 µg U/kg/day.  Since these 
doses are orders of magnitude lower than those used in other studies, it would be reassuring if the findings 
of Raymond-Whish et al. (2007) can be replicated by other laboratories.  A study in rats reported that 
enriched uranium, but not depleted uranium, increased serum testosterone and the expression of genes 
involved in steroidogenesis (Grignard et al. 2008).  In addition, enriched uranium significantly increased 
the expression of transcription factors involved in the regulation of steroidogenic genes.  This is the only 
study available that compared the effects of enriched versus depleted uranium on some reproductive end 
points.  Additional studies comparing the effects of depleted and enriched uranium on other reproductive 
end points (i.e., fertility, sperm parameters, microscopic morphology of reproductive organs, 
estrogenicity, levels of sex hormones) would be valuable to distinguish between chemical and 
radiological activity. 
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Developmental Toxicity.    There are no studies of developmental effects in humans with documented 
exposure to uranium.  Several reports have been published regarding increased incidence of teratogenicity 
in populations presumed to have been exposed to depleted uranium; this subject was reviewed by Hindin 
et al. (2005).  It should be noted that all of the reports lack documentation of individual exposure to 
depleted uranium, some reports lacked methodologically rigorous investigation (like exposure to other 
chemicals and other confounders), and in the incidences of birth defects between supposedly exposed and 
nonexposed groups was not statistically significant in other reports.  Yet, Hindin et al. (2005) concluded 
that the evidence linking exposure to depleted uranium and birth defects, albeit imperfect, indicates a high 
probability of substantial risk.  Studies could be conducted of offspring of women living in areas with 
documented high uranium in the drinking water or the soil to evaluate possible associations between 
uranium and birth defects in humans. 
 
Maternal exposure to uranium during pregnancy has induced fetotoxicity, teratogenicity, and reduced 
neonatal viability in mice (Domingo et al. 1989b, 1989c; Paternain et al. 1989).  An issue that is not 
totally clear is whether this occurs at doses not causing maternal toxicity.  An additional issue that has not 
been explored is evaluation of the contribution of gestational exposure versus lactational exposure to the 
uranium-induced decreased neonatal viability.  Valuable information could be collected to address this 
question by conducting cross-fostering studies.  Gestational exposure to uranium did not affect 
developmental landmarks in mice (Domingo et al. 1989b) or rats (Sánchez et al. 2006).  However, in rats, 
perinatal exposure altered the results of some neurobehavioral tests conducted in the offspring (Houpert et 
al. 2007a; Sánchez et al. 2006).  Histological examination of different brain areas of the offspring as well 
as measurements of neurotransmitters could provide information regarding possible mechanisms involved 
in the neurobehavioral effects of perinatal exposure to uranium.  In contrast with the findings of Houpert 
et al. (2007a) and Sánchez et al. (2006), a study in rats implanted depleted uranium pellets for 120 days 
before mating reported no significant alterations in neurobehavioral tests conducted on the offspring on 
postnatal days 4–63 (Arfsten et al. 2009).  This 2-generation reproductive study also did not report 
significant alterations in viability of the F1 generation or in histology of selected organs or sperm 
parameters on postnatal day 120.  Different results between studies are not totally unexpected since 
exposure protocols were different.  Sánchez et al. (2006) exposed only females via drinking water for 
4 weeks, Houpert et al. (2007a) exposed males and females via drinking water for 3 months, and Arfsten 
et al. (2009) implanted uranium pellets in both males and females.  Information regarding uranium body 
burdens in the parental generation, such as urinary uranium levels, would be helpful for comparing 
studies with differing exposure protocols.  Studies also showed that in mice, gestational exposure to 
uranium can alter ovarian folliculogenesis in the female offspring (Arnault et al. 2008; Raymond-Whish 
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et al. 2007).  In one of these studies (Raymond-Whish et al. 2007), effects occurred at doses much lower 
than those tested in any other animal study.  It would be useful to try to replicate these findings.  Neonatal 
exposure of rats to uranium interfered with tooth eruption and development (Pujadas Bigi and Ubios 
2007; Pujadas Bigi et al. 2003), but only one dose level was tested so that a NOAEL was not defined.  
Studies designed to define a NOAEL and to allow construction of a dose-response curve would be 
helpful.  Recently, it was shown that paternal exposure to uranium via implantation of depleted uranium 
pellets resulted in transmission of genetic damage to somatic cells of unexposed offspring (Miller et al. 
2010).  The investigators noted that studies investigating the effects of depleted uranium exposure on 
germ cell mutagenesis and direct DNA damage to sperm are being completed.  It would be valuable if 
similar studies are conducted with male mice exposed by a route more relevant to exposures of the 
general population such as via contaminated drinking water or food. 
 
Immunotoxicity.    There are limited data on the immunotoxic potential of uranium.  Epidemiology 
studies that examined white blood cell levels or mortality from immune disease have not reported adverse 
effects following inhalation, oral, or dermal exposure (Archer et al. 1973b; Checkoway et al. 1988; Cragle 
et al. 1988; Keane and Polednak 1983; NIOSH 1987; Polednak and Frome 1981; Vich and Kriklava 
1970).  The available inhalation studies in animals also found no evidence of histological changes in the 
spleens of rats, dogs, and monkeys exposed to uranium dioxide dusts (Leach et al. 1970, 1973).  
Intermediate-duration exposure of rats, rabbits, guinea pigs, and dogs to dusts containing various uranium 
compounds for 7–12 months produced no significant histological changes in the lymph nodes, bone 
marrow, or spleen, and no build-up of uranium was seen in these tissues (Stokinger et al. 1953).  
Similarly, rats and mice exposed to oral doses of soluble or insoluble compounds of uranium for 
intermediate- and chronic-duration exposures suffered no immunological damage (Malenchenko et al. 
1978; Maynard et al. 1953; Tannenbaum et al. 1951).  No studies are available that evaluated the 
immunological and lymphoreticular effects in animals following acute- or intermediate-duration 
inhalation exposure, the oral exposure of humans for any duration, the inhalation or oral exposure of 
animals for acute durations, or the dermal exposure of humans and animals to uranium compounds for 
any duration.  Additional animal studies would be useful that use current techniques to evaluate the 
immunological and lymphoreticular dysfunctions that may occur with exposure to uranium compounds. 
 
Neurotoxicity.    In general, studies of uranium workers have not provided evidence of adverse 
neurological effects, although tests to detect subtle neurological alterations were not conducted (Carpenter 
et al. 1988; Cragle et al. 1988; Hadjimichael et al. 1983; Kathren and Moore 1986; NIOSH 1987; 
Polednak and Frome 1981; Reyes et al. 1984; USNRC 1986).  Workers were presumed to have been 
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exposed mainly by the inhalation and dermal routes.  Longitudinal assessments of Gulf War veterans who 
retained depleted uranium fragments and were excreting elevated urinary levels of uranium years after the 
first exposure provided inconsistent results in neurobehavioral tests (McDiarmid et al. 2000, 2001a, 
2004b, 2007, 2009).  Surveillance of this group of subjects should continue to try to identify potentially 
late-appearing effects or normal aging signs that might manifest prematurely.  No information was 
located regarding neurological effects in humans exposed orally to uranium.  Early inhalation studies in 
animals exposed to dusts of fluoride salts of uranium reported frank neurological effects, but did not 
consider the possible contribution of fluoride (Dygert 1949a; Rothstein 1949a).  More recent oral studies 
in animals have reported changes in biochemical parameters, including levels of neurotransmitters and 
their metabolites, in various areas of the brain following acute- and intermediate-duration exposure to 
uranium (Briner 2009; Briner and Murray 2005; Bussy et al. 2006).  Studies also have examined 
neurobehavioral parameters following exposure to uranium; some reported neurobehavioral alterations 
(Briner 2009; Briner and Murray 2005; Houpert et al. 2005, 2007b), while others did not (Arfsten et al. 
2007; Belles et al. 2005).  Studies are needed that conduct morphological, electrophysiological, and 
biochemical evaluations in the same animals following exposure to uranium to shed light into possible 
mechanism(s) of action for uranium-induced neurological effects.  No studies were located that examined 
neurological parameters in animals following chronic-duration exposure to uranium.  Such studies would 
provide information regarding long-term, low-level exposure as could occur to populations exposed to 
excessive uranium in the drinking water or through consumption of food grown in areas with elevated 
concentrations of uranium in the soil. 
 
Epidemiologic and Human Dosimetry Studies.    Epidemiologic studies of uranium miners, 
millers, and processors are available on the health effects from exposure to airborne uranium and radon 
daughters (Archer et al. 1973a, 1973b; Checkoway et al. 1988; Cragle et al. 1988; Gottlieb and Husen 
1982; Hadjimichael et al. 1983; Lundin et al. 1969; NIOSH 1987; Polednak and Frome 1981; Samet et al. 
1984a, 1986; Scott et al. 1972; Waxweiler et al. 1983).  However, some of the studies of miners and 
millers contain confounding factors and lack adequate quantitative exposure information compared with 
the studies of processors, which had fewer confounders and clearly identified an absence of toxic effects 
such as cancer.  New studies that account for these confounding factors, such as effects of inhalable dust 
particles other than uranium, other sources of ionizing radiation, and other potentially pulmonary-toxic 
substances to which these workers are concurrently exposed, and that provide a more accurate 
measurement of the airborne concentrations of uranium to which these workers are exposed would be 
useful.  Animal studies provide strong evidence that the kidney is the most sensitive target of uranium 
toxicity.  Alterations in sensitive biomarkers of renal dysfunction have been observed in workers exposed 
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to airborne soluble uranium compounds (Thun et al. 1985) and in residents consuming drinking water 
with elevated uranium levels (Limson Zamora et al. 1998, 2009; Mao et al. 1995).  However, 
occupational exposure studies of workers exposed to insoluble uranium (as reviewed by Eisenbud and 
Quigley 1956) and ecological drinking water studies (Kurttio et al. 2006a; Seldén et al. 2009) have not 
found significant kidney effects.  Most of these studies provide limited dose-response data, and studies 
examining sensitive end points of renal toxicity, as well as other potential targets of toxicity, are needed 
to assess the relative sensitivity of humans to uranium toxicity as compared to animal species, which are 
used to derive MRLs for uranium.  Also, simple and accurate monitoring methods should be developed 
for workers that would determine the relationship among atmospheric concentration, particle size, 
distribution, physical properties of the uranium aerosol, body burden, and excretion rates and pathways.  
The use of depleted uranium munitions by the military has resulted in the potential uranium exposure to 
military personnel and civilians; additional research regarding the health effects of acute-duration 
inhalation exposure to depleted uranium would be useful to assess the potential for toxicity.  These 
studies should include toxicological end points, lung doses, metabolic fate, and techniques to detect and 
monitor lung exposures. 
 
Biomarkers of Exposure and Effect.     
 
Exposure.  Because uranium is primarily excreted in the urine following inhalation, oral, or dermal 
exposure, measurement of urine uranium levels can accurately estimate uranium body burden (Ballou et 
al. 1986; Cooper et al. 1982; Downs et al. 1967; Leach et al. 1984; McDiarmid et al. 1999b; Morrow et al. 
1982a; Stradling et al. 1984, 1987; West and Scott 1969; Wrenn et al. 1985).  Several methods have been 
developed for chemical detection (e.g., fluorimetry and kinetic phosphorescence analysis) and 
radiological detection (e.g., inductively coupled plasma mass spectrometry [ICP-MS] and alpha 
spectroscopy).  Although correlations between uranium intake and urinary levels have been reported, 
additional studies are needed that would allow for the development of a biokinetic model, which would 
allow estimation of uranium intake based on urinary uranium levels. 
 
Uranium content in soft tissue and bone could also be used as biomarkers of exposure to uranium (Ballou 
et al. 1986; Diamond et al. 1989; Leach et al. 1973, 1984; Morris et al. 1990; Morrow et al. 1972; 
Stokinger et al. 1953; Walinder 1989; Wrenn et al. 1987).  Although soft tissues and bone are the most 
frequently analyzed biological media after urine and feces, these tissues are usually available for analysis 
only at autopsy.  Therefore, this method is impractical and not used for routine screening purposes. 
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Effect.  Currently, there are no available biomarkers for specific exposure to the metallotoxic or 
radiotoxic effects of uranium.  Although the kidney is the most sensitive target of uranium toxicity, 
biomarkers of renal dysfunction such as β2 microglobulin, protein HC, and retinol binding protein are not 
specific to uranium.  Additional studies are needed to correlated these alterations with renal damage and 
establish dose-response relationships. 
 
Absorption, Distribution, Metabolism, and Excretion.    Information is needed on the 
comparative absorption of uranium compounds by the oral route, along with an assessment of its 
clearance from the skeleton.  Quantitative data on the bioavailability of uranium from contaminated soil 
by the oral and dermal routes are also necessary to assess the risk of uranium-contaminated soil at 
hazardous waste sites. 
 
Comparative Toxicokinetics.    Numerous species (mice, rats, rabbits, guinea pigs, dogs, and 
monkeys) have been tested for their response to inhaled or ingested uranium.  The results from these 
studies clearly demonstrate that there is a considerable difference in toxic responses among species.  For 
example, rabbits appear to be unusually susceptible to the lethal effects of uranium (Maynard and Hodge 
1949; Orcutt 1949; Stokinger et al. 1953), whereas dogs developed glandular neoplasms of the lungs 
(Leach et al. 1973), a type of lung cancer that is not observed in humans, and guinea pigs required far 
greater air concentrations (15x) for 2-minute exposures than did rats to produce an effect (Leach et al. 
1984). 
 
Methods for Reducing Toxic Effects.    Most of the available research on methods for reducing the 
toxic effects of uranium have focused on the effectiveness of chelating agents on reducing the 
accumulation of uranium in the body (Bozal et al. 2005; Domingo et al. 1992; Fukuda et al. 2005, 2009; 
Martinez et al. 2000, 2003; Ortega et al. 1989a; Stradling et al. 1991).  Several agents including Tiron, 
CBMIDA, EHBP, and bisodic etidronate have significantly reduced tissue uranium levels, decreased 
renal toxicity, and increased survival when the chelating agent was administered shortly after exposure.  
The effectiveness of bicarbonate in facilitating the excretion of uranium has also been investigated 
(Cooper et al. 1982; Fisher et al. 1991; Fukuda et al. 2008).  However, few studies have investigated the 
effectiveness of these agents when they are administered after long-term uranium exposure and more 
studies are needed.  No studies investigating methods for reducing peak absorption following inhalation 
or oral exposure were identified.  Houpert et al. (2001, 2004) explored the use of dressings with or 
without chelating agents on decreasing the absorption of uranium from wounds.  No studies researching 
methods for interfering with the toxic mechanisms of action were identified.  Further research is needed 
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to validate, refute, or refine method(s) for reducing the body burden, particularly following long-term 
exposure, and research is needed on methods for decreasing absorption and interfering with the 
mechanism of toxicity. 
 
Children’s Susceptibility.    Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above. 
 
Specific information is not available on whether children are more susceptible than adults to the effects of 
uranium.  No reports were located describing toxicity in children as the result of uranium exposure.  It is 
probable, however, that if exposure levels were high enough, signs of renal toxicity would be observed 
similar to that seen in adults exposed accidentally (Lu and Zhao 1990) or intentionally (Pavlakis et al. 
1996).  Because children undergo periods of rapid bone growth and remodeling and uranium is stored in 
bone, there is a need to examine the potential toxicity of uranium to bone.  However, few studies have 
examined this end point and additional studies are needed. 
 
A study by the oral route establishing a threshold for renal effects in weanling and adult rats of the same 
strain is needed to determine if susceptibility to uranium toxicity varies with age.  Histopathological 
studies and urinalysis should be performed, as well as measurement of uranium in excreta for both 
groups.  At termination in this study, uranium content should be measured in tissues, particularly bone 
and kidney.  This will provide information on whether retention of uranium in bone is age-dependent (as 
assumed by analogy with calcium in PBPK models) and on whether kidney burden associated with 
uranium toxicity is age-related. 
 
More information on the absorption of various forms of uranium in young animals would be useful.  Also, 
studies are needed on whether maternally stored bone uranium is mobilized to blood during pregnancy 
and lactation and whether this can increase exposure to the fetus and neonate. 
 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children. 
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3.12.3   Ongoing Studies  
 
Ongoing studies are examining possible kidney toxicity in residents living near uranium mining sites, 
genotoxicity of depleted uranium, and adverse health outcomes in Gulf War veterans exposed to depleted 
uranium. 
 
The Congressionally-mandated Navajo Uranium Assessment and Kidney Health Project is a joint 
Department of Energy (DOE), EPA, and ATSDR effort with three foci: (1) conducting medical 
monitoring; (2) completing safe water projects; and (3) studying the potential effects of heavy metals, 
including uranium, on pregnant women and their infants.  ATSDR, in collaboration with the Indian 
Health Service and the Navajo Nation hospital and clinic staff,  will conduct case control studies of health 
risks faced by individuals residing near mill sites or abandoned mine sites.  The study will include a birth 
cohort study to address the potential association between environmental exposure to a suite of heavy 
metals, including uranium, and both maternal health and reproductive birth outcomes.  The birth cohort 
study is being conducted by the University of New Mexico under a cooperative research agreement with 
ATSDR (EPA 2013a). 
 
The U.S. Department of Energy’s Lawrence Berkeley National Laboratory is currently developing a 
sequestering agent that could be administered following exposure to actinides, such as plutonium, 
americium, uranium, and neptunium, and result in increased excretion of the actinide contaminants. 
 










4.  CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION 
 
4.1   CHEMICAL IDENTITY  
 
Uranium is a naturally occurring element that makes up approximately 2–4 ppm of the earth=s crust.  It is 
more plentiful than silver and about as abundant as molybdenum or arsenic.  Uranium is an actinide 
element, and has the highest atomic mass of any naturally occurring element.  In its refined state, it is a 
heavy, silvery-white metal that is malleable, ductile, slightly paramagnetic, and very dense, second only 
to tungsten.  In nature, it is found in rocks and ores throughout the earth, with the greatest concentrations 
in the United States in the western states of Colorado, Arizona, Wyoming, Texas, Utah, and New Mexico 
(Lide 2008).  In its natural state, crustal uranium occurs as a component of several minerals, such as 
carnotite, uraninite, and pitchblend, but is not found in the metallic state.  The chemical information for 
uranium metal is listed in Table 4-1. 
 
4.2  PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES  
 
The physical properties of uranium and uranium compounds important in the nuclear fuel cycle and 
defense programs are listed in Table 4-2.  The percent occurrence and radioactive properties of naturally 
occurring isotopes of uranium are listed in Table 4-3.  The two decay series for the naturally occurring 
isotopes of uranium are shown in Table 4-4. 
 
Metallurgically, uranium metal may exist in three allotropic forms: orthorhombic, tetragonal, or body-
centered cubic (Lide 2008), and may be alloyed with other metals to alter its structural and physical 
properties to suit the application.  Like aluminum metal powder, uranium metal powder is autopyrophoric 
and can burn spontaneously at room temperature in the presence of air, oxygen, and water.  In the same 
manner, the surface of bulk metal, when first exposed to the atmosphere, rapidly oxidizes and produces a 
thin surface layer of UO2, which resists oxygen penetration and protects the inner metal from oxidation.  
At temperatures of 200–400°C, uranium powder may self-ignite in atmospheres of CO2 and N2.  In order 
to prevent autoignition, uranium machining chips can be stored in open containers and under machine oil 
or water to prevent hydrogen gas buildup.  Burning uranium may be placed under water until 
extinguished, which may be delayed by hydrolysis of the water, which provides some oxygen and 
hydrogen for continued burning.  Water spray, CO2, and halon are ineffective, and halon discharge can be 













Table 4-1.  Chemical Identity of Uranium Metal 
 
 Value Reference 
Chemical name Uranium  
Natural isotopes Uranium-238; uranium-235; uranium-234 HSDB 2011 
Synonyms Uranium; 238U; 238U element; uranium-238; uranium-234; 
uranium-235; uranium, elemental; uranium, metal, 
pyrophoric; uranium, radioactive; uranium, natural 
HSDB 2011 
 
Trade names No data  
Chemical formula U HSDB 2011 
Chemical structure Not applicable  
Identification numbers   
CAS registry 7440-61-1 HSDB 2011 
NIOSH RTECS NIOSH/YR3490000 NIOSH 2010a 
EPA hazardous waste No data HSDB 2011 
OHM/TADS 7217196 HSDB 1995 
DOT/UN/NA/IMO shipping UN2979; uranium metal, pyrophoric  HSDB 2011 
HSDB 2553; 7404, uranium, radioactive HSDB 2011 
NCI No data HSDB 2011 
STCC 4926187; uranium metal, pyrophoric (uranium metal scrap, 
neither irradiated nor requiring protective shielding) 
HSDB 1995 
 
CAS = Chemical Abstracts Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 


























238.0289a 270.028 286.027 842.08 314.023 
Chemical formula U UO2 UO3 U3O8 UF4 









Common names  Brown oxide Orange oxide Yellow cake; 
Block oxide 
Green salta 
CAS Registry No. 7440-61-1a 1344-57-6 1344-58-7 1344-59-8 10049-14-6 
Color Silvery-white Brown Orange-yellow Olive green-black Green 
Physical state Solida Solid crystal Solid crystal Solid Solid crystal 
Odor No data No data No data No data No data 
Melting point, °C 1,135a 2,847 Decomposes Decomposes at 
1,300 
1,036 






Not relevant Not relevant Not relevant Not relevant 
Solubility: 
Water Insoluble Insoluble Insoluble Insoluble 0.01 g/100 g H2O 













acids and alkalis 
Density, g/cm3 18.06–19.1a 10.97 ~7.3 8.30 6.7 
Partition 
coefficients 
Not relevant Not relevant Not relevant Not relevant No data 
Vapor pressure 0 mmHg at 
20°C; 
1 mmHg at 
2,450°C a 
0.463 atm at 
2,847°C 
Not relevant Not relevant Not relevant 
Henry’s law 
constant 
Not relevant Not relevant Not relevant Not relevant Not relevant 
Refractive index No data No data No data No data No data 
Flashpoint No data No data No data No data No data 
Flammability limits Not relevanta No data No data No data No data 
Conversion factorb 1 μg=0.69 pCi 1 μg=0.61 pCi 1 μg=0.57 pCi 1 μg=0.59 pCi 1 μg=0.45 pCi 
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352.019 379.841 308.0245 424.146 502.129 
















Common names No data Green salt No data No data No data 
CAS Registry No. 7783-81-5 10026-10-5 13536-84-0a 6159-44-0 13520-83-7 
Color White 
crystallinea 
Green Yellowa Yellow Yellow 
Physical state Solida Octahedral 
crystal 
Solida Solid crystal Solid crystal 
Odor No data No data No data No data No data 
Melting point, °C 64.5 at 2 atma 590°C Decomposes 
at 300 
Loses 2H2O at 
110 
60 
Boiling point, °C 56.2 
sublimation 
pointa 






No data No data No data No data No data 
Solubility:      




64.4 g/100 g at 
20 °C 
7.7 g/100 mL at 
15 °C 
127 g/100 gH2O 









Soluble in ethanol Soluble in 
ethanol and ether 
Density g/cm3 5.09 at 
20.7°C; 3.595 
at 70°C 
4.72 6.37 2.893 g/cm3 at 
15°C 




Not relevant Not relevant  Not relevant Not relevant Not relevant 
Vapor pressure 115 mmHg at 
25°C c 
No data No data No data No data 
Henry’s law 
constant 
Not relevant Not relevant Not relevant Not relevant Not relevant 
Refractive index No data No data No data No data 1.4967 
Flashpoint No data No data No data No data No data 
Flammability limits No data No data No data No data No data 
Conversion factorb 1 μg=0.47 pCi 1 μg=0.43 pCi 1 μg=0.53 pCi 1 μg=0.39 pCi 1 μg=0.33 pCi 
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394.037 624.131 302.03a 388.12a 
Chemical formula (UO2)(NO3)2 (NH4)2U2O7 UO4a C4H6O6Ua 
Synonyms No data Ammonium 
uranate(VI) 
No data No data 
Common names No data No data No data No data 
CAS Registry No. 10102-06-4 7783-22-4 19525-15-6a 541-09-3a 
Color Yellow Reddish yellow Pale yellowa Yellowa 
Physical state Solid crystal Amorphous 
powder 
Solid Solid crystalsa 
Odor No data No data No data Vinegar-likea 
Melting point, °C No data No data Decomposes at 
90–195°C a 
No data 




Not relevant Not relevant Not relevant Not relevant 
Solubility:     
Water 127 g/100 g H2O Insoluble 0.0006 g/100 cc at 
20°C; 0.008 g/cc 
at 90°C a 
7.694/100 mL at 
15°Ca 
Other solvents Soluble in ether Insoluble in 
alkali; soluble 
in acids 
No data Very soluble in 
alcohola 
Density g/cm3 No data No data 11.66 
(calculated)a 
2.893 at 15°Ca 
Partition 
coefficients 
No data No data No data No data 
Vapor pressure No data No data No data No data 
Henry’s law 
constant 
No data No data No data No data 
Refractive index No data No data No data No data 
Flashpoint No data No data No data No data 
Flammability limits No data No data No data No data 
Conversion factorb 1 μg ≡ 0.42 pCi 1 μg ≡ 0.52 pCi 1 μg ≡ 0.54 pCi 1 μg ≡ 0.42 pCi 
 
aHSDB (2011). 
bCalculated from National Nuclear Data Center data (NNDC 2011). 
cArgonne National Laboratory (2011). 
 













Table 4-3.  Percent Occurrence and Radioactive Properties of Naturally Occurring 
Isotopes of Uranium 
 
Isotope 





(years) By weight By radioactivity  
234U 0.0054 49.03 4772.4 (28.42%) 13.0 (10.0%) 2.455x105 
4774.6 (71.38%)    
235U 0.7204 2.27 4214.7 (5.7%) 13.0 (37.00%) 7.038x108 
4366.1 (17.0%) 93.35 (5.60%)  
4397.8 (55%) 143.76 (10.96%)  
4556.0 (4.2%) 163.33 (5.08%)  
4596.4 (5.0%) 185.715 (57.20%)  
Others  (13.1%) 205.311 (5.01%)  
238U 99.2742 48.70 4151 (21%) 4772.4 (28.42%) 4.468x109 
4198 (79%) 4774.6 (71.38%)  
 








Table 4-4.  235U and 238U Decay Series Showing Sources and Decay Products 
 
238Uranium-238 series, includes uranium-234 series Uranium-235 series 
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Sources:  Aieta et al. 1987; Argonne National Laboratory 2005; half-life data from NNDC 2011 
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Uranium can exist in five oxidation states: +2, +3, +4, +5, and +6 (Lide 2008); however, only the +4 and 
+6 states are stable enough to be of practical importance.  Tetravalent uranium is reasonably stable and 
forms hydroxides, hydrated fluorides, and phosphates of low solubility.  Hexavalent uranium is the most 
stable state, and the most commonly occurring state is U3O8, although there are a few localized storage 
locations for anthropogenic uranium hexafluoride (UF6) in the United States (DOE 2011a).  Major 
compounds of uranium include oxides, fluorides, carbides, nitrates, chlorides, acetates, and others.  One 
of the characteristics of UO2+2 ions is their ability to fluoresce under ultraviolet light. 
 
Although the element uranium was discovered in 1789 by Klaproth, who named it “uranium” after the 
newly discovered planet Uranus, it was not until 1896 that Becquerel discovered that uranium is 
radioactive.  There are 22 known isotopes of uranium, only 3 of which occur naturally (NNDC 2011).  
These three isotopes, 234U, 235U, and 238U, have relative mass abundances within the earth=s undisturbed 
crustal rock of 0.005, 0.72, and 99.275%, respectively.  One gram of natural uranium having this relative 
isotopic abundance has an activity of 0.69 μCi.  Of this 0.69 μCi, 49.0% of the activity is attributable to 
234U, 2.27% of the activity is attributable to 235U, and 48.7% of the activity is attributable to 238U (Agency 
for Toxic Substances and Disease Registry 2011).  This ratio is for undisturbed crustal rock only.  
Although the relative mass abundance of 234U is only 0.005%, it accounts for approximately one-half of 
the total activity.  The relative isotopic abundances given above can be altered to some extent by natural 
processes that are not fully understood, but which can cause different ratios in air, water, and soil as 
demonstrated in EPA reports (EPA 1994a, 2007). 
 
235U is an isotope of particular interest because it is fissile (capable of being fissioned) and, consequently, 
can sustain a nuclear chain reaction in the presence of appropriate energy neutrons.  The predominant 
isotope of uranium found in nature, 238U, is not readily fissionable, but a small portion of its 
transformations result in spontaneous fission rather than the typical alpha decay; these neutrons can be 
sufficient to initiate a chain reaction under appropriate concentration, mass, and neutron thermalization 
conditions.  Consequently, for uranium to be used as a fuel in nuclear reactors, the ratio of 235U to 238U is 
increased from 0.72 to 2–4%  by a process called enrichment.  The enrichment process most used in the 
United States is called gaseous diffusion, but other enrichment processes involving thermal, centrifuge, 
and laser methods can be used, and other countries are actively involved in producing enriched uranium.  
Uranium ore is processed to uranium oxide (U3O8) and then fluorinated to UF6; next, a stream of UF6 gas 
containing all three isotopic compounds is passed through a long series of diffusion stages through which 
the 234U and 235U pass more quickly than the 238U.  Thus, the front end of the stream has an enhanced 235U 
concentration and is called enriched uranium hexafluoride, while the back end of the stream has a reduced 
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235U concentration and is called depleted uranium hexafluoride.  The percent enrichment is a measure of 
the mass percentage of 235U in the final product, and the degree of enrichment is determined by the use.  
Enriched UF6 is typically converted to uranium metal or oxide for power reactor fuel or to metal for 
weapons applications.  Depleted UF6 is either converted to uranium metal for a variety of civilian and 
military applications or stored for future use.  Low enriched uranium (2–4% enriched) is used in civilian 
nuclear power reactors (DOE 2000), while high enriched uranium (>90% enriched) is used in special 
research reactors (most of which have been removed from operation), nuclear submarine reactor cores, 
and nuclear weapons.  Depleted uranium metal is used as radiation shielding, missile projectiles, target 
elements in plutonium production reactors, a gyroscope component, and counterweights or stabilizers in 
aircraft. 
 
Uranium continuously undergoes transformation through the decay process whereby it releases energy to 
ultimately become a stable or nonradioactive element.  For the uranium isotopes, this is a complex 
process involving the serial production of a chain of decay products, called progeny, until a final stable 
element is formed.  The decay products of the uranium isotopes, which are also radioactive, are shown in 
Table 4-4.  238U is the parent isotope of the uranium series (234U is a decay product of 238U), while 235U is 
the parent isotope of the actinium decay series.  All natural uranium isotopes and some of their progeny 
decay by emission of alpha particles; the other members of both series decay by emission of beta particles 
and gamma rays (NNDC 2011).  Both the uranium and the actinium decay series have three features in 
common.  Each series begins with a long-lived parent, 235U or 238U, each series contains an isotope of the 
noble gas radon, and each series ends with a stable isotope of lead, 207Pb or 206Pb. 
 
The amount of time required for one-half of the atoms of a radionuclide to transform is called its 
radioactive half-life.  The rate of decay, and thus the half-life, for each radionuclide is unique.  The half-
life of 238U is very long, 4.5x109 years; the half-lives of 235U and 234U are orders of magnitude lower, 
7.0x108 and 2.5x105 years, respectively.  Since the activity of a given mass of uranium depends on the 
mass and half-life of each isotope present, the greater the relative abundance of the more rapidly decaying 
234U and 235U, the higher the activity will be.  Thus, depleted uranium is less radioactive than natural 
uranium and enriched uranium is more radioactive. 
 
Uranium is unusual among the elements because it is both a chemical and a radioactive material.  The 
hazards associated with uranium are dependent upon uranium’s chemical and physical form, route of 
intake, and level of enrichment.  The chemical form of uranium determines its solubility and, thus, 
transportability in body fluids as well as retention in the body and various organs.  Uranium’s chemical 
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toxicity is the principal health concern, because soluble uranium compounds cause heavy metal damage 
to renal tissue.  The radiological hazards of uranium may be a primary concern when inhaled, enriched 
(DOE 2001) and insoluble uranium compounds are retained long-term in the lungs and associated 
lymphatics. 
 










5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
 
5.1   PRODUCTION 
 
No information is available in the TRI database on facilities that manufacture or process uranium, because 
this chemical is not required to be reported under Section 313 of the Emergency Planning and Community 
Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of 1986) (EPA 
1998a). 
 
Uranium is present in the earth’s crust at approximately 3 ppm (2 pCi/g) (Clark et al. 2006; du Preez 
1989; WNA 2011).  Of the more than 100 uranium ores, the primary (brannerite, carnotite, coffinite, 
davidite, pitchblende, thucholite, uraninite) and secondary (tobernite, autunite, tyuyamunite) are the main 
ores of commercial interest.  The main ores are described in Table 5-1.  The most economically attractive 
uranium ores have uranium concentrations >1,000 ppm (700 pCi/g) (Clayton and Clayton 1981; Weigel 
1983; WNA 2011).  In the United States, the major ore deposits are located in Colorado, Utah, Arizona, 
New Mexico, Wyoming, Nebraska, and Texas (EPA 1985a).  The steps necessary to produce uranium for 
its various uses include mining, milling, conversion to uranium hexafluoride (UF6), enrichment, reduction 
to metal or oxidation to uranium oxide, and fabrication into the desired shape.  The steps for preparing 
commercial reactor grade, submarine reactor grade, or weapons-grade uranium are the same, except the 
last two require a more aggressive enrichment process.  Depleted uranium metal is produced by reducing 
the depleted uranium hexafluoride byproduct.  Conventional fabrication methods are used to configure the 
uranium for specific uses, such as rectangular solid blocks for helicopter rotor counterbalances and 
parabolic or cylindrical solids for military depleted uranium projectiles. 
 
Mining.  Open-pit mining, in situ leaching, and underground mining are three techniques that have been 
used for mining uranium-containing ores (EPA 1985a; WNA 2011).  Uranium is found in all soil and 
rock, but the higher concentrations found in phosphate rock, lignite, and monazite sands are sufficient in 
some areas for commercial extraction (Lide and Frederikse 1994).  The choice of mining method is 
influenced by factors such as the size, shape, grade, depth, thickness, disaggregation, and permeability of 
the ore deposits and the proximity to groundwater (Grey 1993; WNA 2011).  Historically, open-pit and 
underground mining have been most commonly used mining methods.  However, most uranium in the 
United States is currently mined through in situ leaching, which results in little disturbance to the surface 
and generates no tailings or waste rock (Grey 1993; EIA 2010b; WNA 2011).  In situ leaching involves 
leaching (or dissolving) uranium from the host rock with liquids without removing the rock from the  
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Table 5-1.  Uranium Ores 
 
Ore Composition Description 
Primary ores   
 Uraninite UO2 + UO3 A steel-, velvet-, to brownish-black in color; major ore of 
uranium and radium 
 Pitchblende UO2 + UO3 Essentially the same as uraninite 
 Brannerite U(TiFe)2O2 A black, brownish, olive greenish ore; primary mineral in 
granite, associated with uraninite 
 Coffinite U(SiO4)1-x(OH)4x A black or pale-to-dark brown mineral in sandstone, 
associated with uraninite 
 Davidite (CeLa)U(TiFe3+)20(O,OH)38 A black-brownish mineral in granite, associated with 
ilmenite and others 
 Thucholite Mixture of petroleum 
hydrocarbons, uraninite, and 
sulfides 
Black mixture, acronym stands for thorium, uranium, 
carbon, and hydrogen 
 Carnotite K2O $ 2U2O3 $ V2O5 $ 3 H2O 
(uranium potassium vanadate) 
Bright-, lemon-, or greenish-yellow mineral in sandstone 
associated with tyuyamunite and U-V oxides 
Secondary ores  
 Autunite Ca (UO2)2 (PO4)2 $ 10 H2O Yellow-to-greenish mineral produced under oxidizing 
conditions and associated with tormernite 
 Torbernite Cu (UO2)2 (PO4)2 $ 10 H2O An emerald-, grassy-, to apple-green mineral formed in 
an oxidized zone and associated with uraninite and 
autunite 
 Tyuyamunite Ca(UO2)2 (VO4)2 $ 5B8 H2O 
(uranium calcium vanadate) 
A canary-, lemon-, to greenish-yellow mineral associated 
with carnotite 
 
Sources:  Amethyst Galleries 1995; Mindat 2011; MSA 2011; Stockinger 1981; Uranium Institute 1996 
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ground and can only be carried out on unconsolidated sandstone uranium deposits located below the 
water table in a confined aquifer.  A leaching solution is introduced into or below the deposit and pumped 
to the surface, where the uranium-pregnant liquor is processed in a conventional mill to precipitate the 
uranium as yellowcake (U3O8 and other oxides) (DOE 1995b; Grey 1993; WNA 2011). 
 
Milling.  Ore mined in an open-pit or underground mine is crushed and leached in a uranium mill.  The 
initial step in conventional milling involves crushing, grinding, and wet and/or dry classification of the 
crude ore to produce uniformly sized particles that are similar in size to beach sand (Clark et al. 2006; 
WNA 2011).  A slurry generated in the grinding circuit is transferred to a series of tanks for leaching by 
either an alkaline or acid process (Clark et al. 2006; WNA 2011).  Generally, leaching is a simple process 
whereby uranyl ions are extracted by a solvent.  Uranyl ions are stripped from the extraction solvent and 
precipitated as yellowcake, predominantly U3O8 (Clark et al. 2006; EPA 1995; WNA 2011).  Yellowcake 
is pressed, dried, banded, and shipped for refinement and enrichment.  The byproduct of this process is 
the leftover sand, known as tailings (Clark et al. 2006; WNA 2011).  Thus, tailings are the original sand 
minus much of the uranium plus residual process chemicals.  Tailings are less radioactive than the 
original ore; uranium metal production in a conversion facility is done postenrichment.  Generalized flow 
charts for the alkaline and acid leaching processes for ore concentration and uranium production are 
shown in Figure 5-1. 
 
Enrichment.  Next, the U3O8 is chemically converted to UF6.  The enrichment process increases, or 
enriches, the percentage of the fissionable 235U isotope, as well as 234U.  Until recently, the major process 
used for uranium enrichment in the United States has been gaseous diffusion.  The mechanism for 
enrichment is based on the fact that a UF6 molecule containing 235U or 234U is lighter and smaller, and has, 
therefore, a slightly higher thermal velocity than a UF6 molecule containing 238U (WNA 2011).  As the 
UF6 passes through the series of diffusion stages, the 234UF6 and 235UF6 molecules gradually become more 
concentrated downstream and less concentrated upstream, while the 238UF6 concentrates conversely.  The 
lead portion of the stream is collected and recycled to reach the desired enrichment.  The tail portion 
containing a reduced 235UF6 content, called depleted UF6, can be stored in the vicinity of the gaseous 
diffusion plant sites (DOE 1994b).  There are an estimated 686,500 metric tons of depleted uranium 
currently in storage as UF6 (ANL 2011).  A second enrichment technology, gas centrifuge separation, is 
now replacing gas diffusion in the United States and is expected to be the dominant enrichment process in 
coming years (WNA 2011).  During gas centrifuge enrichment, UF6 gas is fed into centrifuge cylinders 
containing rotors that are spun at 50,000–70,000 rpm (WNA 2011).  The heavier 238UF6 molecules  
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concentrate toward the cylinder's outer edge while the lighter 235UF6 molecules concentrate toward the 
center (Clark et al. 2006; WNA 2011).  At the same time, a countercurrent circulation flow along the 
length of the rotor creates a vertical separation of the isotopes as well allowing for them to be drawn off at 
separate ends (Clark et al. 2006; WNA 2011).  The two major advantages of the gas centrifuge are that it 
is much more efficient in both its energy requirements and its ability to separate the isotopes than gas 
diffusion enrichment (WNA 2011).  A third technology, laser separation, is currently under development 
(DOE 1995b; WNA 2011).  A fourth technology, thermal separation, is inefficient and no longer used. 
 
Fuel Fabrication.  In most cases, the enriched UF6 is oxidized to uranium dioxide and formed into pellets 
of ceramic uranium dioxide (UO2).  The pellets are then stacked and sealed inside metal tubes that are 
mounted into special fuel assemblies ready for use in a nuclear reactor (DOE 1995b; Uranium Institute 
1996; WNA 2011). 
 
Product Fabrication.  Uranium metal has commercial and industrial uses due to its great density and 
strength.  It is alloyed with a range of metals to meet other commercial and industrial needs (Clark et al. 
2006).  As with steel, uranium can be formed and fashioned by drop forging, dye casting, and machining 
and is often painted to minimize oxidation.  Some well-known uses for these products are military armor 
and armor piercing munitions, helicopter rotor blade counterbalances, weights in airplane control 
surfaces, and radiation shields for high radioactivity sources (e.g., industrial radiography) (Parkhurst and 
Guilmette 2009a; WNA 2011). 
 
Production.  Uranium production from 1975 to 2009 is shown in Table 5-2.  Peak production of uranium 
occurred in 1980 at 21,852 short tons (1.98x107 kg) and decreased until 1993.  This was the same period 
when the planning and construction of new nuclear power plants ceased in the United States.  Production 
of U3O8 had decreased to 4,443 short tons (4.03x106 kg) in 1990 and to 1,534 short tons (1.39x106 kg) in 
1993, a 65% reduction (ABMS 1994; EPA 1985a).  In 1996, U.S. uranium production was 3,160 short 
tons (2.87x106 kg), an increase of 5% from the 1995 level and the highest level since 1991 (DOE 1996a).  
Underground and open-pit mining have been the two most commonly used methods of mining uranium 
ores.  However, by 1994, uranium was produced primarily by in situ leaching methods.  A summary of 
U.S. mine production from 1985 through 1996 (see Table 5-3) illustrates the shift from underground and 
open-pit mining to in situ leaching.  U.S. uranium production fell to a low of 1,100 short tons in 2003 
before climbing back to just over 2,000 short tons by the end of the decade (EIA 2010b). 
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Table 5-2.  Uranium Production in the United States by Uranium Mills and Other 
Sources 
 
Year Short tonsa of U3O8 Kilograms of U3O8 
1975 11,600 1.05x107 
1976 12,747 1.16x107 
1977 14,939 1.35x107 
1978 18,486 1.68x107 
1979 18,736 1.70x107 
1980 21,852 1.97x107 
1981 19,237 1.74x107 
1982 13,434 1.22x107 
1983 1,0579 9.60x106 
1989 6,919 6.28x106 
1990 4,443 4.03x106 
1991 3,976 3.61x106 
1992 2,823 2.56x106 
1993 1,534 1.39x106 
1994 1,676 1.52x106 
1995 3,022 2.74x106 
1996 3,160 2.87x106 
1997 2,820 2.56x106 
1998 2,550 2.13x106 
1999 2,250 2.04x106 
2000 1,550 1.41x106 
2001 1,300 1.18x106 
2002 1,200 1.09x106 
2003 1,100 9.98x105 
2004 1,250 1.13x106 
2005 1,500 1.36x106 
2006 2,350 2.13x106 
2007 2,250 2.04x106 
2008 1,950 1.77x106 
2009 2,050 1.86x106 
 
aShort ton = 2,000 lbs = 907 kg. 
 
Sources:  ABMS 1994; DOE 1996a, 1997b, 1999a; EIA 2010b; EPA 1985a 
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Percentage of total 
1985 1986 1987 1988 1990 1991 1992 1994 1996 1998 2003 2005 2006 2009 
Underground 52.3 77.8 81.7 56.8 Wb W W 0 W W W W W W 







W W W W W 96.9 93.1 77.8 W 88.0 90.8 W 
 
aDoes not include uranium sources such as mine water, mill site cleanup, mill tailings, or well field restoration. 
bData withheld. 
 
Sources:  DOE 1995, 1996a, 1997b, 1999b; EIA 2010b 
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Leached uranium concentrate was produced in 1996 in Wyoming, Louisiana, Nebraska, New Mexico, and 
Texas.  At the end of 1996, two phosphate byproduct plants and five in situ leaching plants were in 
operation.  In addition, seven phosphate byproduct and in situ leaching plants were inactive, and seven 
conventional uranium mills were being maintained in stand-by mode (DOE 1997b).  During 2010, one 
conventional uranium mill and four uranium in situ leach plants were reported to be in operation in the 
United States (EIA 2010b). 
 
5.2   IMPORT/EXPORT  
 
The importation of uranium increased significantly in the 1980s (EPA 1985a).  In 1983, 3,960 short tons 
of U3O8 equivalent were imported into the United States (USDOC 1984), which was about 37% of the 
domestic production.  In 1987, the amount of U3O8 equivalent imported into the United States was 
5,630 short tons (USDOC 1988).  The amounts of uranium and uranium compounds imported into the 
United States during the period 1989–1997 are presented in Table 5-4 (USDOC 1995, 1997).  The 
importation of uranium and uranium compounds peaked in 1990 at about 23 million kg (about 1 million 
tons) and has remained approximately the same, with some fluctuation, since that time.  Actual uranium 
import values for more recent years have not been located; however, amounts of foreign-origin uranium 
purchased by U.S. suppliers and owners and operators of U.S. Civilian Nuclear Power Reactors are 
available (EIA 2010a).  These data (located in Table 5-6) suggest uranium imports have remained steady 
over the previous two decades.  Close to 27 million kg of foreign-origin uranium were purchased in 2009.  
Imports may be reduced as DOE sells part of its excess uranium inventory (DOE 2008). 
 
The amount of uranium and uranium compounds exported from the United States during 1989–1993 is 
shown in Table 5-5.  The total volume of uranium and uranium compounds exported during 1989–1993 
was 2 orders of magnitude lower than the quantities imported during this same time period.  Exports in 
1996 were 5.2 million kg.  Most of the foreign sales (Canada, France, Germany, Japan, South Korea, 
United Kingdom) occurred after the uranium entered the U.S. market as imports (DOE 1999b).  Amounts 
of uranium sold to firms located outside the United States (Table 5-6) suggest exports have remained 
steady since the mid 1990s (EIA 2010a).  Approximately 10 million kg of uranium were sold in 2009. 
 
5.3   USE  
 
Uranium has been produced for use in the commercial nuclear power industry as low-enriched metal or 
ceramic UO2 fuel pellets; smaller quantities of high-enriched fuel are produced for U.S. Navy ships and 
for weapons manufacture (Clayton and Clayton 1981; EPA 1985b; Peehs et al. 2007; WNA 2011).   
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1990 1991 1992 1993 1994 1995 1996 1997 1998 
U-metal 
(depleted) 





5 2,444 9 25 No data No data 309,681 10 2 
U-oxide 
(natural) 
8,459,924 12,630,433 10,043,472 7,925,762 9,713,406 8,992,532 8,880,669 9,259,002 No data 
U-oxide 
(enriched) 
204,592 200,733 63,875 35,779 14,214 97,976 57,241 158,082 36,121 
U-oxide 
(depleted) 
886,853 19,410 608,472 495 0 0 11,253 0 0 
U-fluoride 
(natural) 
9,432,470 8,109,402 5,844,985 10,827,786 9,583,669 11,140,026 10,936,114 12,210,369 12,965,093 
U-fluoride 
(enriched) 
598,763 874,251 875,831 868,652 1,000,950 934,046 1,024,148 858,807 1,252,438 
U-fluoride 
(depleted) 














4,731 294 1,666 107 0 122 245 100 248 
Ores and 
concentrates 
2,763,185 1,344,927 0 0 No data No data 0 212,434 0 
Mixture 
(depleted) 
0 0 0 4,431 No data No data No data No data No data 
Spent fuel 16,401 5,033 0 115 45 0 23 306 No data 
 
aImport data for more recent years were not located.  See Table 5-6 for amounts of uranium sold to firms located 
outside the United States in recent years. 
 
Sources:  USDOC 1995, 1997, 1999 
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1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 
U-oxide 
(natural) 
6,302 318 0 96,748 6,196 690,449 351,169 192,296 250,443 0 
U-oxide 
(enriched) 
0 0 85 26,596 64 418,873 299,175 323,990 903,810 646,984 
U-fluoride 
(natural) 
85 0 20,175 186,530 4,231 No data No data 0 688,873 53,800 
U-fluoride 
(enriched) 




0 9,801 12,596 8,019 0 No data No data No data No data No data 
U-compounds 
(enriched) 
28,221 0 6,609 3 0 0 66,893 418,447 10,506 99,456 
U-compounds 
(depleted) 
0 90 160 0 0 246,765 379,530 406,079 30,426 41,674 
U-metal No data No data No data No data No data 270 496 299,117 3,159 0 
U-ores and 
concentrates 




No data No data No data No data No data 74,712 45,424 29,759 152,920 0 
Spent fuel 0 21,576 0 0 0 No data No data No data No data No data 
 
aExport data for more recent years were not located.  See Table 5-6 for amounts of uranium purchased from firms 
located outside the United States in recent years. 
bAlloys, dispersions (including cermets), ceramic products, and mixtures containing natural uranium compounds, 
Nesoi (SIC2819). 
 
Sources:  USDOC 1995, 1999 
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Table 5-6.  Foreign Purchases and Foreign Sales of Uranium (kg U3O8 Equivalent) 
by U.S. Suppliers and Owners and Operators of U.S. Civilian Nuclear Power 
Reactors, 1994–2009 
 
Year Foreign purchasesa Foreign salesb 
1994 1.66x107 8.03x106 
1995 1.87x107 4.44x106 
1996 2.06x107 5.22x106 
1997 1.95x107 7.71x106 
1998 1.98x107 6.85x106 
1999 2.16x107 3.85x106 
2000 2.04x107 6.17x106 
2001 2.12x107 5.31x106 
2002 2.39x107 6.98x106 
2003 2.40x107 5.99x106 
2004 3.00x107 5.99x106 
2005 2.97x107 9.30x106 
2006 2.94x107 8.48x106 
2007 2.45x107 6.71x106 
2008 2.59x107 7.80x106 
2009 2.67x107 1.07x107 
 
aPurchases of foreign origin uranium from a firm located outside the United States. 
bSales of uranium to a firm located outside the United States. 
 
Sources:  EIA 2010a 
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Uranium fuel lasts months to years before refueling is needed, and then only a small fraction of the 
uranium has actually been fissioned, making fuel reprocessing an option used in other countries (WNA 
2011).  One pound of completely fissioned uranium produces the same amount of energy as 1,500 tons of 
coal (Lide and Frederikse 1994).  Depleted uranium is used in the manufacture of armor-piercing 
ammunition for the military, in inertial guidance devices and gyro compasses, as counterbalances for 
helicopter rotors, as counterweights for aircraft control surfaces, as radiation shielding material, and as 
x-ray targets (EPA 1985b; Parkhurst and Guilmette 2009a; Peehs et al. 2007; WNA 2011).  In the past, 
uranium salts have been used to produce colored ceramics and glasses (Clark et al. 2006).  Additionally, 
uranium was used in dental porcelains for many years, but this practice has been discontinued (FDA 
1976; WNA 2011).   
 
5.4   DISPOSAL  
 
Radioactive waste containing uranium is usually grouped into three categories:  uranium mill tailings, 
low-level waste, and, in the case of spent reactor fuel, high-level waste (USNRC 2002, 2007). 
 
Uranium mill tailings are the residual sand and trace chemicals from the processing of uranium ore.  
About 150 tons of enriched uranium are required per year to fuel a 1,000-megawatt electric nuclear power 
reactor, and about 500 times that amount of ore is required to obtain the uranium.  The total accumulation 
of uranium in licensed mill tailings piles in the United States is approximately 200 million tons (EPA 
2011z; Murray 1994).  Tailings from mines and mills that process other metals might also be expected to 
contain elevated concentrations of uranium and its progeny (El-Didamony et al. 2013; EPA 2013b; 
Morrison et al. 1988; Radford and Renard 1984; Vidic et al. 2011; Xuan et al. 1993), although this may 
not be readily recognized. 
 
Disposal methods for processed uranium tailings have been discussed by Bearman (1979).  In the late 
1940s, mainly unconfined disposal systems were used.  Untreated solid wastes were stored as open piles 
and, in some cases, were spread in urban areas where they were used as fill and as the sand in concrete 
used to build roads, walks, drives, and concrete block, and in brick mortar.  As a result of the Animas 
River Survey in the United States, tailing control programs were instituted in 1959 to prevent airborne 
and waterborne dispersal of the wastes.  Confined disposal methods were devised to reduce the exposure 
and dispersion of wastes and to reduce seepage of toxic materials into groundwater to the maximum 
extent reasonably achievable.  Under the Uranium Mill Tailings Radiation Control Act (UMTRCA) of 
1978, the U.S. Department of Energy (DOE) designated 24 inactive tailings piles for cleanup.  These 
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24 sites contained a total of about 28 million tons of tailings and covered a total of approximately 
1,000 acres (EPA 1985b).  Two of the sites have been withdrawn from the list and others have combined 
tailings piles, reducing the number of sites to 19 (USNRC 2006).  According to a report by the USNRC 
(2006), cleanup has been completed at all but two of these locations. 
 
In 1977, the EPA issued Environmental Radiation Protection Standards to limit the total individual 
radiation dose due to emissions from uranium fuel cycle facilities, including licensed uranium mills.  This 
standard specified that the “annual dose equivalent does not exceed 25 millirem (0.25 mSv) to the whole 
body, 75 millirem (0.75 mSv) to the thyroid, and 25 millirem (0.25 mSv) to any other organ of any 
member of the public as the result of exposures of planned discharges of radioactive materials “to the 
general environment” (40 CFR 190).  The EPA also established environmental standards for cleanup of 
open lands and buildings contaminated with residual radioactivity from inactive uranium processing sites 
(40 CFR 192). 
 
Low-level radioactive waste (LLRW), which may contain uranium, is disposed of at DOE facilities and at 
commercial disposal facilities (USNRC 2002, 2007).  Since 1963, seven commercial LLRW facilities 
have operated, but only three are currently receiving waste for disposal (USNRC 2007).  A 1992 report 
listed the total volume of LLRW buried at six of the sites to be approximately 50 million cubic feet 
(Murray 1994).  The current total amount of LLRW stored at the seven LLRW facilities was not located; 
however, the yearly total amount stored at the three operating locations was reported to be 4.01, 4.05, 
2.63, and 2.09 million cubic feet in 2005, 2006, 2007, and 2008, respectively (USNRC 2011).  Only a 
small fraction of the LLRW contains uranium.  The method of disposal for commercial and DOE LLRW 
has been shallow land burial, in which the waste is disposed of in large trenches and covered.  This 
method of disposal relies upon natural features to isolate the waste.  Although USNRC regulations for 
LLRW disposal (10 CFR 61) permit shallow land burial, many states have enacted more stringent 
regulations that require artificial containment of the waste in addition to natural containment (Murray 
1994; USNRC 2002, 2007). 
 
High-level radioactive waste (HLRW) includes spent fuel, which is the uranium fuel rods that have been 
used in a nuclear reactor (USNRC 2007).  When the fuel rods are removed from the reactor for refueling, 
they still contain most of the original unfissioned uranium.  However, the hazard from the large activity of 
fission products and plutonium that have been produced in the fuel rods overshadows that of uranium.  
Approximately 47,000 metric tons of spent fuel have been removed from U.S. power reactors through 
2002 (EIA 2010d).  There is currently no permanent disposal facility for HLRW in the United States; 
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these wastes are being stored at commercial nuclear power plants and DOE facilities where they were 
produced (EIA 2010d).  The USNRC has issued standards for the disposal of HLRW (10 CFR 60), and 
the DOE is pursuing the establishment of an HLRW facility.  Efforts to establish an HLRW facility, 
which began over 2 decades ago, have experienced many significant delays.  DOE constructed the 
proposed U.S. HRLW facility in Yucca Mountain, Nevada contiguous to the Nevada Test Site, and EPA 
published the public health and environmental radiation standards for Yucca Mountain (EPA 2008).   










6.  POTENTIAL FOR HUMAN EXPOSURE 
 
6.1   OVERVIEW  
 
Uranium been identified in at least 67 of the 1,699 hazardous waste sites that have been proposed for 
inclusion on the EPA National Priorities List (NPL) (HazDat 2007).  However, the number of sites 
evaluated for uranium is not known.  The frequency of these sites can be seen in Figure 6-1. 
 
Uranium is a naturally occurring radioactive element that is present in nearly all rocks and soils; it has an 
average concentration in U.S. soils of about 2 pCi/g (3 ppm) (du Preez 1989; NCRP 1984a).  Some parts 
of the United States, particularly the western portion, exhibit higher than average uranium levels due to 
natural geological formations.  Most uranium ores contain between 0.05 and 0.2% uranium, up to 
1,000 times the levels normally found in soil (Uranium Institute 1996). 
 
Uranium can undergo oxidation-reduction reactions in the environment or microbial reactions to form 
complexes with organic matter (Premuzic et al. 1995).  The only mechanism for decreasing the 
radioactivity of uranium is radioactive decay.  Since all three of the naturally occurring uranium isotopes 
have very long half-lives (234U, 2.4x105; 235U, 7.0x108; and 238U, 4.5x109 years), the rate at which the 
radioactivity diminishes is very slow (Clark et al. 2006; NCRP 1984a; Peehs et al. 2007).  Therefore, the 
activity of uranium remains essentially unchanged over periods of thousands of years. 
 
Uranium may be redistributed in the environment by both anthropogenic and natural processes.  The three 
primary industrial processes that cause this redistribution are operations associated with the nuclear fuel 
cycle that include the mining, milling, and processing of uranium ores or uranium end products; the 
production of phosphate fertilizers for which the phosphorus is extracted from phosphate rocks containing 
uranium; and the improper disposal of uranium mine tailings (DOE 1981c; Hart et al. 1986; NCRP 1984a; 
Yang and Edwards 1984; USGS 2008, 2009, 2010c).  Essentially no uranium is released from nuclear 
power plants because of the fuel assembly design and the chemical and physical nature of the uranium 
oxide fuel.  Examples of uranium redistribution by natural processes include activities and processes that 
move soil and rock, such as resuspension of soils containing uranium through wind and water erosion, 
volcanic eruptions (Kuroda et al. 1984; USGS 2010a, 2010b, 2010c), operation of coal-burning power 
plants (coal containing significant quantities of uranium), and construction of roads and dams. 
 
Uranium becomes airborne due to direct releases into the air from these processes.  Deposition of 
atmospheric uranium may occur by wet (rain, sleet, or snow) or dry (gravitation or wind turbulence) 
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processes.  The rate of uranium deposition is dependent upon such factors as particle size, particle 
density, particle concentration, wind turbulence, and chemical form.  Data are lacking on residence times 
of particulate uranium in the atmosphere, although UNSCEAR (1988) assumed that it behaves like 
atmospheric dust, for which meteorological models exist. 
 
Uranium deposited by wet precipitation or dry deposition will be deposited on land or in surface waters.  
If land deposition occurs, the uranium can be reincorporated into soil, resuspended in the atmosphere 
(typically factors are around 10-6), washed from the land into surface water, incorporated into 
groundwater, or deposited on or adsorbed onto plant roots (little or none enters the plant through leaves or 
roots).  Conditions that increase the rate of formation of soluble complexes and decrease the rate of 
sorption of labile uranium in soil and sediment enhance the mobility of uranium.  Significant reactions of 
uranium in soil are formation of complexes with anions and ligands (e.g., CO3-2, OH-1) or humic acid, and 
reduction of U+6 to U+4.  Other factors that control the mobility of uranium in soil are the oxidation-
reduction potential, the pH, and the sorbing characteristics of the sediments and soils (Allard et al. 1979, 
1982; Brunskill and Wilkinson 1987; Herczeg et al. 1988; Premuzic et al. 1995; USGS 2008). 
 
Uranium in surface water can disperse over large distances to ponds, rivers, and oceans.  The transport 
and dispersion of uranium in surface water and groundwater are affected by adsorption and desorption of 
uranium on aquatic sediments.  As with soil, factors that control mobility of uranium in water include 
oxidation-reduction potential, pH, and sorbing characteristics of sediments and the suspended solids in the 
water (Brunskill and Wilkinson 1987; Swanson 1985; USGS 2008).  In one study of a stream with low 
concentrations of inorganics, low pH, and high concentrations of dissolved organic matter, the 
concentration of uranium in sediments and suspended solids was several orders of magnitude higher than 
in the surrounding water because the uranium was adsorbed onto the surface of the sediments and 
suspended particles (Brunskill and Wilkinson 1987). 
 
The levels of uranium in aquatic organisms decline with each successive trophic level because of very 
low assimilation efficiencies in higher trophic animals.  Bioconcentration factors measured in fish were 
low (Mahon 1982; Poston 1982; Waite et al. 1988) and were thought to arise from the extraction of 
uranium from the water or simply from the accumulation of uranium on gill surfaces (Ahsanullah and 
Williams 1989).  In plants, uptake of uranium may be restricted to the root system and may actually 
represent adsorption to the outer root membrane rather than incorporation into the interior of the root 
system (Sheppard et al. 1983).  Most of this uranium may be removed by washing the vegetable surfaces; 
cutting away the outer membrane will essentially result in complete removal.  No significant translocation 
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of uranium from soil to the aboveground parts of plants has been observed (Van Netten and Morley 
1983). 
 
The EPA has established a nationwide network called RadNet (formerly ERAMS) for obtaining data 
concerning radionuclides, including natural uranium isotopes, in environmental media.  Sampling 
locations for RadNet were selected to provide optimal population coverage (i.e., located near population 
centers).  Airborne uranium concentrations and precipitation levels of uranium were quite low, in the 
attocurie/m3 (10-3 nanoBq/m3) and 0.006–0.098 picocurie/L (0.0002–0.004 Bq/L/m3) ranges, respectively 
(EPA 1994a).  However, both air and water samples taken near facilities producing uranium ore or 
processing uranium were found to be higher, in the pCi/L range (EPA 1979a; Lapham et al. 1989; Laul 
1994; NCRP 1984a; Tracy and Meyerhof 1987).  The RadNet reports document 234U to 238U 
concentration ratios in drinking water that deviate from the equilibrium value of unity found in 
undisturbed crustal rock.  Theories proposed to account for this natural phenomenon involve water 
contact with soil and permeable rock containing uranium.  The 238U atoms transform through 234Th to 
234U, and any process that removes either of these radionuclides from the solid changes the 234U to 238U 
ratio.  238U atoms at the solid-liquid interface that emit decay alpha particles inward may experience a 
kinetic energy recoil sufficient to either tear the 234Th progeny from the solid or fracture the surficial solid 
layer, making the 234Th more accessible for the enhanced dissolution that thorium typically experiences 
relative to uranium in mineral matrices.  Either process can enhance the relative 234U content of the liquid.  
Should that liquid stabilize in another location and evaporate, the localized solids could show an enhanced 
234U ratio. 
 
A large drinking water study was performed in which data from the National Uranium Resource 
Evaluation (NURE) program plus data prepared for the EPA (DOE 1981b; USGS 2006) were compiled 
for a total of over 90,000 water samples.  Domestic water supplies were represented by 28,000 samples 
and averaged 1.7 pCi/L (2.5 μg/L) uranium, with a population weighted mean value for finished waters, 
based on 100 measurements, of 0.8 pCi/L (1.2 μg/L).  Other studies show the population-weighted 
average concentration of uranium in U.S. community drinking water to range from 0.3 to 2.0 pCi/L (0.4–
3.0 μg/L) (Ohanian 1989), while concentrations of uranium from selected drinking water supplies 
analyzed by EPA laboratories were generally <1 pCi/L (1.5 μg/L) (EPA 1985c, 1997b, 2005a, 2010b). 
 
The uranium content of food has been studied extensively; human daily intake has been estimated to 
range from 0.6 to 1.0 (0.9–1.5 μg/day) pCi/day of natural uranium.  Uranium is adsorbed onto the roots of 
plants; thus, unwashed potatoes, radishes, and other root vegetables that retain their surface membrane are 
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a primary source of uranium in the diet.  Based on consumption rates, potatoes constitute the highest 
dietary intake of uranium (EPA 1985c).  One study showed that the concentration of uranium in plant 
roots was proportional to the uranium concentration in the soil (NCRP 1984a), while a second study did 
not support a linear relationship (Mortvedt 1994). 
 
Estimates of uranium intake for drinking water vary widely, but the mean is approximately 0.8 pCi/L 
uranium.  Drinking water intake is in the range of 0.6–1.0 pCi/day (0.9–1.5 μg/day).  Uranium intake 
from food and water sources is approximately equal (EPA 1991b).  Compared with food and drinking 
water, intake of uranium by the inhalation route is small, with values reported at 0.007 pCi/day 
(0.010 μg/day) (Cothern 1987) and 0.0007 pCi/day (0.0010 μg/day) (UNSCEAR 1988). 
 
Higher rates of uranium intake have been reported for some populations.  The potential for uranium 
intake is greater for individuals who consume foods grown in areas with elevated concentrations of 
uranium in the soil, and for individuals with elevated concentrations of uranium in their drinking water 
(EPA 1985c; NCRP 1984a).  Workers engaged in the extraction and processing of uranium are 
occupationally exposed to uranium.  Industries where uranium exposure are known to have occurred are 
uranium mining and milling, uranium conversion and enrichment, uranium fuel fabrication, and uranium 
weapons production (BEIR IV 1988; Miller 1977; NCRP 1984a; West et al. 1979).  Other groups with the 
potential for exposure due to technologically enhanced natural background radioactivity include 
populations involved in producing and using phosphate fertilizers, and individuals living and working 
near fossil fuel plants (Jaworowski and Grzybowska 1977; NCRP 1984a; Tadmor 1986; Weissman et al. 
1983). 
 
6.2   RELEASES TO THE ENVIRONMENT  
 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005b).  This is not an exhaustive list.  Manufacturing and 
processing facilities are required to report information to the TRI only if they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
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5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005b). 
 
Throughout this chapter, the units used to express concentration or intake of uranium are the same units 
reported by the authors, and are sometimes followed by converted units obtained using a conversion 
factor based on the information provided about the isotopic mixture.  In some cases, values are expressed 
in mass units, while in other cases, values are expressed as activities.  In the case of natural uranium with 
a fixed abundance of the three isotopes in crustal rock, conversion from one unit to the other is possible 
using the conversion factor of 1 µg uranium being equivalent to an activity of 0.685 pCi based on half-
life, abundance, and atomic mass data from the National Nuclear Data Center (NNDC 2011).  Likewise, 
1 ppm is equivalent to 1 μg/g and, therefore, to 0.69 pCi/g for natural uranium.  Other conversion values 
have been used, such as 1 µg of uranium being equivalent to 0.68 pCi (EPA 1991b), 0.72 pCi (EPA 
1985b) and 0.67 pCi (NCRP 1984a).  These different values are largely accounted for by the periodic 
refinement of values for uranium isotopic half-lives, atomic masses, and relative percentages in crustal 
rock. 
 
6.2.1   Air  
 
There is no information on releases of uranium to the atmosphere from manufacturing and processing 
facilities because these releases are not required to be reported (EPA 1998a). 
 
Uranium is introduced into the atmosphere primarily by resuspension of soil, but also by the intentional or 
accidental release of uranium from mining and milling activities, by uranium processing facilities, or by 
burning coal. 
 
Natural processes that involve the weathering of crustal rock and soil can change the crustal ratio of 
uranium isotopes.  In some cases, human activities have also altered the normal crustal distribution of 
naturally occurring radioactive materials, resulting in what has been termed technologically enhanced 
naturally-occurring radioactive material (TNORM) (NCRP 1984a).  No new radioactivity is produced by 
the enhancement, but uranium, its isotopes, and its progeny are redistributed in such a way that real 
exposure or the potential for human exposure may increase.  A major localized source of enhanced 
natural uranium can result from mining and milling operations (Table 6-1). 
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Table 6-1.  Normalized Uranium Effluent Discharges from Uranium Mining, 
Milling, Conversion, Enrichment, and Fuel Fabrication 
 













aIn equilibrium with progeny through U-234. 
bGWy(e) = gigawatts (109 watts) of electricity generated for 1 year. 
 
Source:  UNSCEAR 1982 
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Uranium ore with concentrations of uranium up to 1,000 times the average concentration normally found 
in soil (NCRP 1984a) is removed from its natural location during open-pit, in-situ leach, or underground 
mining operations.  The primary sources of airborne releases from these sources are from the actual 
mining, from ore crushing and grinding, from high-temperature processes such as calcining or sintering, 
and from yellowcake drying and packaging at the mill.  Ore stockpiles can also be a source of airborne 
emissions (NCRP 1993). 
 
Production in the front end of the nuclear fuel cycle (uranium mining and milling) has undergone a 
significant reduction since its peak in the early 1980s (ABMS 1994; EPA 1985a).  Mining and milling 
activities represent a source of minimal uranium release.  Uranium is mined using in situ leaching 
methods and uranium is recovered as a byproduct of the processing of phosphate ore (DOE 1995).  In 
2010, one conventional uranium mill, which recovers uranium from ores mined from the ground, and four 
uranium in situ leach plants were in operation in the United States (EIA 2010). 
 
As part of the nuclear fuel cycle, uranium conversion (EPA 1980b), uranium enrichment (MMES 1985), 
and fuel fabrication facilities also release small amounts of uranium to the atmosphere (Table 6-1).  
Uranium is converted to uranium hexafluoride (UF6) prior to enrichment.  There is the potential for 
release of some UF6 to the atmosphere during the conversion process or from storage of the depleted UF6.  
Upon release to the atmosphere, gaseous UF6 is rapidly hydrolyzed to UO2F2 (particulate) and 
hydrofluoric acid (gas) (Bostick et al. 1985).  Uranium is enriched in the United States by the gaseous 
diffusion process and ultracentrifugation, which produce appropriate enrichments for use in both 
commercial and government-operated facilities.  A large amount of depleted uranium is the byproduct of 
the enrichment process; the depleted uranium is kept in storage for further potential use (DOE 1994b) or 
used in commercial or military applications.  In one study, concentrations of uranium in the air near a 
uranium refinery (crude U refined to highly pure UO3) were found to be 200 times higher than 
background concentrations, which are typically low (Tracy and Meyerhof 1987). 
 
There are numerous locations where uranium has been released to the environment from the mining, 
milling, and processing of ore, or from the use of uranium metal for defense purposes.  These include 
DOE sites associated with nuclear weapons production, USNRC sites associated with uranium recovery 
and the nuclear fuel cycle, and Department of Defense (DOD) sites where enriched uranium nuclear and 
depleted uranium non-nuclear weapons have been tested or used in training (Agency for Toxic Substances 
and Disease Registry 2008; NNSA 2006).  Regulations are in place to guide protection efforts under the 
Formerly Utilized Sites Remedial Action Program (FUSRAP), Uranium Mill Tailings Radiation Control 
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Act of 1978 (UMTRCA), and Title 10 of the Code of Federal Regulations.  The DOE FUSRAP sites 
include 87 Legacy Management (LM) sites in 29 states and territories that have been remediated and 
under DOE surveillance or are associated with current uranium mining (DOE 2011c), and 24 sites being 
evaluated and decommissioned by the U.S. Army Corps of Engineers (ACE 2013; DOE 2013).  USNRC 
currently regulates 16 uranium recovery facilities (http://www.nrc.gov/reading-rm/doc-collections/fact-
sheets/mill-tailings.html), as well as 24 uranium recovery sites (in Washington, Wyoming, Utah, 
Colorado, New Mexico, Oklahoma, and Texas  (http://www.nrc.gov/info-
finder/decommissioning/uranium/) and 2 fuel cycle facilities (in Tennessee and Illinois, 
http://www.nrc.gov/info-finder/decommissioning/fuel-cycle/) undergoing decommissioning. 
 
Another method by which uranium may be introduced into the atmosphere is the natural process of 
erosion and wind activity (USGS 2010b, 2010c).  In geographic areas that contain higher levels of 
uranium in the rocks and soil, such as the western United States, additional natural uranium is introduced 
into the air.  Wind erosion of tailings at uranium mining and milling activities will also result in the 
resuspension of uranium and uranium progeny (e.g., radium-226 and radon-222) (Bigu et al. 1984; Hans 
et al. 1979; USGS 2010b, 2010c).  Approximately 5–10% of the uranium initially present ends up in the 
mill tailing (Uranium Institute 1996). 
 
Volcanic eruption is another natural phenomenon that may increase the concentration of natural uranium 
in the air (USGS 2010a).  After the eruption of Mount St. Helens, increased levels of 238U were observed 
in rainwater at Fayetteville, Arkansas, due to precipitation of 238U from the atmosphere (Essien et al. 
1985; Kuroda et al. 1984).  Other studies indicated that long-lived natural radionuclide (232Th, 226Ra, and 
40K) content in the ash was comparable to that of crustal material (Fruchter et al. 1980). 
 
Uranium releases occur as a result of phosphate mining for production of phosphorous, which is used in 
phosphoric acid and phosphate fertilizers (NCRP 1984a).  Phosphate rock from Florida, Texas, and 
southeastern Idaho contains as much as 120 ppm (80 pCi/g) uranium, a concentration sufficiently high to 
be considered as a commercial source of uranium (NCRP 1975). 
 
Coal also contains variable amounts of uranium and other elements such as sulfur.  The amount 
discharged to the atmosphere depends on the concentration in the coal, the amount burned, the method of 
combustion, the plant design, and the efficiency of fly ash recovery.  Approximately 90% of the coal mass 
is consumed during combustion.  Retained uranium concentrates in the nonvolatile fraction or ash.  The 
uranium concentration of the fly ash, which has been quantified by several investigators (Jaworowski and 
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Grzybowska 1977; Tadmor 1986; Weissman et al. 1983), has been found to be higher than in the original 
coal (NCRP 1984a), indicating that <90% of the uranium is released to the atmosphere.  A 550 MWe 
plant with a coal input of 1.5 million tons/year with a uranium content of approximately 3 tons may 
release 0.06–0.2 Ci (90–300 kg) of 238U and 234U per year (NCRP 1984a), indicating that modern coal 
power plants release more like 10% of the uranium.  A nuclear power plant by comparison releases 
essentially no uranium. 
 
Raw shale oil is also known to contain uranium, and retorting operations may result in the release of 
uranium to the environment.  Studies indicate that shale oil processing operations may increase 
atmospheric levels of 238U and 234U by a maximum of 0.04 fCi/m3 over background levels of uranium 
(Gogolak 1985). 
 
Uranium has been detected in air at 25 of 67 hazardous waste sites where uranium has been identified in 
some environmental component (HazDat 2007). 
 
6.2.2   Water  
 
There is no information on releases of uranium to the water from manufacturing and processing facilities 
because these releases are not required to be reported (EPA 1998a). 
 
The redistribution of uranium and uranium progeny to both surface water and groundwater occurs 
primarily from the natural erosion of rock and soil; some redistribution also comes from the mining, 
milling, and, to a lesser extent, conversion portions of the nuclear fuel cycle (Table 6-1).  Contamination 
of surface water and groundwater by effluents from uranium mining, milling, and production operations 
has been documented (Brandvold et al. 1981; Eadie and Kaufmann 1977; Hart et al. 1986; Swanson 1985; 
Yang and Edwards 1984). 
 
Uranium is discharged to surface water and/or groundwater during mining operations.  If an open-pit or 
underground mine extends below the water table, groundwater must be removed to permit mining 
operations to continue.  This is usually accomplished by pumping and discharging excess water into the 
ground or nearby bodies of water.  Since mine water is generally concentrated with uranium, its 
introduction into surface water bodies may produce measurable increases in uranium levels. 
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Waste waters from open-pit mines are typically one to two orders of magnitude greater in volume and 
radioactivity content than waters from shaft or underground mines (AEC 1974).  A typical open-pit mine 
may discharge a million gallons of water daily, giving releases of approximately 0.5 mCi/day or 
200 mCi/year, these releases consist of less uranium than other elements like radium and radon (AEC 
1974). 
 
Liquid releases from uranium mills have been implicated in contamination of surface water and nearby 
wells and groundwater (Table 6-1).  Contamination of groundwater and surface water can also occur by 
water erosion of tailings piles (Goode and Wilder 1987; Veska and Eaton 1991; Waite et al. 1988).  Since 
extraction of uranium ore during the milling process averages 90–95% recovery, the primary 
contaminants from uranium tailings disposal sites are uranium progeny (e.g., radium-226). 
 
Generation of liquid waste from the uranium conversion process (see Table 6-1) is generally small and is 
handled by placing liquid effluent in lined ponds with sealed bottoms.  The pond effluent is chemically 
neutralized to precipitate out uranium and uranium progeny in pond sludge.  Water in the ponds is 
permitted to evaporate and sludge is disposed of as waste under controlled conditions (AEC 1974). 
 
Liquid discharges containing uranium resulting from uranium enrichment and fuel fabrication are 
generally quite small (see Table 6-1). 
 
In addition to processes of the nuclear fuel cycle, release of uranium has been detected in surface water 
adjacent to a radioactive waste disposal site in Massachusetts (DOE 1981c).  238U measurements indicated 
that surface water located adjacent to the waste disposal site had concentrations of up to 155 pCi/L.  
Additionally, groundwater measurements of 238U and 235U at the disposal site were 4,400 pCi/L and 
2,400 pCi/L, respectively.  These values were elevated compared to values obtained in a study performed 
for the EPA (DOE 1981b).  For the EPA study, a total of 35,000 surface water samples from across the 
United States were analyzed; the average total uranium concentration was 1.1 pCi/L (range 0.01–
582 pCi/L).  Of these, 28,000 were considered samples of domestic water supplies.  In this same study, 
55,000 groundwater samples had a total mean uranium concentration of 3.2 pCi/L (range 0.01–
635 pCi/L). 
 
Uranium has been detected in surface water samples at 22 of 67 hazardous waste sites and in groundwater 
samples at 37 of 67 hazardous waste sites where uranium has been identified in some environmental 
component (HazDat 2007).  Examples of uranium values in groundwater and surface water include the 
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Uravan site (uranium levels ranged from 1,500 to 16,000 pCi/L) and the tailings pond of the United 
Nuclear site (uranium concentrations were as high as 3,900 pCi/L).  A break in the tailings pond dam in 
1979 sent 93 million gallons of tailings liquid into the Rio Puerco (EPA 1988b).  The distribution of 
Superfund NPL sites is shown in Figure 6-1. 
 
6.2.3   Soil  
 
There is no information on releases of uranium to the soil from manufacturing and processing facilities 
because these releases are not required to be reported (EPA 1998a). 
 
Uranium is a naturally occurring radionuclide that is present in nearly all rocks and soils (soils being 
derived from erosion of the rocks).  The average concentration in U.S. soils is about 2 pCi/g (3 ppm); 
however, much higher levels are found in areas such as the Colorado Plateau and lands supporting current 
and previous phosphate mining in Florida, Texas, and South Carolina.  Lower concentrations of uranium 
are found in basic rocks (e.g., basalt, 0.02–0.03 pCi/g), while acidic rocks contain higher uranium 
concentrations (e.g., sedimentary 1.0 pCi/g) (Clayton and Clayton 1981; NCRP 1984a).  The uranium 
present in the rocks and soil as a natural constituent represents natural background levels. 
 
Contamination of the soil can occur either from deposition of uranium originally discharged into the 
atmosphere, or from waste products discharged directly into or on the ground (e.g., water containing 
uranium from either underground or open-pit mines).  Examples of industrial activities that may result in 
soil deposition include uranium mining and milling, uranium processing, phosphate mining, heavy metal 
mining, coal use, and inappropriate waste disposal. 
 
In the process of mining uranium, when the depth of the mine is below the water table (either an open-pit 
or underground mine), the resulting water is pumped from the mine and often discharged directly to the 
ground or into surface water.  For uranium milling, uranium in the ore is extracted (currently 90–95%, 
originally >50%) so that wastes from uranium milling contain only low levels of uranium; however, the 
levels of uranium progeny (e.g., radium) remain essentially unchanged.  Uncontrolled erosion of these 
wastes from open tailings piles not protected from the weather occurred at a Shiprock, New Mexico, 
uranium mill site, resulting in contamination of the surrounding area (Hans et al. 1979).  Uncontrolled 
erosion also occurred in storage areas such as the St. Louis Airport Storage Site in Missouri (DOE 1985).  
Increased levels of uranium, radium, radon, and other decay products of uranium have also been 
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measured around these sites, particularly in the soil.  A number of controlled disposal locations on 
government-owned mill sites exist, but the ones identified involved uncontrolled disposal. 
 
At various facilities that process uranium for defense programs, uranium is released to the atmosphere 
under controlled conditions, resulting in deposition on the soil and surface waters.  Monitoring data from 
the area surrounding the Fernald Environmental Management Project (formerly the Fernald Feed 
Materials Production Center) showed that soil contained uranium released from the facility (Stevenson 
and Hardy 1993). 
 
The uranium content of phosphate rock, a source of phosphorus for fertilizers and phosphoric acid for the 
chemical industry, ranges from several pCi/g to 130 pCi/g (several ~200 μg/g) (Boothe 1977; UNSCEAR 
1977, 1982).  During milling, much of the uranium content becomes concentrated in slag byproducts 
(Melville et al. 1981).  The slag byproducts are often used for bedrock in the paving of roads, thus 
transferring the uranium-rich slag to the soil (DOE 1986a; Melville et al. 1981).  Because of the large 
amounts of phosphate fertilizer produced annually (12–15 million tons), trace amounts of uranium 
progeny remaining in the fertilizer result in the distribution of about 120 Ci (180 metric tons) per year 
over U.S. agricultural lands (Kathren 1984). 
 
Combustion of coal is a significant source of enhanced natural radioactivity (especially combustion of 
coal from the western United States, which contains significantly more uranium than coal from the 
eastern United States).  When coal is burned, some of the radioactivity is released directly to the 
atmosphere, but a significant fraction is retained in the bottom ash.  Enhanced concentrations of uranium 
have been found on the ground around coal-fired power plants (UNSCEAR 1982). 
 
Unauthorized landfill disposal of uranium processing wastes (e.g., Shpack Landfill in Norton, 
Massachusetts, and the Middlesex Municipal Landfill in Middlesex, New Jersey) has resulted in soil 
contamination (DOE 1981c, 1984c).  Also, elevated uranium concentrations have been measured in soil 
samples collected at 45 of 67 hazardous waste sites and in sediment samples at 25 of 67 hazardous waste 
sites (HazDat 2007).  In several cases, the uranium concentrations in soils were significantly elevated.  
For example, uranium concentrations from the Shpack/ALI site were found to be 16,460 pCi/g 
(24,000 μg/g).  At the United States Radium Corporation site (New Jersey), uranium concentrations 
ranged from 90 to 12,000 pCi/g (130–18,000 μg/g); for the Monticello site (Utah), uranium levels were 
reported to range from 1 to 24,000 pCi/g (1.5–36,000 μg/g) (HazDat 2007). 
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The use of depleted uranium ammunition during military conflicts and training exercises will result in the 
localized release of depleted uranium to soil at those locations (Carvalho and Oliveira 2010; Oliver et al. 
2007, 2008a, 2008b; Parrish et al. 2008; Radenkovic et al. 2008; Sansone et al. 2001). 
 
6.3   ENVIRONMENTAL FATE  
 
6.3.1   Transport and Partitioning  
 
The components of an ecosystem can be divided into several major compartments (Figure 6-2) (NCRP 
1984b).  None of the environmental compartments exist as separate entities; they have functional 
connections or interchanges between them.  Figure 6-2 also shows the transport pathways between the 
released uranium and the environmental compartments as well as the mechanisms that lead to intakes by 
the population.  Initial uranium deposition in a compartment, as well as exchanges between compartments 
(mobility), are dependent upon numerous factors such as chemical and physical form of the uranium, 
environmental media, organic material present, oxidation-reduction potential, nature of sorbing materials, 
and size and composition of sorbing particles. 
 
Natural processes of wind and water erosion, dissolution, precipitation, and volcanic action acting on 
natural uranium in rock and soil redistribute far more uranium in the total environment than the industries 
in the nuclear fuel cycle.  However, those industries may release large quantities of uranium in specific 
locations, mainly in the form of solids placed on tailings piles, followed by liquids released to tailings 
ponds and then airborne releases, both directly from the facilities and by wind erosion of the tailings piles.  
Although solid releases represent the largest quantity of uranium redistribution, they remain on the 
facility grounds and are normally inaccessible to the public.  It is the airborne (direct and wind erosion on 
tailings piles) and liquid releases (tailings pond runoff and water erosion of tailings) that most likely 
represent the important pathways for public exposure (i.e., inhalation and ingestion) if pathways can be 
completed. 
 
While entrained in the air, particulate uranium represents an inhalation source for humans, the extent of 
which is dependent upon concentration and particle size.  For particulate uranium to be an inhalation 
hazard to humans, the particulates must be in the size range of 1–10 μm (Bigu and Duport 1992; ICRP 
1979).  In some cases, the solid tailings have been removed from the site for use as fill or construction 
material, which can lead to external radiation exposures primarily from the uranium progeny. 
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Deposition of the atmospheric uranium can occur by dry deposition or wet deposition (Essien et al. 1985).  
Dry deposition results from gravitational settling and impaction on surfaces exposed to turbulent 
atmospheric flow.  The rate of dry deposition is dependent upon particle size distribution, chemical form, 
particle density, and degree of air turbulence.  Few experimental data on the particle size and residence 
time of uranium and uranium compounds present in ambient atmospheres are available; however, 
uranium particles are expected to behave like other particles for which data are available, which show that 
smaller uranium particles (<5 μm) travel longer distances than larger particles because of their longer 
residence time in the atmosphere due to their low settling velocity. 
 
The chemical form of the uranium affects the atmospheric residence time.  One uranium compound for 
which there are data regarding residence time and particle size is uranium hexafluoride, a soluble 
compound, which will hydrolyze in the atmosphere to particulate UO2F2$nH2O and hydrogen fluoride gas 
(Bostick et al. 1985).  In the case of UO2F2, although the particles were small (<2.5 μm), its atmospheric 
residence time was estimated to be only 35 minutes as a result of rapid hydration and agglomeration to 
larger particles that have faster settling velocities (Bostick et al. 1985). 
 
In wet deposition of airborne contaminants, the uranium is washed from the atmosphere by rain, sleet, 
snow, or other forms of moisture.  The rate of wet deposition depends upon particle size and solubility 
(chemical form). 
 
Uranium thus deposited (dry or wet) will usually reside on land or be deposited on surface waters.  If land 
deposition occurs, the uranium can incorporate into the soil or adhere to plant surfaces, be resuspended in 
the atmosphere as a result of wind action, or be washed from the land into surface water and groundwater.  
Resuspension factors are typically quite low (10-6) and protective against significant exposures, but this 
may not apply to windy and arid areas.  Resuspension into the air can be an inhalation source even after 
the plume or source has disappeared. 
 
In addition to the migration of dissolved or suspended uranium due to the movement of water in the 
environment, the transport and dispersion of uranium in surface water and groundwater are affected by 
adsorption and desorption of the uranium on surface water sediments.  On the other hand, migration of 
uranium in soil and subsoil and uptake in vegetation are usually quite local involving distances from 
several centimeters to several meters. 
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In most waters, sediments act as a sink for uranium and the uranium concentrations in sediments and 
suspended solids are several orders of magnitude higher than in surrounding water (Brunskill and 
Wilkinson 1987; Swanson 1985).  Factors that control the mobility of uranium from sediment to the water 
phase are the oxidation-reduction potential, the pH, the characteristics of complexing agents or ligands, 
and the nature of sorbing materials in the water.  Inorganic or organic ligands that can form soluble 
complexes with uranium will result in mobilization of the uranium in water.  However, the stability of 
such complexes is dependent on the pH.  For example, uranium is likely to be in solution as a carbonate 
complex in oxygenated water with high alkalinity (Herczeg et al. 1988); however, in acidic waters 
(pH <6 containing low concentrations of inorganic ions and high concentrations of dissolved organic 
matter), the uranium is in solution as the soluble organic complex (Brunskill and Wilkinson 1987). 
 
The oxidation-reduction potential of water is important in controlling the mobility of uranium.  In anoxic 
waters where the aquatic environment is reductive, U(VI) will be reduced to U(IV) (e.g., changed from a 
soluble compound to an insoluble one).  The U(IV) will be deposited into the sediment due to the 
insolubility of the resulting U(IV) salts (Allard et al. 1979; Herczeg et al. 1988).  Mobilization and 
deposition of uranium as defined by the oxidation-reduction potential of the water has been observed by 
several investigators (Barnes and Cochran 1993; Shaw et al. 1994).  Uranium can also be removed from 
solution by physical adsorption processes, such as adsorption onto oxides of iron or manganese that occur 
as coatings on the particles of soil and sediment (Ames et al. 1982). 
 
The mobility of uranium in soil and its vertical transport (leaching) to groundwater depend on properties 
of the soil such as pH, oxidation-reduction potential, concentration of complexing anions, porosity of the 
soil, soil particle size, and sorption properties, as well as the amount of water available (Allard et al. 1982; 
Bednar et al. 2007; Crancon et al. 2010; DOE 1992; Schimmack et al. 2007).  Retention of uranium by 
the soil may be due to adsorption, chemisorption, ion exchange, or a combination of mechanisms (Allard 
et al. 1982).  Any soil property that alters the sorption mechanism will also alter the mobility of uranium 
in the soil.  The sorption of uranium in most soils is such that it may not leach readily from soil surface to 
groundwater, particularly in soils containing clay and iron oxide (Sheppard et al. 1987), although other 
geological materials such as silica, shale, and granite have poor sorption characteristics (DOE 1992; Erdal 
et al. 1979; Silva et al. 1979; Ticknor 1994). 
 
Sorption in most soils attains a maximum when the neutral hydroxy complex of uranium is at a 
maximum.  However, at pH 6 and above, and in the presence of high carbonate or hydroxide 
concentrations, uranium may form anionic complexes such as the uranyl hydroxide anion, UO2(OH)4-2.  
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The mobility of anionic uranium complexes in soil is dependent upon the nature of the soil.  For example, 
the decrease in sorption in soil with little anion-exchange capacity may result in increased mobility; 
however, increased sorption in soil with high anion-exchange may result in decreased mobility (Allard et 
al. 1982; Ames et al. 1982; Brookins et al. 1993; Ho and Doern 1985; Hsi and Langmuir 1985; Ticknor 
1994). 
 
Other factors also affect the mobility of uranium in soil.  A field study performed near an active carbonate 
leach uranium mill showed that uranium in an alkali matrix can migrate to the groundwater (Dreesen et al. 
1982).  Uranium mobility may also be increased due to the formation of soluble complexes with chelating 
agents produced by microorganisms in the soil (Premuzic et al. 1995). 
 
Uranium may be transported to vegetation by air or by water.  It can be deposited on the plants 
themselves by direct deposition or resuspension, or it can adhere to the outer membrane of the plant’s root 
system with potential limited absorption.  Similarly, uranium deposited on aquatic plants or water may be 
adsorbed or taken up from the water.  The plants, aquatic or terrestrial, may be eaten directly by humans 
or consumed by land or aquatic animals, which provide food for humans.  The uptake or bioconcentration 
of uranium by plants or animals is the mechanism by which uranium in soil, air, and water enters into the 
food chain of humans. 
 
Numerous factors influence the bioaccumulation of uranium, such as the chemical and physical form of 
the uranium; the season of the year and other climatic factors such as temperature, age of the organism, 
specific tissue or organs involved; and the specific characteristics of the local ecosystem, such as total 
suspended and dissolved solids.  Bioconcentration factors for uranium have been measured by several 
investigators in various aquatic organisms.  Mahon (1982) measured bioconcentration factors of 
1,576 and 459 in algae and plankton, respectively.  Horikoshi et al. (1981) determined bioconcentration 
factors in several species of bacteria that ranged from 2,794 to 354,000.  However, bioconcentration by 
the bacteria represented adsorption onto the cell surfaces of the bacteria rather than true biological uptake. 
 
Low bioconcentration factors for uranium were observed in fish.  The highest bioconcentration factors 
observed in fillet of rainbow trout (Oncorhynchus mykiss), white and finescale suckers (Catostomus 
commersoni and C. catastomus), and lake whitefish (Coregonus clupeaformis) did not exceed a value of 
38 (Mahon 1982; Poston 1982; Swanson 1983, 1985).  Ahsanullah and Williams (1989) concluded that 
the primary source of uranium for crab (Pachygrapsus laevimanus) and zebra winkle (Austrocochlea 
porcata) was from water since both fed and starved animals took up uranium at the same rate. 
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Uranium is transported poorly from soils to plants (Dreesen et al. 1982; Moffett and Tellier 1977).  As 
with aquatic organisms, the uptake of uranium by plants is dependent on the nature of the soils (soil 
texture and organic content), the pH, and the concentration of uranium in the soil.  Greater plant uptake is 
expected to occur in soils that contain higher levels of available uranium (i.e., less sorption of uranium to 
soil particles or formation of soluble uranium complexes).  Swiss chard grown in sandy soils contained 
80 times the levels of uranium found in Swiss chard grown in peat soil (Sheppard et al. 1983).  The 
uptake of uranium by native plants, expressed as plant/soil concentration ratio (CR), grown near a mining 
and milling complex was 0.8 compared to a CR of 0.09 for plants grown in soil with background levels of 
uranium (Ibrahim and Wicker 1988).  The effect of soil and plant type on CR values has been reviewed 
by Mortvedt (1994). 
 
Reported CR values for plant/soil interaction vary widely (range, 0.0025–0.81) (Garten 1978; Ibrahim and 
Wicker 1988; Mortvedt 1994).  Although some studies indicate that CR values in plants do not vary 
linearly with the concentration of uranium in the soil (Mortvedt 1994), other reported studies show a 
linear relationship between plant content and soil content of uranium (NCRP 1984a).  It has been 
postulated that uranium uptake by plants may be limited to the outer membrane of the root system and 
may not occur on the interior of the root at all (Van Netten and Morley 1983; Sheppard et al. 1983).  
However, other investigators have reported the transfer of uranium from soil to the stems and leaves of 
plants in which the CR decreased in the following order:  fruit < leaf < root (Morishima et al. 1977).  
Because of the higher root sorption of uranium, it has been postulated that consumption of radishes and 
other root vegetables grown in uranium-containing soils may be a source of human exposure (Van Netten 
and Morley 1983).  Thorough cleansing of the plant exterior, especially if performed in conjunction with 
removal of the outer membrane, may remove most or all of the uranium. 
 
6.3.2   Transformation and Degradation  
 
6.3.2.1   Air  
 
The presence of uranium and uranium compounds in the atmosphere results from activities associated 
with uranium mining, milling, processing, and use.  There is limited information available regarding the 
abiotic transformation and degradation of uranium and uranium compounds, except for uranium 
hexafluoride.  Uranium hexafluoride immediately hydrolyzes on contact with moisture in the air to form 
uranyl fluoride (UO2F2) and hydrofluoric acid (HF).  Uranyl fluoride is hygroscopic and will absorb 
moisture from the air, resulting in an increased settling velocity associated with the larger particle size.  
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The half-life of a release of airborne UF6 is about 35 minutes (Bostick et al. 1985).  Uranyl fluoride is a 
stable oxohalide compound of uranium which is soluble in water, a factor that will increase its mobility in 
the environment once deposition from the air has occurred. 
 
6.3.2.2   Water  
 
The principal abiotic processes that transform uranium in water are formation of complexes and 
oxidation-reduction reactions that have been described in Section 6.3.1.  In seawater at pH 8.2, it was 
shown that U(IV) exists as 100% neutral hydroxo complexes, and UO2+2 and U(VI) exist as 
100% carbonato complexes.  In freshwater at pH 6, U(IV) was shown to exist as 100% hydroxo 
complexes, and UO2+2 existed as 12% hydrated complexes, 18% hydroxo complexes, 8% fluoro 
complexes, and 60% carbonato complexes.  In freshwater at pH 9, U(IV) exists as 100% hydroxo 
complexes, but UO2+2 exists as 100% carbonato complexes (Boniforti 1987). 
 
Oxidation-reduction conditions are important in the geologic transport and deposition of uranium.  
Oxidized forms of uranium (U[VI]) are relatively soluble and can be leached from the rocks to migrate in 
the environment.  When strong reducing conditions are encountered (e.g., presence of carbonaceous 
materials or H2S), precipitation of the soluble uranium will occur. 
 
6.3.2.3   Sediment and Soil  
 
The primary abiotic and biological processes that transform uranium in soil are oxidation-reduction 
reactions that convert U(VI) (soluble) to U(IV) (insoluble).  Reduction of U(VI) to U(IV) can occur as a 
result of microbial action under anaerobic soil or sediment conditions, thereby reducing the mobility of 
uranium in its matrix (Barnes and Cochran 1993; Francis et al. 1989; Gavrilescu et al. 2009).  Further 
abiotic and biological processes that can transform uranium in the environment are the reactions that form 
complexes with inorganic and organic ligands (see Section 6.3.1). 
 
Certain microorganisms (e.g., Thiobacillus ferrooxidans) can facilitate the oxidation of Fe+2 to Fe+3.  The 
Fe+3 ion, in turn, can convert insoluble uranium dioxide to soluble UO2+2 ions by the following reaction: 
 
2Fe+3 + UO2  UO2+2 + 2Fe+2 
 
This reaction enhances the mobility of uranium in soil from mining and milling wastes (Barnes and 
Cochran 1993; de Siloniz et al. 1991; Scharer and Ibbotson 1982).  Uranium may be removed from the 
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pore water of sediments under sulfate reduction conditions; microbes may control this process indirectly 
(Barnes and Cochran 1993). 
 
Handley-Sidhu et al. (2009) observed the oxidation of UO2 from depleted uranium penetrator surfaces in 
waterlogged soils resulting in the formation of mobile U(VI) species. 
 
6.4   LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
 
Reliable evaluation of the potential for human exposure to uranium depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens.  Concentrations of 
uranium in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits 
of current analytical methods.  In reviewing data on uranium levels monitored or estimated in the 
environment, it should also be noted that the amount of chemical identified analytically is not necessarily 
equivalent to the amount that is bioavailable.  The analytical methods available for monitoring uranium in 
a variety of environmental media are detailed in Chapter 7. 
 
In 1973, the EPA established the nationwide network RadNet (formerly called ERAMS) for obtaining 
data in environmental samples.  RadNet consists of a network of sampling stations that provide air, 
surface and drinking water, and milk samples that the EPA uses to obtain environmental concentrations of 
radioactive material.  The objective of this system is to identify trends in the accumulation of long-lived 
radionuclides in the environment (EPA 2007, 2010b).  Sampling locations for RadNet are located near 
primary population centers to provide optimal population coverage. 
 
The ratio of 234U to 238U would be expected to be unity as long as the uranium stays locked inside 
undisturbed crustal rock in secular equilibrium with its progeny, but measurements show that the ratio is 
typically different than unity (EPA 1997b, 2007).  This disequilibrium occurs when the rock is disturbed 
by chemical or physical changes involving water.  In the environment, a portion of the 234U separates 
from the 238U by what is theorized to be a physical process (alpha recoil ejection of the 232Th decay 
product from surfaces of soil particles) or a combination of physical and chemical processes (a 238U 
transformation at the soil particle surface fractures the surface allowing access for water to dissolve the 
more soluble 234Th product) (NCRP 1984a).  These processes can change the uranium isotope ratios in 
air, soil, and water. 
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6.4.1   Air  
 
For airborne particles collected for the RadNet program, 234U, 235U, and 238U analyses are performed on 
semiannually composited air filters collected from continuously operating airborne particulate samplers.  
Following chemical separation, the uranium is quantified by α-spectroscopy. 
 
Table 6-2 shows the results of monitoring for uranium in airborne particles for the October to December 
2007 composites as published in Report 132 (EPA 2007).  Results from October through December 1997 
are included as well (EPA 1997b).  The locations of air samples with the highest total uranium 
concentrations were Las Vegas, Nevada; El Paso, Texas; Ross, Ohio; Lynchburg, Virginia; and Phoenix, 
Arizona (listed in descending concentrations of airborne total uranium).  In all cases, atmospheric levels 
of total uranium were low, in the attocurie/m3 range.  The airborne data show 234U to 238U ratios that range 
from 1.0 to 7.4, many of which are significantly different from the one-to-one ratio found in crustal rock. 
 
Uranium in airborne dust appears to result from resuspension of soil and, consequently, airborne dust has 
the same uranium concentration as the soil particles that produce it.  Airborne dust near uranium mining 
or milling operations would be expected to contain higher than background levels of total uranium and 
have an isotope ratio the same as crustal rock as long as the surface material from which it originated had 
not experienced significant weathering by moisture.  Some examples of airborne uranium levels near 
mining and milling operations when the industry was actively producing uranium ore are included below 
for comparison with EPA values in Table 6-2.  The annual average concentration of uranium in ambient 
air taken near the Jackpile Open Pit mine (New Mexico) was 2.4 fCi/m3 (EPA 1979a), and the 
concentration of uranium in air measured near a Canadian refinery ranged between 1.3 and 134 fCi/m3 
(2–200 ng/m3) with a geometric mean of 13 fCi/m3 (20 ng/m3) (Tracy and Meyerhof 1987).  Air samples 
taken near a uranium mill tailings pile showed a uranium concentration of 1 pCi/m3 (NCRP 1984a).  Near 
the Paducah Gaseous Diffusion Plant in Kentucky, where uranium enrichment is performed, the 
maximum total air alpha activity in 1979 at one location was 0.7 pCi/m3 (DOE 1981a). 
 
6.4.2   Water  
 
Until the early 1980s, uranium in drinking water was not often measured except when contamination was 
suspected.  Welford and Baird (1967) found a concentration of 0.02 pCi/L in New York City tap water.  
UNSCEAR (1977) reported that tap water usually contains <0.03 pCi/L. 
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Augusta, Maine 25±4.1 2.8±1.4 22.1±3.8 — — — 
Detroit, Michigan — — — 16.7±3.8 2±1.4 19.7±4.2 
Lansing, Michigan 14.7±2.5 1.25±0.82 13±2.4 12.5±2.9 0.92±0.85 11.3±2.7 
Minneapolis, Minnesota 9.3±1.6 1.04±0.55 6.6±1.3 — — — 








January–December 1997 January–December 2007 
234U 235U 238U 234U 235U 238U 
Fairbanks, Alaska 13.3±2.5 1.79±0.99  11.6±2.3  — — — 
Birmingham, Alabama — — — 44±11 2.3±2.8 29.4±8.6 
Montgomery, Alabama 19.7±4.2 2.5±1.6 15.7±3.7 13.8±3.9  1.3±1.3 6.8±2.6 
Little Rock, Arkansas 22.9±4.6 1.6±1.3 21.6±4.4 93±18 7.4±4.5 88±17 
Phoenix, Arizona 66±12 6.3±3.9 50±10 64±18 0.7±3.3 42±14 
Berkeley, California 8.7±2.3 0.64±0.71 6.3±2.0 — — — 
Los Angeles, California 26.8±5.9 2.4±1.9 20.5±4.9 39±13 1.7±3.7 26±11 
Richmond, California — — — 9.6±3.2 1±1.2 4.1 
San Diego, California — — — 21.8±6.3 3±2.7 26.1±7 
San Francisco, California — — — 9.6±4.2 1.7±2.1 6.9±3.5 
Denver, Colorado 35.6±5.3 3.7±1.8 31.9±4.9 18.2±3.9 3.7±1.7 16.4±3.6 
Hartford, Connecticut 14±3.0 1.9±1.1 12.3±2.7 15.6±4.4 0.5±1 10.7±3.5 
Washington, District of 
Columbia  
  13.1 0 9.9 
Wilmington, Delaware 14.7±2.9 2.7±1.3 12.8±2.7 16.9±5.2 1.9±2 13.8±4.7 
Jacksonville, Florida 10.5±2.1 0.56±0.50 9.7±2.0 14.5±4.4 0.8±1.4 9.6±3.5  
Miami, Florida 10.1±2.4 0.78±0.81 9.2±2.2 21±6.1 0.9±1.6 17.4±5.5  
Orlando, Florida — — — 11.8±3.6 2.5±1.8 8.6±3 
Atlanta, Georgia — — — 26.3±6.4 3.1±2.2 18.4±5.2 
Honolulu, Hawaii 3.01±0.91 0.47±0.40 2.33±0.78 — — — 
Des Moines, Iowa — — — 16±3.2 1.9±1.2 16±3.2 
Iowa City, Iowa 19.1±3.1 2.5±1.2 14.9±2.7 18.6±4.1 2.6±1.5 16.1±3.7 
Boise, Idaho 22.6±3.9 0.94±0.88 19.7±3.6 — — — 
Idaho Falls, Idaho 16.8±3.5 1.4±1.1 19.6±3.8 — — — 
Chicago, Illinois — — — 43±11 7.2±4.6 38±10 
Indianapolis, Indiana 26.8±3.7 2.5±1.1 22.8±3.4 29.5±6.3 2.5±1.9 28.1±6.1 
Kansas City, Kansas — — — 26.7±5.9 2.4±1.9 27.4±5.9 
Topeka, Kansas 17.1±2.8 2.5±1.1 15.6±2.6 20.8±4.4 2.7±1.5 17±3.9 
Boston, Massachusetts — — — 8.8±2.4 0.37±0.66 5.9±1.9 
Baltimore, Maryland — — — 14.4±4.1 0.19±0.85 8.9±3.2 
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January–December 1997 January–December 2007 
234U 235U 238U 234U 235U 238U 
Welch, Minnesota 14.5±2.2 1.75±0.82 15.5±2.3 — — — 
Welch, Minnesota 4.25±0.79 0.24±0.23 4.22±0.79 — — — 
St. Louis, Missouri — — — 10±2.4 0.75±0.73 11.3±2.6 
Jackson, Mississippi 17.9±4.5 2.9±1.9 17.1±4.4 14.5±5.1 -0.15±0.98 11.9±4.5 
Charlotte, North Carolina 22.9±5.2 1.6±1.6 21.3±5.0 20.9±6.2 1.8±2 20.5±6.1 
Wilmington, North Carolina 23.1±2.4 1.2±0.51 20.6±2.3  12±3.5 0±0.78 13.3±3.7 
Bismarck, North Dakota 17.1±3.4 1.7±1.2 15.9±3.3 23.3±4.8 2.3±1.9 21.4±4.6 
Concord, New Hampshire 9.9±2.0 1.29±0.74 9.6±2.0 10.2±2.9 1.1±1 9.2±2.7 
Edison, New Jersey — — — 10.7±3 0.53±0.82 9.0±2.7 
Trenton, New Jersey 19.3±4.9 1.1±1.4 16±4.4 15.5±4.3 1.7±1.5 12.3±3.8 
Santa Fe, New Mexico 35.2±5.1 2.2±1.3 31.5±4.8 19.4±4 0.67±0.79 18.7±3.9 
Las Vegas, Nevada 44.4±7.2 2.9±1.9 32.8±6.0 55±12 4.4±3.2 36.1±3.9 
Albany, New York — — — 11.3±3.9 1.2±1.5 10±3.6 
Lockport, New York — — — 4±1.7 0.69±0.78 5.7±2 
New York City, New York 13.1±2.9 0.47±0.55 14.5±3.0 18.5±5.5 1.8±2 21.4±6 
Syracuse, New York 10.1±1.7 1.01±0.56 10.3±1.7 — — — 
Yaphank, New York 6.9±1.4 0.41±0.36 5.7±1.3 7.9±2.3 0.16±0.47 3.7±1.5 
Cincinnati, Ohio — — — 11.5±2.5 0.54±0.54 9.2±2.2 
Cleveland, Ohio — — — 24.0±5 0.83±0.94 22.7±4.9 
Columbus, Ohio 20.7±2.6 1.86±0.79 17.2±2.4 19.7±4.2 1.9±1.3 20.6±4.4 
Painesville, Ohio 11.2±1.9 0.9±0.57 9.6±1.7 13.3±2.8 0.37±0.51 11.2±2.5 
Ross, Ohio 34.4±5.0 2.3±1.4 30.7±4.7 17.8±4.3 3.1±1.8 18.1±4.3 
Oklahoma City, Oklahoma — — — 12.6±2.9 0.99±0.81 9.0±2.4 
Portland, Oregon — — — 9.1±3.8 0.4±1.2 9.2±3.8 
Harrisburg, Pennsylvania 10.7±2.2 0.84±0.64 11.5±2.3 8.1±2.9 1.7±1.4 10.1±3.2 
Pittsburgh, Pennsylvania — — — 18.3±4.8 0.9±1.3 14.1±4.1 
San Juan, Puerto Rico — — — 6.2±2.8 0.32±0.94 5.6±2.7 
Providence, Rhode Island — — — 13.1±3.8 1.2±1.3 10.1±3.3 
Barnwell, South Carolina 13.1±1.9 1.29±0.59 11.2±1.7 7.7±2.1 0.4±0.55 7.9±2.2 
Columbia, South Carolina 33.4±5.4 2.5±1.5 31.9±5.3 32.0±7.9 2.7±2.5 26.3±7 
Pierre, South Dakota 14.1±2.5 0.96±0.71 11.3±2.2 19.3±4.4 1.2±1.2 18.9±4.4 
Knoxville, Tennessee 24.1±5.5 2.6±2.1 17.7±4.7 26.9±7.6 5.5±3.6 20.1±6.4 
Memphis, Tennessee — — — 20.7±6.6 3.7±3.2 21.3±6.6 
Nashville, Tennessee 17.2±3.5 1.4±1.1 16.2±3.4 12.6±4.5 0.3±1.2 11.7±4.3 
Oak Ridge/Bethel, Tennessee 11.5±1.9 2.14±0.85 7.4±1.5 12.3±3.3 1.1±1.1 12.4±3.4 
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January–December 1997 January–December 2007 
234U 235U 238U 234U 235U 238U 
Oak Ridge/Melton, Tennessee 7.6±1.1 0.4±0.27 7±1.0 9.9±3.2 0.7±1 8.3±2.9 
Oak Ridge/Y12 E, Tennessee 27.5±3.6 2.8±1.2 17.6±2.8 65±12 6.6±3.2 20.1±5.5 
Oak Ridge/Y12 W, Tennessee 84.2±6.4 5.5±1.3 29.8±3.1 13.0±3.6 1.1±12 9.1±2.9 
Austin, Texas 9.8±1.8 0.6±0.48 8.6±1.7 12.7±2.9 0.15±0.64 8.6±2.3 
Austin/Concordia, Texas — — — 12.2±3 0.74±0.79 12.3±3 
Dallas, Texas — — — 13.7±3 1.07±0.86 12.7±2.9 
El Paso, Texas 57±10 2.8±2.6 48.6±9.3 66±13 4.0±3.1 48±11 
Ft. Worth, Texas — — — 12.2±3 1.03±0.95 13.3±3.1 
Houston, Texas — — — 22.4±5.2 1.1±1.2 22.6±5.1 
Salt Lake City, Utah 35.4±7.1 1.8±1.6 30.1±6.4 33.5±7.6 2.3±2 27.2±6.6 
Lynchburg, Virginia 86.2±8.5 4.1±1.2 10.1±1.8 47.9±8.1 1.3±1.1 9.8±2.8 
Richmond, Virginia — — — 15.3±3.8 0.75±0.95 13.6±3.5 
Virginia Beach, Virginia — — — 10.9±2.9 0.37±0.78  10.5±2.9 
Olympia, Washington 3.8±1.1 0.29±0.41 2.29±0.85 — — — 
Spokane, Washington 16.6±3.4 1.8±1.2 13.4±3.0 17.8±6.7 0.4±0.9 18.1±6.7 
Madison, Wisconsin 10.7±1.6 1.03±0.5 11.9±1.7 — — — 
Milwaukee, Wisconsin — — — 11.5±3 0.48±0.75 11.5±3 
 
aCi = attocurie, 10-18 curie 
 
Sources:  EPA 1997b, 2007 
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A large study was performed in which data from the NURE program plus data prepared for the EPA 
(DOE 1981b) were compiled.  Over 90,000 water samples were analyzed for uranium.  The total data 
included approximately 35,000 surface water samples that averaged 1.1 pCi/L and approximately 
55,000 groundwater samples that averaged 3.2 pCi/L (NCRP 1984a).  The population-weighted average 
concentration was 0.8 pCi/L, which was higher than the 0.03 pCi/L reported by UNSCEAR (1977).   
 
Ohanian (1989) reported a population-weighted average concentration of uranium in U.S. community 
drinking water ranging from 0.3 to 2.0 pCi/L.  Another study showed that the average uranium 
concentrations in drinking water exceeded 2 pCi/L in South Dakota, Nevada, New Mexico, California, 
Wyoming, Texas, Arizona, and Oklahoma.  States in which the average drinking water uranium levels 
exceeded 1 pCi/L are shown in Figure 6-3 (Cothern and Lappenbusch 1983; EPA 1985c).  In another 
study based on NURE data, the mean uranium concentration in samples of more than 28,000 domestic 
water supplies was 1.73 pCi/L, with a median concentration range of 0.1–0.2 pCi/L (Cothern and 
Lappenbusch 1983).  The level of uranium in 2,228 water supplies was ≥10 pCi/L, while in 979 water 
supplies, the uranium concentrations were ≥20 pCi/L.  Most of these water supplies were in small towns 
and served less than a few thousand people (Cothern and Lappenbusch 1983; EPA 1985c). 
 
The EPA RadNet program reports the uranium content of drinking water samples collected at selected 
U.S. population centers (EPA 1997b, 2005a, 2010b).  The data for 234U, 235U, and 238U measured during 
January through December 1997 and during October through December 2005 are presented in Table 6-3.  
The RadNet program collects drinking water samples from 78 population centers across the United States; 
however, analysis of uranium is only performed in samples that show elevated gross alpha radioactivity of 
greater than 2pCi/L (EPA 2010b).  Therefore, the levels listed here represent the upper bound of uranium 
concentrations in all drinking water samples collected under the RadNet program.  The RadNet data are in 
agreement with the earlier measurements reported above that the average concentration of uranium in 
U.S. drinking water is generally <1 pCi/L.  The drinking water samples with the highest total uranium 
concentrations were obtained from Santa Fe, New Mexico; Lincoln, Nebraska; Las Vegas, Nevada; and 
Los Angeles, California (listed in descending concentration of total uranium). 
 
Older data sets compiled by the EPA RadNet program include measurements of the uranium content of 
precipitation (EPA 1994a, 1996b).  Precipitation samples were only collected during the months of March 
through May since these spring rain months usually contain the year’s highest concentrations of uranium 
(EPA 1994a).  The data for 234U, 235U, and 238U for 1996 are presented in Table 6-4.  In all cases, the 
uranium concentrations were low, confirming that the atmospheric content of airborne uranium is small. 
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Figure 6-3.  Average Uranium Concentrations in Drinking Water for States Where 
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January–December 1997 January–December 2006* 
234U 235U 238U 234U 235U 238U 
Los Angeles, California 1.78±0.19 0.098±0.043 1.48±0.17 1.48±0.2 0.071±0.044 1.14±0.17 
Tampa, Florida — — — 0.174±0.061 0.009±0.024 0.134±0.052 
Baxley, Georgia 0.144±0.042 0.035±0.022 0.065±0.028 0.086±0.045 0.027±0.032 0.018±0.025 
Idaho Falls, Idaho 0.8±0.13 0.027±0.025 0.306±0.075 — — — 
Morris, Illinois 0.6±0.11 0.033±0.027 0.03±0.024 0.58±0.11 0.009±0.024 0.078±0.041 
W. Chicago, Illinois 1.42±0.24 0.04±0.04 0.14±0.07 0.114±0.051 0.002±0.018 0.024±0.027 
New Orleans, Louisiana — — — 1.05±0.16 0.052±0.041 0.69±0.13 
Augusta, Maine — — — 1.11±0.16 0.035±0.033 0.93±0.14 
Red Wing, Minnesota 0.43±0.12 0.028±0.039 0.113±0.062 — — — 
Port Gibson, Mississippi — — — 0.131±0.049 0.010±0.018 0.044±0.032 
Lincoln, Nebraska 5.11±0.46 0.358±0.099 3.26±0.33 2.96±0.32 0.097±0.05 1.98±0.24 
Santa Fe, New Mexico 6.57±0.52 0.285±0.077 3.65±0.33 6.52±0.57 0.123±0.053 2.64±0.28 
Las Vegas, Nevada 2.76±0.32 0.061±0.043 1.55±0.22 3.12±0.32 0.089±0.045 1.69±0.21 
Jenkinsville, South 
Carolina 
0.596±0.089 0.027±0.02 0.277±0.059 — — — 
Genoa, Wisconsin 0.63±0.12 0.115±0.056 0.345±0.088 — — — 
Madison, Wisconsin 1.25±0.17 0.016±0.018 0.255±0.069 — — — 
 
Sources:  EPA 1997b, 2006c 
URANIUM  315 
 














234U 235U 238U 
Montgomery, Alabama 0.0163±0.008 0.004±0.0044 0.0036±0.0042 
Little Rock, Arkansas 0.0096±0.0062 0.0044±0.0044 0.0065±0.0049 
Berkeley, California 0.0153±0.0074 0.0038±0.0042 0.0043±0.0048 
Denver, Colorado 0.092±0.019 0.026±0.01 0.044±0.013 
Hartford, Connecticut 0.0169±0.0089 0.0012±0.0038 0.0045±0.0053 
Wilmington, Delaware 0.02±0.0079 0.0025±0.0032 0.0023±0.0027 
Jacksonville, Florida 0.008±0.0054 0.0067±0.0051 0.0051±0.0043 
Miami, Florida 0.022±0.01 0.0027±0.0038 0.0086±0.0064 
Honolulu, Hawaii 0.0156±0.0086 0.0037±0.0051 0.0014±0.003 
Boise, Idaho 0.0114±0.0071 0.01±0.0073 0.0057±0.005 
Idaho Falls, Idaho 0.0311±0.0099 0.0111±0.0066 0.0065±0.0046 
Augusta, Maine 0.023±0.011 0.0067±0.006 0.0086±0.0064 
Lansing, Michigan 0.0138±0.0067 0.0016±0.0028 0.0097±0.0056 
Minneapolis, Minnesota 0.0202±0.0092 0.002±0.0044 0.0132±0.0075 
Welch, Minnesota 0.047±0.02 0.013±0.012 0.024±0.015 
Jackson, Mississippi 0.0145±0.008 0.0134±0.0084 0.0137±0.0081 
Charlotte, North Carolina 0.0101±0.0062 0.0085±0.0060 0.0151±0.0074 
Wilmington, North Carolina 0.0218±0.0086 0.0047±0.0045 0.0106±0.0061 
Bismarck, North Dakota 0.079±0.02  0.019±0.011 0.043±0.014 
Lincoln, Nebraska 0.049±0.016 0.0129±0.0087 0.028±0.011 
Concord, New Hampshire 0.0195±0.0087 0.0113±0.0074 0.024±0.0098 
Trenton, New Jersey 0.0123±0.0069 0.0018±0.0031 0.0044±0.0044 
Las Vegas, Nevada 0.261±0.066 0.018±0.02 0.101±0.042 
Albany, New York 0.0229±0.0082 0.0043±0.0039 0.0094±0.0052 
Yaphank, New York 0.0141±0.0068 0.0051±0.0048 0.0077±0.0051 
Painesville, Ohio 0.0077±0.0063 0.0083±0.0071 0.0035±0.0045 
Portland, Oregon 0.03±0.0095 0.0111±0.0064 0.0129±0.0063 
Harrisburg, Pennsylvania 0.038±0.012 0.0103±0.0065 0.0098±0.0060 
Barnwell, South Carolina 0.0153±0.0072 0.0069±0.0052 0.0085±0.0055 
Columbia, South Carolina 0.0126±0.0065 0.007±0.0053 0.0039±0.0038 
Knoxville, Tennessee 0.0111±0.0057 0.0043±0.0038 0.0043±0.0035 
Nashville, Tennessee 0.0074±0.0068 0.0014±0.0043 0.0016±0.0044 
Austin, Texas 0.0119±0.0066 0.0017±0.003 0.0061±0.0054 
El Paso, Texas 0.043±0.022 0.012±0.014 0.036±0.02 
Salt Lake City, Utah 0.0196±0.0078 0.0021±0.0032 0.0102±0.0056 
Lynchburg, Virginia 0.05±0.013 0.0083±0.0056 0.008±0.0052 
Olympia, Washington 0.0176±0.0072 0.0051±0.0042 0.0052±0.0041 
Madison, Wisconsin 0.0209±0.0098 0.0039±0.0045 0.0065±0.0053 
 
Source:  EPA 1996b 
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In some surface waters that have been contaminated by waste discharge and in groundwaters from natural 
uranium-bearing aquifers, the concentrations of uranium may be higher than the average natural 
background levels for that area.  For example, higher levels of uranium have been observed in water from 
Ambrosia Lake in New Mexico (uranium milling and mining) (Lapham et al. 1989), the agricultural 
draining and evaporation pond water of the San Joaquin Valley in California (Bradford et al. 1990), 
groundwater from Rocky Flats, Colorado (Laul 1994), and groundwater from the Nambe region of 
northern New Mexico (Hakonson-Hayes et al. 2002).  The concentration of uranium in creek waters that 
lead to the Ohio River near the Paducah Gaseous Diffusion Plant in Kentucky ranged from <0.7 to 
470 pCi/L (1–700 μg/L) (DOE 1981a).  Mono Lake, a natural alkaline, saline lake in California, 
contained 185 pCi/L 238U and 222 pCi/L 234U during the period 1978–1980 (Simpson et al. 1982).  
Analysis of water from the Colorado River and its tributaries during 1985 and 1986 showed that the levels 
of total uranium ranged from 3.4 to 60 pCi/L (Stewart et al. 1988). 
 
Higher levels of uranium can be found in groundwater.  Orloff et al. (2004) found elevated levels of 
uranium in well water in a South Carolina community (range of 1.7–5,830 pCi/L, equivalent to 1.8–
7,780 mg/L, and a mean of 620 µg/L based on isotopic content).  The U.S. Geological Service measured 
uranium concentrations above 30 µg/L in 65 out of 350 wells (19%) located in the Eastern San Joaquin 
Valley, California during sampling from 2004 to 2008 (Jurgens et al. 2010).  Median and maximum 
concentrations were 18.0 and 2,500 µg/L in 98 observation wells, 8.7 and 503 µg/L, respectively, in 
122 domestic wells, and 1.8 and 41.3 µg/L, respectively, in 121 public supply wells. 
 
As part of the Navajo Uranium Assessment and Kidney Health Project, EPA (2013a) analyzed water from 
240 unregulated wells on Navajo land.  Uranium levels in 29 sources exceeded the MCL of 30 µg/L; the 
uranium concentrations in these 29 sources ranged from 31 to 700 µg/L.    
 
Discharge of dewatering effluents from underground uranium mines and runoff from uranium mine 
tailings piles have contaminated surface waters and aquifers in New Mexico with elevated levels of gross 
alpha activity and uranium (NMHED 1989).  The concentration of uranium in mine discharge water in 
New Mexico was 31,500 μg/L (equivalent to 22,680 pCi/L, assuming that the uranium content is natural 
uranium) (EPA 1985c).  Groundwater from an aquifer adjacent to a uranium mill tailings pile in Falls 
City, Texas, was also found to have concentrations of uranium above natural background levels (DOE 
1994). 
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The concentrations of 234U and 238U in groundwater from Cambrian-Ordovician sandstone aquifers in 
Illinois range from <0.1 to 8.0 pCi/L (Gilkeson and Cowart 1987).  The ratio of the activity of 234U to 238U 
ranged from 2.0 to >40.  The lowest ratios were found in unconfined aquifers in primary recharge zones, 
while ratios >20 were found in the confined zones aquifer.  It was suggested that glacial recharge in 
unconfined zones might be responsible for the high 234U to 238U ratios (Gilkeson and Cowart 1987).  
Fifty-five groundwater samples from the Lockatong and Passaic Formation in the Newark Basin in New 
Jersey were analyzed during 1985–1987.  These samples were found to contain 0.1–40 pCi/L total 
uranium, with a median value of 2.1 pCi/L (Szabo and Zapecza 1987).  Uranium concentrations measured 
in seven samples of groundwater from the Raymond Basin in California ranged from 5.3 to 43.7 pCi/L 
(Wiegand et al. 1987). 
 
Water in a private well in Maine, thought to be of geologic origin, was reported to contain as much as 
403 μg/L uranium (approximately 270 pCi/L) (Lowry et al. 1987).  Uranium concentrations as high as 
1,160 µg/L were measured in drinking water from a home in northwestern Connecticut (Magdo et al. 
2007).  The source of the uranium was found to be a 500-foot well carrying groundwater from the 
Brookfield Gneiss geological formation.  Hughes et al. (2005) measured elevated uranium concentrations 
ranging from 44.3 to 5,570 µg/L in water from nine private wells located near Simpsonville, South 
Carolina.  Elevated levels of uranium measured in waters from private wells in northern and northeastern 
Nebraska were thought to be due to the upward migration of uranium from bedrock and heavy use of 
phosphate fertilizers.  Uranium values up to 110 pCi/L were measured (NEDH 1989).  The concentrations 
of uranium in U.S. groundwaters were estimated using a conceptual model based on the geochemical and 
hydrological characteristics of aquifers. 
 
The population-weighted average uranium concentration in groundwaters used as sources of drinking 
water in all 50 states was found to range from 0.05 to 4.6 pCi/L, with a mean value of 0.55 pCi/L 
(Longtin 1988).  This mean is lower than the population-weighted uranium value for finished waters of 
0.8 pCi/L (NCRP 1984a).  Some methods that may be suitable for reducing the concentration of uranium 
in drinking water include lime softening, coagulation/precipitation, and filtering; however, these methods 
may not efficiently remove the uranium. 
 
Concentrations of 238U and 234U measured in bottled water samples from 17 locations in Italy were 
generally <120 mBq/kg (Forte et al. 2001).  The highest reported concentrations of these isotopes were 
1,936 and 2,842 mBq/kg, respectively. 
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Jia et al. (2006) measured concentrations of 0.27–16.2 mBq/L for 238U, 0.41–15.6 mBq/L for 234U, and 
0.012–0.695 mBq/L for 235U in water samples collected in Bosnia and Herzegovina.  Two water samples 
were reported to contain depleted uranium.  Carvalho and Oliveira (2010) reported mean uranium 
concentrations of 0.5 and 0.4 mg/kg measured in public drinking water supplies from Kosovo and Bosnia-
Herzegovina during 2001.  These levels are similar to those reported in other countries and do not reflect 
enhanced presence of uranium resulting from the use of depleted uranium in these areas during the 1999 
military conflict (Carvalho and Oliveira 2010; Sahoo et al. 2007). 
 
6.4.3   Sediment and Soil  
 
Table 6-5 shows the average concentrations of uranium in several types of rocks and soils (NCRP 1984a).  
The radioactivity in soils is similar to that in the rocks, usually bedrock, from which it derives.  The 
average soil concentration of 234U from Table 6-5 is 0.6 pCi/g.  Since the activity of 234U accounts for 
approximately one-half of the total activity in natural uranium (see Chapter 4), the value in Table 6-5 may 
be multiplied by two to obtain the total uranium in soils (approximately 1.2 pCi/g). 
 
There are wide variations from the values presented in the table, particularly in areas where uranium 
minerals are more concentrated.  Concentrations of uranium in Louisiana soils ranged from 2.35 to 
3.98 μg/g (1.6–2.7 pCi/g) (Meriwether et al. 1988), while uranium concentrations in phosphate rock in 
north and central Florida ranged from 4.5 to 83.4 pCi/g (6.8–124 μg/g) (EPA 1985c). 
 
Soil samples adjacent to Los Alamos, New Mexico, taken during 1974–1977 contained total uranium in 
the range of 0.1–5.1 μg/g (0.067–3.4 pCi/g), with a mean concentration of 1.6 pCi/g (2.4 μg/g) (Purtymun 
et al. 1987).  The concentrations of uranium in soils adjacent to the Hanford Fuel Fabrication Facility near 
Richland, Washington, that were collected during 1978–1981 ranged from 0.51 to 3.1 pCi/g (0.76–
4.6 μg/g), with a median value of 1.2 pCi/g (1.8 μg/g).  The control samples for the Hanford Fuel 
Fabrication Study contained uranium at concentrations of 0.21–0.86 pCi/g (0.32–1.128 μg/g), with a 
median value of 0.49 pCi/g (0.73 μg/g) (Price and Kinnison 1982).  Uranium in the soil within the 
property boundary of the Paducah Gaseous Diffusion Plant in Kentucky ranged from 3.3 to 4.8 pCi/g 
(4.9–7.1 μg/g), whereas off-site samples taken as far as 12 miles away contained uranium at levels of 3.8–
6.0 pCi/g (6.4–9.0 μg/g) (DOE 1981a).  Soil monitoring data from the area surrounding the Feed Material 
Production Center at Fernald, Ohio, showed that the uranium concentrations within an 8-km2 area were 
between 3 and 23 pCi/g (4.5–34 μg/g) compared to an mean of 2.2 pCi/g (3.3 μg/g) for natural 
background levels (Stevenson and Hardy 1993).  Other investigators have detected uranium levels in  
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Table 6-5.  Uranium in Rocks and Soils  
 
Material pCi/g 238Ua 
Igneous rocks 
Basalt (crustal average) 0.2–0.3 
Maficb 0.2–0.3 
Salicb 1.3–1.6 




Clean quartz <0.3 
Dirty quartz 1.0c 
Arkose 0.3–0.7c 
Beach sands (unconsolidated) 1 
Carbonate rocks 0.7 
Soils 0.6 
 
aTo obtain the series equilibrium radioactivity for total alpha, beta, or approximate gamma emission (excluding 
bremsstrahlung and x-rays), multiply by 8, 6, or 3, respectively. 
bThe median and mean value are given. 
cIndicates that the values are not well defined. 
 
Source:  NCRP 1975 
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surface soils at the Fernald site as high as 50 times natural background levels (Miller et al. 1994).  Moon 
et al. (2006) measured uranium concentrations as high as 300 µg/g at a soil depth of 6 inches at the Oak 
Ridge Reservation in Oak Ridge, Tennessee.  The contamination was attributed to past waste disposal 
activities at the site. 
 
Carvalho and Oliveira (2010) reported mean uranium concentrations of 1.8 and 3 mg/kg measured in soils 
from Kosovo and Bosnia-Herzegovina during 2001.  Higher uranium concentrations were localized to 
areas impacted by depleted uranium ammunition (Carvalho and Oliveira 2010; Sansone et al. 2001). 
 
6.4.4   Other Environmental Media  
 
Concentrations of uranium have been determined in meat and fish (Table 6-6).  The uranium content 
measured in tissues of cattle herds grazing in pastures close to the Rocky Flats Plant in Colorado was 
slightly higher than in other cattle, reflecting possible contamination from this source (Smith and Black 
1975).  The average concentrations of uranium in game fish (surface feeders) collected from a reservoir at 
locations upstream and downstream from the Los Alamos National Laboratory were 2.9 ng/g dry weight 
(dw) (0.0019 pCi/g) and 4.9 ng/g dw (0.0033 pCi/g), respectively (Fresquez et al. 1994).  The 
corresponding values in nongame, bottom-feeding fish were 7.9 ng/g dw (0.0058 pCi/g) and 17.7 ng/g dw 
(0.012 pCi/g), respectively.  The concentrations of uranium in fish muscle (dw) from a Canadian lake 
receiving uranium mill effluents were 7–11 times higher than in fish caught in uncontaminated lakes, but 
this uranium may have only been attached to the gills (Swanson 1985). 
 
The mean uranium concentration in vegetation from Ambrosia Lake, New Mexico (a site of mining and 
milling activities) was measured at 0.3 pCi/g dw compared to 4 fCi/g dw for vegetation from a control 
site (Lapham et al. 1989).  Although the concentrations of uranium in muscle from exposed cattle were 
indistinguishable from uranium levels in muscle from control cattle, levels of uranium in liver and kidney 
tissues were 4 times higher in exposed cattle than in control cattle, and levels of uranium in femur 
samples were 13 times higher than in controls, indicating that kidney and liver slightly bioconcentrate 
uranium while muscle does not (Lapham et al. 1989).  Thomas et al. (2005) detected uranium 
concentrations >1 µg/g in bone, liver, kidney, muscle, and rumen content samples from 14 out of 
45 Saskatchewan moose and 4 out of 4 Saskatchewan cattle. 
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6.5   GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
 
General population exposure to uranium occurs by ingestion of food and drinking water and by inhalation 
of air.  The pathways are shown in Figure 6-2. 
 
Table 6-6 depicts uranium levels in various types of food in the United States.  Measurements of normal 
levels of dietary 234U and 238U indicate that foods consumed contain about 0.3–0.5 pCi/day for each 
uranium isotope (0.6–1.0 pCi/day [0.9–1.5 μg/day] total uranium) (EPA 1985c; Welford and Baird 1967).   
 
Based on consumption rates, root crops such as potatoes, parsnips, turnips, and sweet potatoes contribute 
approximately 38% of total dietary intake of uranium (EPA 1985c). 
 
Ingestion of food grown in the vicinity of a uranium mill may lead to an intake up to 3 pCi/day uranium 
(Rayno 1983).  Other investigators have estimated a dietary intake of 2.86–4.55 mg/day for individuals 
living near a uranium mine (Yamamoto et al. 1971). 
 
An alternate method for estimating uranium intake is to measure the daily excretion of uranium in urine 
and feces.  Using this method in a study of 12 subjects in Utah, it was estimated that the average dietary 
intake for the Salt Lake City population was 4.4±0.6 μg, an intake that is higher than that reported for 
New York City, Chicago, and San Francisco residents (1.3–1.4 μg) (Singh et al. 1990). 
 
Intakes of uranium in food may also increase when certain ceramic glazed dishes are used for serving or 
storing food (Landa and Councell 1992).  Leaching occurs on contact with acidic foods or beverages.  
Experiments show that when a ceramic glazed plate was kept in contact with a 4% acetic acid solution for 
24 hours, the concentration of uranium in the leachate was 31.8 mg/L (Landa and Councell 1992). 
 
Uranium glazed commercial ceramic dinnerware is no longer made and sold because it was determined 
that the uranium is leachable by acidic foods and beverages (Landa and Councell 1992).  Experiments 
show that when a Fiesta tableware plate was kept in contact with 20 mL of 4% acetic acid solution for 
24 hours, the quantity of uranium in the leachate was 600 μg (400 pCi).  Other liquids were much less 
effective at leaching uranium, with water giving a value over 3 orders of magnitude lower, and other 
uranium glazed ceramics were much less leachable (Landa and Councell 1992). 
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Table 6-6.  Concentrations of Uranium in Some Foods 
 
Type of food 
Uranium concentration 
(ng/g raw weight) 
 
Reference 
Whole grain products 1.45 NCRP 1984a 
Potatoes 2.66–2.92; 15B18 EPA 1985c; NCRP 1984a  
Carrots 7.7  EPA 1985c 
Root vegetables 0.94–1.20 NCRP 1984a 
Cabbage 4.7 EPA 1985c 
Meat 0.58–1.32; 20 EPA 1985c; NCRP 1984a 
Poultry 0.14–0.42 NCRP 1984a 
Beef 14 EPA 1985c 
Beef liver 26 EPA 1985c 
Beef kidney 70 EPA 1985c 
Eggs 0.23; 9.6 EPA 1985c; NCRP 1984a 
Dairy products 0.08–0.31 NCRP 1984a 
Cow milk 4 EPA 1985c 
Milk 1–2 EPA 1985c 
Fresh fish 0.43–0.85; 11 EPA 1985c; NCRP 1984a 
Shellfish 9.5–31.0 NCRP 1984a 
Welsh onion 69 EPA 1985c 
Flour 0.25–0.68 NCRP 1984a 
Wheat bread 19 EPA 1985c 
Baked products 1.32–1.5; 12 EPA 1985c; NCRP 1984a 
Polished rice 1.43–6.0; 15 EPA 1985c; NCRP 1984a 
Macaroni 0.4–0.63 NCRP 1984a 
Tea 5 EPA 1985c 
Coffee 6 EPA 1985c 
Parsley 60 EPA 1985c 
Red pepper 5 EPA 1985c 
Mustard 0.2 EPA 1985c 
Table salt 40 EPA 1985c 
Canned vegetables 0.09–0.18 NCRP 1984a 
Fruit juices 0.04–0.12 NCRP 1984a 
Canned fruits 0.18–0.29 NCRP 1984a 
Fresh fruits 0.71–1.29 NCRP 1984a 
Dried beans 1.5–3.67 NCRP 1984a 
Fresh vegetables 0.52–0.92 NCRP 1984a 
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Uranium intakes from food in Japanese diets from two control areas ranged from 0.86 to 1.02 μg/day 
(Yamamoto et al. 1971).  Another study reported a mean value of 0.71 μg/day for Japanese males from 
31 prefectures (Shiraishi et al. 1992).  Galletti et al. (2003) estimated a total dietary intake of uranium in 
the range of 2.9–4.8 µg/day for the Italian population.  Worldwide intake values for uranium have been 
reported at an average of 1 pCi/day (1.5 μg/day) (range 0.6–3.2 pCi/day [0.9–4.8 μg/day]) (Linsalata 
1994). 
 
Concentrations of uranium from selected drinking water supplies in the United States were analyzed by 
the EPA laboratories and found to be generally <1 pCi/L (EPA 1985c, 1997b, 2005a, 2010b).  Based on 
data obtained from the NURE program plus data prepared for the EPA (DOE 1981b; USGS 2006), a 
population-weighted average of 0.8 pCi/L uranium was determined.  In another study, Ohanian (1989) 
reported population-weighted average concentrations of uranium in U.S. community drinking water 
ranging from 0.3 to 2.0 pCi/L.  Considering an individual water intake of approximately 1.7 L/day, and an 
average intake of uranium from drinking water of 0.8 pCi/L as reported in the EPA study, the total intake 
of uranium for an individual from drinking water each day is approximately 1.4 pCi. 
 
Uranium is also taken into the body by the inhalation route.  The average daily intake of uranium from 
inhalation of air has been estimated to range from 0.007 pCi/day (0.010 μg/day) (Cothern 1987) to 
0.0007 pCi/day (0.0010 μg/day) (UNSCEAR 1988).  This value may be somewhat higher for persons 
living near sources of uranium emission.  Glass makers and potters who use uranium-containing enamels 
may be exposed to small amounts of uranium from handling the powder or from fuming operations in 
glass making (Rossol 1997).  In general, however, exposure to uranium from inhalation is small 
compared to exposure from food and drinking water. 
 
Measurements of concentrations of uranium have been made in human tissues and body fluids resulting 
from consumption of food and water and from natural background sources.  Levels of uranium measured 
between 1999 and 2008 in the urine of members of the general U.S. population from the National Health 
and Nutrition Examination Survey (NHANES) are listed in Tables 6-7 and 6-8 (CDC 2012).  The range 
of geometric mean values is 0.006–0.009 µg U/g creatinine (or 0.005–0.010 µg U/L urine), respectively. 
 
Two longtime residents of Los Alamos, New Mexico (one a smoker and one nonsmoker) were shown to 
have uranium tissue concentrations for the skeleton (average 5.8 μg/g wet weight) and liver (average 
0.08 μg/kg) in closer agreement with the Reference Man (Kathren 1997; ICRP 1975) than those reported 
in New York City residents (Fisenne and Welford 1986).  Values of uranium in whole blood measured in  
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Table 6-7.  Geometric Mean and Selected Percentile of Urinary Concentrations of 
Uranium (µg/g Creatinine) for the U.S. Population from the National Health 
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6.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
Table 6-7.  Geometric Mean and Selected Percentile of Urinary Concentrations of 
Uranium (µg/g Creatinine) for the U.S. Population from the National Health 
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Females 99–00 0.008 (0.007– 0.007 (0.006– 0.013 (0.010– 0.025 (0.019– 0.034 (0.027– 1,237 
0.010) 0.010) 0.017) 0.033) 0.054) 























































































































































































































aNot calculated:  proportion of results below limit of detection was too high to provide a valid result. 
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Table 6-8.  Geometric Mean and Selected Percentile of Urinary Concentrations of 
Uranium (µg/L) for the U.S. Population from the National Health and Nutrition 
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Table 6-8.  Geometric Mean and Selected Percentile of Urinary Concentrations of 
Uranium (µg/L) for the U.S. Population from the National Health and Nutrition 
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6.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
Table 6-8.  Geometric Mean and Selected Percentile of Urinary Concentrations of 
Uranium (µg/L) for the U.S. Population from the National Health and Nutrition 
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aNot calculated: proportion of results below limit of detection was too high to provide a valid result. 
 
Note:  Limit of detection for survey years 99–00, 01–02, 03–04, 05–06, and 07–08 are 0.004, 0.004, 0.005, 0.002, and 0.002, 
respectively 
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New York City residents and Illinois residents averaged 0.14 μg/kg (0.09 pCi/kg) and 0.1 μg/kg 
(0.07 pCi/kg), respectively, compared to a mean value worldwide of 0.58 μg/kg (Fisenne 1988).  Mean 
concentrations of uranium were measured in the organs of persons representing all age groups from 
different parts of the United States.  The uranium values for lungs, liver, kidney, and bone (vertebrae, rib, 
and skeleton) were 0.5–1.17 μg/kg (0.34–0.78 pCi/kg), 0.12–0.33 μg/kg (0.08–0.22 pCi/kg), 0.39–
1.00 μg/kg (0.26–0.67 pCi/kg), and 0.25–1.9 μg/kg (0.17–1.3 pCi/kg), respectively (Fisenne and Welford 
1986; Fisenne 1988; Singh et al. 1986b).  These differences reflect dietary variations. 
 
Workers engaged in the extraction and processing of uranium are occupationally exposed to uranium.  
Industries where uranium exposures are known to have occurred are uranium mining and milling, 
uranium conversion and enrichment, uranium fuel fabrication, and nuclear weapons production.   
 
Epidemiologic surveys were initiated in the United States as early as 1950 to study the effects of uranium 
exposure on uranium millers, and similar studies were performed of workers at the Oak Ridge Gaseous 
Diffusion Plant in Oak Ridge, Tennessee, where uranium conversion and enrichment were performed.  
Those studies attributed the health decrement to radon progeny and other toxicants and not directly to the 
uranium (BEIR IV 1988). 
 
Exposure to enriched uranium, used as a uranium fuel in nuclear energy production, may present a 
combined chemical and radiological health hazard.  However, access to enriched or high specific activity 
uranium is strictly regulated by the USNRC and the DOE.  Therefore, the potential for significant human 
exposure to enriched uranium should be limited to rare accidental releases in the workplace. 
 
6.6   EXPOSURES OF CHILDREN  
 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility. 
 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
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sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
 
As for adults in the general population, small exposures occur from normal ingestion of food and drinking 
water and inhaling air.  These exposures may be higher in areas with naturally high uranium soil levels or 
near uranium processing sites and hazardous waste sites containing uranium.  Levels of uranium 
measured between 1999 and 2008 in the urine of various ages of the U.S. population from NHANES are 
listed in Tables 6-7 and 6-8 (CDC 2012).  Concentrations measured in children aged 6–11 and 12–
19 years were similar to those measured in adults aged ≥20 years, across all years. 
 
A study of uranium content in bone from three age groups (<13, 13–20, and 20–25 years old) reported 
somewhat higher uranium content in the youngest compared to the oldest age group (approximately 1.5–
3-fold); however, there were only 2–4 subjects in each group and the results were not statistically 
significant (Broadway and Strong 1983).  No information on uranium levels in amniotic fluid, meconium, 
cord blood, neonatal blood, or breast milk was located. 
 
At hazardous waste sites, uranium that is found in excess of natural background levels is most likely to be 
in soil and presents a special hazard for young children.  Hand-to-mouth activity and eating contaminated 
dirt will result in oral exposure to uranium.  The hazard in this case depends on the form of uranium 
present at the waste site.  Soluble uranium compounds (e.g., uranyl nitrate) are absorbed by the 
gastrointestinal tract to a much greater degree than insoluble uranium compounds (e.g., insoluble oxides 
of uranium), and a large toxicity database in animals supports the higher toxicity of the soluble forms (see 
Chapter 3).  Uranium in soil at non-hazardous waste sites is almost entirely (>99%) in the form of 
insoluble oxides of uranium, which have very low bioavailability. 
 
As for adults, the potential for uranium exposure is greater for children who consume foods grown in 
areas with elevated concentrations of uranium in the soil and for children with elevated concentrations of 
uranium in their drinking water (EPA 1985c; NCRP 1984a).  Other home exposures are unlikely since no 
household products or products used in crafts, hobbies, or cottage industries contain significant amounts 
of uranium, except in cases where uranium-bearing rocks are used in and around the home for decorative, 
collection, or construction purposes (Agency for Toxic Substances and Disease Registry 1997). 
 
No information is available on whether children differ from adults in their weight-adjusted intake of 
uranium.  The fractional absorption of uranium (as uranyl nitrate and uranyl citrate) by the oral route was 
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higher in neonatal than in adult rats and swine (Sullivan 1980b; Sullivan and Gorham 1982).  In a 
mathematical model developed by the ICRP for risk assessment, one of the assumptions is that the 
fractional absorption of ingested uranium is twice as high in children under the age of 1 year compared to 
adults. 
 
Uranium exposure to children from parents’ work clothes, skin, hair, tools, or other objects from the 
workplace is possible if the parent uses uranium at work.  However, in a comprehensive review of 
incidents of home contamination by workers (NIOSH 1997), no cases of uranium contamination were 
described. 
 
As a radionuclide, uranium is potentially genotoxic and thus, it is important to know if parental exposure 
to uranium could affect the developing fetus or germ cells.  However, epidemiological studies of workers 
exposed to uranium show no evidence of genotoxic effects.  This is most likely due to the very low 
specific activity, the low systemic absorption of uranium, and the lack of concentration of uranium in the 
germ cells.  Genotoxic effects to parental germ cells or to a developing fetus are not likely at probable 
levels of exposure to uranium from the environment or at hazardous waste sites.  Some uranium is stored 
in bone, but it is not known if this uranium is released during pregnancy and lactation, when it could 
result in exposure to the fetus or infant. 
 
6.7   POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
 
Higher rates of uranium exposure have been reported for some populations.  The potential for uranium 
exposure is greater for individuals who consume foods grown in areas with elevated concentrations of 
uranium in the soil, and for individuals with elevated concentrations of uranium in their drinking water 
(EPA 1985c; NCRP 1984a; Orloff et al. 2004).  Industries where higher exposures to uranium are known 
to occur include uranium mining and milling, uranium conversion and enrichment, uranium fuel 
fabrication, and nuclear weapons production (BEIR IV 1988; Miller 1977; NCRP 1984a; West et al. 
1979).  Other groups with the potentially higher exposures include persons involved in producing and 
using phosphate fertilizers and individuals living and working near fossil fuel plants (Jaworowski and 
Grzybowska 1977; NCRP 1984a; Tadmor 1986; Weissman et al. 1983).  Uranium compounds were 
previously used in dental appliances, and individuals with dental work of this kind have potentially higher 
exposures (Sairenji et al. 1980). 
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The use of depleted uranium in high-density tank armor and armor piercing munitions may result in 
higher exposures of military personnel who are located in, or nearby, an armored vehicle penetrated by a 
depleted uranium munition (kinetic energy penetrator) during combat.  The primary routes of exposure to 
depleted uranium include inhalation of aerosols formed during the high energy collisions of depleted 
uranium munitions with vehicle armor, embedding of depleted uranium fragments in wounds to the body, 
and ingestion resulting from contact with depleted uranium residue on contaminated surfaces (Parkhurst 
and Guilmette 2009a; Szrom et al. 2009).  The handling of coated and intact depleted uranium plates and 
unfired depleted uranium munitions should not result in exposure to uranium. 
 
The Capstone Depleted Uranium Aerosol Characterization and Risk Assessment Study, begun in 
November 2000, was conducted to determine the level of exposure to depleted uranium aerosols resulting 
from perforation of armored Abrams Tanks and Bradley Fighting Vehicles with large caliber depleted 
uranium munitions (Guilmette and Parkhurst 2007; Parkhurst and Guilmette 2009a).  Results of the 
Capstone study show mean depleted uranium concentrations measured inside the unventilated combat 
vehicles ranging from 3.0 to 16 g/m3 10 seconds after perforation and falling to 0.020–0.15 g/m3 within 
30 minutes (Parkhurst et al. 2009).  Levels were much lower in a ventilated Abrams tank with a maximum 
concentration of 0.22 g/m3 measured 1 minute after perforation and 0.011 g/m3 after 30 minutes 
(Guilmette and Parkhurst 2007; Parkhurst et al. 2009).  Based on the aerosol measurements, median 
inhalation intakes of depleted uranium were determined to be 10–280 mg for a combat vehicle crew 
member exiting 1 minute after perforation, 43–710 mg for a combat vehicle crew member exiting 
5 minutes after perforation, and 27–200 mg for a first responder entering 5 minutes after perforation and 
remaining in the combat vehicle for 10 minutes (Guilmette et al. 2009; Parkhurst and Guilmette 2009b).  
A depleted uranium inhalation intake rate ranging from 0.447 to 14.5 mg/hour was estimated for military 
personnel and civilian employees located near vehicles containing depleted uranium fragments but not 
directly involved in the perforation incident (Szrom et al. 2009).  Ingestion intake rates for these 
individuals were estimated to be 1.78–38.9 mg/hour resulting from hand-to-mouth transfer from contact 
with depleted uranium contaminated surfaces (Szrom et al. 2009). 
 
Depleted uranium was reportedly used in the military conflicts in Iraq during 1991 and 2003, in Bosnia 
during 1994, and in Kosovo during 1999 (Oeh et al. 2007b).  Several studies have monitored the levels of 
uranium in the urine of individuals with reported exposure to the depleted uranium used during these 
conflicts (Hooper et al. 1999; McDiarmid et al. 1999b, 2001b, 2004a; Miller et al. 2008; Oeh et al. 2007a, 
2007b; Toohey 2003).  Table 6-9 lists urinary concentrations measured in these studies.  In general, the 
levels of uranium measured in the urine of individuals reporting exposure were not different than levels in  
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Table 6-9.  Urinary Levels of Uranium in Individuals Exposed through Military Use 





Concentration (µg U/g creatinine) 
Reference Mean Minimum Maximum 
U.S. Gulf War veterans,  
1993–1994 
    Hooper et al. 1999  
 Reported depleted uranium 
exposure without 
embedded fragments 
10 0.03 — —  
 With embedded depleted 
uranium fragments 
15 4.47 — 22.48  
1997     McDiarmid et al. 
1999b; Toohey 2003 
 Non-exposed 22 0.02 0.01 0.05  
 Reported depleted uranium 
exposurea 
29 3.59 0.01 30.74a  
1997–1999     Toohey 2003 
 With embedded depleted 
uranium fragments (30–
840 mg) 
7 — 0.46 24.77  
1998–1999     McDiarmid et al. 
2001b 
 Reported depleted uranium 
exposure 
169 0.01b  0.001 0.432  
1998–2002     McDiarmid et al. 
2004a 
 Reported depleted uranium 
exposure without 
embedded fragments 
440 0.001 0.005c 0.042d  
 With embedded depleted 
uranium fragments 
6 0.083 0.008c 2.895  
Peacekeepers and residents 
in Kosovo, 1999–2006 
    Oeh et al. 2007a, 
2007b 
 German peacekeepers 726 0.0139 0.006 0.1715  
 Kosovo residents 25 0.0251 0.00292 0.2668  
 Unexposed controls from 
southern Germany 
63 0.0128 0.0014 0.775  
British Forces     Miller et al. 2008 
 Military personnel not 
having served in Iraq 
732 0.0027b <0.001 0.556  
 
aAll values >1.0 µg U/g creatinine occurred in nine veterans containing embedded fragments. 
bMedian value. 
c10th percentile value. 
d95th percentile value. 
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non-exposed individuals.  A notable exception is seen with individuals having depleted uranium-
containing fragments embedded within their bodies (Hooper et al. 1999; McDiarmid et al. 1999b, 2004a; 
Toohey 2003).  Measured urinary uranium levels in these individuals are consistently elevated, reaching 
as high as 30 µg U/g creatinine. 
 
6.8   ADEQUACY OF THE DATABASE  
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of uranium is available.  Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research  
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of uranium. 
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
 
6.8.1   Identification of Data Needs  
 
Physical and Chemical Properties.    Pertinent data on the physical and chemical properties of 
uranium and uranium compounds are available in the literature. 
 
Production, Import/Export, Use, Release, and Disposal.    According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this 
information for 2010, became available in May of 2008.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions. 
 
Data regarding the past and present production (ABMS 1994; EPA 1985a) and import/export volumes 
(USDOC 1995) for uranium are available.  The uses of uranium and uranium compounds are well known 
(Clayton and Clayton 1981; EPA 1985c).  Other than glazed ceramic foodware and decorative items 
(Landa and Councell 1992) and dental appliances (Sairenji et al. 1980), consumer contact with uranium 
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products is negligible.  Since uranium is not covered under SARA, Title III, manufacturers and users are 
not required to report releases to the EPA.  There is a lack of data on the release and disposal of uranium 
during mining, milling, and chemical processing and its use during fuel cycle operations.  The disposal of 
uranium is governed by the USNRC regulations (10 CFR 61), and releases of uranium to the environment 
are governed by USNRC and EPA regulations (10 CFR 20, Appendix B; 40 CFR 190; 40 CFR 192).  
Since significant amounts of depleted uranium are used on modern battlefields, it would be useful to have 
more information on the export of depleted uranium to other nations, the disposal of related wastes in the 
United States, and the mass of depleted uranium released to long-distance air transport when projectiles 
are used against different target types. 
 
Environmental Fate.    For solids, there is a need to determine uptake factors into edible portions of 
plants and not just adherence to the root structure.  For the solid-liquid interface, a method is needed to 
determine a method by which 234U to 238U ratio deviates from unity such that the EPA ERAMS water 
sample results indicate disequilibrium.  Uranium enters the atmosphere in particulate form from natural 
sources and from uranium mining, milling, and processing.  Dry or wet deposition from the atmosphere to 
soil and water can occur (Essien et al. 1985).  Little experimental data on the particle size and residence 
time of uranium and uranium compounds present in ambient atmospheres are available.  Additional data 
regarding the measured particle size of uranium compounds in ambient air, settling velocity, and 
knowledge of the chemical forms and lifetime of the particles in air would be useful.  Although some 
studies have characterized the oxidation states and chemical forms of some uranium compounds (UO2 and 
UO3) (Dodge and Francis 1994; Wersin et al. 1994), more data identifying the chemical forms of uranium 
in the environment are needed to better understand the fate and transport of uranium.  Since significant 
amounts of depleted uranium are used on modern battlefields, it would be useful to have more 
information on the export of depleted uranium to other nations and the disposal of related wastes in the 
United States, as well as estimates of projectile quantities that aerosolize to a significant extent and 
associated downwind air contamination levels. 
 
Bioavailability from Environmental Media.    The absorption and distribution of uranium as a result 
of inhalation and ingestion exposures have been discussed in Sections 3.5.1 and 3.5.2.  However, 
quantitative data relating to physical/chemical properties such as particle size, chemical form, and degree 
of absorption with the bioavailability of uranium from inhaled air particles and inhaled and/or ingested 
soil particles, are lacking.  Such studies would be useful in assessing potential public health impact of 
uranium to people living near a hazardous waste site. 
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Food Chain Bioaccumulation.    Information about uranium bioaccumulation in fish (Mahon 1982; 
Poston 1982; Swanson 1983; Waite et al. 1988) is available.  Data concerning levels of uranium in 
various foods (EPA 1985c) are also available.  These data indicate that uranium does not biomagnify in 
the food chain (Ahsanullah and Williams 1989; Morishima et al. 1977; Swanson 1983, 1985).  Data on 
the levels of uranium in food grown in contaminated areas are limited.  Additional data are needed on 
whether the uptake of uranium in fish is restricted to the gills and how much actually distributes to the 
meat. 
 
Exposure Levels in Environmental Media.    Reliable monitoring data for the levels of uranium in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of 
uranium in the environment can be used in combination with the known body burden of uranium to assess 
the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites. 
 
The levels of uranium in airborne particles and precipitation have been monitored since 1973 (EPA 1994).  
Data from several large studies of uranium in domestic water supplies are available (Cothern and 
Lappenbusch 1983; DOE 1981b), as are data from studies of groundwater and surface water (NCRP 
1984a).  The primary source of information on the occurrence of uranium in drinking water is the 
National Inorganics and Radionuclides Survey (NIRS) conducted by EPA (EPA 1991b).  Some 
monitoring data are available for uranium-contaminated soils and sediments associated with the nuclear 
fuel cycle.  Better information on background levels in the environment and speciation of uranium in soils 
and sediments would be useful for determining which species lead to actual public exposure. 
 
Exposure Levels in Humans.    Although some data on the urinary levels of uranium in humans 
exposed to natural background levels (food, water, and air) are available (CDC 2012), these data are 
nationally representative and do not reflect high exposures, such as those experienced in the Southwest 
area of the United States.  Biomonitoring studies are needed in areas with higher natural uranium 
exposure to develop a baseline for comparison.  Additionally, there are limited data on the uranium 
content in human tissues in the general population and in populations living in areas with higher 
background uranium levels.  The principal source of information about occupationally exposed 
individuals is the U.S. Transuranium and Uranium Registries (USTUR) Tissue Program and database, 
established to document uranium levels and distribution in human tissues for occupationally exposed 
workers (PNL 1981).  Several major database files are available.  The Radiochemical file contains 
information about radiochemical analysis of tissue donations from occupationally exposed individuals.  
The Health Physics file contains bioassay and other health physics data.  These two databases are 
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regularly updated.  The Medical file contains abstracted personal, medical, and clinical data; the 
Pathology file contains autopsy and pathology information; and the Skeletal Estimate file contains 
estimated actinide concentrations for unanalyzed half skeletons from donors (USTUR 1999).   
 
This information is necessary for assessing the need to conduct health studies on these populations. 
 
Exposures of Children.    Children will be exposed to uranium in the same manner as adults in the 
general population (i.e., ingestion of food and water and inhalation of air).  Concentrations measured in 
the urine of children aged 6–11 and 12–19 years during the National Health and Nutrition Examination 
Survey (NHANES) were similar to those measured in adults aged 20 years and older (CDC 2012), across 
all years.  A study of uranium content in bone from three age groups (<13, 13–20, and 20–25 years old) 
reported somewhat higher uranium content in the youngest compared to the oldest age group 
(approximately 1.5–3-fold); however, there were only 2–4 subjects in each group and the results were not 
statistically significant (Broadway and Strong 1983).  Since the skeletons of children are growing (higher 
rate of bone formation), it is possible that a higher fraction of circulating uranium will be deposited in 
bone than in adults.  Further information is needed on bone levels of uranium in children to determine if 
this is the case.  Uranium is found in all soil, and at potentially higher levels at some hazardous waste 
sites.  Since children may have oral exposure to soil through hand-to-mouth activity, bioavailability 
studies of uranium in soil may be useful to assess the risk of this type of exposure.  There is some 
evidence that neonatal animals absorb uranium in the gastrointestinal tract to a greater extent than adults.  
Experiments to confirm this finding and to determine how long into maturation a difference exists would 
help refine risk assessment for uranium exposure in children. 
 
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility. 
 
Exposure Registries.    A voluntary exposure registry, the USTUR for occupationally exposed 
individuals, was established at Richland, Washington, in 1968 as the National Plutonium Registry for 
investigation of the potential hazards for occupational exposure to uranium.  In 1971, additional 
radiochemistry support was provided by Los Alamos National Laboratory.  The U.S. Uranium Registry 
was created as a separate entity in 1978, and the two registries operated in parallel until 1987, when a 
single director was given responsibility for both registries.  In 1992, the management and operation of the 
registries was combined at Washington State University under a grant from the U.S. DOE.  The primary 
goals are to develop information on the distribution and dose of uranium and transuranic elements in 
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humans, providing data for verification or development of radiation protection standards, and to 
determine and evaluate health effects due to exposure to these radioactive elements. 
 
6.8.2   Ongoing Studies  
 
Ongoing studies are examining the levels of potential exposure to depleted uranium used for military 
purposes. 










7.  ANALYTICAL METHODS 
 
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring uranium, its metabolites, and other biomarkers of exposure and effect to 
uranium.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
 
7.1   BIOLOGICAL MATERIALS  
 
Uranium can enter the human body through inhalation, ingestion, or penetration through the skin.  
Measurement of the quantities of uranium in the body can be performed by two primary methods, in vivo 
measurements and in vitro measurements.  In vivo techniques measure the quantities of internally 
deposited uranium directly using a whole-body counter, while in vitro techniques permit estimation of 
internally deposited uranium by analysis of body fluids, excreta, or (in rare instances) tissues obtained 
through biopsy or postmortem tissue sectioning (USTUR 2011).  Some of these analytical methods are 
summarized in Table 7-1. 
 
The accurate and precise quantification of uranium in biological materials by either in vivo or in vitro 
methodologies requires that standard, certified sources with known concentrations of appropriate 
radionuclides be available and used appropriately on properly calibrated equipment.  The U.S. national 
primary standards laboratories for developing and disseminating ionizing radiation standards include 
DOE laboratories for special nuclear materials standards and the National Institute of Standards and 
Technology (NIST) for the remaining standards.  Also, the Health Physics Society accredits secondary 
standards laboratories for developing and disseminating NIST-traceable radioactive sources (HPS 2011).  
DOE does not produce Certified Reference Materials for biological matrices.  However, NIST does 
produce human biological standard reference materials (SRMs) for uranium in two matrices (human lung 
powder [SRM4351, 234U and 238U each 1.0x10-4 Bq/g] and urine [SRM2668, two concentrations, 0.0340 
or 13.37 µg/L with 626 or 618 mg creatinine/L, respectively] (NIST 2011). 
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Table 7-1.  Analytical Methods for Determining Uranium in Biological Samples 
 
Sample 




limit Accuracy Reference 





Not given 92% at 0.9 dpm 
spike 
Hinton 1983 
Urine Spiked urine wet ashed; 








78% Singh and Wrenn 
1988 
Urine Sample treated with HCl 
and H2O2, clean-up on 





5 μg/L 87% at 11 μg/L Kressin 1984 
Urine Sample wet ashed, 
enrichment on anion 
exchange column, 








Urine Sample digestion with 





1 μg/L 86% at 7 μg/L Hinton and White 
1981 
Urine Wet-ashed; solubilized KPA ~0.050 μg/L 90B110% Birkenfeld et al. 
1995 






<6 μg/L 80% at 2 μg 
added uranium 
Pleskach 1985 
Urine Sample with 232U spike 











No data Kelly et al. 1987 
Urine Acidification; dilution ICP-MS 3 ng/L No data Karpas et al. 
1996 
Urine Dilution with acid, triton-
X-100 
ICP-MS 0.004 µg/L 3.71 RSD (%) at 
0.08 µg/L 
Caldwell et al. 
2005 










>95%  Todorov et al. 
2009 
Urine Compilation from  
ANSI, DOE, EPA, IAEA, 
ICRP 
Not provided 0.04–1 pCi/L 
(0.0007–
0.07 Bq/L) 
Not provided HPS 1996 
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Table 7-1.  Analytical Methods for Determining Uranium in Biological Samples 
 
Sample 




limit Accuracy Reference 












Ejnik et al. 2005 
Soft tissue Spiked tissues wet 








85B92% Singh and Wrenn 
1988 
Soft tissue Spiked sample wet 
digested; purification by 
anion exchange; loaded 
into a single ion-
exchange bead as a point 





<5 pg/L 77% Kelley and 
Fassett 1983 
Bones Spiked sample dry 









60B93% Singh and Wrenn 
1988; Singh et al. 
1984 
Bone ash Spiked sample wet 
ashed; clean-up by 





0.4 μg/kg for 
238U 
>95% Fisenne et al. 
1980 
Feces Spiked sample dry and 









58% Singh and Wrenn 
1988 
Bone ash Sampled dried; wet-
ashed; homogenization; 
dissolution in acid 
ICP-MS 3 ng/g No data Twiss et al. 1994 






No data Gonzales et al. 
1988 
 
aThis detection limit was reported by Melgard 1988. 
 
ANSI = American National Standard Institute; DOE = Department of Energy; DRC = dynamic reaction cell; 
EPA = Environmental Protection Agency; IAEA = International Atomic Energy Agency; ICP = inductively coupled 
plasma; ICRP = International Commission on Radiological Protection; KPA = kinetic phosphorescence analysis; 
MS = mass spectrometry; NAA = neutron activation analysis 
 
URANIUM  342 
 








Ough et al. (2006) conducted an interlaboratory comparison of analytical methods of synthetic urine 
samples containing natural and depleted uranium.  The laboratories used ICP-sector field-MS (ICP-SF-
MS), quadrupole ICP-MS (ICP-Q-MS), thermal ionization mass spectrometry (TIMS), and instrumental 
and delayed neutron activation analysis (I/DNAA) methods.  The study showed that the ICP-SF-MS and 
ICP-Q-MS had the greatest accuracy and precision in measuring total uranium; the TIMS method also 
had a high precision, but lower accuracy.  In tests of the 238U/235U isotope ratio, the TIMS results had the 
lowest accuracy, but the highest precision.  The ICP-SF-MS and ICP-Q-MS had high accuracy and 
precision in the isotope ratio tests; I/DNAA method was not analyzed for the isotope tests.  The relative 
sensitivity of the instrument detection limits was TIMS>ICP-SF-MS>ICP-Q-MS>I/DNAA. 
 
7.1.1   Internal Uranium Measurements  
 
In vivo or direct measurements of uranium in the body are made with radiation detector systems and 
associated electronics called whole-body counters that measure radiation as it leaves the body from 
internally deposited uranium.  In vivo assays are the most direct method of quantifying internally 
deposited radioactive materials.  However, not all radionuclides emit radiations than may be detected with 
sufficient accuracy outside the body (234U and 238U due to low-energy, low-intensity gamma emissions, 
for example) (NCRP 1978). 
 
The most commonly used detectors for uranium in vivo counting are sodium iodide, phoswich (NaI and 
CsI sandwich), and hyperpure germanium, which measure the gamma rays emitted during uranium decay 
(DOE 1988, 2009).  Since the gamma radiations emitted from uranium and a number of its progeny are 
the same as those emitted by uranium in the environment, shielded rooms are normally used to house the 
uranium internal monitoring equipment to ensure that background radiation is as low as possible (DOE 
1999b; MARLAP 2004; Parrington et al. 1996).  Although whole-body counters may be made in many 
configurations, a chest counter is usually used for inhaled uranium.  In vivo analysis is widely used 
throughout the nuclear industry, both commercial and government, for quantifying levels of insoluble 
uranium in the body.  In vitro analysis (see Section 7.1.2) is often used in conjunction with whole-body 
counting for monitoring workers handling uranium (DOE 2009). 
 
In vivo counting systems are calibrated using tissue-equivalent phantoms.  These phantoms have shapes 
similar to the human torso and are made of polystyrene or other tissue equivalent material.  Standard 
uranium sources of known activity are inserted into the phantom at locations where uranium would be 
expected to accumulate in a human body (DOE 1988).  Relationships are determined between the 
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uranium activity measured by the detection system and the known activity in the phantom (DOE 1988; 
HPS 1996). 
 
There are limitations associated with in vivo counting uranium measurements.  First, soluble uranium is 
readily excreted, with fractions retained for varying periods in the bone and kidney, so detectability 
depends on factors such as intake quantity, chemical and physical form, biodistribution fraction, time 
since intake, background uranium contribution, analysis time, and detection system efficiency.  Second, 
only the 235U isotope is typically evaluated using sodium iodide or hyperpure germanium detector 
systems, since 234U and 238U decay results in the emission of gamma rays of such low intensity and energy 
that they are difficult for these systems to quantify (NCRP 1987).  In such cases, indirect in vitro methods 
can be used for measuring uranium in urine or feces (DOE 2009).  Analytical equipment and procedures 
vary widely among laboratories and often require individual-specific input (NCRP 1987).  Routine 
bioassay monitoring is recommended for uranium processing facility workers at high risk of incurring an 
intake when the quantity of uranium handled reaches 0.5 kg (320 µCi), 5 kg (3,200 µCi), or 50 kg 
(32,000 µCi), respectively, when the process occurs in an open room or on a bench top with possible 
escape from a process vessel, in a fume hood, or in a glove box (DOE 2009).  The Minimum Testing 
Level (amount of radioactive material a test laboratory should be able to measure in a performance test) 
for laboratories engaged in biomonitoring is 0.81 nCi (30 Bq) for in vivo lung monitoring (HPS 1996).  
The radiological limit is based on 50-rem to bone surfaces for class F uranium (formerly class D 
uranium),  5-rem to the whole body for class M uranium (formerly class W uranium), and 50-rem to the 
extrathoracic portion of the respiratory tract for class S uranium (formerly class Y uranium) (DOE 2009). 
 
7.1.2   External Measurements  
 
In vitro uranium analyses are routinely performed in support of a personnel monitoring program, or in 
cases where the size of an operation does not justify the cost of whole-body counter facilities.  These 
analyses are usually done on urine samples, but other types of body materials may also be used (e.g., 
feces or blood).  Urinalysis is effective for analysis of transportable or soluble uranium.  A fraction of 
insoluble uranium also appears in the urine (DOE 2009). 
 
The excretion of uranium in fecal material results primarily from intakes by ingestion, and includes 
uranium swallowed after inhalation.  Uranium will usually appear in feces within hours after intake, thus 
providing a rapid means of determining whether an intake has occurred.  Fecal analysis requires 
prechemistry preparation that includes ashing of the sample, cleaning by co-precipitation, and solvent 
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extraction followed by electrodeposition.  Alpha spectroscopy is then performed (Singh and Wrenn 
1988).  In the other methods, electrodeposition is replaced with an equipment-specific step, such as direct 
injection for ICP-MS and mixing with a scintillation cocktail for liquid scintillation.  Urinalysis is 
typically favored over both fecal and blood analysis because it is generally more sensitive and less costly, 
and because fecal analysis provides no uptake or retention information and blood analyses is invasive. 
 
The analysis of uranium is rarely performed in favor of modeling using biokinetic and biodynamic 
parameters linked to bioassay results, unless it is conducted as part of an autopsy.  The U.S. Transuranium 
and Uranium Registries (USTUR) maintains the bodies and tissues of uranium workers who donated their 
bodies to scientific research.  USTUR has developed methods for accepting, handling, storing, preparing, 
analyzing, and disposing of donated human tissues.  Tissues analyzed for uranium content are prepared by 
ashing, anion exchange, and electrodeposition followed by alpha spectroscopy (USTUR 2011). 
 
Several methods that do not require chemical separation are available for measuring uranium in urine (in 
units of total mass or total activity).  These methods include spectrophotometric (total mass), fluorometric 
(total mass), kinetic phosphorescence analysis (KPA) (total mass), and gross alpha (total activity) 
analyses (DOE 2009; Elliston et al. 2001, 2005; MARLAP 2004; Wessman 1984).  Photometric 
techniques such as fluorometry and phosphorometry are not frequently used, but kinetic phosphorescence 
analysis is widely used.  Measurements of total uranium do not provide the relative isotopic abundance of 
the uranium isotopes, but this may only be important when converting between activity and mass when 
the isotopic ratios are uncertain, or when differentiating between natural and depleted uranium (Magnoni 
et al. 2001; Roth et al. 2003). 
 
If quantification of an individual uranium isotope is needed (e.g., 234U, 235U, or 238U), the most commonly 
used methods require chemical separation followed by α-spectrometry, or chemical separation and 
electrodeposition followed by α-spectrometry (see Table 7-1).  Mass spectrometers are more expensive, 
but provide sensitive, accurate, low-level analysis of uranium isotopes in much less time and with greater 
throughput than other methods due to greatly reduced sample preparation and analysis times (Twiss et al. 
1994; MARLAP 2004; MARSSIM 2000). 
 
The Minimum Testing Level for laboratories engaged in in vitro analysis of 234U, 235U, and 238U in 
biological samples using α-spectroscopy is 0.54 pCi (0.02 Bq) per liter or per sample (HPS 1996).  An 
acceptable minimum testing level of 20 μg/L of urine has also been established for natural uranium based 
on mass determination (HPS 1996). 
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7.2   ENVIRONMENTAL SAMPLES  
 
Two types of methods are commonly used for measurement of uranium in environmental samples.  The 
first are field surveys using portable survey instruments, and the second is analysis of samples procured in 
the field that are returned to the laboratory for quantification. 
 
Accurately measuring the uranium in the field and in environmental samples requires that standard, 
certified radioactive sources with known concentrations of uranium, or other appropriate radionuclides, be 
available and used properly.  The U.S. national primary standards laboratories for developing and 
disseminating ionizing radiation standards are the DOE (for special nuclear materials only) and the NIST 
for the remainder.  Also, the Health Physics Society accredits secondary standards laboratories for 
calibrating portable radiation meters and developing and disseminating NIST-traceable radioactive 
sources (HPS 2011).  DOE can provide environmental uranium standards for metal (natural and depleted 
uranium), compounds (hexafluoride, oxide, nitrate, and octaoxide), isotopic mixtures, and minerals 
(phosphate rock, carnotite, pitchblende, monazite, and octaoxide) (DOE 2011b).  NIST produces 
environmental uranium standards in 4 matrices (aqueous solution [SRM3164, SRM4321c] and natural 
water [SRM1640a], coal [SRMs 1632c and 1635], glass [SRMs 610 and 612–617], and urban particulate 
matter [SRM1648]) (NIST 2011).  Specifics for these include: SRM3164 (natural uranium aqueous 
solution; 9.994 mg/g), SRM 4321b (natural uranium aqueous solution; 234, 235, and 238U; 6.5, 0.3, 6.3 nCi/g; 
242.0, 11.14, 233.1 Bq/g, respectively), SRM 617 (trace elements in glass, 0.02 ppm uranium), SRM1635 
(trace elements in coal, uranium, 0.24 mg/kg) (NIST 2011). 
 
7.2.1   Field Measurements of Uranium 
 
Uranium measurements in the field are typically qualitative in nature in that the instruments simply 
respond to alpha emissions, regardless of their isotopic origin.  However, the levels can be measured 
quantitatively if key parameters are known, such as relative abundances of all alpha-emitting isotopes 
present, thickness of the layer being assessed, and detection efficiency of the instrument for the type of 
surface being assessed.  Measurements in the past have typically been made using a portable, hand-held 
alpha scintillation detector (e.g., ZnS) equipped with a count rate meter, which detects alpha radiation 
while discriminating against beta-emitters in the same area.  However, the need for low detection limits in 
radiological remediation efforts has found a more suitable and sensitive instrument in the large-area gas-
flow proportional counter.  These instruments can be carried by an individual or attached to a holder for 
maintaining a selected surface-to-detector distance.  The latter method can be integrated into a system 
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which moves along a surface at a predetermined velocity recording spatially-related real-time data for 
later graphical imaging of absolute surface activity distributions (DOE 1988).  These surveys can also be 
performed on people whose skin or clothing is contaminated.  Survey instruments can provide a quick 
estimate or a measure of the level of activity that might be present.  However, more accurate 
measurement of uranium activity may require that samples be taken for laboratory analyses.  Under 
normal usage, the lowest level of uranium that can be reliably detected using an alpha scintillation survey 
meter is 200–500 disintegrations per minute/100 cm2 (0.09–0.23 nCi/100 cm2) (DOE 1988); however, 
detection of levels several time lower is practical with gas flow proportional counters, especially when 
used in the integrate mode.  Detection capability varies with the type of detector used, the active area of 
the probe, the electronics, etc. 
 
Several limitations are associated with the measurement of uranium by portable survey instruments.  First, 
the uranium must be present on the surface of the material being surveyed.  Since uranium decays by 
emission of α particles, which travel only short distances in materials, any uranium that is imbedded in the 
surface being surveyed will be partially or completely masked.  Secondly, when performing surveys, it 
must be possible to place the detector very close to the surface being surveyed (i.e., approximately one-
quarter of an inch) (DOE 1988, 1994a), and uneven surfaces that are unintentionally touched can tear the 
detector window, disabling the instrument.  Additional information is available in MARSSIM (2000) on 
the use and usefulness of field survey instruments. 
 
7.2.2   Collection of Environmental Samples 
 
The Multi-Agency Radiological Laboratory Analytical Protocols Manual (MARLAP 2004) recommends 
that a field sampling plan be developed to provide comprehensive guidance for collecting, preparing, 
preserving, shipping, and tracking field samples and recording field data.  The principal objective is to 
provide representative samples of the proper size for analysis.  The design should address input and 
recommendations of representatives from the field sampling team, health physics professional staff, 
analytical laboratory, statistical and data analysts, quality assurance personnel, and end-users of data.  
Field organizations conduct operations according to standard operating procedures that may include but 
should not be limited to the following: 
 
• Developing a technical basis for defining the size of individual samples; 
 
• Selecting field equipment and instrumentation; 
 
• Using proper sample containers and preservatives; 
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• Using consistent container labels and sample identification codes; 
 
• Documenting field sample conditions and exceptions; 
 
• Documenting sample location; 
 
• Tracking, accountability, custody, and shipment forms; 
 
• Providing legal accountability, such as chain-of-custody record, when required; 
 
• Selecting samples for field quality control (QC) program; 
 
• Decontaminating equipment and avoiding sample cross-contamination; 
 
• Specifying sample packaging, radiological surveys of samples, shipping, and tracking; and 
 
• Documenting the health and safety plan. 
 
The in situ high purity germanium (HPGe) gamma spectrometry system is used to assess concentrations 
of radioactive materials in undisturbed soils (MARSSIM 2000).  The detector is able to discriminate 
among different radionuclides on the basis of characteristic gamma and x-ray energies.  Another in situ 
technology, laser ablation-ICP-atomic emission spectrometry or MS (LA-ICP-AES/MS), sends a probe to 
various soil depths where a laser ablates a 1 m3 sample (MARSSIM 2000).  The material is then passed 
through a plasma torch where it becomes ionized and electrically excited, producing an ionic emission 
spectrum.  As with the in situ HPGe system, the surface material is not consumed during the operation 
and results can be obtained in real-time. 
 
7.2.3   Laboratory Analysis of Environmental Samples  
 
Analytical methods for measuring uranium in environmental samples are summarized in Table 7-2.  The 
available methods can be divided into two groups: chemical methods to determine the total mass of 
uranium in a sample, and radiological methods to determine amounts of individual isotopes.  
Environmental media that have been tested for uranium include air filters, swipes, biota, water, soil, and 
others; a full range of laboratory analysis methods has been used to quantify the total uranium or its 
individual isotopes.  The equipment and methods tend to improve over time.  The radiological analysis 
methods include alpha counting (with ionization, proportional, scintillation, or other solid state detectors), 
alpha spectroscopy, beta counting (with thin-window GM, ionization, proportional, and solid state 
detectors), beta spectrometry, or gamma spectroscopy (with NaI or HPGe systems).  The equipment and 
method selection depends on the results needed and the non-uranium radionuclides that may be present 
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Air particulate collection on 
glass fiber filter; digestion in 
HNO3 
Spiked air particulate dry 
and wet ashed; dissolution; 
coprecipitation with iron 
hydroxide and Ca oxalate, 




Sample collection on 
cellulose filters; ashing; 
extraction with 
triisooctylamine; purification 
by anion exchange 
chromatography and 
coprecipitation. 
Collection on cellulose filters 
Coprecipitation with iron 
hydroxide, radiochemical, 
ion-exchange and solvent 
extractive purification, and 
electrodeposition on steel 
Direct analysis or 
concentration by co-




clean-up by ion-exchange 
Sample chelation in EDTA; 
addition of Fluron 
Sample concentration by 
cation-exchange resin, 
separation by ion-exchange 






















0.1 μg/L in 
final solution 
0.02 dpm/Lb 
238Ufor  in 
solution 
0.015 pCi 
0.03 μg per 
filter 


























Querol et al. 
1997 
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detection limit Accuracy Reference 
Water Sample fusion with NaF and Fluorometry 5 μg/L 117.5% at ASTM 1986 
LiF (total uranium) 6.3 μg/L (ASTM 
Method 
D2907-83) 
Water Coprecipitation with iron α-Spectrometry 0.02 dpm/L 97.7B108% ASTM 1986 
hydroxide; purification by (isotope at 0.028B (EPA Method 
ion-exchange quantification) 0.044 Bq/L D3972-82) 
chromatography and 
electrodeposition 
Water Solvent extraction; 





No data Stewart et al. 
1988 
dissolution in HClO4; quantification) 
reprecipitation with TiF3; 
filtration 
Water Preconcentration by NAA (total 3 μg/L >80% Holzbecher 
complexation with oxine and uranium) and Ryan 
adsorption on activated 1980 
carbon 
Water Preconcentration by ion-
exchange chromatography; 
(235UNAA  and 
238U) 
No data No data Gladney et al. 
1983 
purification by ion-exchange 
and solvent extraction 
Water Extraction by ion-exchange; Delayed neutron 0.4 μg/L No data Zielinski and 
dissolution in low oxygen analysis (total McKown 1984 
solvent; irradiation uranium) 
Water Wet-ashed; reaction with Pulsed-laser 0.05 ppb 103% ASTM 1994 
complexant phosphorimetry  (average) (Method 
5174-91) 
Water Solvent extraction Fluorescence 6.1–10.5 ppm No data ASTM 1994 








0.3 ng/L for 
238U 
±1.8% Aldstadt et al. 
1996 
quantification) 
Ground- Separation and Spectro- 1B2 μg/L No data Kerr et al. 
water concentration on two HPLC photometry (total 1988 
columns; complexation with uranium) 
Arsenazo III 
Water and Acid digestion; filtration ICP-MS (total 0.1 μg/L 105B110% EPA 1991a 
wastes (dissolved); acid digestion uranium) (EPA Method 
(total recoverable) 200.8) 
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detection limit Accuracy Reference 
Seawater Uranium enriched by 
chelation with APDC in the 
presence of Fe+2, 
complexation with APDC 







No data Nagj et al. 
1986 




0.02B0.2 nM No data Van den Berg 
and Nimmo 
1987 
Sediment Sediment dried and well-
mixed; dissolution in 
HCl-HClO4-HF; purification 






No data No data Anderson and 
Fleer 1982 
Soil Soil leached with HCl-HNO3-
HF; purification by ion-






No data No data Golchert et al. 
1980 















Ashing; fusion with KF and 









Ashing; extraction into 
triisooctylamine, strip from 
triisooctylamine with HNO3 






No data No data EPA 1984b 
Minerals Dissolution in HNO3-HF-

















0.03 dpm No data Wessman 
1984 
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Wet ashing with HNO3-H2O-









54B73% Singh and 
Wrenn 1988 
Vegetation Sample dried and 




0.1 μg/L in 
final solution 
No data Boomer and 
Powell 1987 
Vegetation Sample dried and 
homogenized; wet ashing 





0.05 mg/kg in 
plant ash 




Dilution and filtration water Laser 
fluorometry (total 
soluble uranium) 









0.04 mg/L No data Byerley et al. 
1987 
Field survey None Scintillation 
detector and 










aThis detection limit was reported by Melgard 1988. 
bThis detection limit was reported by Wessman 1984. 
 
APDC = ammonium pyrrolidine dithiocarbamate; Bq = Bequerel and 1 pCi = 0.37 Bq; dpm = disintegration per 
minute and 1 pCi = 2.22 dpm; EDTA = ethylenediaminetetraacetic acid; FI = flow injection; HPLC = high 
performance liquid chromatography; ICP = inductively coupled plasma spectrometry; INAA = instrumental neutron 
activation and analysis; MS = mass spectrometry; NAA = neutron activation analysis; nM = nanomole or 10-9 of a 
mol 
 
URANIUM  352 
 








(DOE 2009).  The use of high resolution α-spectroscopy is common, although gamma spectroscopy is 
usable with great care.  The chemical methods which are often used include spectrophotometry, 
fluorometry, and kinetic phosphorescence, with the addition of various mass spectrometer applications 
(ICP-MS, AES-MS, and accelerator-MS).  If conversions between mass and activity are to be made 
accurately, prior knowledge of the relative abundance of the various uranium isotopes must be available 
or measured radiologically.  A few media-specific methods that have been used successfully for 
measuring uranium concentrations in environmental samples are described below.  The current trend, 
however, is away from prescriptive methods and toward performance-based methods which enable the 
user to optimize their available analytical tools. 
 
A cornerstone of this method is the development of Data Quality Objectives and the use of Data Quality 
Assessment to ensure that the selected method is properly developed and the results are of the appropriate 
quality (DOE 2010; EPA 2000, 2006a, 2006b).  Field sampling quality assurance (QA) addresses a range 
of practices aimed at minimizing errors and evaluating sampling performance, and is a responsibility of 
all individuals involved.  Aspects of field QA/QC include the use of standard operating procedures for 
sample collection and analysis; chain-of-custody and sample-identification procedures; instrument 
standardization, calibration, and verification; technician and analyst training; sample preservation, 
handling, and decontamination; and QC samples such as field and trip blanks, duplicates, and equipment 
rinses (ORNL 2011). 
 
DOE’s method for analyzing environmental materials is based on the methods of Hindman (1983), Sill 
and Williams (1981), and Welford et al. (1960) and involves preparing vegetation, soft tissue, and water 
samples by concentrating or isolating uranium from the media prior to separation in an anion exchange 
column, followed by alpha spectrometry (DOE 2000). 
 
In one analytical method for air filters, the air filters are ashed, silica content is volatilized with hydrogen 
fluoride, and uranium is extracted with triisooctylamine, purified by anion exchange chromatography and 
co-precipitated with lanthanum as fluoride.  The precipitated uranium is collected by filtration, dried, and 
α-spectroscopy is performed (EPA 1984b).  The activities of 234U, 235U, and 238U are determined based on 
the number of counts that appear in the α energy region unique to each isotope.  This method is used by 
the EPA National Air and Radiation Environmental Laboratory for measurement of uranium in air as part 
of the Environmental Radiation Ambient Monitoring System (see Chapter 6). 
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Singh and Wrenn (1988) describe a method for uranium isotopic analysis of air filters.  Air filters are 
ashed, redissolved, and co-precipitated with iron hydroxide and calcium oxalate.  The uranium is further 
purified by solvent extraction and electrodeposition.  An alpha spectroscopy detection level of 
0.02 dpm/L for 238U in solution was reported (Singh and Wrenn 1988). 
 
Considerable work has been done to develop methods for analysis of uranium in water.  In 1980, the EPA 
published standardized procedures for measurement of radioactivity in drinking water, which included 
uranium analysis by both radiochemical and fluorometric methods (EPA 1980c), and more recently 
developed an ICP-MS method.  An example of each is provided below. 
 
The radiochemical method quantifies gross α activity utilizing either a gas flow proportional counter or a 
scintillation detection system following chemical separation.  In the EPA radiochemical method, the 
uranium is co-precipitated with ferric hydroxide, purified through anion exchange chromatography, and 
converted to a nitrate salt.  The residue is transferred to a stainless steel planchet, dried, flamed, and 
counted for α particle activity (EPA 1980c). 
 
For the fluorometric method, uranium is concentrated by co-precipitation with aluminum phosphate and 
dissolved in diluted nitric acid containing magnesium nitrate as a salting agent, and the co-precipitated 
uranium is extracted into ethyl acetate and dried.  The uranium is dissolved in nitric acid, sodium fluoride 
flux is added, and the samples are fused over a heat source (EPA 1980b). 
 
The ICP-MS method was developed for measuring total uranium in water and wastes.  The sample 
preparation is minimalCfiltration for dissolved uranium and acid digestion for total recoverable uranium.  
Recovery is quantitative (near 100%) for a variety of aqueous and solid matrices and detection limits are 
low, 0.1 μg/L for aqueous samples and 0.05 mg/kg for solid samples (EPA 1991a). 
 
The EPA developed two methods for the radiochemical analysis of uranium in soils, vegetation, ores, and 
biota, using the equipment described above.  The first is a fusion method in which the sample is ashed, 
the silica is volatilized, the sample is fused with potassium fluoride and pyrosulphate, a 236U tracer is 
added, and the uranium is extracted with triisooctylamine, purified on an anion exchange column, 
coprecipitated with lanthanum, filtered, and prepared in a planchet.  Individual uranium isotopes are 
separately quantified by high resolution α-spectroscopy and the sample concentration calculated using the 
236U yield.  The second is a nonfusion method in which the sample is ashed, the silica is volatilized, a 236U 
tracer is added, and the uranium is extracted with triisooctylamine, stripped with nitric acid, co-
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precipitated with lanthanum, transferred to a planchet, and analyzed in the same way by high resolution 
α-spectroscopy (EPA 1984). 
 
The detection capability of any measurement process is an important performance characteristics, along 
with precision and accuracy.  The lower limit of detection (LLD) has been adopted to refer to the intrinsic 
detection capability of the measurement process (sampling through data reduction and reporting.  Factors 
that influence the LLD include background count rate, sensitivity of detector, and, particularly, the length 
of time a sample and background are counted.  Because of these variables, LLDs between laboratories, 
employing the same or similar chemical separation procedures, will vary.  Additional examples of the 
techniques for quantification of uranium (as described above) are available, as well as examples of less 
frequently used techniques.  These are identified in Table 7-3. 
 
7.3   ADEQUACY OF THE DATABASE  
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of uranium is available.  Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of uranium. 
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
 
7.3.1   Identification of Data Needs  
 
Methods for Determining Biomarkers of Exposure and Effect.    Analytical methods with 
satisfactory sensitivity and precision are available to determine the levels of uranium in human tissues and 
body fluids.  However, improved methods are needed to assess the biological effects of uranium in 
tissues. 
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Table 7-3.  Additional Analytical Methods for Determining Uranium in 
Environmental Samples 
 












Solvent extraction as 
MHFA complex; 







99–103% Abbassi 1989 






6.6 μg/L No data Perez et al. 1990 






No data No data Ramachandraiah 
et al. 1993 














Solvent extraction as 
MHFA complex; 










separation by extraction 
with trioctylphosphine 
oxide; destruction of 










Wet digestion; solvent 
extraction 
ICP-OES No data 101% Feeney et al. 
1983 









Direct analysis ICP low ppm No data Greene et al. 
1985 





ICP 29 μg/L 98% Kamata et al. 
1987 
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acetone and tri-n-butyl 
phosphate 
































































Chang et al. 1990 
Fujino et al. 1994 
Mlakar and 
Branica 1989 
Wang et al. 1994 
Miller et al. 1994 
Riley 1982 




Toole et al. 1991 




AES = atomic emission spectrometry; Bq = Bequerel; ICP = inductively coupled plasma (spectrometry);  
MHFA = N-p-methoxyphenyl-2-furylacrylohydroxamic acid; MS = mass spectrometry; NAA = neutron activation 






Table 7-3.  Additional Analytical Methods for Determining Uranium in 
Environmental Samples 
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Uranium is in essentially all food, water, and air, so everyone is exposed to some levels.  In a study 
reported by NIOSH (1981) and Thun et al. (1985), enhanced levels of β2-microglobulin levels were 
observed in the urine of uranium workers.  It was postulated that enhanced excretion of β2-microglobulin 
might be used as an indication of uranium exposure; however, NIOSH (1981) and Thun et al. (1985) were 
unable to establish a dose-response correlation between level of exposure and excretion of the β2-micro-
globulin.  Limson Zamora et al. (1998) identified changes in several potential biomarkers of effect 
following exposure to uranium, in which each individual biomarker could be affected by a range of 
chemicals, but the results suggested that it may be possible to identify a series of biomarkers whose 
combined responses could serve as a single uranium-specific biomarker of effect.  Development of new or 
combination biomarkers for high uranium exposures would be useful. 
 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.    Analytical methods with the required sensitivity and accuracy are available for quantification 
of uranium, both total and isotopic, in environmental matrices (Table 7-2).  Knowledge of the levels of 
uranium in various environmental media, along with the appropriate modeling (see Chapters 3 and 5), can 
be used to evaluate potential human exposures through inhalation and ingestion pathways. 
 
Whether in the environment or in the human body, uranium will undergo radioactive decay to form a 
series of radioactive nuclides that end in a stable isotope of lead (see Chapter 4).  Examples of these 
include radioactive isotopes of the elements thorium, radium, radon, polonium, and lead.  Analytical 
methods with the required sensitivity and accuracy are also available for quantification of these elements 
in the environment where large sample are normally available (EPA 1980b, 1984), but not necessarily for 
the levels from the decay of uranium in the body.  More sensitive analytical methods are needed for 
accurately measuring very low levels of these radionuclides. 
 
7.3.2   Ongoing Studies  
 
No ongoing studies were identified. 
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES 
 
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites. 
 
The international and national regulations, advisories, and guidelines regarding uranium in air, water, and 
other media are summarized in Table 8-1. 
 
ATSDR has derived an MRL of 0.002 mg U/m3 for intermediate-duration inhalation exposure to 
insoluble uranium compounds based on a NOAEL of 1.1 mg U/m3 and a LOAEL of 8.2 mg U/m3 for 
renal effects in dogs exposed to uranium dioxide 6 hours/day, 6 days/week for 5 weeks (Rothstein 1949b) 
and an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human 
variability). 
 
ATSDR has derived an MRL of 0.0001 mg U/m3 for intermediate-duration inhalation exposure to soluble 
uranium compounds based on a LOAEL of 0.15 mg U/m3 for renal effects in dogs exposed to uranyl 
fluoride 6 hours/day, 6 days/week for 5 weeks (Rothstein 1949a) and an uncertainty factor of 300 (3 for 
the use of a minimal LOAEL, 10 for extrapolation from animals to humans, and 10 for human 
variability). 
 
ATSDR has derived an MRL of 0.0008 mg U/m3 for chronic-duration inhalation exposure to insoluble 
uranium compounds based on a LOAEL of 5.1 mg U/m3 for lung fibrosis in monkeys exposed to uranium 
dioxide 5.4 hours/day, 5 days/week for 5 years (Leach et al. 1970, 1973) and an uncertainty factor of 
1,000 (10 for the use of a LOAEL, 10 for extrapolation from animals to humans, and 10 for human 
variability). 
 
ATSDR has derived an MRL of 0.00004 mg U/m3 for chronic-duration inhalation exposure to soluble 
uranium compounds based on a BMCL10 of 0.019 mg U/m3 for renal effects in dogs exposed to uranium 
tetrachloride 33 hours/week for 1 year (Stokinger et al. 1953) and an uncertainty factor of 100 (10 for 
extrapolation from animals to humans and 10 for human variability). 
 
ATSDR has derived an MRL of 0.002 mg/kg/day for acute-duration oral exposure to soluble uranium 
compounds based on an average BMDL05 of 0.2 mg U/kg/day for developmental effects in the offspring 
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of mice administered via gavage uranyl acetate dehydrate on gestation days 6–15 (Domingo et al. 1989c) 
and an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human 
variability). 
 
ATSDR has derived an MRL of 0.0002 mg/kg/day for intermediate-duration oral exposure to soluble 
uranium compounds based on a LOAEL of 0.06 mg U/kg/day for renal effects in rats exposed to uranyl 
nitrate hexahydrate in drinking water for 91 days (Gilman et al. 1998a) and an uncertainty factor of 300 
(3 for use of a minimal LOAEL, 10 for extrapolation from animals to humans, and 10 for human 
variability). 
 
EPA derived a reference dose (RfD) of 0.003 mg/kg/day for uranium soluble salts based on a LOAEL of 
2.8 mg/kg/day for initial weight loss and moderate nephrotoxicity in rabbits exposed to uranium in the 
diet for 30 days (Maynard and Hodge 1949) and an uncertainty factor of 1,000 (10 for the use of a 
LOAEL, 10 for intraspecies variability, and 10 for interspecies variability) (IRIS 2012).  This RfD 
(developed in 1989) is currently under review by EPA. 
 
IARC, the U.S. Department of Human and Health Services, and the NTP have not classified uranium as 
to its carcinogenicity.  According to the Integrated Risk Information System (IRIS) database, the EPA 
withdrew its carcinogenic assessment of natural uranium in 1993 (IRIS 2012). 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 
 
Agency Description Information Reference 
INTERNATIONAL    
Guidelines:    
 IARC Carcinogenicity classification  IARC 2012 
  Mixtures of uranium isotopes Limited evidence in 
humans for 
carcinogenicity 
  233U, 234U, 235U, and 238U (natural, 
enriched, and depleted uranium) 




 ICRP Recommended dose limits  ICRP 1991 
  Occupational  
   Effective dosea 20 mSv per year, 
averaged over defined 
periods of 5 years 
   Annual equivalent dose  
    Lens of the eye 150 mSv 
    Skinb 500 mSv 
    Hands and feet 500 mSv 
  Public  
   Effective dosec 1 mSv in a year 
   Annual equivalent dose  
    Lens of the eye 15 mSv 
    Skin 50 mSv 
    Hands and feet No data 
 WHO Air quality guidelines No data WHO 2010 
 Provisional drinking water quality 
guidelines 
0.015 mg/Ld WHO 2008 
 TDI 0.6 μg/kg/day 
NATIONAL    
Regulations and 
Guidelines: 
   
a. Air    
 ACGIH TLV (8-hour TWA)  ACGIH 2012 
  Uranium, soluble and insoluble 
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8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 

























 Uranium, soluble and insoluble 






Hazardous air pollutant 
NAAQS 
National emission standards for 
radon-222 emissions from underground 
uranium mines 
National emission standards for 
radionuclide emissions from federal 
facilities other than USNRC licensees 
and not covered by Subpart H 
National emission standards for 
radon-222 emissions from the disposal 
of uranium mill tailings that are no 
longer operational 
National emission standards for 
radon-222 emissions from operating 
mill tailings 
REL (10-hour TWA) 
 Uranium, metal and insoluble 
Ufcompounds, as  
Uf Uranium, soluble compounds, as  
STEL 
 Uranium, metal and insoluble 
Ufcompounds, as  
IDLH 
 Uranium, metal, insoluble, and 
Ufsoluble compounds, as  
gEffluent concentrations in the air  
 
 
30.6 mg/m  
No data 
30.6 mg/m  
30.6 mg/m  






220 pCi/(m -sec) 
220 pCi/(m -sec) 
 
30.2 mg/m  
30.05 mg/m  
 
30.6 mg/m  
 








42 USC 7412 
EPA 2010a 
EPA 2011k 
40 CFR 61.22, 
Subpart B 
EPA 2011l 
40 CFR 61.102, 
Subpart I 
EPA 2011j 
40 CFR 61.222, 
Subpart T 
EPA 2011i 




10 CFR 20, 
Appendix B 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 
 



























































































































10 CFR 20, 
Appendix B 
URANIUM  364 
 








Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 
 
Agency Description Information Reference 
NATIONAL (cont.)    
 Occupational ALIs 
ginhalation  
and DACs for  USNRC 2012a 
10 CFR 20, 









 W 4x10-1 1x10-10 
 Y 3x10-1 1x10-10 
231U D 8x10-3 3x10-6 
 W 6x10-3 2x10-6 
 Y 5x10-3 2x10-6 
232U D 4x10-1 9x10-11 
 W 4x10-1 2x10-10 
 Y 8x10-3 3x10-12 
233U D 2x100 5x10-10 
 W 7x10-1 3x10-10 
 Y 4x10-2 2x10-11 
234U D 2x100 5x10-10 
 W 7x10-1 3x10-10 
 Y 4x10-2 2x10-11 
235U D 2x100 6x10-10 
W 8x10-1 3x10-10 
Y 4x10-2 2x10-11 
 Occupational ALIs 
ginhalation  
and DACs for  USNRC 2012a 
10 CFR 20, 









 W 8x10-1 3x10-10 
 Y 4x10-2 2x10-11 
237U D 3x10-3 1x10-6 
 W 2x10-3 7x10-7 
 Y 2x10-3 6x10-7 
238U D 2x100 6x10-10 
 W 8x10-1 3x10-10 
 Y 4x10-2 2x10-11 
239U D 2x105 8x10-5 
 W 2x105 7x10-5 
 Y 2x105 6x10-5 
240U D 4x103 2x10-6 
 W 3x103 1x10-6 









 Y 5x10-2 2x10-11 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 
 
Agency Description Information Reference 
NATIONAL (cont.)    
 Occupational dose limits  USNRC 2012b 
10 CFR 20, 
Subpart C   Adults 5 rems (0.05 Sv) 
   Lens dose 15 rems (0.15 Sv) 
   Shallow-dose equivalent to the 
skin of the whole body or to the 
skin of any extremity 
50 rems (0.5 Sv) 
  Minors 10% of the annual 
dose limits specified for 
adult workers 
 OSHA PEL (8-hour TWA) for general industry  OSHA 2012c 
29 CFR 1910.1000, 
Table Z-1   Uranium, soluble compounds, as U 0.05 mg/m
3 
  Uranium, insoluble compounds, 
as U 
0.25 mg/m3 
 Each area or room in which natural 
uranium is used or stored shall be 
conspicuously posted with a sign or 
signs bearing the radiation caution 
symbol 
Amount >100 times the 
quantity of such 
material specified in 
10 CFR, Part 20 
OSHA 2012a 
29 CFR 1910.1096 
 Each container in which natural 
uranium is transported, stored, or used 
shall bear a durable, clearly visible 
label bearing the radiation caution 
symbol 
Quantity >10 times the 
quantity specified in 
10 CFR, Part 20, 
Appendix C 
OSHA 2012b 
29 CFR 1910.1096 
b. Water    
 EPA Designated as hazardous substances 
in accordance with Section 311(b)(2)(A) 
of the Clean Water Act 
No data EPA 2011b 
40 CFR 116.4 
 Drinking water contaminant candidate 
list 
No data EPA 1998b 
63 FR 10274 
 Drinking water standards and health 
advisories 
 EPA 2011c 
  MCL 0.03 mg/L 
  MCLG Zero 
  DWEL 0.02 mg/L 
 National primary drinking water 
standards 
 EPA 2009a 
  MCL 0.03 mg/L 
  Potential health effects from long-
term exposure above the MCL 
Increased risk of cancer 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 
 
Agency Description Information Reference 
NATIONAL (cont.)    
  Common sources of contaminant in 
drinking water 
Erosion of natural 
deposits 
 
  Public health goal Zero 
 National recommended water quality 
criteria 
No data EPA 2009b 
 Reportable quantities of hazardous 
substances designated pursuant to 
Section 311 of the Clean Water Act 
No data EPA 2011p 
40 CFR 117.3 
 USNRC Effluent concentrations in the water  USNRC 2012a 
10 CFR 20, 

























c. Food    
 FDA Bottled water  FDA 2012a 
21 CFR 165.110   Uranium 30 µg/L 
 EAFUSh No data FDA 2012b 
d. Other    
 ACGIH Carcinogenicity classification  ACGIH 2012 
  Uranium, soluble and insoluble 
compounds, as U 
A1i 
 BEI  
  Uranium in urine, end of shift 200 μg/L 
 EPA Carcinogenicity classification No data IRIS 2012 
 RfC No data 
 RfD 0.003 mg/kg/day 
 Environmental radiation protection 
standards for management and 
disposal of spent nuclear fuel, high-
level and transuranic radioactive 
wastes 
 EPA 2011d 
40 CFR 191, 
Appendix A 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 
 
Agency Description Information Reference 
NATIONAL (cont.)    
  Release limit per 1,000 metric tons 
of heavy metal or other unit of waste 
for 233U, 234U, 235U, 236U, or 238U 
100  
 Environmental standards for the 
uranium fuel cycle 
Yes EPA 2011e 
40 CFR 190.10, 
Subpart B 
 Identification and listing of hazardous 
waste 
No data EPA 2011g 
40 CFR 261, 
Appendix VIII 
 Exclusion from Identification and listing 
of hazardous waste 
 EPA 2011f 
40 CFR 261.4 
   Uranium Yes 
 Inert pesticide ingredients in pesticide 
products 
No data EPA 2011h 
 
 National oil and hazardous substances 
pollution contingency plan;  
 EPA 2011m 
40 CFR 300, 
Appendix A   Hazard ranking system   
   Uranium Yes 
  National priorities list  EPA 2011n 
40 CFR 300, 
Appendix B    Uranium Yes 
 NPDES permit application testing 
requirements; hazardous substance 
required to be tested by existing 
dischargers if expected to be present 
 EPA 2011o 
40 CFR 122, 
Appendix D 
  Uranium Yes 
 Master Testing List No data EPA 2012b 
 EPA Standards for cleanup of land and 
buildings contaminated with residual 
radioactive materials from inactive 
uranium processing sites; listed 
constituents 
Combined 234Uand 238U EPA 2011q 
40 CFR 192, 
Subpart B 
 Standards for management of uranium 
byproduct materials pursuant to Section 
84 of the Atomic Energy Act of 1954, as 
amended 
Yes EPA 2011r 
40 CFR 192, 
Subpart D 
 Standards for the control of residual 
radioactive materials from inactive 
uranium processing sites 
 EPA 2011t 
40 CFR 192, 
Subpart A 
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES 
 
 
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 
 
Agency Description Information Reference 
NATIONAL (cont.)    
  Maximum concentration of 
constituents for groundwater 
protection; combined 234U and 238U 
30 pCi/L  
 Standards for owners and operators of 
hazardous waste TSD facilities; 
groundwater monitoring list 
No data EPA 2011s 
40 CFR 264, 
Appendix IX 
 Superfund, emergency planning, and 
community right-to-know 
  
  Designated CERCLA hazardous 
substance and reportable quantity 
 EPA 2011u 
40 CFR 302.4 




































  Effective date of toxic chemical 
release reporting 
No data EPA 2011w 
40 CFR 372.65 
  Extremely hazardous substances 
and its threshold planning quantity 
No data EPA 2011v 
40 CFR 355, 
Appendix A 
 TSCA chemical lists and reporting 
periods 
No data EPA 2011x 
40 CFR 712.30 
 TSCA health and safety data reporting No data EPA 2011y 
40 CFR 716.120 
 USNRC Releases to the sewers; monthly 
average concentration 
 USNRC 2012a 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 
 
Agency Description Information Reference 




























 Occupational ALIs for oral ingestion  USNRC 2012a 
10 CFR 20, 

























 NTP Carcinogenicity classification  NTP 2012 
77 FR 2728   Uranium (depleted) Nominated to the 
Report on Carcinogens 
 
aWith the further provision that the effective dose should not exceed 50 mSv in any single year.  Additional 
restrictions apply to the occupational exposure of pregnant women. 
bThe guideline value is designated as provisional because of outstanding uncertainties regarding the toxicology and 
epidemiology of uranium as well as difficulties concerning its technical achievability in smaller supplies. 
cThe limitation on the effective dose provides sufficient protection for the skin against stochastic effects.  An 
additional limit is needed for localized exposure in order to prevent deterministic effects. 
dIn special circumstances, a higher value of effective dose could be allowed in a single year, provided that the 
average over 5 years does not exceed 1 mSv per year. 
ePAC-1: mild, transient health effects.  PAC-2: irreversible or other serious health effects that could impair the ability 
to take protective action.  PAC-3: life-threatening health effects. 
fNIOSH potential occupational carcinogen. 
gThree classes (D,W,Y) of radioactive material, which refer to their retention (approximately days, weeks, or years) in 
the pulmonary region of the lung.  This classification applies to a range of clearance half-times of <10 days for D, for 
W from 10 to 100 days, and for Y >100 days. 
hThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS. 
iA1: confirmed human carcinogen 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Uranium 
 
Agency Description Information Reference 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; 
AIHA = American Industrial Hygiene Association; ALI = annual limit on intake; BEI = biological exposure indices; 
CERCLA = Comprehensive Environmental Response, Compensation, and Liability Act; CFR = Code of Federal 
Regulations; DAC = derived air concentration; DOE = Department of Energy; DWEL = drinking water equivalent 
level; EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency; 
ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; FR = Federal Register; 
GRAS = Generally Recognized As Safe; IARC = International Agency for Research on Cancer; ICRP = International 
Commision on Radiological Protection; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk 
Information System; MCL = maximum contaminant level; MCLG = maximum contaminant level goal; 
NAAQS = National Ambient Air Quality Standards; NIOSH = National Institute for Occupational Safety and Health; 
NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; PAC = Protective 
Action Criteria; PEL = permissible exposure limit; REL = recommended exposure limit; RfC = inhalation reference 
concentration; RfD = oral reference dose; STEL = short-term exposure level; TDI = tolerable daily intake; 
TLV = threshold limit values; TSCA = Toxic Substances Control Act; TSD = treatment, storage, and disposal; 
TWA = time-weighted average; U = uranium; USC = United States Code; USNRC = U.S. Nuclear Regulatory 
Commission; WHO = World Health Organization 
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10.  GLOSSARY 
 
Some terms in this glossary are generic and may not be used in this profile. 
 
Absorbed Dose, Chemical—The amount of a substance that is either absorbed into the body or placed in 
contact with the skin.  For oral or inhalation routes, this is normally the product of the intake quantity and 
the uptake fraction divided by the body weight and, if appropriate, the time, expressed as mg/kg for a 
single intake or mg/kg/day for multiple intakes.  For dermal exposure, this is the amount of material 
applied to the skin, and is normally divided by the body mass and expressed as mg/kg. 
 
Absorbed Dose, Radiation—The mean energy imparted to the irradiated medium, per unit mass, by 
ionizing radiation.  Units:  rad (rad), gray (Gy). 
 
Absorbed Fraction—A term used in internal dosimetry.  It is that fraction of the photon energy (emitted 
within a specified volume of material) which is absorbed by the volume.  The absorbed fraction depends 
on the source distribution, the photon energy, and the size, shape and composition of the volume. 
 
Absorption—The process by which a chemical penetrates the exchange boundaries of an organism after 
contact, or the process by which radiation imparts some or all of its energy to any material through which 
it passes. 
 
Absorption Coefficient—Fractional absorption of the energy of an unscattered beam of x- or gamma-
radiation per unit thickness (linear absorption coefficient), per unit mass (mass absorption coefficient), or 
per atom (atomic absorption coefficient) of absorber, due to transfer of energy to the absorber.  The total 
absorption coefficient is the sum of individual energy absorption processes (see Compton Effect, 
Photoelectric Effect, and Pair Production). 
 
Absorption Coefficient, Linear—A factor expressing the fraction of a beam of x- or gamma radiation 
absorbed in a unit thickness of material.  In the expression I=Ioe-μx, Io is the initial intensity, I the intensity 
of the beam after passage through a thickness of the material x, and μ is the linear absorption coefficient. 
 
Absorption Coefficient, Mass—The linear absorption coefficient per cm divided by the density of the 
absorber in grams per cubic centimeter.  It is frequently expressed as μ/ρ, where μ is the linear absorption 
coefficient and ρ the absorber density. 
 
Absorption Ratio, Differential—Ratio of concentration of a nuclide in a given organ or tissue to the 
concentration that would be obtained if the same administered quantity of this nuclide were uniformly 
distributed throughout the body. 
 
Activation—The process of making a material radioactive by bombardment with neutrons or protons. 
 
Activity—The number of radioactive nuclear transformations occurring in a material per unit time (see 
Curie, Becquerel).  The term for activity per unit mass is specific activity. 
 
Activity Median Aerodynamic Diameter (AMAD)—The diameter of a unit-density sphere with the 
same terminal settling velocity in air as that of the aerosol particle whose activity is the median for the 
entire size distribution of the aerosol. 
 
Acute Exposure, Chemical—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
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Acute Exposure, Radiation—The absorption of a relatively large amount of radiation (or intake of a 
radioactive material) over a short period of time. 
 
Acute Radiation Syndrome—The symptoms which taken together characterize a person suffering from 
the effects of intense radiation.  The effects occur within hours or days. 
 
Ad libitum—Available in excess and freely accessible. 
 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit surface area or 
per unit weight of organic carbon of a specific particle size in the soil or sediment to the concentration of 
the chemical in solution at equilibrium. 
 
Adsorption Ratio (Kd)—See Distribution Coefficient 
 
Alpha Particle—A positively charged particle ejected spontaneously from the nuclei of some radioactive 
elements.  It is identical to a helium nucleus, i.e., 2 neutrons and two protons, with a mass number of 4 
and an electrostatic charge of +2. 
 
Alpha Track—The track of ionized atoms (pattern of ionization) left in a medium by an alpha particle 
that has traveled through the medium. 
 
Annihilation (Positron-Electron)—An interaction between a positive and a negative electron in which 
they both disappear; their rest mass, being converted into electromagnetic radiation (called annihilation 
radiation) with two 0.51 MeV gamma photons emitted at an angle of 180 to each other. 
 
Annual Limit on Intake (ALI)—The derived limit for the amount of radioactive material taken into the 
body of an adult worker by inhalation or ingestion in a year.  It is the smaller value of intake of a given 
radionuclide in a year by the reference man that would result in a committed effective dose equivalent of 
5 rem or a committed dose equivalent of 50 rem to any organ or tissue. 
 
Atom—The smallest particle of an element that cannot be divided or broken up by chemical means.  It 
consists of a central core called the nucleus, which contains protons and neutrons and an outer shell of 
electrons. 
 
Atomic Mass (u)—The mass of a neutral atom of a nuclide, usually expressed in terms of "atomic mass 
units."  The "atomic mass unit" is one-twelfth the mass of one neutral atom of carbon-12; equivalent to 
1.6604x10-24 g. 
 
Atomic Mass Number—See Mass Number. 
 
Atomic Number—The number of protons in the nucleus of an atom.  The "effective atomic number" is 
calculated from the composition and atomic numbers of a compound or mixture.  An element of this 
atomic number would interact with photons in the same way as the compound or mixture.  (Symbol: Z). 
 
Atomic Weight—The weighted mean of the masses of the neutral isotopes of an element expressed in 
atomic mass units. 
 
Attenuation—A process by which a beam from a source of radiation is reduced in intensity by 
absorption and scattering when passing through some material. 
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Attenuation Coefficient—The fractional reduction in the intensity of a beam of radiation as it passes 
through an absorbing medium.  It may be expressed as reduction per unit distance, per unit mass 
thickness, or per atom, and is called the linear, mass, or atomic attenuation coefficient, respectively. 
 
Auger Effect—The emission of an electron from the extranuclear portion of an excited atom when the 
atom undergoes a transition to a less excited state. 
 
Background Radiation—The amount of radiation to which a member of the general population is 
exposed from natural sources, such as terrestrial radiation from naturally occurring radionuclides in the 
soil, cosmic radiation originating from outer space, and naturally occurring radionuclides deposited in the 
human body. 
 
Becquerel (Bq)—International System of Units unit of activity and equals that quantity of radioactive 
material in which one transformation (disintegration) occurs per second (see Units). 
 Terabecquerel (TBq)—One trillion becquerel. 
 Gigabecquerel (GBq)—One billion becquerel. 
 Megabecquerel (MBq)—One million becquerel. 
 Kilobecquerel (kBq)—One thousand becquerel. 
 Millibecquerel (mBq)—One-thousandth of a becquerel. 
 Microbecquerel (μBq)—One-millionth of a becquerel. 
 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible. 
 
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
 
Beta Particle—An electron that is emitted from the nucleus of an atom during one type of radioactive 
transformation.  A beta particle has a mass and charge equal in magnitude to that of the electron.  The 
charge may be either +1 or -1.  Beta particles with +1 charges are called positrons (symbolized β+), and 
beta particles with -1 charges are called negatrons (symbolized β-). 
 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
 
Biologic Effectiveness of Radiation—See Relative Biological Effectiveness. 
 
Biological Half-time—The time required for a biological system, such as that of a human, to eliminate by 
natural process half of the amount of a substance (such as a chemical substance, either stable or 
radioactive) that has entered it. 
 
Biomagnification—The progressive increase in the concentration of a bioaccumulated chemical in 
organisms as that chemical is passed from the bottom to the top of the food web. 
 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
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Body Burden, Chemical—The total amount of a chemical found in an animal or human body. 
 
Body Burden, Radioactivity—The amount of radioactive material found in an animal or human body. 
 
Bone Seeker—Any compound or ion which migrates in the body and preferentially deposits into bone. 
 
Branching—The occurrence of two or more modes by which a radionuclide can undergo radioactive 
decay.  For example, 214Bi can undergo alpha or beta minus decay, 64Cu can undergo beta minus, beta 
plus, or electron capture decay.  An individual atom of a nuclide exhibiting branching disintegrates by one 
mode only.  The fraction disintegrating by a particular mode is the "branching fraction" for that mode.  
The "branching ratio" is the ratio of two specified branching fractions (also called multiple 
disintegration). 
 
Bremsstrahlung—X rays that are produced when a charged particle accelerates (speeds up, slows down, 
or changes direction) in the strong field of a nucleus. 
 
Buildup Factor—The ratio of the radiation intensity, including both primary and scattered radiation, to 
the intensity of the primary (unscattered) radiation. 
 
Cancer Effect Level (CEL)—The lowest dose of chemical or radiation in a study, or group of studies, 
that produces significant increases in the incidence of cancer (or tumors) between the exposed population 
and its appropriate control. 
 
Capture, Electron—A mode of radioactive decay involving the capture of an orbital electron by its 
nucleus.  Capture from a particular electron shell, e.g., K or L shells, is designated as "K-electron capture" 
or "L-electron capture." 
 
Capture, K-Electron—Electron capture from the K shell by the nucleus of the atom.  Also loosely used 
to designate any orbital electron capture process. 
 
Carcinogen—A chemical or radiation that is capable of inducing cancer. 
 
Carcinoma—Malignant neoplasm composed of epithelial cells, regardless of their derivation. 
 
Case-Control Study—A type of epidemiological study which examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research but are not actual research studies. 
 
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure.  These may suggest potential topics for scientific research, but are not actual research studies. 
 
Cataract—A clouding of the crystalline lens of the eye which obstructs the passage of light. 
 
Ceiling Value—A concentration of a substance that should not be exceeded, even temporarily. 
 
Charged Particle—A nuclear particle, atom, or molecule carrying a positive or negative charge. 
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Chronic Exposure—A long-term, continuous exposure to a chemical or radioactive material.  For 
example, exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles. 
 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
 
Collective Dose—The sum of the individual doses received in a given period of time by a specified 
population from exposure to a specified source of radiation.  Collective dose is expressed in units such as 
man-rem and person-sievert. 
 
Compton Effect—An attenuation process observed for x- or gamma radiation in which an incident 
photon interacts with an orbital electron of an atom to produce a recoil electron and a scattered photon 
whose energy is less than the incident photon. 
 
Containment—The confinement of a chemical or radioactive substance in such a way that it is prevented 
from being dispersed from its container or into the environment, or is released only at a specified rate. 
 
Contamination—Deposition of a stable or radioactive substance in any place where it is not desired. 
 
Cosmic Rays—High-energy particulate and electromagnetic radiations that originate outside the earth's 
atmosphere and interact with the atmosphere to produce a shower of secondary cosmic rays. 
 
Count (Radiation Measurements)—The external indication of a radiation-measuring device designed to 
enumerate ionizing events.  It refers to a single detected event.  The term “count rate” refers to the total 
number registered in a given period of time.  The term is sometimes erroneously used to designate a 
disintegration, ionizing event, or voltage pulse. 
 
Counter, Gas-flow Proportional (GPC)—An instrument for detecting beta particle radiation.  Beta 
particles are detected by ionization of the counter gas which results in an electrical impulse at an anode 
wire. 
 
Counter, Geiger-Mueller (GM counter)—Highly sensitive, gas-filled radiation-measuring device that 
detects (counts) individual photons or particulate radiation. 
 
Counter, Scintillation—The combination of a crystal or phosphor, photomultiplier tube, and associated 
circuits for counting light emissions produced in the phosphors by ionizing radiation.  Scintillation 
counters generally are more sensitive than GM counters for gamma radiation. 
 
Counting, Cerenkov—Relatively energetic β-particles pass through a transparent medium of high 
refractive index and a highly-directional, bluish-white light ("Cerenkov" light) is emitted.  This light is 
detected using liquid scintillation counting equipment. 
 
Cross-sectional Study—A type of epidemiological study of a group or groups which examines the 
relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
 
Curie (Ci)—A unit of radioactivity.  One curie equals that quantity of radioactive material in which there 
are 3.7x1010 nuclear transformations per second.  The activity of 1 gram of radium is approximately 1 Ci. 
 
 Attocurie (aCi)—One-thousandth of a femtocurie (3.7x10-8 disintegrations per second). 
URANIUM  432 
 








 Femtocurie (fCi)—One-billionth of a microcurie (3.7x10-5 disintegrations per second). 
 Megacurie (MCi)—One million curies (3.7x1016 disintegrations per second). 
 Microcurie (μCi)—One-millionth of a curie (3.7x104 disintegrations per second). 
 Millicurie (mCi)—One-thousandth of a curie (3.7x107 disintegrations per second). 
 Nanocurie (nCi)—One-billionth of a curie (3.7x101 disintegrations per second). 
 Picocurie (pCi)—One-millionth of a microcurie (3.7x10-2 disintegrations per second). 
 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
 
Daughter Products—See Progeny and Decay Product 
 
Decay Chain or Decay Series—A sequence of radioactive decays (transformations) beginning with one 
nucleus.  The initial nucleus, the parent, decays into a daughter or progeny nucleus that differs from the 
first by whatever particles were emitted during the decay.  If further decays take place, the subsequent 
nuclei are also usually called daughters or progeny.  Sometimes, to distinguish the sequence, the daughter 
of the first daughter is called the granddaughter, etc. 
 
Decay Constant (λ)—The fraction of the number of atoms of a radioactive nuclide which decay in unit 
time (see Disintegration Constant). 
 
Decay Product, Daughter Product, Progeny—A new nuclide formed as a result of radioactive decay.  
A nuclide resulting from the radioactive transformation of a radionuclide, formed either directly or as the 
result of successive transformations in a radioactive series.  A decay product (daughter product or 
progeny) may be either radioactive or stable. 
 
Decay, Radioactive—Transformation of the nucleus of an unstable nuclide by spontaneous emission of 
radiation, such as charged particles and/or photons (see Disintegration). 
 
Delta Ray—An electron removed from an atom of a medium that is irradiated, or through which 
radiation passes, during the process of ionization (also called secondary electron).  Delta rays cause a 
track of ionizations along their path. 
 
Derived Air Concentration (DAC)—The concentration of radioactive material in air that, if breathed by 
the reference man for a working year of 2000 hours under conditions of light work (at a rate of 1.2 liters 
of air per hour), would result in an intake of one ALI (see Annual Limit on Intake). 
 
Deterministic Effect—A health effect, the severity of which varies with the dose and for which a 
threshold is believed to exist (also called a non-stochastic effect). 
 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical or radiation prior to conception (either parent), during prenatal development, 
or postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any 
point in the life span of the organism. 
 
Disintegration Constant—Synonymous with decay constant.  The fraction of the number of atoms of a 
radioactive material that decays per unit time (see Decay Constant.) 
 
Disintegration, Nuclear—A spontaneous nuclear transformation (radioactivity) characterized by the 
emission of energy and mass from the nucleus.  When large numbers of nuclei are involved, the process is 
characterized by a definite half-life (see Transformation, Nuclear). 
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Distribution Coefficient (Kd)—Describes the distribution of a chemical between the solid and aqueous 








 ,  Units = (L solution)/(kg solid), 
where [C]s is the concentration of the chemical associated with the solid phase in units of (mg)/(kg solid), 
and [C]w is the concentration of the chemical in the aqueous phase in units of (mg)/(L solution).  As the 
magnitude of Kd decreases, the potential mobility of the chemical to groundwater systems increases and 
vice versa. 
 
Dose—A general term denoting the quantity of a substance, radiation, or energy absorbed.  For special 
purposes it must be appropriately qualified.  If unqualified, it refers to radiation absorbed dose. 
 
Absorbed Dose—The energy imparted to matter by ionizing radiation per unit mass of irradiated 
material at the place of interest.  The unit of absorbed dose is the rad.  One rad equals 100 ergs 
per gram.  In SI units, the absorbed dose is the gray which is 1 J/kg (see Rad). 
 
Cumulative Dose (Radiation)—The total dose resulting from repeated or continuous exposures 
to radiation. 
 
Dose Assessment—An estimate of the radiation dose to an individual or a population group usually by 
means of predictive modeling techniques, sometimes supplemented by the results of measurement. 
 
Dose Equivalent (DE)—A quantity used in radiation safety practice to account for the relative biological 
effectiveness of the several types of radiation.  It expresses all radiations on a common scale for 
calculating the effective absorbed dose.  The NRC defines it as the product of the absorbed dose, the 
quality factor, and all other modifying factors at the location of interest.  ICRP has changed its definition 
to be the product of the absorbed dose and the radiation weighting factor.  (The unit of dose equivalent is 
the rem.  In SI units, the dose equivalent is the sievert, which equals 100 rem.) 
 
Dose, Fractionation—A method of administering therapeutic radiation in which relatively small doses 
are given daily or at longer intervals. 
 
Dose, Protraction—A method of administering therapeutic radiation by delivering it continuously over a 
relatively long period at a low dose rate. 
 
Dose, Radiation—The amount of energy imparted to matter by ionizing radiation per unit mass of the 
matter, usually expressed as the unit rad, or in SI units, the gray.  100 rad1 gray (Gy) (see Absorbed 
Dose). 
 
Committed Dose Equivalent (HT,50)—The dose equivalent to organs or tissues of reference (T) 
that will be received from an intake of radioactive material by an individual during the 50 years 
following the intake. 
 
Committed Effective Dose Equivalent (HE,50)—The sum of the products of the weighting 
factors applicable to each of the body organs or tissues that are irradiated and the committed dose 
equivalent to those organs or tissues. 
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Effective Dose —A dose value that attempts to normalize the detriment to the body (for cancer 
mortality and morbidity, hereditary effects, and years of life lost) from a non-uniform exposure to 
that of a uniform whole body exposure.  Effective dose is calculated as the sum of products of the 
equivalent dose and the tissue weighting factor (wT) for each tissue exposed.  (E = ∑DT,R wR wT). 
 
Effective Dose Equivalent (HE)—This dose type is limited to internal exposures and is the sum 
of the products of the dose equivalent to the organ or tissue (HT) and the weighting factors (wT) 
applicable to each of the body organs or tissues that are irradiated.  (HE = ∑wT HT). 
 
Equivalent Dose—A dose quantity that places the biological effect of all radiation types on a 
common scale for calculating tissue damage.  Alpha particles, for example, are considered to 
cause 20 times more damage than gamma rays.  Equivalent dose is calculated as the sum of 
products of the average absorbed dose (in gray) in an organ or tissue (DT,R) from each type of 
radiation and the radiation weighting factor (wR) for that radiation (∑DT,R wR). 
 
External Dose—That portion of the dose equivalent received from radiation sources outside the 
body. 
 
Internal Dose—That portion of the dose equivalent received from radioactive material taken into 
the body. 
 
Limit—A permissible upper bound on the radiation dose. 
 
Maximum Permissible Dose (MPD)—The greatest dose equivalent that a person or specified 
part thereof shall be allowed to receive in a given period of time. 
 
Median Lethal Dose (MLD)—Dose of radiation required to kill, within a specified period 
(usually 30 days), 50% of the individuals in a large group of animals or organisms.  Also called 
the LD50, or LD50/30 if for 30 days. 
 
Threshold Dose—The minimum absorbed dose that will produce a detectable degree of any 
given effect. 
 
Tissue Dose—Absorbed dose received by tissue in the region of interest, expressed in rad (see 
Dose, Gray, and Rad). 
 
Dose Rate—The amount of radiation dose delivered per unit time.  Generically, the rate at which 
radiation dose is delivered to any material or tissue. 
 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
 
Dosimetry—Quantification of radiation doses to cells, tissues, organs, individuals or populations 
resulting from radiation exposures. 
 
Early Effects (of radiation exposure)—Effects that appear within 60 days of an acute exposure. 
 
Electron—A stable elementary particle having an electric charge equal to ±1.60210x10-19 C (Coulombs) 
and a rest mass equal to 9.1091x10-31 kg.  A positron is a positively charged "electron" (see Positron). 
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Electron Volt—A unit of energy equivalent to the energy gained by an electron in passing through a 
potential difference of one volt.  Larger multiple units of the electron volt are frequently used:  keV for 
thousand or kilo electron volts; MeV for million or mega electron volts (eV).  1 eV=1.6x10-12 erg. 
 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurred.  The terms, as used here, include malformations and variations, altered growth, and in 
utero death. 
 
Energy—Capacity for doing work.  Gravitationally, "potential energy" is the energy inherent in a mass 
because of its spatial relation to other masses.  Chemically or radiologically, “potential energy” is the 
energy released when a chemical reaction or radiological transformation goes to completion.  "Kinetic 
energy" is the energy possessed by a mass because of its motion (SI unit: joules): 
 
Binding Energy (Electron)—The amount of energy that must be expended to remove an 
electron from an atom. 
 
Binding Energy (Nuclear)—The energy represented by the difference in mass between the sum 
of the component parts and the actual mass of the nucleus.  It represents the amount of energy 
that must be expended to break a nucleus into its component neutrons and protons. 
 
Excitation Energy—The energy required to change a system from its ground state to an excited 
state.  Each different excited state has a different excitation energy. 
 
Ionizing Energy—The energy required to knock an electron out of an atom.  The average energy 
lost by electrons or beta particles in producing an ion pair in air or in soft tissue is about 34 eV. 
 
Radiant Energy—The energy of electromagnetic radiation, such as radio waves, visible light, x 
and gamma rays. 
 
Enrichment, Isotopic—An isotopic separation process by which the relative abundances of the isotopes 
of a given element are altered, thus producing a form of the element that has been enriched in one or more 
isotopes and depleted in others.  In uranium enrichment, the percentage of uranium-235 in natural 
uranium can be increased from 0.7% to >90% in a gaseous diffusion process based on the different 
thermal velocities of the constituents of natural uranium (234U, 235U, 238U) in the molecular form UF6. 
 
EPA Health Advisory—An estimate of acceptable drinking water levels for a chemical substance based 
on health effects information.  A health advisory is not a legally enforceable federal standard, but serves 
as technical guidance to assist federal, state, and local officials. 
 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period. 
 
Equilibrium, Radioactive—In a radioactive series, the state which prevails when the ratios between the 
activities of two or more successive members of the series remains constant. 
 
Secular Equilibrium—If a parent element has a very much longer half-life than the daughters 
(so there is not appreciable change in its amount in the time interval required for later products to 
attain equilibrium) then, after equilibrium is reached, equal numbers of atoms of all members of 
the series disintegrate in unit time.  This condition is never exactly attained, but is essentially 
established in such a case as 226Ra and its transformation series to stable 206Pb.  The half-life of 
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226Ra is about 1,600 years; of 222Rn, approximately 3.82 days, and of each of the subsequent 
members, a few minutes.  After about a month, essentially the equilibrium amount of radon is 
present; then (and for a long time) all members of the series disintegrate the same number of 
atoms per unit time.  At this time, the activity of the daughter is equal to the activity of the parent. 
 
Transient Equilibrium—If the half-life of the parent is short enough so the quantity present 
decreases appreciably during the period under consideration, but is still longer than that of 
successive members of the series, a stage of equilibrium will be reached after which all members 
of the series decrease in activity exponentially with the period of the parent.  At this time, the 
ratio of the parent activity to the daughter activity is constant. 
 
Equilibrium, Electron—The condition in a radiation field where the energy of the electrons entering a 
volume equals the energy of the electrons leaving that volume. 
 
Excitation—The addition of energy to a system, thereby transferring it from its ground state to an excited 
state.  Excitation of a nucleus, an atom, or a molecule can result from absorption of photons or from 
inelastic collisions with other particles.  The excited state of an atom is an unstable or metastable state and 
will return to ground state by radiation of the excess energy. 
 
Exposure (Chemical)—Contact of an organism with a chemical or physical agent.  Exposure is 
quantified as the amount of the agent available at the exchange boundaries of the organism (e.g., skin, 
lungs, gut) and available for absorption. 
 
Exposure (Radiation)—Subjection to ionizing radiation or to a radioactive material.  For example, 
exposure in air is a measure of the ionization produced in air by x or gamma radiation; the sum of the 
electric charges on all ions of one sign produced in air when all electrons liberated by photons in a 
volume of air are completely stopped in air (dQ), divided by the mass of the air in the volume (dm).  The 
unit of exposure in air is the roentgen, or coulomb per kilogram (SI units).  One roentgen is equal to 
2.58x10-4 coulomb per kilogram (C/kg). 
 
Ex Vivo—Outside of the living body. 
 
Fission, Nuclear—A nuclear transformation characterized by the splitting of a nucleus into at least two 
other nuclei with emission of several neutrons, accompanied by the release of a relatively large amount of 
energy. 
 
Gamma Ray, Penetrating—Short wavelength electromagnetic radiation of nuclear origin. 
 
Genotoxicity—Effects of chemical and physical agents on the hereditary material (DNA) and on the 
genetic processes of living cells.   
 
Gray (Gy)—SI unit of absorbed dose, 1 J/kg.  One gray equals 100 rad (see Units). 
 
Half-life, Effective—See Half-Time, Effective. 
 
Half-life, Radioactive—Time required for a radioactive substance to lose 50% of its activity by decay.  
Each radio-nuclide has a unique physical half-life.  Known also as physical half-time and symbolized as 
Tr or Trad. 
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Half-time, Biological—Time required for an organ, tissue, or the whole body to eliminate one-half of any 
absorbed substance by regular processes of elimination.  This is the same for both stable and radioactive 
isotopes of a particular element, and is sometimes referred to as half-time, symbolized as tbiol or Tb. 
 
Half-time, Effective—Time required for a radioactive element in an organ, tissue, or the whole body to 
be diminished 50% as a result of the combined action of radioactive decay and biological elimination, 
symbolized as Te or Teff. 
 
Biological half-time × Radioactive half-life Effective half-time = Biological half-time + Radioactive half-life 
 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
 
Immunological Effects—Functional changes in the immune response. 
 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period. 
 
Intensity—Amount of energy per unit time passing through a unit area perpendicular to the line of 
propagation at the point in question. 
 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
 
Internal Conversion—Process in which a gamma ray knocks an electron out of the same atom from 
which the gamma ray was emitted.  The ratio of the number of internal conversion electrons to the 
number of gamma quanta emitted in the de-excitation of the nucleus is called the "conversion ratio." 
 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.  Literally, “in 
glass.” 
 
In Vivo—Occurring within the living organism.  Literally, “in life.” 
 
Ion—Atomic particle, atom or chemical radical bearing a net electrical charge, either negative or positive. 
 
Ion Pair—Two particles of opposite charge, usually referring to the electron and positive atomic or 
molecular residue resulting after the interaction of ionizing radiation with the orbital electrons of atoms. 
 
Ionization—The process by which a neutral atom or molecule acquires a positive or negative charge. 
 
Primary Ionization—(1) In collision theory:  the ionization produced by the primary particles as 
contrasted to the "total ionization" which includes the "secondary ionization" produced by delta 
rays.  (2) In counter tubes:  the total ionization produced by incident radiation without gas 
amplification. 
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Specific Ionization—Number of ion pairs per unit length of path of ionizing radiation in a 
medium; e.g., per centimeter of air or per micrometer of tissue. 
 
Total Ionization—The total electric charge of one sign on the ions produced by radiation in the 
process of losing its kinetic energy.  For a given gas, the total ionization is closely proportional to 
the initial ionization and is nearly independent of the nature of the ionizing radiation.  It is 
frequently used as a measure of absorption of radiation energy. 
 
Ionization Density—Number of ion pairs per unit volume. 
 
Ionization Path (Track)—The trail of ion pairs produced by an ionizing particle in its passage through 
matter. 
 
Ionizing Radiation—Any radiation capable of knocking electrons out of atoms and producing ions.  
Examples: alpha, beta, gamma and x rays, and neutrons. 
 
Isobars—Nuclides having the same mass number but different atomic numbers. 
 
Isomers—Nuclides having the same number of neutrons and protons but capable of existing, for a 
measurable time, in different quantum states with different energies and radioactive properties.  
Commonly the isomer of higher energy decays to one with lower energy by the process of isomeric 
transition. 
 
Isotopes—Nuclides having the same number of protons in their nuclei, and hence the same atomic 
number, but differing in the number of neutrons, and therefore in the mass number.  Identical chemical 
properties exist in isotopes of a particular element.  The term should not be used as a synonym for nuclide 
because isotopes refer specifically to different nuclei of the same element. 
 
 Stable Isotope—A nonradioactive isotope of an element. 
 
Joule—The S.I. unit for work and energy.  It is equal to the work done by raising a mass of one newton 
through a distance of one meter (J = Nm), which corresponds to about 0.7 ft-pound. 
 
Kerma (k)—A measure of the kinetic energy transferred from gamma rays or neutrons to a unit mass of 
absorbing medium in the initial collision between the radiation and the absorber atoms.  The SI unit is 
J/kg.  The special name of this unit is the rad (traditional system of units) or Gray (SI). 
 
Labeled Compound—A compound containing one or more radioactive atoms intentionally added to its 
structure.  By observations of radioactivity or isotopic composition, this compound or its fragments may 
be followed through physical, chemical, or biological processes. 
 
Late Effects (of radiation exposure)—Effects which appear 60 days or more following an acute 
exposure. 
   
LD50/30—The dose of a chemical or radiation expected to cause 50% mortality in those exposed within 
30 days.  For radiation, this is about 350 rad (3.5 gray) received by humans over a short period of time. 
 
Lethal Concentration(Lo) (LCLo)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
 
URANIUM  439 
 








Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population 
within a specified time, usually 30 days. 
 
Lethal Dose(Lo) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that is 
expected to have caused death in humans or animals within a specified time, usually 30 days. 
 
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
 
Linear Energy Transfer (LET)—A measure of the energy that a charged particle transfers to a material 
per unit path length. 
 
Average LET—The energy of a charged particle divided by the length of the path over which it 
deposits all its energy in a material.  This is averaged over a number of particles. 
 
High-LET—Energy transfer characteristic of heavy charged particles such as protons and alpha 
particles where the distance between ionizing events is small on the scale of a cellular nucleus. 
 
Low-LET—Energy transfer characteristic of light charged particles such as electrons produced 
by x and gamma rays where the distance between ionizing events is large on the scale of a 
cellular nucleus. 
 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest dose of chemical in a study, or group 
of studies, that produces statistically or biologically significant increases in frequency or severity of 
adverse effects between the exposed population and its appropriate control. 
 
Lung Clearance Class (fast, F; medium, M; slow, S)—A classification scheme for inhaled material 
according to its rate of clearance from the pulmonary region of the lungs to the blood and the 
gastrointestinal tract. 
 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
 
Mass Numbers (A)—The number of nucleons (protons and neutrons) in the nucleus of an atom. 
 
Minimal Risk Level—An estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors.  The default value for a MF is 1. 
 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
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Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
 
Mutagen—A substance that causes changes (mutations) in the genetic material in a cell.  Mutations can 
lead to birth defects, miscarriages, or cancer. 
 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 




Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
substance. 
 
Neutrino (ν)—A neutral particle of infinitesimally small rest mass emitted during beta plus or beta minus 
decay.  This particle accounts for conservation of energy in beta plus and beta minus decays.  It plays no 
role in damage from radiation. 
 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a substance at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
 
Nuclear Reactor—A power plant that heats the medium (typically water) by using the energy released 
from the nuclear fission of uranium or plutonium isotopes instead of burning coal, oil, or natural gas.  All 
of these sources of energy simply heat water and use the steam which is produced to turn turbines that 
make electricity or propel a ship. 
 
Nucleon—Common name for a constituent particle of the nucleus.  Applied to a proton or neutron. 
 
Nuclide—A species of atom characterized by the constitution of its nucleus.  The nuclear constitution is 
specified by the number of protons (Z), number of neutrons (N), and energy content; or, alternatively, by 
the atomic number (Z), mass number A(N+Z), and atomic mass.  To be regarded as a distinct nuclide, the 
atom must be capable of existing for a measurable time.  Thus, nuclear isomers are separate nuclides, 
whereas promptly decaying excited nuclear states and unstable intermediates in nuclear reactions are not 
so considered. 
 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who 
were not exposed to the risk factor).  An odds ratio of greater than 1 is considered to indicate greater risk 
of disease in the exposed group compared to the unexposed. 
 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
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Pair Production—An absorption process for x- and gamma radiation in which the incident photon is 
absorbed in the vicinity of the nucleus of the absorbing atom, with subsequent production of an electron 
and positron pair (see annihilation).  This reaction can only occur for incident photon energies exceeding 
1.02 MeV. 
 
Parent—Any radionuclide nuclide which, upon disintegration, yields a new nuclide (termed the progeny 
or daughter), either directly or as a later member of a radioactive series. 
 
Permissible Exposure Limit (PEL)—A maximum allowable atmospheric level of a substance in 
workplace air averaged over an 8-hour shift. 
 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models: data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments 
which, in general, do not represent real, identifiable anatomic regions of the body whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism and excretion of chemicals by the body. 
 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically-based dose-
response model which quantitatively describes the relationship between target tissue dose and toxic end 
points.  These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
 
Physiologically Based Pharmacokinetic (PBPK) Model—A model comprising a series of 
compartments representing organs or tissue groups with realistic weights and blood flows.  These models 
require a variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, 
alveolar ventilation rates and, possibly membrane permeabilities.  The models also utilize biochemical 
information such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
 
Photoelectric Effect—An attenuation process observed for x and gamma radiation in which an incident 
photon interacts with a tightly bound inner orbital electron of an atom delivering all of its energy to knock 
the electron out of the atom.  The incident photon disappears in the process. 
 
Photon—A quantum of electromagnetic energy (E) whose value is the product of its frequency (ν) in 
hertz and Planck's constant (h).  The equation is:  E = hν. 
 
Population dose—See Collective dose. 
 
Positron—A positively charged electron. 
 
Potential, Ionization—The energy expressed as electron volts (eV) necessary to separate one electron 
from an atom, resulting in the formation of an ion pair. 
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Power, Stopping—A measure of the ability of a material to absorb energy from an ionizing particle 
passing through it; the greater the stopping power, the greater the energy absorbing ability (see Linear 
Energy Transfer). 
 
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
 
Progeny—The decay product or daughter products resulting after a radioactive decay or a series of 
radioactive decays.  The progeny can also be radioactive, and the chain continues until a stable nuclide is 
formed. 
 
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
 
Proton—Elementary nuclear particle with a positive electric charge equal numerically to the charge of 
the electron and a rest mass of 1.007 mass units. 
 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air). 
 
Quality—A term describing the distribution of the energy deposited by a particle along its track; 
radiations that produce different densities of ionization per unit intensity are said to have different 
"qualities." 
 
Quality Factor (Q)—The linear-energy-transfer-dependent factor by which absorbed doses are 
multiplied to obtain (for radiation protection purposes) a quantity that expresses - on a common scale for 
all ionizing radiation - the approximate biological effectiveness of the absorbed dose. 
  
Type of radiation Quality Factor 
X, gamma, or beta 1 
Alpha particles 20 
Neutrons of unknown energy 10 
High energy protons 10 
 
Rad—The traditional unit of absorbed dose equal to 100 ergs per gram, or 0.01 joule per kilogram (0.01 
Gy) in any medium (see Absorbed Dose). 
 
Radiation—The emission and propagation of energy through space or through a material medium in the 
form of waves (e.g., the emission and propagation of electromagnetic waves, or of sound and elastic 
waves).  The term radiation or radiant energy, when unqualified, usually refers to electromagnetic 
radiation.  Such radiation commonly is classified according to frequency, as microwaves, infrared, visible 
(light), ultraviolet, and x and gamma rays (see Photon.) and, by extension, corpuscular emission, such as 
alpha and beta radiation, neutrons, or rays of mixed or unknown type, as cosmic radiation. 
 
Radiation, Annihilation—Photons produced when an electron and a positron unite and cease to 
exist.  The annihilation of a positron-electron pair results in the production of two photons, each 
of 0.51 MeV energy. 
 
Radiation, Background—See Background Radiation. 
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Radiation, Characteristic (Discrete)—Radiation originating from an excited atom after removal 
of an electron from an atom.  The wavelength of the emitted radiation is specific, depending only 
on the element and particular energy levels involved. 
 
Radiation, External—Radiation from a source outside the body. 
 
Radiation, Internal—Radiation from a source within the body (as a result of deposition of 
radionuclides in body tissues). 
 
Radiation, Ionizing—Any electromagnetic or particulate radiation capable of producing ions, 
directly or indirectly, in its passage through matter (see Radiation). 
 
Radiation, Monoenergetic—Radiation of a given type in which all particles or photons originate 
with and have the same energy. 
 
Radiation, Scattered—Radiation which during its passage through a substance, has been 
deviated in direction.  It may also have been modified by a decrease in energy. 
 
Radiation, Secondary—A particle or ray that is produced when the primary radiation interacts 
with a material, and which has sufficient energy to produce its own ionization, such as 
bremsstrahlung or electrons knocked from atomic orbitals with enough energy to then produce 
ionization (see Delta Rays). 
 
Radiation Weighting Factor (also called Quality Factor)—In radiation protection, a factor (1 for x-
rays, gamma rays, beta particles; 20 for alpha particles) weighting the absorbed dose of radiation of a 
specific type and energy for its effect on tissue. 
 
Radioactive Material—Material containing radioactive atoms. 
 
Radioactivity—Spontaneous nuclear transformations that result in the formation of new elements.  These 
transformations are accomplished by emission of alpha or beta particles from the nucleus or by the 
capture of an orbital electron.  Each of these reactions may or may not be accompanied by a gamma 
photon. 
 
Radioactivity, Artificial—Man-made radioactivity produced by particle bombardment or 
nuclear fission, as opposed to naturally occurring radioactivity. 
 
Radioactivity, Induced—Radioactivity produced in a substance after bombardment with 
neutrons or other particles.  The resulting activity is "natural radioactivity" if formed by nuclear 
reactions occurring in nature and "artificial radioactivity" if the reactions are caused by man. 
 
Radioactivity, Natural—The property of radioactivity exhibited by more than 50 naturally 
occurring radionuclides. 
 
Radioisotope—An unstable or radioactive isotope of an element that decays or disintegrates 
spontaneously, emitting radiation. 
 
Radionuclide—Any radioactive isotope of any element.  Approximately 5,000 natural and artificial 
radioisotopes have been identified. 
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Radiosensitivity—Relative susceptibility of cells, tissues, organs, organisms, or any living substance to 
the injurious action of radiation.  Radiosensitivity and its antonym, radioresistance, are used 
comparatively, rather than absolutely. 
 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  It 
can be derived from a NOAEL, LOAEL, or benchmark concentration, with uncertainty factors generally 
applied to reflect limitations of the data used.  The inhalation reference concentration is for continuous 
inhalation exposures and is appropriately expressed in units of mg/m3 or ppm. 
 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of a 
daily oral exposure to the human population (including sensitive subgroups) that is likely to be without an 
appreciable risk of deleterious effects during a lifetime.  It can be derived from a NOAEL, LOAEL, or 
benchmark dose, with uncertainty factors generally applied to reflect limitations of the data used.   
 
Relative Biological Effectiveness (RBE)—The RBE is a factor used to compare the biological 
effectiveness of absorbed radiation doses (i.e., rad) due to different types of ionizing radiation.  More 
specifically, it is the experimentally determined ratio of an absorbed dose of a radiation in question to the 
absorbed dose of a reference radiation (typically 60Co gamma rays or 200 kVp x rays) required to produce 
an identical biological effect in a particular experimental organism or tissue (see Quality Factor). 
 
Rem—The traditional unit of dose equivalent that is used in the regulatory, administrative, and 
engineering design aspects of radiation safety practice.  The dose equivalent in rem is numerically equal 
to the absorbed dose in rad multiplied by the quality factor (1 rem is equal to 0.01 sievert). 
 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
CERCLA.  Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount 
established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act.  Quantities 
are measured over a 24-hour period. 
 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
 
Roentgen (R)—A unit of exposure (in air) to ionizing radiation.  It is the amount of x or gamma rays 
required to produce ions carrying 1 electrostatic unit of electrical charge in 1 cubic centimeter of dry air 
under standard conditions.  Named after William Roentgen, a German scientist who discovered x rays in 
1895. 
 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group. 
 
Self-Absorption—Absorption of radiation (emitted by radioactive atoms) by the material in which the 
atoms are located; in particular, the absorption of radiation within a sample being assayed. 
 
Short-Term Exposure Limit (STEL)—The maximum concentration to which workers can be exposed 
for up to 15 minutes continually.  No more than four excursions are allowed per day, and there must be at 
least 60 minutes between exposure periods.  The daily TLV-TWA may not be exceeded. 
 
SI Units—The International System of Units as defined by the General Conference of Weights and 
Measures in 1960.  These units are generally based on the meter/kilogram/second units, with special 
quantities for radiation including the becquerel, gray, and sievert. 
 
Sickness, Acute Radiation (Syndrome)—The complex symptoms and signs characterizing the condition 
resulting from excessive exposure of the whole body (or large part) to ionizing radiation.  The earliest of 
these symptoms are nausea, fatigue, vomiting, and diarrhea, and may be followed by loss of hair 
(epilation), hemorrhage, inflammation of the mouth and throat, and general loss of energy.  In severe 
cases, where the radiation dose is relatively high (over several hundred rad or several gray), death may 
occur within two to four weeks.  Those who survive six weeks after exposure of a single high dose of 
radiation may generally be expected to recover. 
 
Sievert (Sv)—The SI unit of any of the quantities expressed as dose equivalent.  The dose equivalent in 
sieverts is equal to the absorbed dose, in gray, multiplied by the quality factor (1 sievert equals 100 rem).  
The sievert is also the SI unit for effective dose equivalent, which is the sum of the products of the dose 
equivalent to each organ or tissue and its corresponding tissue weighting factor. 
 
Specific-Activity—Radioactivity per unit mass of a radionuclide, expressed, for example, as Ci/gram or 
Bq/kilogram. 
 
Specific Energy—The actual energy per unit mass deposited per unit volume in a small target, such as 
the cell or cell nucleus, as the result of one or more energy-depositing events.  This is a stochastic 
quantity as opposed to the average value over a large number of instance (i.e., the absorbed dose). 
 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
 
Stochastic Effect—A health effect that occurs randomly and for which the probability of the effect 
occurring, rather than its severity, is assumed to be a linear function of dose without a threshold (also 
called a nondeterministic effect). 
 
Stopping Power—The average rate of energy loss of a charged particle per unit thickness of a material or 
per unit mass of material traversed. 
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Surface-seeking Radionuclide—A bone-seeking internal emitter that deposits and remains on the bone 
surface for a long period of time, although it may eventually diffuse into the bone mineral.  This contrasts 
with a volume seeker, which deposits more uniformly throughout the bone volume. 
 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
 
Target Theory (Hit Theory)—A theory explaining some biological effects of radiation on the basis that 
ionization, occurring in a discrete volume (the target) within the cell, directly causes a lesion which 
subsequently results in a physiological response to the damage at that location.  One, two, or more "hits" 
(ionizing events within the target) may be necessary to elicit the response. 
 
Teratogen—A chemical that causes birth defects. 
 
Threshold Limit Value (TLV)—The maximum concentration of a substance to which most workers can 
be exposed without adverse effect.  TLV is a term used exclusively by the ACGIH.  Other terms used to 
express similar concepts are the MAC (Maximum Allowable Concentration) and PEL (Permissible 
Exposure Limits). 
 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
 
Tissue Weighting Factor (Wt)—Organ- or tissue-specific factor by which the equivalent dose is 
multiplied to give the portion of the effective dose for that organ or tissue.  Recommended values of 
tissue weighting factors are: 
 
Tissue/Organ Tissue Weighting Factor 
Gonads 0.70 










Bone surface 0.01 
Remainder (adrenals, brain, upper large 
intestine, small intestine, pancreas, spleen, 
thymus, and uterus) 
0.05 
 
Toxic Dose (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, which 
is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
 
Toxicokinetic—The absorption, distribution and elimination of toxic compounds in the living organism. 
 
Toxicosis—A diseased condition resulting from poisoning. 
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Transformation, Nuclear—The process of radioactive decay by which a nuclide is transformed into a 
different nuclide by absorbing or emitting particulate or electromagnetic radiation. 
 
Transition, Isomeric—The process by which a nuclide decays to an isomeric nuclide (i.e., one of the 
same mass number and atomic number) of lower quantum energy.  Isomeric transitions (often abbreviated 
I.T.) proceed by gamma ray and internal conversion electron emission. 
 
Tritium—The hydrogen isotope with one proton and two neutrons in the nucleus (Symbol: 3H).  It is 
radioactive and has a physical half-life of 12.3 years. 
 
Unattached Fraction—That fraction of the radon daughters, usually 218Po and 214Po, which has not yet 
attached to a dust particle or to water vapor.  As a free atom, it has a high probability of being exhaled and 
not retained within the lung.  It is the attached fraction which is primarily retained. 
 
Uncertainty Factor (UF)—A factor used in operationally deriving the RfD from experimental data.  UFs 
are intended to account for (1) the variation in sensitivity among the members of the human population, 
(2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating 
from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using 
LOAEL data rather than NOAEL data.  Usually each of these factors is set equal to 10. 
 
Units, Prefixes—Many units of measure are expressed as submultiples or multiples of the primary unit 
(e.g., 10-3 curie is 1 mCi and 103 becquerel is 1 kBq). 
 
Factor Prefix Symbol Factor Prefix Symbol 
10-18 atto A 103 kilo k 
10-15 femto F 106 mega M 
10-12 pico p 109 giga G 
10-9 nano N 1012 tera T 
10-6 micro Μ 1015 peta P 
10-3 milli M 1018 exa E 









Becquerel* (Bq) 1 disintegration per second = 2.7x10-11 Ci 
Curie (Ci) 3.7x1010 disintegrations per second = 3.7x1010 Bq 
Gray* (Gy) 1 J/kg = 100 rad 
Rad (rad) 100 erg/g = 0.01 Gy 
Rem (rem) 0.01 sievert 
Sievert* (Sv) 100 rem 
 
 *International Units, designated (SI) 
 
Working Level (WL)—Any combination of short-lived radon daughters in 1 liter of air that will result in 
the ultimate emission of 1.3x105 MeV of potential alpha energy. 
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Working Level Month (WLM)—A unit of exposure to radon daughters corresponding to the product of 
the radon daughter concentration in Working Level (WL) and the exposure time in nominal months 
(1 nominal month = 170 hours).  Inhalation of air with a concentration of 1 WL of radon daughters for 
170 working hours results in an exposure of 1 WLM. 
 
Xenobiotic—Any chemical that is foreign to the biological system. 
 
X rays—Penetrating electromagnetic radiations whose wave lengths are very much shorter than those of 
visible light.  They are usually produced by bombarding a metallic target with fast electrons in a high 
vacuum.  X rays (called characteristic x rays) are also produced when an orbital electron falls from a high 
energy level to a low energy level. 
 
Zero-Threshold Linear Hypothesis (or No-Threshold Linear Hypothesis)—The assumption that a 
dose-response curve derived from data in the high dose and high dose-rate ranges may be extrapolated 
through the low dose and low dose range to zero, implying that, theoretically, any amount of radiation 
will cause some damage. 
 










APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach or the benchmark dose level/uncertainty factor approach.  They are below levels that might 
cause adverse health effects in the people most sensitive to such chemical-induced effects.  MRLs are 
derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations 
and for the oral and inhalation routes of exposure.  Currently, MRLs for the dermal route of exposure are 
not derived because ATSDR has not yet identified a method suitable for this route of exposure.  MRLs 
are generally based on the most sensitive chemical-induced end point considered to be of relevance to 
humans.  Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are 
not used as a basis for establishing MRLs.  Exposure to a level above the MRL does not mean that 
adverse health effects will occur. 
 










MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public.  They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop 
F-57, Atlanta, Georgia 30333. 
 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Uranium (insoluble forms) 
CAS Numbers: Multiple 
Date: July 2012 
Profile Status: Draft 2, Postpublic Comment 
Route: [X] Inhalation  [ ] Oral 
Duration: [ ] Acute  [X] Intermediate  [ ] Chronic 
Graph Key: 66 
Species: Dog 
 
Minimal Risk Level:  0.002  [ ] mg/kg/day  [ ] ppm  [X] mg/m3 
 
Reference:  Rothstein A.  1949b.  Uranium dioxide.  In: Voegtlin C, Hodge HC, eds.  Pharmacology and 
toxicology of uranium compounds.  National Nuclear Energy Series: Manhattan Project Technical 
Section, Division VI, Vol. 1.  New York, NY: McGraw-Hill.  pp. 614-621. 
 
Experimental design:  Groups of 6–19 dogs of unspecified strain and gender were exposed to 1.3, 9.3, or 
10.4 mg/m3 uranium dioxide (1.1, 8.2, or 9.2 mg U/m3) 6 days/week for 5 weeks.  Based on other studies 
conducted by this investigator (Rothermel 1949; Rothstein 1949c), it is assumed that the animals were 
exposed for 6 hours/day.  Exposure to 8.2 mg U/m3 was conducted in head-only exposure units and 
exposure to 1.1 or 9.2 mg U/m3 were performed in full-body exposure units.  The median particle size 
was 0.4 µm with a geometric standard deviation of 2.  The following parameters were used to assess 
toxicity:  mortality, body weight changes, standard hematology (except in the 8.2 mg U/m3 group), 
clinical chemistry (serum nonprotein nitrogen and urea nitrogen levels), urinalysis (protein, amino acid, 
catalase, phosphate, and ketone levels), and histopathology.  Separate control studies were conducted 
(Sprague 1949) in which animals were exposed in control chambers by full or head-only exposure for a 
duration similar to study conditions.  Body weight, mortality, biochemical, hematological, and 
histopathological data were collected.  Dogs (n = 6–19; unspecified sex and strain) were exposed to 
uranium dioxide dust at concentrations of 1.1, 8.2, or 9.2 mg U/m3 for 5 weeks, 6 days/weeks, 
6 hours/day.  (Doses were analytically determined, not estimated.)  Studies conducted at 8.2 mg U/m3 
were conducted in head exposure units.  Studies conducted at the other concentrations were performed in 
full exposure units.  The AMAD for the particles is assumed to be 1.5–2.1 μm; average 1.8 μm (see 
Pozzani 1949).  Mortality, body weight changes, standard hematology (except in the 8.2 mg U/m3 group), 
blood and urine chemistries, pathology, and uranium distribution in tissues were measured. 
 
Effect noted in study and corresponding doses:  No dogs died from exposure to uranium dioxide dust.  
Additionally, no alterations in body weight gain or hematology, serum clinical chemistry, or urinalysis 
parameters were noted.  Histopathological alterations were limited to the kidneys; “very slight” renal 
tubular degeneration was observed in two of six dogs at 8.2 mg U/m3; no alterations were observed in two 
dogs examined from the 9.2 mg U/m3 group. 
 
Dose and end point used for MRL derivation: 
 
[X] NOAEL  [ ] LOAEL 
 
The study identified a NOAEL of 1.1 mg U/m3 and a LOAEL of 8.2 mg/m3 for minimal microscopic 
lesions in the renal tubules.  The NOAEL of 1.1 mg U/m3 was used as the point of departure for the MRL; 
BMD modeling was not used to estimate the point of departure due to the limited reporting of incidence 
data. 
 










Uncertainty Factors used in MRL derivation: 
 
 [  ]  10 for use of a LOAEL 
 [x]  10 for extrapolation from animals to humans 
 [x]  10 for human variability 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration:  Human equivalent values were not calculated because regional deposited dose ratios are 
not available for dogs (EPA 1994d); thus, the NOAELADJ was used as the point of departure with an 
uncertainty factor of 10 for extrapolation from animals to humans. 
 
Was a conversion used from intermittent to continuous exposure?  The NOAEL was adjusted for 
intermittent exposure: 
 
NOAELADJ =  (1.1 mg/m3) * (6 hours/24 hours) * (6 days/7 days) = 0.24 mg/m3  
 
Other additional studies or pertinent information that lend support to this MRL:  Intermediate-duration 
inhalation studies in animals have examined the toxicity of various insoluble uranium compounds 
including uranium dioxide, uranium peroxide, uranium trioxide, and triuranium octaoxide in several 
animal species (Dygert 1949c, 1949d; Rothstein 1949b, 1949c; Stokinger et al. 1953).  The results of 
these studies suggest that the kidney and the respiratory tract are sensitive targets of uranium toxicity, 
with the kidney being the most sensitive target.  Very slight renal tubular damage was observed in dogs 
exposed to 8.2 mg U/m3 as uranium dioxide for 5 weeks (Rothstein 1949b), moderate tubular necrosis 
was observed in rabbits exposed to 15.4 mg U/m3 as uranium peroxide for 23 days (Dygert 1949d), 
moderate necrosis was observed in rats, rabbits, and dogs exposed to 16 mg U/m3 as uranium trioxide for 
4 weeks (Rothstein 1949c), and marked tubular necrosis was observed in rabbits exposed to 19.4 mg 
U/m3 as uranium dioxide for 5 weeks (Rothstein 1949b).  Although there are limited data to make species 
comparisons, data for uranium dioxide suggest that rabbits are more sensitive than rats, mice, or guinea 
pigs; the data do not allow for a comparison between rabbits and dogs.  In addition to the renal effects 
observed in rats, rabbits, and dogs exposed to uranium trioxide, very slight pulmonary lesions were 
observed in dogs and rats exposed to 16 mg U/m3 and severe effects were observed in rabbits dying early 
after exposure to 16 mg U/m3 (Rothstein 1949c).  Additionally, the results of the Rothstein (1949b) study 
which is the basis of the MRL are supported by the findings of slight to mild tubular degeneration in dogs 
exposed to 10 mg U/m3 as uranium dioxide for 1 year; no effects were observed at 1 mg U/m3 (Stokinger 
et al. 1953). 
 
Agency Contacts (Chemical Managers):  Sam Keith, Obaid Faroon, Nickolette Roney, Franco 
Scinicariello, Sharon Wilbur 











MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Uranium (soluble forms) 
CAS Numbers: Multiple 
Date: July 2012 
Profile Status: Draft 2, Postpublic Comment 
Route: [X] Inhalation  [ ] Oral 
Duration: [ ] Acute  [X] Intermediate  [ ] Chronic 
Graph Key: 67 
Species: Dog 
 
Minimal Risk Level:  0.0001  [ ] mg/kg/day  [ ] ppm  [X] mg/m3 
 
Reference:  Rothstein A.  1949a.  Uranyl fluoride.  In: Voegtlin C, Hodge HC, eds.  Pharmacology and 
toxicology of uranium compounds.  National Nuclear Energy Series: Manhattan Project Technical 
Section, Division VI, Vol 1.  New York, NY: McGraw-Hill.  pp. 548-560. 
 
Experimental design:  Groups of 2–6 dogs per group (strain and gender not specified) were exposed to 
0.19, 2.8, or 12.2 mg/m3 of uranyl fluoride dust (0.15, 2.2, or 9.2 mg U/m3) for 6 hours/day, 6 days/week 
for 5 weeks.  (Doses were analytically determined, not estimated.)  The AMAD for the particles is 
assumed to be 1.5–2.1 μm; average 1.8 μm (see Pozzani 1949).  Separate control studies were conducted 
(Sprague 1949) in which animals were exposed in control chambers by full or head-only exposure for a 
duration similar to study conditions.  Clinical signs of toxicity, mortality, body weight changes, 
hematology, and blood and urine chemistries were monitored.  At the termination of the study, the 
animals were sacrificed, selected organs were histopathologically examined, and uranium levels were 
determined. 
 
Effect noted in study and corresponding doses:  Anorexia, rhinitis, and polydipsia were observed in the 
two dogs exposed to 9.2 mg U/m3; prior to death, vomiting blood, severe muscle weakness, and exhibited 
lassitude were observed.  No deaths or clinical signs were observed at 0.15 or 2.2 mg U/m3.  Severe 
weight loss was also observed at 9.2 mg U/m3; no alterations in body weight gain were observed at 
0.15 or 2.2 mg U/m3.  At 9.2 mg U/m3, both dogs had increased blood NPN levels with the maximum 
value over 200 mg%.  At 2.2 mg U/m3, blood NPN and urinary amino acid levels were normal while one 
of three dogs had increased urinary protein levels.  At 9.2 mg U/m3, severe renal damage was seen in 
dogs.  Moderate renal damage (no additional information provided) was observed at 2.2 mg U/m3 and 
very slight damage was observed in about 50% of the dogs at 0.15 mg U/m3. 
 
Dose and end point used for MRL derivation: 
 
[ ] NOAEL  [X] LOAEL 
 
The study identified a LOAEL of 0.15 mg U/m3 for minimal microscopic lesions in the renal tubules; 
BMD modeling was not used to estimate the point of departure because incidence data were not available 
for all groups. 
 
Uncertainty Factors used in MRL derivation: 
 
 [x]  3 for use of a minimal LOAEL 
 [x]  10 for extrapolation from animals to humans 
 [x]  10 for human variability 











Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration:  Human equivalent values were not calculated because regional deposited dose ratios are 
not available for dogs (EPA 1994d); thus, the LOAELADJ was used as the point of departure with an 
uncertainty factor of 10 for extrapolation from animals to humans. 
 
Was a conversion used from intermittent to continuous exposure?  The LOAEL was adjusted for 
intermittent exposure: 
 
LOAELADJ =  (0.15 mg/m3) * (6 hours/24 hours) * (6 days/7 days) = 0.032 mg/m3 
 
Other additional studies or pertinent information that lend support to this MRL:  The toxicity of various 
soluble and poorly soluble uranium compounds has been tested in several animal species (Dygert 1949a, 
1949b; Roberts 1949; Rothermel 1949; Rothstein 1949a; Spiegl 1949; Stokinger et al. 1953).  These 
studies identify the kidney and respiratory tract as the most sensitive targets of uranium toxicity.  The 
renal effects consisted of tubular degeneration and necrosis at concentrations of ≥0.2 mg U/m3.  
Compound and species differences in toxicity were found.  The more soluble compounds were more toxic 
and dogs and rabbits were more sensitive than rats, mice, and guinea pigs. 
 
In addition to the renal effects, pulmonary toxicity has been observed in animals particularly after 
exposure to uranium hexafluoride.  Exposure to 2 mg U/m3 for 30 days resulted in severe pulmonary 
edema in rabbits and slight pneumonia in dogs (Spiegl 1949).  At higher concentrations (13.3 mg U/m3), 
lung edema, hemorrhage, and emphysema were observed in rats, rabbits, and guinea pigs (Spiegl 1949).  
Since uranium hexafluoride is readily hydrolyzed to uranyl fluoride and hydrogen fluoride and hydrogen 
fluoride is a strong respiratory irritant resulting in pulmonary edema, it is likely that the observed 
respiratory effects are due to the hydrogen fluoride exposure.  Respiratory effects have also been observed 
in rabbits and rats exposed to 6.8 mg U/m3 as ammonium diuranate (Dygert 1949b).  In rabbits, 
ammonium diuranate exposure (6.8 mg U/m3) resulted in extensive respiratory tract irritation, evidence 
by nasal bleeding and pulmonary edema, hemorrhage, and necrosis.  Respiratory irritation (nasal bleeding 
and interstitial bronchiopneumonia) was also observed in rats exposed to 6.8 mg U/m3.  It is possible that 
these effects were secondary to the release of the ammonium ion, rather than uranium toxicity.  
Respiratory effects have not been consistently observed following exposure to other uranium compounds. 
 
The kidney effects were observed at lower concentrations than the respiratory effects and the dogs were 
the most sensitive species.  The lowest LOAEL values identified in dogs are 0.13 mg U/m3 as uranyl 
nitrate for proteinuria (Roberts 1949) and 0.15 mg U/m3 as uranyl fluoride for tubular damage (Rothstein 
1949a).  In the Roberts (1949) study, an increase in urinary protein excretion was observed between days 
9 and 12 and then returned to normal; very mild histological changes which the investigator noted was not 
of sufficient severity to be of concern were observed in the renal cortex in two dogs exposed for 10 days.  
Since the two LOAEL values are almost identical, the Rothstein (1949a) study was selected as the basis 
of the MRL because it included histological examination of dogs exposed for an intermediate duration 
(the one dog examined at the end of the Roberts study had severe chronic nephritis, which masked an 
uranium-induced renal effects).  Although the lowest LOAEL value in rats (0.13 mg U/m3) was similar to 
the lowest LOAEL values in dogs, the intermediate and chronic databases for soluble uranium 
compounds provide strong evidence that dogs are more sensitive than rats. 
 
Agency Contacts (Chemical Managers):  Sam Keith, Obaid Faroon, Nickolette Roney, Franco 
Scinicariello, Sharon Wilbur 
 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Uranium (insoluble forms) 
CAS Numbers: Multiple 
Date: July 2012 
Profile Status: Draft 2, Postpublic Comment 
Route: [X] Inhalation  [ ] Oral 
Duration: [ ] Acute  [ ] Intermediate  [X] Chronic 
Graph Key: 92 
Species: Monkey 
 
Minimal Risk Level:  0.0008  [ ] mg/kg/day  [ ] ppm  [X] mg/m3 
 
Reference:  Leach LJ, Maynard EA, Hodge HC, et al.  1970.  A five-year inhalation study with natural 
uranium dioxide (UO2) dust.  I.  Retention and biological effects in the monkey, dog, and rat.  Health 
Physics 18:599-612. 
 
Leach LJ, Yuile CL, Hodge HC, et al.  1973.  A five-year inhalation study with natural uranium dioxide 
(UO2) dust.  II.  Postexposure retention and biologic effects in the monkey, dog, and rat.  Health Physics 
25: 239-258. 
 
Experimental design:  Rhesus monkeys (5 males, 20 females) were exposed to 5.8 mg/m3 uranium 
dioxide (5.1 mg U/m3) 5.4 hours/day, 5 days/week for 5 years; the mass median particle diameter was 
1.03 µm with a geometric standard deviation of 2.40.  Another group of one male and five female 
monkeys served as controls.  Groups of 1–2 monkeys were killed after 1 day, 4 days, 15 days, 1 month, 
2 months, 3 months, 5 months, 1 year, 1.5 years, 1.8 years, 1.9 years, 3.6 years, 4.1 years, or 4.7 years; 
two monkeys were killed at 5 years.  Six monkeys were observed for 6.5 years after exposure termination; 
two were killed after 12 months, one after 6 years, and three after 6.5 years; the results of the recovery 
period examinations were reported in Leach et al. (1973).  The following parameters were used to assess 
toxicity:  general health, body weight, peripheral hematology, blood NPN levels, and histopathology of 
major tissues and organs.  No uranium dioxide-related deaths were observed. 
 
Effect noted in study and corresponding doses:  No alterations in body weight, hematological parameters, 
or blood NPN levels were found.  Histological alterations were limited to the lungs and tracheobronchial 
lymph nodes.  After 2–3 months of exposure, granular black pigment accumulations were found in the 
lungs and tracheobronchial lymph nodes.  After 3.6 years of exposure, slight fibrosis was observed in the 
lungs and hyaline fibrosis was observed in the tracheobronchial lymph nodes; the severity of the fibrosis 
increased with exposure duration and was not observed in the controls.  Fibrosis was still present in the 
lungs and tracheobronchial lymph nodes 6.5 years postexposure. 
 
Dose and end point used for MRL derivation: 
 
[ ] NOAEL  [X] LOAEL 
 
The study identified a LOAEL of 5.1 mg U/m3 for fibrosis in the lungs and tracheobronchial lymph 
nodes; BMD modeling was not used due to the small number of animals sacrificed at each time period. 
 
Uncertainty Factors used in MRL derivation: 
 
 [x]  10 for use of a LOAEL 
 [x]  10 for extrapolation from animals to humans 










 [x]  10 for human variability 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration:  Human equivalent values were not calculated because regional deposited dose ratios are 
not available for monkeys (EPA 1994d).  The LOAELADJ was used as the point of departure with an 
uncertainty factor of 10 for extrapolation from animals to humans. 
 
Was a conversion used from intermittent to continuous exposure?  The LOAEL was adjusted for 
intermittent exposure: 
 
LOAELADJ =  (5.1 mg U/m3) * (5.4 hours/24 hours) * (5 days/7 days) = 0.82 mg U/m3 
 
Other additional studies or pertinent information that lend support to this MRL:  There are limited data 
available to assess the toxicity of chronic exposure to insoluble uranium compounds.  Slight to mild renal 
tubular degeneration was observed in dogs exposed to 10 mg U/m3 as uranium dioxide for 1 year 
(Stokinger et al. 1953); no alterations were observed at 1 mg U/m3.  Although several tissues were 
examined histologically, significant alterations were only noted for the kidneys.  Stokinger et al. (1953) 
also exposed rats to 1 or 10 mg U/m3 as uranium dioxide, but no uranium-related alterations were 
observed.  In a second chronic duration study, no adverse effects were observed in rats or dogs exposed to 
5.1 mg U/m3 as uranium dioxide for 1–5 years (Leach et al. 1970).  However, fibrosis in the 
tracheobronchial lymph nodes and fibrosis and metaplasia in the lungs were observed in dogs during a 
6.5-year postexposure period (Leach et al. 1973).  In monkeys, exposure to 5.1 mg U/m3 resulted in lung 
fibrosis beginning after 3.6 years of exposure (Leach et al. 1970); the severity of the fibrosis increased 
with exposure duration.  Fibrosis was also present in the lungs and tracheobronchial lymph nodes in 
monkeys sacrificed during the 6.5-year postexposure period (Leach et al. 1973).  The investigators noted 
that the fibrosis may have been a radiotoxic effect based on the magnitude of the radiation dose, the 
absence of renal effects, and the similarity of the lesions to those observed following exposure to 
plutonium dioxide; the alpha-radiation tissue doses were >500 rad (5 Gy) for the lungs and 7,000 rad 
(70 Gy) for the lymph nodes.  However, it is unclear whether the damage was chemically or 
radiologically induced (or both); similar degenerative effects in the lungs have also been observed 
following prolonged exposure to diverse inorganic dusts.  An elevation of blood nonprotein nitrogen level 
was also observed in the monkeys during the postexposure period, but no histological alterations were 
observed in the kidneys (Leach et al. 1973). 
 
Agency Contacts (Chemical Managers):  Sam Keith, Obaid Faroon, Nickolette Roney, Franco 
Scinicariello, Sharon Wilbur 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Uranium (soluble forms) 
CAS Numbers: Multiple 
Date: July 2012 
Profile Status: Draft 2, Postpublic Comment 
Route: [X] Inhalation  [ ] Oral 
Duration: [ ] Acute  [ ] Intermediate  [X] Chronic 
Graph Key: 100 
Species: Dog 
 
Minimal Risk Level:  0.00004  [ ] mg/kg/day  [ ] ppm  [X] mg/m3 
 
Reference:  Stokinger HC, Baxter RC, Dygert HP, et al. 1953.  Uranium Tetrachloride: Toxicity 
following inhalation for 1 and 2 years.  In: Voegtlin C, Hodge HC, eds.  Pharmacology and toxicology of 
uranium compounds.  National Nuclear Energy Series: Manhattan Project Technical Section, Division VI, 
Vol 1.  New York, NY: McGraw-Hill.  pp. 1522-1553. 
 
Experimental design:  Dogs of both sexes (11–12 males, 9–10 females) were exposed to uranium 
tetrachloride in inhalation chambers for 33 hours/week for 1 year at concentrations of 0.05 and 
0.20 mg U/m3.  (Doses were analytically determined, not estimated.)  A control group of five male and 
seven female dogs were similar exposed to chamber air in a separate experiment.  The size-mass median 
particle size of uranium tetrachloride dust was 1.58 µm (range of 1.19–2.21 µm; geometric standard 
deviation of 2.24) for the 0.05 mg U/m3 exposures and 1.83 µm (range of 1.07–3.35 µm; geometric 
standard deviation of 2.25) for the 0.2 mg U/m3 exposures.  The animals were monitored for body weight 
alterations, clinical signs of toxicity, and biochemical alterations in the blood and urine.  At the 
termination of the study, the animals were sacrificed and selected organs were histopathologically 
examined. 
 
Effect noted in study and corresponding doses:  All dogs survived the 1-year exposure period.  No 
alterations in body weight gain, hematological parameters, or blood NPN levels were observed.  Urinary 
protein levels were elevated, as compared to controls; however, pre-exposure levels were also elevated, 
precluding evaluating the clinical significance of the effect.  Alterations in bromsulfalein retention test, 
indicating impaired liver function, were observed in the four dogs tested (0.2 mg U/m3 group); no 
alterations in blood clotting times were observed.  In the absence of histological evidence of liver damage, 
the change was not considered clinically significant.  Renal tubular atrophy was observed in 2/16 dogs 
exposed to 0.05 mg U/m3 (not statistically significant using Fisher Exact test).  Slight tubular atrophy in 
the inner cortex was observed in 7/14 dogs exposed to 0.2 mg U/m3. 
 
Dose and end point used for MRL derivation:   
 
[ ] NOAEL  [ ] LOAEL  [X] BMCL10 0.019 mg U/m3 for renal toxicity 
 
Data for the incidence of renal tubular atrophy were analyzed using all available dichotomous models in 
the EPA BMDS (version 2.1.2) using the extra risk option.  The multistage model was run for all 
polynomial degrees up to n-1 (where n is the number of dose groups including control).  Adequate model 
fit was judged by three criteria: goodness-of-fit p-value (p>0.1), visual inspection of the dose-response 
curve, and scaled residual at the data point (except the control) closest to the predefined benchmark 
response (BMR).  Among all of the models meeting adequate fit criteria, the BMCL from the model with 
the lowest Akaike Information Criteria (AIC) was chosen.  BMCs and lower bounds on the BMC 
(BMCLs) associated with a BMR of 10% extra risk were calculated for all models and are presented in 










Table A-1.  As assessed by the chi-square goodness-of-fit statistic, all of the models provided adequate fit 
to the data.  The BMCs ranged from 0.032 to 0.082 mg U/m3 and the BMCLs ranged from 0.019 to 
0.054 mg U/m3.  The quantal-linear and the multistage (1-degree polynomial) had the lowest AIC values; 
the BMCL10 of 0.019 mg U/m3 estimated for both models was selected as a point of departure.  The fit of 
the quantal-linear model is presented in Figure A-1. 
 
Table A-1.  Model Predictions for the Incidence of Renal Tubular Atrophy in Dogs 




of-fit  p-valuea AIC BMC10 (mg U/m3) BMCL10 (mg U/m3) 
Gammab 35.4648 1 35.4648 0.0411568 0.0196557 
Logistic 36.7375 0.3616 36.7375 0.0825225 0.054177 
Log Logistic 35.4648 1 35.4648 0.0418036 0.0146656 
Log Probit 35.4648 1 35.4648 0.0426877 0.00300431 
Multistage (1 degree 
polynomial) 35.4648 0.9485 33.5743 0.0324681 0.019467 
Multistage (2 degree 
polynomial) 33.5743 1 35.4648 0.0402323 0.0196557 
Probit 36.5663 0.3921 36.5663 0.0756112 0.0502782 
Weibullb 35.4648 1 35.4648 0.0409589 0.0196557 
Quantal-Linear 33.5743 0.9485 33.5743 0.0324681 0.019467 
 
aValues <0.10 fail to meet conventional goodness-of-fit criteria. 
bPower restricted to ≥1. 
 
AIC = Akaike Information Criteria; BMC = benchmark concentration associated with the selected benchmark 
response of 10% extra risk; BMCL = 95% lower confidence limit on the BMC 
 
 
































Quantal Linear Model with 0.95 Confidence Level
09:14 01/10 2011
BMDL BMD




*BMC and BMCL indicated are associated with 10% extra risk and are in units of mg U/m3. 
 
Uncertainty Factors used in MRL derivation: 
 
 [  ]  10 for use of a LOAEL 
 [x]  10 for extrapolation from animals to humans 
 [x]  10 for human variability 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration:  Human equivalent values were not calculated because regional deposited dose ratios are 
not available for dogs (EPA 1994d).  The BMCLADJ was used as the point of departure with an 
uncertainty factor of 10 for extrapolation from animals to humans. 
 
Was a conversion used from intermittent to continuous exposure?  The BMCL was adjusted for 
intermittent exposure: 
 
BMCLADJ =  (0.019 mg U/m3) * (33 hours/168 hours) = 0.0037 mg U/m3 
 
Other additional studies or pertinent information that lend support to this MRL:  There are limited human 
data on the chronic toxicity of soluble uranium.  Thun et al. (1985) examined uranium mill workers 
exposed to yellowcake (26–86% ammonium diuranate), which was considered biologically soluble, for at 
least 1 year.  Significant increases in urinary excretion of β2-microglobulin and amino acids were 
observed in the uranium workers, suggesting impaired renal tubular function.  Clearance of 
β-2-microglobulin relative to that of creatinine was significantly associated with the length of time that 










the uranium workers had spent in the yellowcake area.  Although urinary uranium levels were reported, 
atmospheric concentrations were not reported. 
 
Stokinger et al. (1953) examined the chronic toxicity of uranium hexafluoride, uranium tetrachloride, and 
uranyl nitrate in dogs and rats following a 1-year exposure.  Slight to mild renal tubular atrophy was 
observed in dogs and rats exposed to 0.2 mg U/m3 as uranium hexafluoride or uranium tetrachloride; no 
effects were observed at 0.05 mg U/m3.  Exposure to uranyl nitrate resulted in mild to moderate tubular 
atrophy in dogs exposed to 0.25 mg U/m3 (NOAEL of 0.15 mg U/m3) and mild to marked tubular atrophy 
in rats exposed to 2 mg U/m3 (NOAEL of 0.25 mg U/m3). 
 
Agency Contacts (Chemical Managers):  Sam Keith, Obaid Faroon, Nickolette Roney, Franco 
Scinicariello, Sharon Wilbur 
 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Uranium (soluble forms) 
CAS Numbers: Multiple 
Date: July 2012 
Profile Status: Draft 2, Postpublic Comment 
Route: [ ] Inhalation  [X] Oral 
Duration: [X] Acute  [ ] Intermediate  [ ] Chronic 
Graph Key: 14 
Species: Mouse 
 
Minimal Risk Level:  0.002  [X] mg/kg/day  [ ] ppm  [ ] mg/m3 
 
Reference:  Domingo JL, Paternain JL, Llobet JM, et al.  1989c.  The developmental toxicity of uranium 
in mice.  Toxicology 55:143-152. 
 
Experimental design:  Groups of 20 pregnant Swiss mice were administered via gavage 0, 5, 10, 25, or 
50 mg/kg/day uranyl acetate dihydrate (0, 2.8, 5.6, 14, or 28 mg U/kg/day) on gestation days 6–15.  Body 
weights, food consumption, and general appearance were monitored daily.  At termination, maternal liver 
and kidney weights were measured and uterine contents (number of implantation sites, resorptions, dead 
fetuses, and live fetuses) were evaluated.  Live fetuses were evaluated for body weight, body length, sex, 
gross morphological abnormalities, visceral malformations, visceral anomalies (evaluated in 1/3 of 
fetuses), and skeletal defects (evaluated in 2/3 of fetuses). 
 
Effect noted in study and corresponding doses:  Significant decreases in maternal body weight were 
observed in all uranium groups; during the exposure period, the dams in the 2.6, 5.6, 14, and 28 mg 
U/kg/day groups weighed 33, 53, 75, and 88% less than controls, respectively.  Significant decreases in 
food intake were also observed in the dams exposed to ≥5.6 mg U/kg/day.  A significant decrease in the 
number of live fetuses was observed at 5.6 mg U/kg/day, but was not observed at the two higher dose 
levels.  No significant alterations in the number of early or late resorptions, number of dead fetuses, or sex 
ratio were observed.  Significant decreases in fetal body weight were observed at ≥2.8 mg U/kg/day and 
decreases in fetal length were observed at ≥5.6 mg U/kg/day.  Significant increases in the incidences of 
external defects were observed at 2.8 mg U/kg/day.  The alterations included cleft palate (significant at 
≥5.6 mg U/kg/day) and hematomas (significant at 2.8 and 28 mg U/kg/day).  The total number of skeletal 
defects was significantly increased at 14 and 28 mg U/kg/day; skeletal defects included bipartite 
sternebrae (significant at 2.8, 14, and 28 mg U/kg/day), some metatarsal of hindlimb poorly ossified 
(significant at 14 and 28 mg U/kg/day), delayed ossification of skull (significant at 14 and 28 mg 
U/kg/day), and caudal reduced ossification (significant at 14 and 28 mg U/kg/day). 
 
Dose and end point used for MRL derivation:   
 
[ ] NOAEL  [ ] LOAEL  [X] BMDL  0.2 mg U/kg/day for developmental toxicity 
 
The results of the Domingo et al. (1989c) study suggest maternal body weight gain and fetal body weight 
and external and skeletal alterations as sensitive end points of uranium toxicity.  It is possible that the 
developmental effects were secondary to the maternal toxicity; however, some of these effects may also 
be primary effects of uranium on the developing fetus.  BMD modeling was used to identify potential 
points of departure for maternal and fetal end points.  The maternal end point was decreased maternal 
body weight gain and the fetal end points included decreased fetal body weights and external and skeletal 
alterations.  As summarized in Table A-2, there were significant increases in the incidence of litters with a 
particular types of external defect or skeletal defect and increases in the total number of litters with 










external or skeletal defects.  At all but the lowest dose tested, the increase in the incidence of external 
defects was primarily due to increases in the incidence of cleft palate.  The incidence of hematomas does 
not appear to be dose-related.  Thus, only the incidence of cleft palate was considered for BMD modeling.  
The skeletal defects consisted of increases in the incidence of bipartite sternebrae and reduced or delayed 
ossification in several locations (skull, caudal, hindlimb metatarsals, and proximal phalanges).  
Unfortunately, the investigators did not provide the information on the total number of litters with 
reduced or delayed ossification.  To estimate potential points of departure for skeletal defects, the 
incidence data for bipartite sternebrae and the total incidence of skeletal defects were modeled.   
 














Number of litters 18 17 18 18 18 
Cleft palate 0 2  (12%) 13a (72%) 13a (72%) 16a (89%) 
Hematomas (dorsal or in 
facial area) 
0 6b (35%) 2 (11%) 4 (22%) 8b (44%) 
Total external defects 0 8c (47%) 14a (78%) 14a (78%) 17b (94%) 
Bipartite sternebrae 0 6c (35%) 3 (17%) 9a (50%) 13a (72%) 
Poor ossification of 
hindlimb metatarsal  
4 (22%) 9 (53%) 15 (83%) 18b (100%) 18a (100%) 
Poor ossification of 
proximal phalanges 
2 (11%) 0 6 (33%) 13b (72%) 14b (78%) 
Delayed skull ossification  0 0 3 (17%) 9c (50%) 12c (67%) 
Reduced caudal 
ossification 
4 (22%) 9 (53%) 12 (67%) 18b (100%) 18b (100%) 
Total skeletal defects 4 (22%) 11 (65%) 15 (83%) 18c (100%) 18c (100%) 
 
aSignificantly different from controls (p<0.01). 
bSignificantly different from controls (p<0.001). 
cSignificantly different from controls (p<0.05). 
 
Source:  Domingo et al. 1989c 
 
Data for the number of litters with cleft palate, bipartite sternebrae, and total skeletal defects (summarized 
in Table A-2) were analyzed using all available dichotomous models in the EPA BMDS (version 2.1.2) 
using the extra risk option.  The multistage model was run for all polynomial degrees up to n-1 (where n 
is the number of dose groups including control).  Adequate model fit was judged by three criteria: 
goodness-of-fit p-value (p>0.1), visual inspection of the dose-response curve, and scaled residual at the 
data point (except the control) closest to the predefined BMR.  For a given end point, the BMDL from the 
model with the lowest AIC (among all of the models meeting adequate fit criteria) was chosen.  BMDs 
and lower bounds on the BMD (BMDLs) associated with a BMR of 5% extra risk for dichotomous data 
were calculated for all models and are presented in Table A-3. 
 










Table A-3.  Model Predictions for Developmental Effects in the Offspring of Mice 












 Gammab 78.21 8.69 0.0693 ND (GF) ND (GF) 
 Logistic 92.12 18.44 0.0004 ND (GF) ND (GF) 
 Log Logistic 77.98 6.15 0.1047 0.75 0.20 
 Log Probit 76.56 7.06 0.133 ND (LSR) ND (LSR) 
 Multistage (1 degree 
polynomial) 
78.21 8.69 0.0693 ND (GF) ND (GF) 
 Multistage (2 degree 
polynomial) 
78.21 8.69 0.0693 ND (GF) ND (GF) 
 Multistage (3 degree 
polynomial) 
78.21 8.69 0.0693 ND (GF) ND (GF) 
 Multistage (4 degree 
polynomial) 
78.21 8.69 0.0693 ND (GF) ND (GF) 
 Probit 92.80 18.94 0.0003 ND (GF) ND (GF) 
 Weibullb 78.21 8.69 0.0693 ND (GF) ND (GF) 
 Quantal-Linear 78.58 8.4 0.078 ND (GF) ND (GF) 
Total skeletal defects 
 Gammab 63.69 0.24 0.889 0.39 0.12 
 Logistic 61.85 0.46 0.9275 0.37 0.25 
 Log Logistic 64.42 0.77 0.6808 0.84 0.12 
 Log Probit 64.02 0.49 0.7828 0.85 0.30 
 Multistage (1 degree 
polynomial) 
61.87 0.29 0.9617 0.17 0.12 
 Multistage (2 degree 
polynomial) 
63.54 0.14 0.9326 0.23 0.12 
 Multistage (3 degree 
polynomial) 
63.45 0.07 0.9653 0.20 0.12 
 Multistage (4 degree 
polynomial) 
63.40 0.03 0.9848 0.19 0.12 
 Probit 61.86 0.49 0.9205 0.36 0.26 
 Weibullb 63.64 0.21 0.902 0.33 0.12 
 Quantal-Linear 61.87 0.29 0.9617 0.17 0.12 










Table A-3.  Model Predictions for Developmental Effects in the Offspring of Mice 












 Gammab 94.61 7.49 0.0578 ND (GF) ND (GF) 
 Logistic 97.86 7.44 0.0591 ND (GF) ND (GF) 
 Log Logistic 93.02 4.37 0.224 0.64 0.42 
 Log Probit 97.82 8.65 0.0343 ND (GF) ND (GF) 




ND (GF) ND (GF) 




ND (GF) ND (GF) 




ND (GF) ND (GF) 




ND (GF) ND (GF) 
 Probit 97.69 7.43 0.0595 2.80 2.11 
 Weibullb 94.61 7.49 0.0578 ND (GF) ND (GF) 
 Quantal-Linear 94.61 7.49 0.0578 ND (GF) ND (GF) 
 
aValues <0.10 fail to meet conventional goodness-of-fit criteria. 
bPower restricted to ≥1. 
 
AIC = Akaike Information Criteria; BMD = benchmark dose associated with the selected benchmark response of 5% 
extra risk; BMDL = 95% lower confidence limit on the BMC ND (GF) = not determined, goodness-of-fit criteria <0.10; 
ND (LSR) = not determined, largest scaled residual >2 
 
The fetal body weight data and the maternal body weight gain data, summarized in Table A-4 were fit to 
all available continuous models in EPA’s Benchmark Dose Software (BMDS, version 2.1.2).  The 
following procedure for fitting continuous data was used:  the simplest model (linear) was first applied to 
the data while assuming constant variance; if the data were consistent with the assumption of constant 
variance (p≥0.1), then the fit of the linear model to the means was evaluated and the polynomial, power, 
and Hill models were fit to the data while assuming constant variance.  Adequate model fit was judged by 
three criteria: goodness-of-fit p-value (p>0.1), visual inspection of the dose-response curve, and scaled 
residual at the data point (except the control) closest to the predefined BMR.  Among all of the models 
providing adequate fit to the data, the BMDL from the model with the lowest AIC was chosen.  If the test 
for constant variance was negative, then the linear model was run again while applying the power model 
integrated into the BMDS to account for nonhomogenous variance.  If the nonhomogenous variance 
model provided an adequate fit (p≥0.1) to the variance data, then the fit of the linear model to the means 
was evaluated and the polynomial, power, and Hill models were fit to the data and evaluated while the 
variance model was applied.  Model fit and point of departure selection proceeded as described earlier.  If 
the test for constant variance was negative and the nonhomogenous variance model did not provide an 
adequate fit to the variance data, then the data set was considered unsuitable for modeling.  For all fetal 
body weight models, a BMR of 5% relative deviation was used; a BMR of 10% was used for all maternal 
body weight gain models.  Although the Hill model with constant variance or nonconstant variance 










provided an adequate fit to means for the fetal body weight data, the models did not provide adequate fit 
to the variance and were not considered suitable for identifying a point of departure for an MRL.  None of 
the available models provided adequate fit for the maternal body weight gain data. 
 
Table A-4.  Maternal Body Weight Gain and Fetal Body Weights  
 












Maternal body weight gain 
on gestation days 6-15 (g) 
±standard deviation  
14.5±6.6 9.7±1.8a 6.8±9.5a 3.6±8.4b 1.8±6.2c 
Fetal body weight (g) 
±standard deviation 
1.40±0.15 1.04±0.25a 0.93±0.24a 0.84±0.11a 0.77±0.17a 
 
aSignificantly different from controls (p<0.001). 
bSignificantly different from controls (p<0.05). 
cSignificantly different from controls (p<0.01). 
 
Source:  Domingo et al. 1989c 
 
The potential points of departure for the acute-duration oral MRL are summarized in Table A-5.  The 
BMDL05 values for external and skeletal defects ranged from 0.20 to 0.42 mg U/kg/day and the LOAEL 
value for the maternal and fetal body weight effects was 2.8 mg U/kg/day.  The BMDL05 of 0.20 mg 
U/kg/day for cleft palate was selected as the basis of the MRL.  Because this value is lower than the other 
potential points of departure, it is likely to be protective for these effects.  The fit of the log logistics 
model to the cleft palate data is presented in Figure A-2. 
 





Point of departure  
(mg U/kg/day) 
Source 
Cleft palate 0.20 BMDL05 (log logistic model) 
Total skeletal defects 0.25 BMDL05 (logistic model) 
Bipartite sternebrae 0.42 BMDL05 (log logistic model) 
Fetal body weight  0.28 LOAEL/uncertainty factor of 10 
Maternal body weight gain 0.28 LOAEL/uncertainty factor of 10 
 
 





























Log-Logistic Model with 0.95 Confidence Level
10:15 01/24 2011
BMDL BMD




*BMD and BMDL indicated are associated with 5% extra risk and are in units of mg U/kg/day. 
 
Uncertainty Factors used in MRL derivation: 
 
 [  ]  10 for use of a LOAEL 
 [x]  10 for extrapolation from animals to humans 
 [x]  10 for human variability 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  Not 
applicable. 
 
Was a conversion used from intermittent to continuous exposure?  Not applicable. 
 
Other additional studies or pertinent information that lend support to this MRL: There are limited human 
data on the oral toxicity of uranium.  Signs of gastrointestinal irritation (nausea, vomiting, diarrhea) were 
observed in a subject ingesting 14.3 mg U/kg as uranyl nitrate in drinking water (Butterworth 1955); other 
potential targets of toxicity were not examined.  Acute oral exposure studies in rats and mice have 
examined the lethality, systemic toxicity, neurotoxicity, and developmental toxicity of uranium.  
Information on the systemic toxicity is limited to two single-exposure toxicity study in rats (Domingo et 
al. 1987) and mice (Martinez et al. 2003) administered lethal doses and a repeated exposure study in mice 
(Ozmen and Yurekli 1998).  In the 2 weeks following administration of a single gavage dose of 118 mg 
U/kg as uranyl acetate to rats, significant increases in urine volume (in the absence of changes in water 
consumption), plasma creatinine and urea, and urinary total protein and creatinine were observed; 
hyperemia and microhemorrhagic foci were also observed in the liver and kidneys at the end of the 
2-week observation period (Domingo et al. 1987).  In mice, administration of 166 mg U/kg as uranyl 
nitrate resulted in increases in blood urea and creatinine levels and proximal tubular necrosis (Martinez et 










al. 2003).  Similarly, significant increases in BUN and creatinine levels were observed in mice exposed to 
508 mg U/kg/day as uranyl acetate in the diet for 5 days (Ozmen and Yurekli 1998); the study did not 
include a histological examination of the kidney or other tissues.  Neurological effects consisted of 
increased motor activity (Briner and Murray 2005) and increased open field activity (Briner 2009) in mice 
administered 28 or 6 mg U/kg/day, respectively, as depleted uranyl acetate in drinking water for 2 weeks; 
exposure to 28 mg U/kg/day also resulted in a 53% decrease in body weight gain.  Gestational exposure 
to ≥2.8 mg U/kg/day as uranyl acetate resulted in significant decreases in fetal body weights and increases 
in the occurrence hematomas in the fetuses of mice exposed on gestation days 6–15 (Domingo et al. 
1989a); increases in the incidence of cleft palate were observed at ≥5.6 mg U/kg/day.  Decreases in 
maternal body weight gain were observed at ≥2.8 mg U/kg/day.  Exposure of neonatal rats (1 or 7 days of 
age) to 42.7 mg U/kg/day as uranyl nitrate administered via gavage in water, resulted in significant 
reductions in bone formation, increases in bone resorption, and diminished tooth development (Pujadas 
Bigi et al. 2003). 
 
 
Agency Contacts (Chemical Managers):  Sam Keith, Obaid Faroon, Nickolette Roney, Franco 
Scinicariello, Sharon Wilbur 










MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Uranium (soluble forms) 
CAS Numbers: Multiple 
Date: July 2012 
Profile Status: Draft 2, Postpublic Comment 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [X] Intermediate  [ ] Chronic 
Graph Key: 39 
Species: Rat 
 
Minimal Risk Level:  0.0002  [X] mg/kg/day  [ ] ppm  [ ] mg/m3 
 
Reference:  Gilman AP, Villeneuve DC, Secours VE, et al.  1998a.  Uranyl nitrate 28-day and 91-day 
toxicity studies in the Sprague-Dawley rat.  Toxicol Sci 41(1):117-128. 
 
Experimental design:  Five groups of Sprague-Dawley rats (15/sex/dose, 60 g) were exposed to uranium 
as uranyl nitrate in drinking water (0, 0.96, 4.8, 24, 120, and 600 mg/L) for 91 days.  Time-weighted 
average doses calculated by the authors from fluid intake data were <0.0001 (control group), 0.06, 0.31, 
1.52, 7.54, and 36.73 mg U/kg/day in males and <0.0001 (control), 0.09, 0.42, 2.01, 9.98, and 53.56 mg 
U/kg/day in females.  Clinical signs were monitored daily and body weights were measured weekly; fluid 
intake and feed consumption were also measured, but the frequency was not reported.  Hematological 
parameters serum clinical chemistry (sodium, potassium, phosphate, bilirubin, alkaline phosphatase, 
aspirate aminotransferase, total protein, calcium, cholesterol, glucose, uric acid, lactate dehydrogenase, 
sorbitol dehydrogenase), organ weights, and histopathology (tissues examined: adrenal, brain [three 
sections], bone marrow, bronchi, colon, duodenum, epididymis, stomach [gastric cardia, fundus, and 
pylorus], heart, kidney, liver, lungs, mesenteric and mediastinal lymph nodes, ovary, pancreas, 
parathyroid, pituitary, salivary glands, skeletal muscle, spleen, testes, thoracic aorta, thymus, thyroid, 
trachea, and uterus) were assessed at termination.  Uranium residues were measured in samples of brain, 
liver, spleen, liver, kidney, and bone in the control and two highest dose groups. 
 
Effect noted in study and corresponding doses:  Hematological and biochemical parameters were not 
affected in a significant exposure-related manner.  Statistically significant increases in renal lesions 
included cytoplasmic vacuolization (0/15, 9/15, 7/15, 12/15, 9/15, 7/15), tubular dilation (0/15, 4/15, 
5/15, 10/15, 4/15, 5/15), and lymphoid cuffing (0/15, 6/15, 6/15, 2/15, 7/15, 10/15) in males at ≥0.06 mg 
U/kg/day; capsular sclerosis (0/15, 5/15, 4/15, 3/15, 6/14, 5/14), tubular anisokaryosis (0/15, 5/15, 4/15, 
3/15, 6/14, 5/14; not significant at 2.01 mg U/kg/day), and interstitial reticulin sclerosis (1/15, 9/15, 8/15, 
7/15, 6/14, 5/14) in females at ≥0.09 mg U/kg/day; nuclear vesiculation in males (0/15, 6/15, 10/15, 6/15, 
8/15) and females (0/15, 6/15, 6/15, 7/15, 4/14, 7/14) at ≥0.06/0.09 mg U/kg/day; and glomerular 
adhesions (2/15, 4/15, 10/15, 10/15, 10/15, 11/15) and cytoplasmic degeneration (0/15, 2/15, 11/15, 
13/15, 7/15, 7/15) in males at ≥0.31 mg U/kg/day.  Lesions were also observed in the liver at all doses 
including anisokaryosis, vesiculation, increased portal density, perivenous vacuolation, and homogeneity; 
the investigators considered these adaptive and likely reversible.  Thyroid lesions were observed in both 
sexes (multifocal reduction of follicular size, increased epithelial height in males at 0.31 mg/kg/day and 
females at 2.01 mg/kg/day).  A decreased amount and density of colloid in the thyroid was observed in 
males only.  Sinus hyperplasia of the spleen was observed in males and females at 
36.73/53.56 mg/kg/day. 
 










Dose and end point used for MRL derivation:  0.06 mg U/kg/day, renal toxicity.  This is considered a 
minimal LOAEL. 
 
[ ] NOAEL  [X] LOAEL 
 
Uncertainty Factors used in MRL derivation: 
 
 [x]  3 for use of a minimal LOAEL 
 [x]  10 for extrapolation from animals to humans 
 [x]  10 for human variability 
  
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No, doses were 
calculated by the authors on the basis of measured water intake. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  Not 
applicable. 
 
Was a conversion used from intermittent to continuous exposure?  Not applicable. 
 
Other additional studies or pertinent information that lend support to this MRL:  No studies have been 
identified that examined the toxicity of uranium in humans following an intermediate-duration oral 
exposure.  A number of studies have examined the intermediate-duration oral toxicity of uranium in 
laboratory animals.  Most of these studies involved exposure to soluble uranium compounds such as 
uranyl nitrate and uranyl acetate; there are limited data on moderately soluble or insoluble uranium 
compounds.  The available data suggest that the kidney is the most sensitive target of uranium toxicity; at 
higher dose levels, neurological, reproductive, and developmental effects have been reported.  At lower 
concentrations, histological alterations have been observed in the proximal tubules, glomerulus, and/or 
renal interstitium in rats and mice exposed to uranyl nitrate in drinking water (Berradi et al. 2008; Gilman 
et al. 1998a, 1998b, 1998c; McDonald-Taylor et al. 1992, 1997).  At higher concentrations (40.38 mg 
U/kg/day), evidence of renal dysfunction (e.g., glycosuria, proteinuria) has also been observed (Gilman et 
al. 1998c).  The Gilman et al. (1998a, 1998b) studies identified the LOAELs of 0.06 and 0.05 mg 
U/kg/day for renal effects in rats and rabbits, respectively; neither study identified NOAEL values. 
 
The LOAELs for neurological, reproductive, and developmental effects are similar and are about 50-fold 
higher than the LOAEL for renal effects.  Neurological effects such as sleep and behavior alterations and 
decreased spatial memory were observed in rats exposed to 2.5–2.7 mg U/kg/day as enriched uranyl 
nitrate (Houpert et al. 2005, 2007b).  However, no neurological effects were observed in rats similarly 
exposed to the same dose of depleted uranyl nitrate (Houpert et al. 2005).  The investigators suggest that 
the observed effects may have been related to radiological activity.  The reproductive effects consisted of 
decreases in male fertility in rats and mice following exposure to ≥5.6 mg U/kg/day as uranyl acetate 
(Linares et al. 2005; Llobet et al. 1991) and alterations in ovarian folliculogenesis in mice at ≥1.25 mg 
U/kg/day as uranyl nitrate (Arnault et al. 2008; Feugier et al. 2008; Kundt et al. 2009).  A recent study by 
Raymond-Whish et al. (2007) also reported alterations in ovarian folliculogenesis in mice, but the effects 
were at an extremely low dose (0.00039 mg U/kg/day).  Additional data are needed to support whether 
reproductive effects occur at this dose level and to evaluate the toxicological significance of the observed 
effect (reduced number of small primary follicles, but no effect on primordial, secondary/growing, 
healthy, or atretic follicle populations).  Developmental effects have been observed in rats and mice; most 
effects occurred at maternally toxic doses.  The observed effects included neurobehavioral effects in the 
offspring of rats exposed premating and during gestation and lactation to 4.3 mg U/kg/day as enriched 
uranyl nitrate (Houpert et al. 2007a), decreases in pup body weight at ≥2.8 mg U/kg/day as uranyl acetate 
(Paternain et al. 1989; Sanchez et al. 2006), decreases in litter size, live fetuses, or viability at ≥14 mg 










U/kg/day as uranyl acetate (Domingo et al. 1989b; Paternain et al. 1989), and altered ovarian 
folliculogenesis in 3-month-old pups of dams exposed to 1.25 mg U/kg/day as uranyl nitrate (Arnault et 
al. 2008). 
 
The LOAELs of 0.05 and 0.06 mg U/kg/day for kidney effects in rats and rabbits (Gilman et al. 1998a, 
1998b) were considered as possible points of departure for an intermediate-duration oral MRL for soluble 
uranium compounds.  Although the rabbit study identified the slightly lower LOAEL, the rat LOAEL was 
selected as the point of departure for the MRL due to possible subclinical infection in the rabbits.  Gilman 
et al. (1998b, 1998c) conducted two 91-day studies in rabbits.  The kidney uranium levels for the two 
studies were not comparable; rabbits in the first study (Gilman et al. 1998b) had higher kidney uranium 
levels than in the second study (Gilman et al. 1998c) even though the dose was lower in the first study 
(28.70 mg U/kg/day dose and 4.98 µg U/g kidney level in the Gilman et al. 1998b study compared to 
40.98 mg U/kg/day dose and 3.48 µg U/g kidney level in the Gilman et al. 1998c study).  In the Gilman et 
al. (1998b) study, the male rabbits were not SPF derived and four animals developed Pasteurella 
multocida infections during the study; Gilman et al. (1998c) suggested that even though the affected 
rabbits were removed from the study, it is possible that other animals had a subclinical infection and that 
this may have increased sensitivity.  Thus, the rat study was selected as the basis of the MRL; the rats 
used in the Gilman et al. (1998a) study were SPF derived.  The Raymond-Whish et al. (2007) study was 
not selected as the point of departure because there are no other data to support this extremely low value 
and the toxicological significance of this slight change in one follicle population is not known. 
 
Other Issues 
The results of a serial study in which rats were exposed to several doses of uranyl nitrate in the diet for up 
to one year (Maynard et al. 1953) coupled with the rat 2-year study (Maynard and Hodge 1949; Maynard 
et al. 1953) suggest that at low exposures the renal tubular epithelium is regenerated and continued 
exposure does not result in more severe effects.  However, at higher doses, the capacity to regenerate the 
renal tubular epithelium is exceeded and tubular atrophy is observed.  In the serial study (Maynard et al. 
1953), exposure to 170 mg U/kg/day as uranyl nitrate in the diet resulted in regeneration of the renal 
tubular epithelium after 2 weeks of exposure; there was no progression of renal damage with continued 
exposure and the renal tubules in rats exposed for 2 weeks were similar to those exposed for 1 year.  
Additionally, a 2 year exposure to 170 mg U/kg/day did not result in any further damage to the kidneys 
(Maynard and Hodge 1949; Maynard et al. 1953).  In contrast, regeneration was observed in the first 
month of the exposure to 660 mg U/kg/day, however, with continued exposure, tubular atrophy was 
observed at 6–8 weeks.  The severity of the atrophy and the areas of the kidney affected by uranium 
increased with duration.  Given these data on the ability of the kidney to repair renal damage at low doses, 
the intermediate-duration oral MRL may be protective for chronic exposures. 
 
 
Agency Contacts (Chemical Managers):  Sam Keith, Obaid Faroon, Nickolette Roney, Franco 
Scinicariello, Sharon Wilbur 














Public Health Statement 
 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 




Relevance to Public Health 
 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions: 
 
 1. What effects are known to occur in humans? 
 
 2. What effects observed in animals are likely to be of concern to humans? 
 
 3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
 
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
 
Interpretation of Minimal Risk Levels 
 
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
 










MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure. 
 
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used 







Tables and Figures for Levels of Significant Exposure (LSE) 
 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
 
 











See Sample LSE Table 3-1 (page B-6) 
 
(1) Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
 
(2) Exposure Period.  Three exposure periods—acute (less than 15 days), intermediate (15–
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
 
(3) Health Effect.  The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
 
(4) Key to Figure.  Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
 
(5) Species.  The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
 
(6) Exposure Frequency/Duration.  The duration of the study and the weekly and daily exposure 
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
 
(7) System.  This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
 
(8) NOAEL.  A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b"). 











(9) LOAEL.  A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from 
Serious LOAELs. 
 
(10) Reference.  The complete reference citation is given in Chapter 9 of the profile. 
 
(11) CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
 
(12) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 




See Sample Figure 3-1 (page B-7) 
 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
 
(13) Exposure Period.  The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
 
(14) Health Effect.  These are the categories of health effects for which reliable quantitative data 
exists.  The same health effects appear in the LSE table. 
 
(15) Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
 
(16) NOAEL.  In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
 
(17) CEL.  Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the 
LSE table. 
 










(18) Estimated Upper-Bound Human Cancer Risk Levels.  This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 
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Wong et al. 1982 
NTP 1982 
NTP 1982 
a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 










(CEL, lung tumors, 
nasal tumors) 
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APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AMAD activity median aerodynamic diameter 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BMC benchmark concentration 
BMCL lower 95% confidence limit on the BMC 
BMCL05 BMCL associated with a BMR of 5% 
BMCL10 BMCL associated with a BMR of 10% 
BMD benchmark dose 
BMDL lower 95% confidence limit on the BMD 
BMDL05 BMDCL associated with a BMR of 5% 
BMDL10 BMDCL associated with a BMR of 10% 
BMR benchmark response 
BSC Board of Scientific Counselors 
BUN blood urea nitrogen 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 










DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
   NA/IMCO    North America/Intergovernmental Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank 
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System 
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 










LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 




mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NPN blood nonprotein nitrogen 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 










OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic 
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg picogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity 
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 










USGS United States Geological Survey 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
 
> greater than 
≥ greater than or equal to 
= equal to 
< less than 








q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
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OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY, AND BIOLOGY 
 
 
Understanding the basic concepts in radiation physics, chemistry, and biology is important to the evaluation and 
interpretation of radiation-induced adverse health effects and to the derivation of radiation protection principles.  
This appendix presents a brief overview of the areas of radiation physics, chemistry, and biology and is based to a 
large extent on the reviews of Mettler and Moseley (1985), Hobbs and McClellan (1986), Eichholz (1982), Hendee 
(1973), Cember (1996, 2009), and Early et al. (1979). 
 
D.1 RADIONUCLIDES AND RADIOACTIVITY 
 
The substances we call elements are composed of atoms.  Atoms in turn are made up of neutrons, protons and 
electrons: neutrons and protons in the nucleus and electrons in a cloud of orbits around the nucleus.  Nuclide is the 
general term referring to any nucleus along with its orbital electrons.  The nuclide is characterized by the 
composition of its nucleus and hence by the number of protons and neutrons in the nucleus.  All atoms of an element 
have the same number of protons (this is given by the atomic number) but may have different numbers of neutrons 
(this is reflected by the atomic mass numbers or atomic weight of the element).  Atoms with different atomic mass 
but the same atomic numbers are referred to as isotopes of an element. 
 
The numerical combination of protons and neutrons in most nuclides is such that the nucleus is quantum 
mechanically stable and the atom is said to be stable, i.e., not radioactive; however, if there are too few or too many 
neutrons, the nucleus is unstable and the atom is said to be radioactive.  Unstable nuclides undergo radioactive 
transformation, a process in which a neutron or proton converts into the other and a beta particle is emitted, or else 
an alpha particle is emitted.  Each type of decay is typically accompanied by the emission of gamma rays.  These 
unstable atoms are called radionuclides; their emissions are called ionizing radiation; and the whole property is 
called radioactivity.  Transformation or decay results in the formation of new nuclides some of which may 
themselves be radionuclides, while others are stable nuclides.  This series of transformations is called the decay 
chain of the radionuclide.  The first radionuclide in the chain is called the parent; the subsequent products of the 
transformation are called progeny, daughters, or decay products. 
 
In general there are two classifications of radioactivity and radionuclides:  natural and artificial (man-made).  
Naturally-occurring radioactive material (NORM) exists in nature and no additional energy is necessary to place 
them in an unstable state.  Natural radioactivity is the property of some naturally occurring, usually heavy elements, 
that are heavier than lead.  Radionuclides, such as radium and uranium, primarily emit alpha particles.  Some lighter 
elements such as carbon-14 and tritium (hydrogen-3) primarily emit beta particles as they transform to a more stable 
atom.  Natural radioactive atoms heavier than lead cannot attain a stable nucleus heavier than lead.  Everyone is 
exposed to background radiation from naturally-occurring radionuclides throughout life.  This background radiation 
is the major source of radiation exposure to man and arises from several sources.  The natural background exposures 
are frequently used as a standard of comparison for exposures to various artificial sources of ionizing radiation. 
 
Artificial radioactive atoms are produced either as a by-product of fission of uranium or plutonium atoms in a 
nuclear reactor or by bombarding atoms with particles (such as neutrons, protons, or heavy nuclei) at high velocity 
via a particle accelerator.  Goals of these efforts can include producing medical isotopes or new elements.  These 
artificially produced radioactive elements usually decay by emission of particles, such as alpha particles, positive or 
negative beta particles, and one or more high energy photons (gamma rays).  Unstable (radioactive) atoms of any 
element can be produced. 
 
Both naturally occurring and artificial radioisotopes find application in medicine, industrial products, and consumer 
products.  Some specific radioisotopes, called fall-out, are still found in the environment as a result of nuclear 
weapons use or testing, or nuclear power plant accidents (e.g., Three Mile Island Unit 2, Chernobyl, and Fukushima 
Dai-ichi). 
 










D.2 RADIOACTIVE DECAY 
 
D.2.1 Principles of Radioactive Decay 
 
The stability of an atom is the result of the balance of the forces of the various components of the nucleus.  An atom 
that is unstable (a radionuclide) will release energy (decay) in various ways and transform to stable atoms or to 
intermediate radioactive species called progeny or daughters, often with the release of ionizing radiation.  If there 
are either too many or too few neutrons for a given number of protons, the resulting nucleus may undergo 
transformation.  For some elements, a chain of progeny decay products may be produced until stable atoms are 
formed.  Radionuclides can be characterized by the type and energy of the radiation emitted, the rate of decay, and 
the mode of decay.  The mode of decay indicates how a parent compound undergoes transformation.  Radiations 
considered here are primarily of nuclear origin, i.e., they arise from nuclear excitation, usually caused by the capture 
of charged or uncharged nucleons by a nucleus, or by the radioactive decay or transformation of an unstable nuclide.  
The type of radiation may be categorized as charged or uncharged particles, protons, and fission products) or 
electromagnetic radiation (gamma rays and x rays).  Table D-1 summarizes the basic characteristics of the more 
common types of radiation encountered. 
 
D.2.2 Half-Life and Activity 
 
For any given radionuclide, the rate of decay is a first-order process that is constant, regardless of the radioactive 
atoms present and is characteristic for each radionuclide.  The process of decay is a series of random events; 
temperature, pressure, or chemical combinations do not affect the rate of decay.  While it may not be possible to 
predict exactly which atom is going to undergo transformation at any given time, it is possible to predict, on 
average, the fraction of the radioactive atoms that will transform during any interval of time. 
 
The activity is a measure of the quantity of radioactive material.  For these radioactive materials it is customary to 
describe the activity as the number of disintegrations (transformations) per unit time.  The unit of activity is the curie 
(Ci), which was originally related to the activity of one gram of radium, but is now defined as the disintegration or 
transformation rate occurring in a quantity of radioactive material.  The definition is: 
 
1 curie (Ci)  = 3.7x1010 disintegrations (transformations)/second (dps) or 
    = 2.22x1012 disintegrations (transformations)/minute (dpm). 
 
The SI unit of activity is the becquerel (Bq); 1 Bq = that quantity of radioactive material in which there is 
1 transformation/second.  Since activity is proportional to the number of atoms of the radioactive material, the 
quantity of any radioactive material is usually expressed in curies, regardless of its purity or concentration.  The 
transformation of radioactive nuclei is a random process, and the number of transformations is directly proportional 
to the number of radioactive atoms present.  For any pure radioactive substance, the rate of decay is usually 
described by its radiological half-life,  t½, i.e., the time it takes for a specified source material to decay to half its 
initial activity.  The specific activity is an indirect measure of the rate of decay, and is defined as the activity per unit 
mass or per unit volume. The higher the specific activity of a radioisotope, the faster it is decaying. 
 
The activity of a radionuclide at time t may be calculated by: 
 
 A = Aoe-0.693t/t½,  
 
where A = the activity in dps or curies or becquerels, 
  Ao = the activity at time zero, 
  t = the time at which measured, and 
 t½ = the radiological half-life of the radionuclide (t½ and t must be in the same units of time).   
 
The time when the activity of a sample of radioactivity becomes one-half its original value is the radioactive half-
life and is expressed in any suitable unit of time. 
 










Table D-1.  Characteristics of Nuclear Radiations 
 
   Typical 
energy range 
Path lengthb  
Radiation Rest massa Charge Air Solid Comments 
Alpha (α) 4.00 amu +2 4–10 MeV 5–10 cm 25–80 μm Identical to ionized 
He nucleus 
Negatron (β–) 5.48x10-4 amu; 
0.51 MeV 
–1 0–4 MeV 0–10 m 0–1 cm Identical to electron 
Positron (β+) 5.48x10-4 amu; 
0.51 MeV 
+1 0-4 MeV 0–10 m 0–1 cm Identical to electron 
except for sign of 
charge 
Neutron 1.00866 amu; 
939.565 MeV 
0 0–15 MeV b b Half life:  10.183 min 
X ray (e.m.  photon) – 0 5 keV–100 keV b b Photon from 
transition of an 
electron between 
atomic orbits 
Gamma ()  
(e.m.  photon) 
– 0 10 keV–3 MeV b b Photon from nuclear 
transformation 
 
a The rest mass (in amu) has an energy equivalent in MeV that is obtained using the equation E=mc2, where 1 amu = 932 MeV. 
b Path lengths are not applicable to x- and gamma rays since their intensities decrease exponentially; path lengths in solid tissue 
are variable, depending on particle energy, electron density of material, and other factors. 
 
   amu = atomic mass unit; e.m.  = electromagnetic; MeV = MegaElectron Volts 
 
 
The specific activity is a measure of activity, and is defined as the activity per unit mass or per unit volume. This 
activity is usually expressed in curies per gram and may be calculated by 
 
 curies/gram   =  1.3x108 / (t½) (atomic weight)     or   
  
      [3.577 x 105 x  mass(g)] / [t½  x   atomic weight] 
 
where t½ = the radiological half-life in days. 
 
In the case of radioactive materials contained in living organisms, an additional consideration is made for the 
reduction in observed activity due to regular processes of elimination of the respective chemical or biochemical 
substance from the organism.  This introduces a rate constant called the biological half-life (tb) which is the time 
required for biological processes to eliminate one-half of the activity.  This time is virtually the same for both stable 
and radioactive isotopes of any given element. 
 
Under such conditions the time required for a radioactive element to be halved as a result of the combined action of 
radioactive decay and biological elimination is the effective clearance half-time: 
 
  teff = (tb x t½) / (tb + t½). 
 
Table D-2 presents representative effective half-lives of particular interest. 
 
 










Table D-2.  Half-Lives of Some Radionuclides in Adult Body Organs 
 
  Half-lifea 
Radionuclide Critical organ Physical Biological Effective 
Uranium 238 Kidney 4,460,000,000 y 4 d 4 d 
Hydrogen 3b 
(Tritium) 
Whole body 12.3 y 10 d 10 d 
Iodine 131 Thyroid 8 d 80 d 7.3 d 
Strontium 90 Bone 28 y 50 y 18 y 
Plutonium 239 Bone surface 24,400 y 50 y 50 y 
 Lung 24,400 y 500 d 500 d 
Cobalt 60 Whole body 5.3 y 99.5 d 95 d 
Iron 55 Spleen 2.7 y 600 d 388 d 
Iron 59 Spleen 45.1 d 600 d 42 d 
Manganese 54 Liver 303 d 25 d 23 d 
Cesium 137 Whole body 30 y 70 d 70 d 
 
ad = days, y = years 
bMixed in body water as tritiated water 
 
D.2.3 Interaction of Radiation with Matter 
 
Both ionizing and nonionizing radiation will interact with materials; that is, radiation will lose kinetic energy to any 
solid, liquid or gas through which it passes by a variety of mechanisms.  The transfer of energy to a medium by 
either electromagnetic or particulate radiation may be sufficient to cause formation of ions.  This process is called 
ionization.  Compared to other types of radiation that may be absorbed, such as radio waves or microwave radiation, 
ionizing radiation deposits a relatively large amount of energy into a small volume. 
 
The method by which incident radiation interacts with the medium to cause ionization may be direct or indirect.  
Electromagnetic radiations (x rays and gamma photons) and neutral particles (neutrons) are indirectly ionizing; that 
is, they give up their energy in various interactions with cellular molecules, and the energy is then utilized to 
produce a fast-moving charged particle such as an electron.  It is the electron that then may react with and transfer 
energy to a target molecule.  This particle is called a “primary ionizing particle.  Charged particles, in contrast, strike 
the tissue or medium and directly react with target molecules, such as oxygen or water.  These particulate radiations 
are directly ionizing radiations.  Examples of directly ionizing particles include alpha and beta particles.  Indirectly 
ionizing radiations are always more penetrating than directly ionizing particulate radiations. 
 
Mass, charge, and velocity of a particle, as well as the electron density of the material with which it interacts, all 
affect the rate at which ionization occurs.  The higher the charge of the particle and the lower the velocity, the 
greater the propensity to cause ionization.  Heavy, highly charged particles, such as alpha particles, lose energy 
rapidly with distance and, therefore, do not penetrate deeply.  The result of these interaction processes is a gradual 
slowing down of any incident particle until it is brought to rest or "stopped" at the end of its range. 
 
D.2.4 Characteristics of Emitted Radiation 
 
D.2.4.1  Alpha Emission.  In alpha emission, an alpha particle consisting of two protons and two neutrons is 
emitted with a resulting decrease in the atomic mass number by four and reduction of the atomic number of two, 
thereby changing the parent to a different element.  The alpha particle is identical to a helium nucleus consisting of 
two neutrons and two protons.  It results from the radioactive decay of some heavy elements such as uranium, 
plutonium, radium, thorium, and radon.  All alpha particles emitted by a given radioisotope have the same energy.  










Most of the alpha particles that are likely to be found have energies in the range of about 4 to 8 MeV, depending on 
the isotope from which they came. 
 
The alpha particle has an electrical charge of +2.  Because of this double positive charge and their size, alpha 
particles have great ionizing power and, thus, lose their kinetic energy quickly.  This results in very little penetrating 
power.  In fact, an alpha particle cannot penetrate a sheet of paper.  The range of an alpha particle (the distance the 
charged particle travels from the point of origin to its resting point) is about 4 cm in air, which decreases 
considerably to a few micrometers in tissue.  These properties cause alpha emitters to be hazardous only if there is 
internal contamination (i.e., if the radionuclide is inside the body). 
 
D.2.4.2  Beta Emission.  A beta particle (β) is a high-velocity electron ejected from a disintegrating nucleus.  
The particle may be either a negatively charged electron, termed a negatron (β) or a positively charged electron, 
termed a positron (β).  Although the precise definition of "beta emission" refers to both β and β, common usage 
of the term generally applies only to the negative particle, as distinguished from the positron emission, which refers 
to the β particle. 
 
D.2.4.2.1  Beta Negative Emission.  Beta particle (β) emission is another process by which a radionuclide, 
with a neutron excess achieves stability.  Beta particle emission decreases the number of neutrons by one and 
increases the number of protons by one, while the atomic mass number remains unchanged.4  This transformation 
results in the formation of a different element.  The energy spectrum of beta particle emission ranges from a certain 
maximum down to zero with the mean energy of the spectrum being about one-third of the maximum.  The range in 
tissue is much less.  Beta negative emitting radionuclides can cause injury to the skin and superficial body tissues, 
but mostly present an internal contamination hazard. 
 
D.2.4.2.2  Positron Emission.  In cases in which there are too many protons in the nucleus, positron 
emission may occur.  In this case a proton may be thought of as being converted into a neutron, and a positron (β) 
is emitted.1  This increases the number of neutrons by one, decreases the number of protons by one, and again leaves 
the atomic mass number unchanged.  The gamma radiation resulting from the annihilation (see glossary) of the 
positron makes all positron emitting isotopes more of an external radiation hazard than pure β emitters of equal 
energy. 
 
D.2.4.2.3  Gamma Emission.  Radioactive decay by alpha, beta, or positron emission, or electron capture 
often leaves some of the energy resulting from these changes in the nucleus.  As a result, the nucleus is raised to an 
excited level.  None of these excited nuclei can remain in this high-energy state.  Nuclei release this energy returning 
to ground state or to the lowest possible stable energy level.  The energy released is in the form of gamma radiation 
(high energy photons) and has an energy equal to the change in the energy state of the nucleus.  Gamma and x rays 
behave similarly but differ in their origin; gamma emissions originate in the nucleus while x rays originate in the 
orbital electron structure or from rapidly changing the velocity of an electron (e.g., as occurs when shielding high 
energy beta particles or stopping the electron beam in an x ray tube). 
 
D.3 ESTIMATION OF ENERGY DEPOSITION IN HUMAN TISSUES 
 
Two forms of potential radiation exposures can result: internal and external.  The term exposure denotes physical 
interaction of the radiation emitted from the radioactive material with cells and tissues of the human body.  An 
exposure can be "acute" or "chronic" depending on how long an individual or organ is exposed to the radiation.  
Internal exposures occur when radionuclides, which have entered the body (e.g., through the inhalation, ingestion, or 
dermal pathways), undergo radioactive decay resulting in the deposition of energy to internal organs.  External 
exposures occur when radiation enters the body directly from sources located outside the body, such as radiation 
emitters from radionuclides on ground surfaces, dissolved in water, or dispersed in the air.  In general, external 
exposures are from material emitting gamma radiation, which readily penetrate the skin and internal organs.  Beta 
and alpha radiation from external sources are far less penetrating and deposit their energy primarily on the skin's 
outer layer.  Consequently, their contribution to the absorbed dose of the total body dose, compared to that deposited 
by gamma rays, may be negligible. 
                                                           
4 Neutrinos accompany negative beta particle emissions; anti-neutrinos accompany positron emissions 











Characterizing the radiation dose to persons as a result of exposure to radiation is a complex issue.  It is difficult to:  
(1) measure internally the amount of energy actually transferred to an organic material and to correlate any observed 
effects with this energy deposition; and (2) account for and predict secondary processes, such as collision effects or 
biologically triggered effects, that are an indirect consequence of the primary interaction event.  Radiation exposure 
(a measure of ionization density in air) is sometimes used as a surrogate for radiation dose in tissue from external 
radiation.  Both exposure and dose are described below. 
 
D.3.1 Exposure (Roentgen).    The roentgen (R) is a unit of x or gamma-ray exposure and is a measured by 
the amount of ionization caused in air by gamma or x radiation.  One roentgen produces 2.58x10-4 coulomb per 
kilogram of air.  In the case of gamma radiation, over the commonly encountered range of photon energy, the energy 
deposition in tissue for an exposure of 1 R is about 0.0096 joules (J)/kg of tissue.  Exposure is only defined for x and 
gamma radiation ionization in air, and is often incorrectly interchanged with the term dose. 
 
D.3.2  Absorbed Dose (Gy, rad) and Absorbed Dose Rate (Gy/hr, rad/hr).    The absorbed dose 
is defined as the energy absorbed from the incident radiation by a unit mass of the tissue or organ (dm).  The 
differential equation for absorbed dose is: 
 
 D = de/dm 
 
where:  D = absorbed dose 
   e = mean energy deposited 
   m = mass in which the energy was deposited. 
 
The SI unit of absorbed dose in any medium is the J/kg with the special name of Gray (Gy), where 1 J/kg = 10,000 
ergs/gram = 1 Gy.  In the historical system, 0.01 J/kg = 100 ergs/g = 1 rad, so 1 Gy = 100 rad..  For neutrons, the 
absorbed dose may be estimated using the similar metric, kinetic energy released in matter (kerma).  Kerma is the 
sum of initial kinetic energies of all charged ionizing particles liberated in a unit mass.   
 
Absorbed dose is a measurable quantity, so there are primary national and international standards for its 
determination.  In practice, absorbed dose is averaged over organ or tissue volumes.  This allows the absorbed dose 
from both external and internal sources of radiation to be added.  For low doses, the acceptance of the linear no 
threshold (LNT) theory allows the correlation of dose with degree of adverse deterministic health effects.  Radiation 
that does not penetrate tissue well (low energy x-rays, beta particles, and alpha particles) can produce a nonuniform 
distribution of absorbed dose resulting in differential health effects across an organ or tissue.  An example is using 
shielding in radiation therapy so that a kidney tumor receives a lethal dose while sparing as much health tissue as 
practical, thus maximizing the remaining kidney function. 
 
Internal and external absorbed doses delivered by radiation sources are not usually instantaneous but are distributed 
over extended periods of time.  The resulting rate of change of the absorbed dose to a small volume of mass is 
referred to as the absorbed dose rate, which has units of Gy/unit time or rad/unit time. 
 
As a rough conversion, an exposure of 1 R in air results in an absorbed dose to soft tissue of approximately 0.01 
J/kg. 
 
See text below on other units of measure.   
 
D.4 UNITS IN RADIATION PROTECTION AND REGULATION 
 
D.4.1  Equivalent Dose (or Dose Equivalent)   
 
Equivalent dose (international term) and dose equivalent (US term)are a radiation protection quantity used for 
setting limits that help ensure that deterministic effects (e.g. damage to a particular tissue) are kept within acceptable 
levels.  The SI unit of equivalent dose is the J/kg, has the special name of Sievert (Sv) or rem, and is abbreviated HT. 
It is a special radiation protection quantity that is used, for administrative and radiation safety purposes only, to 





express the absorbed dose in a manner which considers the difference in biological effectiveness of various kinds of 
ionizing radiation.  The equivalent dose concept is applicable only to doses that are not great enough to produce 
biomedical effects.  
 
The equivalent dose in an organ or tissue (HT) is determined by multiplying the absorbed dose by a radiation 
weighting factor and any modifying factors at the location of interest.  The absorbed dose in an organ or tissue from 
radiation of type R (DT,R) is a measurable or estimable quantity, while the radiation weighting factor (ωR) for each 
primary radiation type (ωR) has been studied and recommendations made for their values.  The formula for 
calculating equivalent dose is: 
 
 HT =   or  
 
Where   = radiation weighting factor, 
   = absorbed dose to tissue T from radiation type R, and 
   = quality factor. 
 
The radiation weighting factor (ω) or quality factor (Q) is a dimensionless quantity that depends in part on the 
stopping power for charged particles, and it accounts for the differences in biological effectiveness found among the 
types of radiation.  Originally, relative biological effectiveness (RBE) was used rather than ω or Q to define the 
quantity, rem, which is of use in risk assessment.  The NRC and DOE in the US, and the ICRU and ICRP in most of 
the remaining international community havepublished values for quality factors and radiation weighting factors 
provided in Tables D-3 and D-4.   
 
The equivalent dose rate (or dose equivalent rate in the US) is the time rate of change of the equivalent dose (or dose 
equivalent) to organs and tissues and is expressed as Sv/unit time (or rem/unit time). 
 







Radiation Weighting Factor 
(ICRP 2007) 
(wR) 
Photons (x and γ rays) 
Electrons 
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High energy protons 
Protons and charged pions 
Alpha particles, multiple-charged 
particles, fission fragments and heavy 
particles of unknown charge 
 
Alpha particles, fission fragments, 
heavy ions 
 
Neutrons of unknown energy 
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USNRC.  2011.  Standards for the protection against radiation, tables 1004(b).1 and 1004(b).2.  10 CFR 20.1004.  U.S. Nuclear 
Regulatory Commission, Washington, D.C.  
ICRP  
Radiation weighting factors for neutrons are based on particle energy according to the following formulas (ICRP 
2007): 
 
 ωR =  
 
Table D-4 Mean Quality Factors, Q, and Fluence per Unit Dose Equivalent for Monoenergetic 
Neutrons 
   Neutron energy (MeV) Quality factora(Q) Fluence per unit dose equivalentb(neutrons cm−2rem−1) 
(thermal) 2.5×10−8 2 980×106 
   1×10−7 2 980×106 
   1×10−6 2 810×106 
   1×10−5 2 810×106 
   1×10−4 2 840×106 
   1×10−3 2 980×106 
   1×10−2 2.5 1010×106 
   1×10−1 7.5 170×106 
   5×10−1 11   39×106 
   1 11   27×106 
   2.5 9   29×106 
   5 8   23×106 
   7 7   24×106 
   10 6.5   24×106 
   14 7.5   17×106 
   20 8   16×106 
   40 7   14×106 
   60 5.5   16×106 
   1×102 4   20×106 










   2×102 3.5   19×106 
   3×102 3.5   16×106 
   4×102 3.5   14×106 
 
 
D.4.2  Relative Biological Effectiveness 
 
RBE is used to denote the experimentally determined ratio of the absorbed dose from one radiation type to the 
absorbed dose of a reference radiation required to produce an identical biological effect under the same conditions.  
Gamma rays from cobalt-60, cesium-137, and 200–250 keV x-rays have been used as reference standards.  The term 
RBE has been widely used in experimental radiobiology, and the term radiation weighting factor used in 
calculations of dose equivalent for radiation safety purposes (ICRP 2007; NCRP 1971; UNSCEAR 1982).  RBE 
applies only to a specific biological end point, in a specific exposure, under specific conditions to a specific species.  
There are no generally accepted values of RBE. 
 
D.4.3  Effective Dose or Effective Dose Equivalent 
 
In an attempt to compare stochastic (e.g., cancer) detriment from absorbed dose of radiation in a limited portion of 
the body with the detriment from total body dose, the ICRP (1977) derived a concept of effective dose equivalent.  
ICRP changed this term to effective dose in 1990 (ICRP 1990) and reintroduced the term “effective dose equivalent” 
in 2007 (ICRP 2007).  The term “effective dose equivalent” allows for the addition or direct comparison of cancer 
and genetic risk from various partial or whole body doses.  In the U.S., the term “effective dose equivalent” is 
presently used by the NRC (NRC 2011) and DOE. 
 
The effective dose (or effective dose equivalent) approach was developed to overcome limitations in using absorbed 
dose as a metric of the stochastic impact of ionizing radiation.  The absorbed dose is usually defined as the mean 
absorbed dose within an organ or tissue.  This represents a simplification of the actual problem.  Normally when an 
individual ingests or inhales a radionuclide or is exposed to external radiation that enters the body (gamma), the dose 
is not uniform throughout the whole body.   
 
The simplifying assumption is that the detriment will be the same whether the body is uniformly or non-uniformly 
irradiated.  This required the development of a tissue weighting factor, which represents the estimated proportion of 
the stochastic risk resulting from tissue, T, to the stochastic risk when the whole body is uniformly irradiated for 
occupational exposures under certain conditions (ICRP 1977). 
 
The effective dose (or effective dose equivalent) (HE) is weighted for both the type of radiation (R) and the type of 
tissue (T), and has the formula: 
 
   HE = ,  
 
where  HE = the effective dose (or effective dose equivalent) in tissue T, 
 ωT = the tissue weighting factor in tissue T, 
 HT = the equivalent dose (or dose equivalent dose), 
 ωR = the radiation weighting factor, and 
 DT,R = the absorbed dose from radiation R to tissue T. 
 
Tissue weighting factors for selected tissues are listed in Table D-5. 
 










Table D-5.  Tissue Weighting Factors for Calculating Effective Dose (or Effective Dose 
Equivalent) for Selected Tissues 
 
 Tissue Weighting factor 




Bladder  0.05 0.04 
Bone marrow (red) 0.12 0.12 0.12 
Bone surface 0.03 0.01 0.01 
Brain   0.01 
Breast 0.15 0.05 0.12 
Colon – 0.12 0.12 
Esophagus – 0.05 0.04 
Gonads 0.25 0.20 0.08 
Liver – 0.05 0.04 
Lung 0.12 0.12 0.12 
Salivary glands   0.01 
Skin – 0.01 0.01 
Stomach – 0.12 0.12 
Thyroid 0.03 0.05 0.04 
Subtotal 0.70 0.95 0.88 
Remainder 0.30 0.05 0.12a 
Total 1.00 1.00 1.00 
ICRP60 = International Commission on Radiological Protection, 1990 Recommendations of the ICRP  
NCRP115 = National Council on Radiation Protection and Measurements.  1993.  Risk Estimates for 
Radiation Protection, Report 115.  Bethesda, Maryland 
NRC = Nuclear Regulatory Commission, Title 10, Code of Federal Regulations, Part 20 
aICRP Publication 103 remainder tissues include adrenals, extrathoracic (ET) region, gall bladder, 
heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, prostate, small intestine, spleen, 
thymus, uterus/cervix  
 
The ICRU (1980), ICRP (1984), and NCRP (1985) recommended that the terms rad, roentgen, curie, and 
rem be replaced by the SI units:  gray (Gy), Coulomb per kilogram (C/kg), Becquerel (Bq), and sievert (Sv), 
respectively.  The relationship between the historical units and the international system of units (SI) for 
radiological quantities is shown in Table D-6. 
 
















curie (Ci) 3.7x1010 
transformations s-1 
becquerel (Bq) s-1 
Absorbed dose (D) 
rad (rad) 10-2 Jkg-1 gray (Gy) Jkg-1 
Absorbed dose rate 
(Ď) rad per second  
(rad s-1) 






rem 10-2 Jkg-1 sievert (Sv) Jkg-1 











Rate (or Dose 
equivalent rate) 
Effective dose (or 
rem per second 
-1)(rem s  
rem 
-110-2 Jkg-1 s  
10-2 Jkg-1 
sievert per second 
-1)(Sv s  
sievert (Sv) 




Linear energy kiloelectron 1.602x10-10 -1Jm  kiloelectron volts per -11.602x10-10 Jm  





Jkg-1 = Joules per kilogram; s-1Jkg-1  = Joules per kilogram per second; Jm-1 = Joules per meter; s-1 = per second 
 
D.4.4    Working Levels and Working Level Months (for Radon Dosimetry).    Working level 
(WL) is a measure of the atmospheric concentration of radon and its short-lived progeny.  One WL is defined as any 
combination of short-lived radon progeny (through polonium-214 [214Po]), per liter of air, that will result in the 
emission of 1.3x105 MeV of alpha energy.  An activity concentration of 100 pCi 222Rn/L of air, in equilibrium with 
its progeny, corresponds approximately to a potential alpha-energy concentration of 1 WL.  The WL unit can also be 
used for thoron or 220Rn.  In this case, 1.3x105 MeV of alpha energy (1 WL) is released by 7.5 pCi 220Rn/L in 
equilibrium with its progeny.  The potential alpha energy exposure of miners is commonly expressed in the unit 
Working Level Month (WLM).  One WLM corresponds to inhalinga concentration of 1 WL for the reference period 
of 170 hours, or more generally 
 
WLM = concentration (WL) x exposure time (months) / (one “month” = 170 working hours). 
 
D.5 Dosimetry Models 
 
Dosimetry models are used to estimate the dose from internally deposited radioactive substances.  The models for 
internal dosimetry consider the amount of radionuclides entering the body, the factors affecting their movement or 
transport through the body, distribution and retention of radionuclides in the body, and the energy deposited in 
organs and tissues from the radiation that is emitted during spontaneous decay processes.  The dose pattern for 
radioactive materials in the body may be strongly influenced by the route of entry of the material.  For industrial 
workers, inhalation of radioactive particles with pulmonary deposition and puncture wounds with subcutaneous 
deposition have been the most frequent.  The general population has been exposed via ingestion, inhalation, and 
external exposure to low levels of naturally occurring radionuclides as well as artificial radionuclides used in nuclear 
medicine procedures and released from isotope generation facilities, nuclear weapons testing, and nuclear reactor 
operations and accidents. 
 
The models for external dosimetry consider only the photon doses (and neutron doses, where applicable) to organs 
of individuals who are immersed in air or are exposed to a contaminated object.   
 
D.5.1  Ingestion.    Ingestion of radioactive materials is most likely to occur from eating food or drinking water 
containing naturally occurring radioactive material and possibly also contaminated with artificial radionuclides.  
Also, a portion of inhaled radionuclides initially deposited in the lung will relocate to the throat and be swallowed.  
Ingestion of a sufficient amount of radioactive material may result in toxic effects as a result of either absorption of 
the radionuclide or irradiation of the gastrointestinal tract during passage through the tract, or a combination of both.  
The fraction of a radioactive material absorbed from the gastrointestinal tract is variable, depending on the specific 
element, the physical and chemical form of the material ingested, and the diet, as well as some other metabolic and 
physiological factors.  The absorption of some elements is influenced by age, usually with higher absorption in the 
very young. 
 
D.5.2  Inhalation.    The nose and mouth have long been recognized as being a major portal of entry for both 
nonradioactive and radioactive materials.  The deposition of particles within the lung is largely dependent upon the 
size and shape of the particles being inhaled (sometimes termed the atmospheric mean aerodynamic diameter or 
AMAD).  After a particle is deposited, its retention will depend upon the physical and chemical properties of the 
dust and the physiological status of the lung.  The retention of the particle in the lung depends on the location of 










deposition, in addition to the physical and chemical properties of the particles.  The converse of pulmonary retention 
is pulmonary clearance.  There are three distinct mechanisms of clearance which operate simultaneously.  Ciliary 
clearance acts only in the upper respiratory tract.  The second and third mechanisms act mainly in the deep 
respiratory tract.  These are phagocytosis and absorption.  Phagocytosis is the engulfing of foreign bodies by 
alveolar macrophages and their subsequent removal either up the ciliary "escalator" or by entrance into the 
lymphatic system.  Some inhaled soluble particles are absorbed into the blood and translocated to other organs and 
tissues. 
 
D.5.3 Internal Emitters 
 
An internal emitter is a radionuclide that is inside the body.  The absorbed dose from internally deposited 
radioisotopes depends on the energy absorbed per unit tissue by the irradiated tissue.  For a radioisotope distributed 
uniformly throughout an infinitely large medium, the concentration of absorbed energy must be equal to the 
concentration of energy emitted by the isotope.  An infinitely large medium may be approximated by a tissue mass 
whose dimensions exceed the range of the particle.  All alpha and most beta radiation will be absorbed in the organ 
(or tissue) of reference.  Gamma-emitting isotope emissions are penetrating radiation, and a substantial fraction of 
gamma energy may not be absorbed in tissue.  The dose to an organ or tissue is a function of the effective retention 
half-time, the energy released in the tissue, the amount of radioactivity initially introduced, and the mass of the 
organ or tissue. 
 
D.6 BIOLOGICAL EFFECTS OF RADIATION 
 
When biological material is exposed to ionizing radiation, a chain of cellular events occurs as the ionizing particle 
passes through the biological material.  A number of theories have been proposed to describe the interaction of 
radiation with biologically important molecules in cells and to explain the resulting damage to biological systems 
from those interactions.  Many factors may modify the response of a living organism to a given dose of radiation.  
Factors related to the exposure include the dose rate, the energy of the radiation, and the temporal pattern of the 
exposure (e.g., protracted or fractionated exposures).  Biological considerations include factors such as species, age, 
sex, and the portion of the body exposed.  Several excellent reviews of the biological effects of radiation have been 
published, and the reader is referred to these for a more in-depth discussion (Brodsky 1996; Klaassen 2001; Hobbs 
and McClellan 1986; ICRP 1984; Mettler and Moseley 1985; Rubin and Casarett 1968). 
 
D.6.1 Radiation Effects at the Cellular Level 
 
 According to Mettler and Moseley (1985), at acute doses up to 10 rad (100 mGy), single strand breaks in DNA may 
be produced.  These single strand breaks may be repaired rapidly.  With doses in the range of 0.5-5 Gy (50–500 rad), 
irreparable double-stranded DNA breaks are likely, resulting in cellular reproductive death after one or more 
divisions of the irradiated parent cell.  At large doses of radiation, usually greater than 5 Gy (500 rad), direct cell 
death before division (interphase death) may occur from the direct interaction of free-radicals with essentially 
cellular macromolecules.  Morphological changes at the cellular level, the severity of which are dose-dependent, 
may also be observed. 
 
The sensitivity of various cell types varies.  According to the Bergonie-Tribondeau law, the sensitivity of cell lines 
is directly proportional to their mitotic rate and inversely proportional to the degree of differentiation (Mettler and 
Moseley 1985).  Rubin and Casarett (1968) devised a classification system that categorized cells according to type, 
function, and mitotic activity.  The categories range from the most sensitive type, "vegetative intermitotic cells," 
found in the stem cells of the bone marrow and the gastrointestinal tract, to the least sensitive cell type, "fixed 
postmitotic cells," found in striated muscles or long-lived neural tissues. 
 
Cellular changes may result in cell death, which if extensive, may produce irreversible damage to an organ or tissue 
or may result in the death of the individual.  If the cell recovers, altered metabolism and function may still occur, 
which may be repaired or may result in the manifestation of clinical symptoms.  These changes may also be 
expressed at a later time as tumors, cellular mutations, or transformed tissue (scar tissue) which may result in 
abnormal tissue or compromised function. 











D.6.2 Radiation Effects at the Organ Level 
 
In most organs and tissues the injury and the underlying mechanism for that injury are complex and may involve a 
combination of events.  The extent and severity of this tissue injury are dependent upon the radiosensitivity of the 
various cell types in that organ system.  Rubin and Casarett (1968) describe and schematically display the events 
following radiation in several organ system types.  These include:  a rapid renewal system, such as the 
gastrointestinal mucosa; a slow renewal system, such as the pulmonary epithelium; and a nonrenewal system, such 
as neural or muscle tissue.  In the rapid renewal system, organ injury results from the direct destruction of highly 
radiosensitive cells, such as the stem cells in the bone marrow.  Injury may also result from constriction of the 
microcirculation and from edema and inflammation of the basement membrane, designated as the histohematic 
barrier (HHB), which may progress to fibrosis.  In slow renewal and nonrenewal systems, the radiation may have 
little effect on the parenchymal cells, but ultimate parenchymal atrophy and death over several months result from 
HHB fibrosis and occlusion of the microcirculation. 
 
D.6.3 Low Level Radiation Effects 
 
Cancer is the major latent harmful effect produced by ionizing radiation and the one that most people exposed to 
radiation are concerned about.  The ability of alpha, beta, and gamma radiation to produce cancer in virtually every 
tissue and organ in laboratory animals has been well-demonstrated, while radiogenic cancer has not been observed 
in some human tissues and organs.  The development of cancer is not an immediate effect.  In humans, radiation-
induced leukemia has the shortest latent period at 2 years, thyroid cancer after Chernobyl showed up in children 
about four years after the accident, while other radiation induced cancers have latent periods >20 years.  For the non-
radiogenic cancers, it has been hypothesized either that repair mechanisms effectively protect the individual or that 
the latency period exceeds the current human life span (Raabe 2010).  The mechanism by which cancer is induced in 
living cells is complex and is a topic of intense study.  Exposure to ionizing radiation can produce cancer; however, 
some sites appear to be more common than others, such as the breast, lung, stomach, and thyroid.   
 
DNA is a major target molecule during exposure to ionizing radiation.  Other macromolecules, such as lipids and 
proteins, are also at risk of damage when exposed to ionizing radiation.  The genotoxicity of ionizing radiation is an 
area of intense study, as damage to the  DNA is ultimately responsible for many of the adverse toxicological effects 
ascribed to ionizing radiation, including cancer.  Damage to genetic material is basic to developmental or teratogenic 
effects, as well.   
 
There is limited evidence of non-cancer human effects at low radiation doses.  Non-cancer effects that have been 
reported are associated with the Japanese atomic bomb survivor population and include neurological and 
cardiovascular effects.  Neurological effects were observed in fetuses exposed to prompt radiation during the 
detonations while they were in gestation weeks 8–15, less so for weeks 16–25, and were not observed for other 
developmental time frames.  Cardiovascular effects have been reported for atomic bomb survivors following 
60 years of follow-up.  These include a statistically significant increase in heart disease (% elevated relative risk per 
Gy with 95% confidence interval = 14 [6–23] %/Gy, p<0.001) and a non-statistically significant increase in stroke 
(9 [1–17]%/Gy, p=0.02) above a dose of 0.5 Gy.  These radiation-induced circulatory effects may be increased by 
other factors such as smoking, microvascular damage in the kidney and associated hypertension, high serum 
cholerterol, diabetes, and infection. 
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